<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedBookArticle><BookDocument><PMID Version="1">31613449</PMID><ArticleIdList><ArticleId IdType="bookaccession">NBK547669</ArticleId></ArticleIdList><Book><Publisher><PublisherName>StatPearls Publishing</PublisherName><PublisherLocation>Treasure Island (FL)</PublisherLocation></Publisher><BookTitle book="statpearls">StatPearls</BookTitle><PubDate><Year>2025</Year><Month>01</Month></PubDate><BeginningDate><Year>2025</Year><Month>01</Month></BeginningDate><Medium>Internet</Medium></Book><ArticleTitle book="statpearls" part="article-29832">Systemic Inflammatory Response Syndrome</ArticleTitle><Language>eng</Language><AuthorList Type="authors" CompleteYN="Y"><Author ValidYN="Y"><LastName>Baddam</LastName><ForeName>Sujatha</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Huntsville Hospital, Huntsville</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Burns</LastName><ForeName>Bracken</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>East Tennessee State University (ETSU)</Affiliation></AffiliationInfo></Author></AuthorList><PublicationType UI="D000072643">Study Guide</PublicationType><Abstract><AbstractText><b>Systemic Inflammatory Response Syndrome</b> Systemic inflammatory response syndrome (SIRS) is an exaggerated defense response of the body to a noxious stressor, which can include infection, trauma, surgery, acute inflammation, ischemia or reperfusion, or malignancy, aimed at localizing and then eliminating the endogenous or exogenous source of the insult. This response involves the release of acute-phase reactants, which are direct mediators of widespread autonomic, endocrine, hematological, and immunological alterations in the subject. Even though the purpose is defensive, the dysregulated cytokine storm can cause a massive inflammatory cascade leading to reversible or irreversible end-organ dysfunction and even death. <b>&#xa0;</b>Objectively, SIRS is defined by the presence of any 2 of the following criteria: Body temperature &gt;100.4&#xa0;&#xb0;F (38 &#xb0;C)&#xa0;or &lt;96.8 &#xb0;F (36 &#xb0;C). Heart rate &gt;90 bpm. Respiratory rate &gt;20 breaths/minute or PaCO<sub>2</sub> &lt;32 mm Hg (4.3 kPa). Leukocyte count &gt;12,000/&#x3bc;L, &lt;4,000/&#x3bc;L, or &gt;10% immature forms (bands). <b>Sepsis, Septic Shock, and Multiple Organ Dysfunction Syndrome&#xa0;</b> SIRS with a suspected infectious source is termed sepsis. Culture confirmation is not required early in diagnosis. Historically, "severe sepsis" described sepsis with organ dysfunction; however, the Sepsis-3 task force removed this category in 2016, consolidating it under the revised definition of sepsis as "life-threatening organ dysfunction caused by a dysregulated host response to infection. This distinction is no longer used clinically but may appear in older literature. Septic shock represents the most severe form, marked by circulatory, cellular, and metabolic abnormalities that persist despite adequate fluid resuscitation. Together, sepsis and septic shock are considered a continuum of worsening host response to infection. The American College of Chest Physicians/Society of Critical Care Medicine-sponsored sepsis definitions consensus conference also identified the entity of multiple organ dysfunction syndrome (MODS) as the presence of altered organ function in acutely ill septic patients such that homeostasis is not maintainable without intervention. In the pediatric population, the definition is modified to a mandatory requirement of abnormal leukocyte count or temperature to establish the diagnosis, as abnormal heart rate and respiratory rates are more common in children.&#xa0;Recent survey data show that most pediatric clinicians define sepsis as infection with life-threatening organ dysfunction, moving away from older pediatric criteria that relied on SIRS and the redundant term "severe sepsis." The SCCM task force now recommends using the Phoenix Sepsis Score, where a score &#x2265;2 in a child with suspected infection indicates sepsis due to dysfunction in respiratory, cardiovascular, coagulation, or neurologic systems. Septic shock is defined by cardiovascular dysfunction, marked by hypotension for age, lactate &gt;5 mmol/L, or need for vasoactive support. In summary, almost all septic patients exhibit SIRS, but not all patients with SIRS are septic. Kaukonen et al explained exceptions to this theory by suggesting that there are subgroups of hospitalized patients, particularly at extremes of age, who do not meet the criteria for SIRS on presentation but progress to severe infection, multiple organ dysfunction, and death. Establishing laboratory indices to identify such subgroups of patients and the clinical criteria that we currently rely upon has been gaining prominence over recent years. Several scores exist to assess the severity of damage to individual organ systems. The Acute Physiology and Chronic Health Evaluation (APACHE) score version II and III, multiple organ dysfunction (MOD) score, sequential organ failure assessment (SOFA), and logistic organ dysfunction (LOD) score are to name a few. <b>Historical Evolution of&#xa0;Systemic Inflammatory Response Syndrome</b> The emergence of new insights into the pathophysiology and treatment of sepsis in the early 1990s highlighted the growing need to identify a uniform group of potential subjects for clinical trials exploring novel therapeutic strategies. In response to the surge of ongoing research, a consensus has emerged emphasizing the importance of a time-sensitive approach to diagnosis and intervention, aiming to improve patient survival and reduce morbidity. The ability to recognize individuals affected by various conditions across different care settings using standardized, easy-to-apply clinical parameters became essential. To address this, the American College of Chest Physicians and the Society of Critical Care Medicine convened a consensus conference on sepsis definitions in Chicago, Illinois, in August 1991, with the intention of establishing a standard set of clinical criteria for broad application. This effort led to the introduction of the SIRS definition. A second consensus meeting, held in Washington, DC, in 2001, expanded on this foundation by introducing a conceptual framework for staging sepsis using the PIRO model&#x2014;predisposition, insult or infection, response, and organ dysfunction. This model aimed to enhance the understanding and clinical categorization of sepsis, offering a more structured approach to guide research and therapeutic decisions. The goal of the initial definition was to be highly sensitive using easily available parameters across all healthcare settings. An unavoidable corollary of such a definition was, therefore, the lack of specificity. Additional limitations of the SIRS definition include&#xa0;the following: 1. The universal prevalence of the parameters in an ICU setting. 2. Lack of ability to distinguish between beneficial host response from pathologic host response that contributes to organ dysfunction. 3. Distinguishing between infectious and noninfectious etiology purely based on the definition. 4. Lack of weight to each criterion, eg, fever and elevated respiratory rate, has precisely the same significance as leukocytosis or tachycardia by the SIRS definition. 5. Inability to predict organ dysfunction&#xa0;. Kaukonen et al, in their study of over 130,000 septic patients, established that 1 out of 8 patients in their observational study of sepsis did not meet &#x2265;2 SIRS criteria. They also established that each criterion in the SIRS definition does not translate to an equivalent risk of organ dysfunction or death. <b>Sequential organ failure assessment</b> In 2016, following this debate, the European Society of Intensive Care Medicine and the Society of Critical Care Medicine (SCCM) established a task force that proposed Sepsis-3, a revised definition for sepsis. The new definition excluded the establishment of SIRS criteria to define sepsis and made it more nonspecific, as any life-threatening organ dysfunction caused by the dysregulated host response to infection. The task force claimed that the sequential organ failure assessment (SOFA) has better predictive validity for sepsis than the SIRS criteria. It has better prognostic accuracy and the ability to predict in-hospital mortality. To reduce the complexity of calculating the SOFA, a simplified version of the SOFA, known as qSOFA, was introduced. The qSOFA score is a modified version of the SOFA. A score &#x2265;2 is associated with the following poor outcomes due to sepsis: A systolic blood pressure of &#x2264;100 mm Hg indicates a potential problem with the cardiovascular system&#xa0;. A respiratory rate of &#x2265;22&#xa0;breaths/min suggests possible respiratory distress. A Glasgow Coma Scale score of &lt;15 indicates a change in the patient's level of consciousness. Although the validity of qSOFA is limited in an ICU setting, it has consistently outperformed SIRS criteria in predicting organ dysfunction in a non-ICU and ER setting. The use of vasopressors, mechanical ventilation, and aggressive therapeutic interventions in the ICU limits the efficacy of qSOFA.&#xa0;Interestingly, Hague et al, in their study of the utility of SIRS criteria in gastrointestinal surgery, also found it a useful criterion for identifying postoperative complications. A 2023 systematic review comparing qSOFA and SIRS in emergency and critical care settings found that while qSOFA excels in predicting mortality with greater specificity and AUROC values, SIRS criteria are met significantly faster, which may offer practical advantages for early triage. These findings underscore the trade-off between early detection and prognostic accuracy, guiding clinicians in tailoring their approach according to the specific setting and resource availability.</AbstractText><CopyrightInformation>Copyright &#xa9; 2025, StatPearls Publishing LLC.</CopyrightInformation></Abstract><Sections><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s1">Continuing Education Activity</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s2">Introduction</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s3">Etiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s4">Epidemiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s5">Pathophysiology</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s6">History and Physical</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s7">Evaluation</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s8">Treatment / Management</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s9">Differential Diagnosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s10">Prognosis</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s11">Complications</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s12">Deterrence and Patient Education</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s13">Enhancing Healthcare Team Outcomes</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s14">Review Questions</SectionTitle></Section><Section><SectionTitle book="statpearls" part="article-29832" sec="article-29832.s15">References</SectionTitle></Section></Sections><ContributionDate><Year>2025</Year><Month>6</Month><Day>20</Day></ContributionDate><ReferenceList><Reference><Citation>Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, Bellomo R, Bernard GR, Chiche JD, Coopersmith CM, Hotchkiss RS, Levy MM, Marshall JC, Martin GS, Opal SM, Rubenfeld GD, van der Poll T, Vincent JL, Angus DC. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016 Feb 23;315(8):801-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992 Jun;101(6):1644-55.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlapbach LJ, Watson RS, Sorce LR, Argent AC, Menon K, Hall MW, Akech S, Albers DJ, Alpern ER, Balamuth F, Bembea M, Biban P, Carrol ED, Chiotos K, Chisti MJ, DeWitt PE, Evans I, Flauzino de Oliveira C, Horvat CM, Inwald D, Ishimine P, Jaramillo-Bustamante JC, Levin M, Lodha R, Martin B, Nadel S, Nakagawa S, Peters MJ, Randolph AG, Ranjit S, Rebull MN, Russell S, Scott HF, de Souza DC, Tissieres P, Weiss SL, Wiens MO, Wynn JL, Kissoon N, Zimmerman JJ, Sanchez-Pinto LN, Bennett TD, Society of Critical Care Medicine Pediatric Sepsis Definition Task Force International Consensus Criteria for Pediatric Sepsis and Septic Shock. JAMA. 2024 Feb 27;331(8):665-674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10900966</ArticleId><ArticleId IdType="pubmed">38245889</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaukonen KM, Bailey M, Pilcher D, Cooper DJ, Bellomo R. Systemic inflammatory response syndrome criteria in defining severe sepsis. N Engl J Med. 2015 Apr 23;372(17):1629-38.</Citation><ArticleIdList><ArticleId IdType="pubmed">25776936</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J, Opal SM, Vincent JL, Ramsay G, SCCM/ESICM/ACCP/ATS/SIS 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference. Crit Care Med. 2003 Apr;31(4):1250-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682500</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Opal SM, Marshall JC, Tracey KJ. Sepsis definitions: time for change. Lancet. 2013 Mar 02;381(9868):774-5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4535310</ArticleId><ArticleId IdType="pubmed">23472921</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando SM, Rochwerg B, Seely AJE. Clinical implications of the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). CMAJ. 2018 Sep 10;190(36):E1058-E1059.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6131078</ArticleId><ArticleId IdType="pubmed">30201611</ArticleId></ArticleIdList></Reference><Reference><Citation>Finkelsztein EJ, Jones DS, Ma KC, Pab&#xf3;n MA, Delgado T, Nakahira K, Arbo JE, Berlin DA, Schenck EJ, Choi AM, Siempos II. Comparison of qSOFA and SIRS for predicting adverse outcomes of patients with suspicion of sepsis outside the intensive care unit. Crit Care. 2017 Mar 26;21(1):73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5366240</ArticleId><ArticleId IdType="pubmed">28342442</ArticleId></ArticleIdList></Reference><Reference><Citation>Koirala U, Thapa PB, Joshi MR, Singh DR, Sharma SK. Systemic Inflammatory Response Syndrome following Gastrointestinal Surgery. JNMA J Nepal Med Assoc. 2017 Apr-Jun;56(206):221-225.</Citation><ArticleIdList><ArticleId IdType="pubmed">28746319</ArticleId></ArticleIdList></Reference><Reference><Citation>Svendsen M, Steindal SA, Hamilton Larsen M, Trygg Solberg M. Comparison of the systematic Inflammatory response syndrome and the quick sequential organ failure assessment for prognostic accuracy in detecting sepsis in the emergency department: A systematic review. Int Emerg Nurs. 2023 Jan;66:101242.</Citation><ArticleIdList><ArticleId IdType="pubmed">36571931</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoover L, Bochicchio GV, Napolitano LM, Joshi M, Bochicchio K, Meyer W, Scalea TM. Systemic inflammatory response syndrome and nosocomial infection in trauma. J Trauma. 2006 Aug;61(2):310-6; discussion 316-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">16917443</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996 Apr;109(4):1033-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Jentzer JC, Lawler PR, van Diepen S, Henry TD, Menon V, Baran DA, D&#x17e;av&#xed;k V, Barsness GW, Holmes DR, Kashani KB. Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. Circ Cardiovasc Qual Outcomes. 2020 Dec;13(12):e006956.</Citation><ArticleIdList><ArticleId IdType="pubmed">33280435</ArticleId></ArticleIdList></Reference><Reference><Citation>Horeczko T, Green JP, Panacek EA. Epidemiology of the Systemic Inflammatory Response Syndrome (SIRS) in the emergency department. West J Emerg Med. 2014 May;15(3):329-36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4025532</ArticleId><ArticleId IdType="pubmed">24868313</ArticleId></ArticleIdList></Reference><Reference><Citation>Churpek MM, Zadravecz FJ, Winslow C, Howell MD, Edelson DP. Incidence and Prognostic Value of the Systemic Inflammatory Response Syndrome and Organ Dysfunctions in Ward Patients. Am J Respir Crit Care Med. 2015 Oct 15;192(8):958-64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4642209</ArticleId><ArticleId IdType="pubmed">26158402</ArticleId></ArticleIdList></Reference><Reference><Citation>Pittet D, Rangel-Frausto S, Li N, Tarara D, Costigan M, Rempe L, Jebson P, Wenzel RP. Systemic inflammatory response syndrome, sepsis, severe sepsis and septic shock: incidence, morbidities and outcomes in surgical ICU patients. Intensive Care Med. 1995 Apr;21(4):302-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">7650252</ArticleId></ArticleIdList></Reference><Reference><Citation>Dremsizov T, Clermont G, Kellum JA, Kalassian KG, Fine MJ, Angus DC. Severe sepsis in community-acquired pneumonia: when does it happen, and do systemic inflammatory response syndrome criteria help predict course? Chest. 2006 Apr;129(4):968-78.</Citation><ArticleIdList><ArticleId IdType="pubmed">16608946</ArticleId></ArticleIdList></Reference><Reference><Citation>Comstedt P, Storgaard M, Lassen AT. The Systemic Inflammatory Response Syndrome (SIRS) in acutely hospitalised medical patients: a cohort study. Scand J Trauma Resusc Emerg Med. 2009 Dec 27;17:67.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2806258</ArticleId><ArticleId IdType="pubmed">20035633</ArticleId></ArticleIdList></Reference><Reference><Citation>Talmor M, Hydo L, Barie PS. Relationship of systemic inflammatory response syndrome to organ dysfunction, length of stay, and mortality in critical surgical illness: effect of intensive care unit resuscitation. Arch Surg. 1999 Jan;134(1):81-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">9927137</ArticleId></ArticleIdList></Reference><Reference><Citation>NeSmith EG, Weinrich SP, Andrews JO, Medeiros RS, Hawkins ML, Weinrich MC. Demographic differences in systemic inflammatory response syndrome score after trauma. Am J Crit Care. 2012 Jan;21(1):35-41; quiz 42.</Citation><ArticleIdList><ArticleId IdType="pubmed">22210698</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry MA, Bland KI, Chaudry IH. Trauma and immune response--effect of gender differences. Injury. 2007 Dec;38(12):1382-91.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2692838</ArticleId><ArticleId IdType="pubmed">18048037</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest. 1997 Jul;112(1):235-43.</Citation><ArticleIdList><ArticleId IdType="pubmed">9228382</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. Clin Chim Acta. 2012 Nov 12;413(21-22):1737-41.</Citation><ArticleIdList><ArticleId IdType="pubmed">22789964</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, Zurawski G, Moshrefi M, Qin J, Li X, Gorman DM, Bazan JF, Kastelein RA. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005 Nov;23(5):479-90.</Citation><ArticleIdList><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Tracey KJ. The inflammatory reflex. Nature. 2002 Dec 19-26;420(6917):853-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12490958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayampanathan AA. Systematic review of complications and outcomes of diabetic patients with burn trauma. Burns. 2016 Dec;42(8):1644-1651.</Citation><ArticleIdList><ArticleId IdType="pubmed">27595452</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochicchio GV, Napolitano LM, Joshi M, McCarter RJ, Scalea TM. Systemic inflammatory response syndrome score at admission independently predicts infection in blunt trauma patients. J Trauma. 2001 May;50(5):817-20.</Citation><ArticleIdList><ArticleId IdType="pubmed">11379594</ArticleId></ArticleIdList></Reference><Reference><Citation>Karzai W, Oberhoffer M, Meier-Hellmann A, Reinhart K. Procalcitonin--a new indicator of the systemic response to severe infections. Infection. 1997 Nov-Dec;25(6):329-34.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102374</ArticleId><ArticleId IdType="pubmed">9427049</ArticleId></ArticleIdList></Reference><Reference><Citation>Martiny P, Goggs R. Biomarker Guided Diagnosis of Septic Peritonitis in Dogs. Front Vet Sci. 2019;6:208.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6610427</ArticleId><ArticleId IdType="pubmed">31316998</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrejaitiene J, Sirvinskas E, Zebrauskiene I. [Procalcitonin: a new infection marker. Its use in intensive care]. Medicina (Kaunas) 2002;38(5):491-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">12474679</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Sepsis Biomarkers. J Pediatr Intensive Care. 2019 Mar;8(1):11-16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6506678</ArticleId><ArticleId IdType="pubmed">31073503</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Wang Y, Yang Q, Dong Y. Procalcitonin-guided antibiotic therapy in critically ill adults: a meta-analysis. BMC Infect Dis. 2017 Jul 24;17(1):514.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5525369</ArticleId><ArticleId IdType="pubmed">28738787</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Tripathy S, Jyoti A, Singh SG. Recent advances in biosensors for diagnosis and detection of sepsis: A comprehensive review. Biosens Bioelectron. 2019 Jan 15;124-125:205-215.</Citation><ArticleIdList><ArticleId IdType="pubmed">30388563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ciriello V, Gudipati S, Stavrou PZ, Kanakaris NK, Bellamy MC, Giannoudis PV. Biomarkers predicting sepsis in polytrauma patients: Current evidence. Injury. 2013 Dec;44(12):1680-92.</Citation><ArticleIdList><ArticleId IdType="pubmed">24119650</ArticleId></ArticleIdList></Reference><Reference><Citation>Agarwal R, Schwartz DN. Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review. Clin Infect Dis. 2011 Aug;53(4):379-87.</Citation><ArticleIdList><ArticleId IdType="pubmed">21810753</ArticleId></ArticleIdList></Reference><Reference><Citation>Selberg O, Hecker H, Martin M, Klos A, Bautsch W, K&#xf6;hl J. Discrimination of sepsis and systemic inflammatory response syndrome by determination of circulating plasma concentrations of procalcitonin, protein complement 3a, and interleukin-6. Crit Care Med. 2000 Aug;28(8):2793-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">10966252</ArticleId></ArticleIdList></Reference><Reference><Citation>Baddam S, Tubben RE. StatPearls [Internet] StatPearls Publishing; Treasure Island (FL): 2025. Apr 28, Lactic Acidosis.</Citation></Reference><Reference><Citation>Hu L, Shi Q, Shi M, Liu R, Wang C. Diagnostic Value of PCT and CRP for Detecting Serious Bacterial Infections in Patients With Fever of Unknown Origin: A Systematic Review and Meta-analysis. Appl Immunohistochem Mol Morphol. 2017 Sep;25(8):e61-e69.</Citation><ArticleIdList><ArticleId IdType="pubmed">28885233</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf TA, Wimalawansa SJ, Razzaque MS. Procalcitonin as a biomarker for critically ill patients with sepsis: Effects of vitamin D supplementation. J Steroid Biochem Mol Biol. 2019 Oct;193:105428.</Citation><ArticleIdList><ArticleId IdType="pubmed">31323346</ArticleId></ArticleIdList></Reference><Reference><Citation>Bracho-Riquelme RL, Reyes-Romero MA. Leptin in sepsis: a well-suited biomarker in critically ill patients? Crit Care. 2010;14(2):138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887146</ArticleId><ArticleId IdType="pubmed">20392294</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef AA, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-alpha in critically ill patients: a prospective observational study. Crit Care. 2010;14(2):R33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2887140</ArticleId><ArticleId IdType="pubmed">20230641</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou AG, Mastora Z, Orfanos SE, Jahaj E, Maniatis NA, Koutsoukou A, Armaganidis A, Kotanidou A. Elevated biomarkers of endothelial dysfunction/activation at ICU admission are associated with sepsis development. Cytokine. 2014 Oct;69(2):240-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25016133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mussap M, Cibecchini F, Noto A, Fanos V. In search of biomarkers for diagnosing and managing neonatal sepsis: the role of angiopoietins. J Matern Fetal Neonatal Med. 2013 Oct;26 Suppl 2:24-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">24059548</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku R, Oda S, Nakada TA, Sadahiro T, Nakamura M, Hirayama Y, Abe R, Tateishi Y, Ito M, Iseki T, Hirasawa H. Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine. 2013 Jan;61(1):112-7.</Citation><ArticleIdList><ArticleId IdType="pubmed">23046618</ArticleId></ArticleIdList></Reference><Reference><Citation>Hou YQ, Xu P, Zhang M, Han D, Peng L, Liang DY, Yang S, Zhang Z, Hong J, Lou XL, Zhang L, Kim S. Serum decoy receptor 3, a potential new biomarker for sepsis. Clin Chim Acta. 2012 Apr 11;413(7-8):744-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">22280900</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S, Mi L, Zhang L. Specific elevation of DcR3 in sera of sepsis patients and its potential role as a clinically important biomarker of sepsis. Diagn Microbiol Infect Dis. 2012 Aug;73(4):312-7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3396789</ArticleId><ArticleId IdType="pubmed">22647538</ArticleId></ArticleIdList></Reference><Reference><Citation>Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA, Xia J, Fjell CD, Boyd JH, Hancock RE. An Endotoxin Tolerance Signature Predicts Sepsis and Organ Dysfunction at Initial Clinical Presentation. EBioMedicine. 2014 Nov 01;1(1):64-71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4326653</ArticleId><ArticleId IdType="pubmed">25685830</ArticleId></ArticleIdList></Reference><Reference><Citation>Evans L, Rhodes A, Alhazzani W, Antonelli M, Coopersmith CM, French C, Machado FR, Mcintyre L, Ostermann M, Prescott HC, Schorr C, Simpson S, Wiersinga WJ, Alshamsi F, Angus DC, Arabi Y, Azevedo L, Beale R, Beilman G, Belley-Cote E, Burry L, Cecconi M, Centofanti J, Coz Yataco A, De Waele J, Dellinger RP, Doi K, Du B, Estenssoro E, Ferrer R, Gomersall C, Hodgson C, M&#xf8;ller MH, Iwashyna T, Jacob S, Kleinpell R, Klompas M, Koh Y, Kumar A, Kwizera A, Lobo S, Masur H, McGloughlin S, Mehta S, Mehta Y, Mer M, Nunnally M, Oczkowski S, Osborn T, Papathanassoglou E, Perner A, Puskarich M, Roberts J, Schweickert W, Seckel M, Sevransky J, Sprung CL, Welte T, Zimmerman J, Levy M. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021 Nov;47(11):1181-1247.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8486643</ArticleId><ArticleId IdType="pubmed">34599691</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, Suppes R, Feinstein D, Zanotti S, Taiberg L, Gurka D, Kumar A, Cheang M. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med. 2006 Jun;34(6):1589-96.</Citation><ArticleIdList><ArticleId IdType="pubmed">16625125</ArticleId></ArticleIdList></Reference><Reference><Citation>De Waele JJ, Schouten J, Beovic B, Tabah A, Leone M. Antimicrobial de-escalation as part of antimicrobial stewardship in intensive care: no simple answers to simple questions-a viewpoint of experts. Intensive Care Med. 2020 Feb;46(2):236-244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224113</ArticleId><ArticleId IdType="pubmed">32025778</ArticleId></ArticleIdList></Reference><Reference><Citation>Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016 Feb 15;62(4):e1-50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4725385</ArticleId><ArticleId IdType="pubmed">26679628</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Renault A, Brun-Buisson C, Megarbane B, Quenot JP, Siami S, Cariou A, Forceville X, Schwebel C, Martin C, Timsit JF, Misset B, Ali Benali M, Colin G, Souweine B, Asehnoune K, Mercier E, Chimot L, Charpentier C, Fran&#xe7;ois B, Boulain T, Petitpas F, Constantin JM, Dhonneur G, Baudin F, Combes A, Boh&#xe9; J, Loriferne JF, Amathieu R, Cook F, Slama M, Leroy O, Capellier G, Dargent A, Hissem T, Maxime V, Bellissant E, CRICS-TRIGGERSEP Network Hydrocortisone plus Fludrocortisone for Adults with Septic Shock. N Engl J Med. 2018 Mar 01;378(9):809-818.</Citation><ArticleIdList><ArticleId IdType="pubmed">29490185</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurmyshkina OV, Bogdanova AA, Volkova TO, Poltoraka AN. [Septic Shock: Innate Molecular Genetic Mechanisms of the Development of Generalized Inflammation]. Ontogenez. 2015 Jul-Aug;46(4):225-39.</Citation><ArticleIdList><ArticleId IdType="pubmed">26480482</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995 Jan 11;273(2):117-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799491</ArticleId></ArticleIdList></Reference><Reference><Citation>Shapiro N, Howell MD, Bates DW, Angus DC, Ngo L, Talmor D. The association of sepsis syndrome and organ dysfunction with mortality in emergency department patients with suspected infection. Ann Emerg Med. 2006 Nov;48(5):583-90, 590.e1.</Citation><ArticleIdList><ArticleId IdType="pubmed">17052559</ArticleId></ArticleIdList></Reference><Reference><Citation>Bochicchio GV, Napolitano LM, Joshi M, Knorr K, Tracy JK, Ilahi O, Scalea TM. Persistent systemic inflammatory response syndrome is predictive of nosocomial infection in trauma. J Trauma. 2002 Aug;53(2):245-50; discussion 250-1.</Citation><ArticleIdList><ArticleId IdType="pubmed">12169929</ArticleId></ArticleIdList></Reference><Reference><Citation>Brun-Buisson C. The epidemiology of the systemic inflammatory response. Intensive Care Med. 2000;26 Suppl 1(Suppl 1):S64-74.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094973</ArticleId><ArticleId IdType="pubmed">10786961</ArticleId></ArticleIdList></Reference><Reference><Citation>Chao A, Chou WH, Chang CJ, Lin YJ, Fan SZ, Chao AS. The admission systemic inflammatory response syndrome predicts outcome in patients undergoing emergency surgery. Asian J Surg. 2013 Jul;36(3):99-103.</Citation><ArticleIdList><ArticleId IdType="pubmed">23810158</ArticleId></ArticleIdList></Reference><Reference><Citation>Henriksen DP, Laursen CB, Hallas J, Pedersen C, Lassen AT. Time to initial antibiotic administration, and short-term mortality among patients admitted with community-acquired severe infections with and without the presence of systemic inflammatory response syndrome: a follow-up study. Emerg Med J. 2015 Nov;32(11):846-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25762652</ArticleId></ArticleIdList></Reference></ReferenceList></BookDocument><PubmedBookData><History><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>6</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31613449</ArticleId></ArticleIdList></PubmedBookData></PubmedBookArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32615109</PMID><DateCompleted><Year>2020</Year><Month>07</Month><Day>16</Day></DateCompleted><DateRevised><Year>2020</Year><Month>08</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>7</Issue><PubDate><Year>2020</Year><Month>Jul</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Liver transplantation in hepatocellular carcinoma after tumour downstaging (XXL): a randomised, controlled, phase 2b/3 trial.</ArticleTitle><Pagination><StartPage>947</StartPage><EndPage>956</EndPage><MedlinePgn>947-956</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(20)30224-2</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(20)30224-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Indications for liver transplantation for hepatocellular carcinoma are evolving and so-called expanded criteria remain debated. Locoregional therapies are able to downstage hepatocellular carcinoma from beyond to within the Milan criteria. We aimed to investigate the efficacy of liver transplantation after successful hepatocellular carcinoma downstaging.</AbstractText><AbstractText Label="METHODS">We did an open-label, multicentre, randomised, controlled trial designed in two phases, 2b and 3, at nine Italian tertiary care and transplantation centres. Patients aged 18-65 years with hepatocellular carcinoma beyond the Milan criteria, absence of macrovascular invasion or extrahepatic spread, 5-year estimated post-transplantation survival of at least 50%, and good liver function (Child-Pugh A-B7) were recruited and underwent tumour downstaging with locoregional, surgical, or systemic therapies according to multidisciplinary decision. After an observation period of 3 months, during which sorafenib was allowed, patients with partial or complete responses according to modified Response Evaluation Criteria in Solid Tumors were randomly assigned (1:1) by an interactive web-response system to liver transplantation or non-transplantation therapies (control group). A block randomisation (block size of 2), stratified by centre and compliance to sorafenib treatment, was applied. Liver transplantation was done with whole or split organs procured from brain-dead donors. The control group received sequences of locoregional and systemic treatment at the time of demonstrated tumour progression. The primary outcomes were 5-year tumour event-free survival for phase 2b and overall survival for phase 3. Analyses were by intention to treat. Organ allocation policy changed during the course of the study and restricted patient accrual to 4 years. This trial is registered with ClinicalTrials.gov, NCT01387503.</AbstractText><AbstractText Label="FINDINGS">Between March 1, 2011, and March 31, 2015, 74 patients were enrolled. Median duration of downstaging was 6 months (IQR 4-11). 29 patients dropped out before randomisation and 45 were randomly assigned: 23 to the transplantation group versus 22 to the control group. At data cutoff on July 31, 2019, median follow-up was 71 months (IQR 60-85). 5-year tumour event-free survival was 76&#xb7;8% (95% CI 60&#xb7;8-96&#xb7;9) in the transplantation group versus 18&#xb7;3% (7&#xb7;1-47&#xb7;0) in the control group (hazard ratio [HR] 0&#xb7;20, 95% CI 0&#xb7;07-0&#xb7;57; p=0&#xb7;003). 5-year overall survival was 77&#xb7;5% (95% CI 61&#xb7;9-97&#xb7;1) in the transplantation group versus 31&#xb7;2% (16&#xb7;6-58&#xb7;5) in the control group (HR 0&#xb7;32, 95% CI 0&#xb7;11-0&#xb7;92; p=0&#xb7;035). The most common registered grade 3-4 serious adverse events were hepatitis C virus recurrence (three [13%] of 23 patients) and acute transplant rejection (two [9%]) in the transplantation group, and post-embolisation syndrome (two [9%] of 22 patients) in the control group. Treatment-related deaths occurred in four patients: two (8%) of 23 patients in the transplantation group (myocardial infarction and multi-organ failure) versus two (9%) of 22 patients in the control group (liver decompensation).</AbstractText><AbstractText Label="INTERPRETATION">Although results must be interpreted with caution owing to the early closing of the trial, after effective and sustained downstaging of eligible hepatocellular carcinomas beyond the Milan criteria, liver transplantation improved tumour event-free survival and overall survival compared with non-transplantation therapies Post-downstaging tumour response could contribute to the expansion of hepatocellular carcinoma transplantation criteria.</AbstractText><AbstractText Label="FUNDING">Italian Ministry of Health.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mazzaferro</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy. Electronic address: vincenzo.mazzaferro@istitutotumori.mi.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Citterio</LastName><ForeName>Davide</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bhoori</LastName><ForeName>Sherrie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bongini</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miceli</LastName><ForeName>Rosalba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carlis</LastName><ForeName>Luciano</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colledan</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salizzoni</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Romagnoli</LastName><ForeName>Renato</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>General and Liver Transplant Surgery Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vivarelli</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tisone</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rossi</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gruttadauria</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Di Sandro</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Carlis</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luc&#xe0;</LastName><ForeName>Maria Grazia</ForeName><Initials>MG</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Giorgio</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mirabella</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Luca</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>General Surgery and Abdominal Transplantation Unit, Hepatology, University of Milano-Bicocca andNiguarda-C&#xe0;Granda Hospital, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fagiuoli</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Organ Failure and Transplantation, Gastroenterology, Hepatology and Liver Transplantation, Ospedale Papa Giovanni XXIII, Bergamo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martini</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>General Surgery 2U and Liver Transplantation Center, University of Turin, AOU Citt&#xe0;della Salute e della Scienza di Torino, Turin, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iavarone</LastName><ForeName>Massimo</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology and Hepatology, CRC A M and A Migliavacca Center for Liver Disease, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Svegliati Baroni</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hepatobiliary and Abdominal Transplantation Surgery, Hepatology, Department of Experimental and Clinical Medicine, Polytechnic University of Marche, Ancona, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Angelico</LastName><ForeName>Mario</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical Sciences and Medical Sciences University of Rome-Tor Vergata, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ginanni Corradini</LastName><ForeName>Stefano</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery and Organ Transplantation, Sapienza University, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Volpes</LastName><ForeName>Riccardo</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Abdominal Surgery and Organ Transplantation Unit, Department for the Treatment and Study of Abdominal Diseases and Abdominal Transplantation, ISMETT, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mariani</LastName><ForeName>Luigi</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology and Trial Organization, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Regalia</LastName><ForeName>Enrico</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Flores</LastName><ForeName>Maria</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Droz Dit Busset</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sposito</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy; HPB Surgery, Hepatology and Liver Transplantation, Fondazione IRCCS Istituto Nazionale Tumori di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01387503</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2020 Jul;21(7):867-869. doi: 10.1016/S1470-2045(20)30333-8.</RefSource><PMID Version="1">32615100</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>Lancet Oncol. 2020 Aug;21(8):e373. doi: 10.1016/S1470-2045(20)30387-9.</RefSource><PMID Version="1">32758474</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006528" MajorTopicYN="N">Carcinoma, Hepatocellular</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008113" MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016031" MajorTopicYN="N">Liver Transplantation</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>4</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>7</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32615109</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(20)30224-2</ArticleId><ArticleId IdType="pii">S1470-2045(20)30224-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">30442501</PMID><DateCompleted><Year>2019</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1474-5488</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>12</Issue><PubDate><Year>2018</Year><Month>Dec</Month></PubDate></JournalIssue><Title>The Lancet. Oncology</Title><ISOAbbreviation>Lancet Oncol</ISOAbbreviation></Journal><ArticleTitle>Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial.</ArticleTitle><Pagination><StartPage>1617</StartPage><EndPage>1629</EndPage><MedlinePgn>1617-1629</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/S1470-2045(18)30578-3</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1470-2045(18)30578-3</ELocationID><Abstract><AbstractText Label="BACKGROUND">Immunotherapy with the chimeric anti-GD2 monoclonal antibody dinutuximab, combined with alternating granulocyte-macrophage colony-stimulating factor and intravenous interleukin-2 (IL-2), improves survival in patients with high-risk neuroblastoma. We aimed to assess event-free survival after treatment with ch14.18/CHO (dinutuximab beta) and subcutaneous IL-2, compared with dinutuximab beta alone in children and young people with high-risk neuroblastoma.</AbstractText><AbstractText Label="METHODS">We did an international, open-label, phase 3, randomised, controlled trial in patients with high-risk neuroblastoma at 104 institutions in 12 countries. Eligible patients were aged 1-20 years and had MYCN-amplified neuroblastoma with stages 2, 3, or 4S, or stage 4 neuroblastoma of any MYCN status, according to the International Neuroblastoma Staging System. Patients were eligible if they had been enrolled at diagnosis in the HR-NBL1/SIOPEN trial, had completed the multidrug induction regimen (cisplatin, carboplatin, cyclophosphamide, vincristine, and etoposide, with or without topotecan, vincristine, and doxorubicin), had achieved a disease response that fulfilled prespecified criteria, had received high-dose therapy (busulfan and melphalan or carboplatin, etoposide, and melphalan) and had received radiotherapy to the primary tumour site. In this component of the trial, patients were randomly assigned (1:1) to receive dinutuximab beta (20 mg/m<sup>2</sup> per day as an 8 h infusion for 5 consecutive days) or dinutuximab beta plus subcutaneous IL-2 (6&#x2008;&#xd7;&#x2008;10<sup>6</sup> IU/m<sup>2</sup> per day on days 1-5 and days 8-12 of each cycle) with the minimisation method to balance randomisation for national groups and type of high-dose therapy. All participants received oral isotretinoin (160 mg/m<sup>2</sup> per day for 2 weeks) before the first immunotherapy cycle and after each immunotherapy cycle, for six cycles. The primary endpoint was 3-year event-free survival, analysed by intention to treat. This trial was registered with ClinicalTrials.gov, number NCT01704716, and EudraCT, number 2006-001489-17, and recruitment to this randomisation is closed.</AbstractText><AbstractText Label="FINDINGS">Between Oct 22, 2009, and Aug 12, 2013, 422 patients were eligible to participate in the immunotherapy randomisation, of whom 406 (96%) were randomly assigned to a treatment group (n=200 to dinutuximab beta and n=206 to dinutuximab beta with subcutaneous IL-2). Median follow-up was 4&#xb7;7 years (IQR 3&#xb7;9-5&#xb7;3). Because of toxicity, 117 (62%) of 188 patients assigned to dinutuximab beta and subcutaneous IL-2 received their allocated treatment, by contrast with 160 (87%) of 183 patients who received dinutuximab beta alone (p&lt;0&#xb7;0001). 3-year event-free survival was 56% (95% CI 49-63) with dinutuximab beta (83 patients had an event) and 60% (53-66) with dinutuximab beta and subcutaneous IL-2 (80 patients had an event; p=0&#xb7;76). Four patients died of toxicity (n=2 in each group); one patient in each group while receiving immunotherapy (n=1 congestive heart failure and pulmonary hypertension due to capillary leak syndrome; n=1 infection-related acute respiratory distress syndrome), and one patient in each group after five cycles of immunotherapy (n=1 fungal infection and multi-organ failure; n=1 pulmonary fibrosis). The most common grade 3-4 adverse events were hypersensitivity reactions (19 [10%] of 185 patients in the dinutuximab beta group vs 39 [20%] of 191 patients in the dinutuximab plus subcutaneous IL-2 group), capillary leak (five [4%] of 119 vs 19 [15%] of 125), fever (25 [14%] of 185 vs 76 [40%] of 190), infection (47 [25%] of 185 vs 64 [33%] of 191), immunotherapy-related pain (19 [16%] of 122 vs 32 [26%] of 124), and impaired general condition (30 [16%] of 185 vs 78 [41%] of 192).</AbstractText><AbstractText Label="INTERPRETATION">There is no evidence that addition of subcutaneous IL-2 to immunotherapy with dinutuximab beta, given as an 8 h infusion, improved outcomes in patients with high-risk neuroblastoma who had responded to standard induction and consolidation treatment. Subcutaneous IL-2 with dinutuximab beta was associated with greater toxicity than dinutuximab beta alone. Dinutuximab beta and isotretinoin without subcutaneous IL-2 should thus be considered the standard of care until results of ongoing randomised trials using a modified schedule of dinutuximab beta and subcutaneous IL-2 are available.</AbstractText><AbstractText Label="FUNDING">European Commission 5th Frame Work Grant, St. Anna Kinderkrebsforschung, Fondation ARC pour la recherche sur le Cancer.</AbstractText><CopyrightInformation>Copyright &#xa9; 2018 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ladenstein</LastName><ForeName>Ruth</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>St Anna Children's Hospital, Vienna, Austria; Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria. Electronic address: ruth.ladenstein@ccri.at.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>P&#xf6;tschger</LastName><ForeName>Ulrike</ForeName><Initials>U</Initials><AffiliationInfo><Affiliation>Department for Studies and Statistics and Integrated Research, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valteau-Couanet</LastName><ForeName>Dominique</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Children and Adolescent Oncology Department, Gustave Roussy, Paris-Sud University, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luksch</LastName><ForeName>Roberto</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castel</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Unit, Hospital Universitario y Politecnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yaniv</LastName><ForeName>Isaac</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Pediatric Oncology Unit, Schneider Children's Medical Center of Israel, Sackler Faculty of Medicine Tel Aviv University, Petach Tikvah, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Laureys</LastName><ForeName>Genevieve</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology/Oncology and Stem Cell Transplantation University Hospital Ghent, Ghent, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brock</LastName><ForeName>Penelope</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Pediatric Oncology, Great Ormond Street Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michon</LastName><ForeName>Jean Marie</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Children, Adolescent and Young Adults Department, Institut Curie, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Owens</LastName><ForeName>Cormac</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Haemato-Oncology, Our Lady's Children's Hospital, Dublin, Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trahair</LastName><ForeName>Toby</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Kids Cancer Centre, Sydney Children's Hospital, Randwick, NSW, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chan</LastName><ForeName>Godfrey Chi Fung</ForeName><Initials>GCF</Initials><AffiliationInfo><Affiliation>Department of Paediatrics &amp; Adolescent Medicine, Queen Mary Hospital, Hong Kong.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruud</LastName><ForeName>Ellen</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Paediatric Medicine, Rikshospitalet, Oslo, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schroeder</LastName><ForeName>Henrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University Hospital of Aarhus, Aarhus, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beck Popovic</LastName><ForeName>Maja</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Paediatrics and Paediatric Surgery, Paediatric Haematology Oncology Unit, University Hospital Lausanne, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schreier</LastName><ForeName>Guenter</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Health and Bioresources, AIT Austrian Institute of Technology GmbH, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loibner</LastName><ForeName>Hans</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Apeiron Biologics AG, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ambros</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Biology, Vienna, Austria; Children's Cancer Research Institute, Vienna, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Holmes</LastName><ForeName>Keith</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Paediatric Surgery, St George's Hospital, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castellani</LastName><ForeName>Maria Rita</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Department di Ematologica e Onco-Ematologica, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaze</LastName><ForeName>Mark N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Department of Oncology, University College London Hospitals NHS Foundation Trust, National Institute for Health Research University College London Hospitals Biomedical Research Centre, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garaventa</LastName><ForeName>Alberto</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Oncology Unit, Istituto Giannina Gaslini, Genoa, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pearson</LastName><ForeName>Andrew D J</ForeName><Initials>ADJ</Initials><AffiliationInfo><Affiliation>Paediatric and Adolescent Drug Development Team, Oak Centre for Children and Young People, Institute of Cancer Research, Royal Marsden Hospital, Sutton, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lode</LastName><ForeName>Holger N</ForeName><Initials>HN</Initials><AffiliationInfo><Affiliation>Paediatric Haematology-Oncology Department, University Medicine Greifswald, Greifswald, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01704716</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>8177</GrantID><Acronym>CRUK_</Acronym><Agency>Cancer Research UK</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>11</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Oncol</MedlineTA><NlmUniqueID>100957246</NlmUniqueID><ISSNLinking>1470-2045</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000911">Antibodies, Monoclonal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007376">Interleukin-2</NameOfSubstance></Chemical><Chemical><RegistryNumber>7SQY4ZUD30</RegistryNumber><NameOfSubstance UI="C112746">dinutuximab</NameOfSubstance></Chemical><Chemical><RegistryNumber>EH28UP18IF</RegistryNumber><NameOfSubstance UI="D015474">Isotretinoin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Lancet Oncol. 2018 Dec;19(12):1549-1551. doi: 10.1016/S1470-2045(18)30627-2.</RefSource><PMID Version="1">30442498</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000367" MajorTopicYN="N">Age Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000911" MajorTopicYN="N">Antibodies, Monoclonal</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007376" MajorTopicYN="N">Interleukin-2</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015474" MajorTopicYN="N">Isotretinoin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009447" MajorTopicYN="N">Neuroblastoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077982" MajorTopicYN="N">Progression-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2018</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2018</Year><Month>7</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>7</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>11</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>6</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>11</Month><Day>17</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">30442501</ArticleId><ArticleId IdType="doi">10.1016/S1470-2045(18)30578-3</ArticleId><ArticleId IdType="pii">S1470-2045(18)30578-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37658072</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>04</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>23</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>Epidemiology and mortality in patients hospitalized for burns in Catalonia, Spain.</ArticleTitle><Pagination><StartPage>14364</StartPage><MedlinePgn>14364</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">14364</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-023-40198-2</ELocationID><Abstract><AbstractText>Burn injuries are one of the leading causes of morbidity worldwide. Although the overall incidence of burns and burn-related mortality is declining, these factors have not been analysed in our population for 25 years. The aim of this study has been to determine whether the epidemiological profile of patients hospitalized for burns has changed over the past 25 years. We performed a retrospective cohort study of patients hospitalised between 1 January 2011 and 31 December 2018 with a primary diagnosis of burns. The incidence of burns in our setting was 3.68/10<sup>5</sup> population. Most patients admitted for burns were men (61%), aged between 35 and 45 years (16.8%), followed by children aged between 0 and 4 years (12.4%). Scalding was the most prevalent mechanism of injury, and the region most frequently affected was the hands. The mean burned total body surface (TBSA) area was 8.3%, and the proportion of severely burned patients was 9.7%. Obesity was the most prevalent comorbidity (39.5%). The median length of stay was 1.8 days. The most frequent in-hospital complications were sepsis (16.6%), acute kidney injury (7.9%), and cardiovascular complications (5.9%). Risk factors for mortality were advanced age, high abbreviated burn severity index score, smoke inhalation, existing cardiovascular disease full-thickness burn, and high percentage of burned TBSA. Overall mortality was 4.3%. Multi-organ failure was the most frequent cause of death, with an incidence of 49.5%. The population has aged over the 25 years since the previous study, and the number of comorbidities has increased. The incidence and severity of burns, and the percentage of burned TBSA have all decreased, with scalding being the most prevalent mechanism of injury. The clinical presentation and evolution of burns differs between children and adults. Risk factors for mortality were advanced age, smoke inhalation, existing cardiovascular disease, full-thickness burn, and high percentage of burned TBSA.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Nature Limited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Abarca</LastName><ForeName>L</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Vall d'Hebron, 08035, Barcelona, Spain. labarcavilchez@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guilabert</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Alicante, Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>N</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Clinic, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Us&#xfa;a</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Anesthesia and Critical Care Department, Hospital Universitari Vall d'Hebron, 08035, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barret</LastName><ForeName>Juan P</ForeName><Initials>JP</Initials><AffiliationInfo><Affiliation>Plastic Surgery Department and Burn Centre, Hospital Universitari Vall d'Hebron, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Colomina</LastName><ForeName>Maria J</ForeName><Initials>MJ</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, Critical Care and Pain Clinic, Hospital Universitari de Bellvitge, Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>09</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012906">Smoke</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002318" MajorTopicYN="Y">Cardiovascular Diseases</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012906" MajorTopicYN="N">Smoke</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>PG honorary for lectures from Baxter Spain. MJC fees for lectures from Baxter Spain.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>2</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>4</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>2</Day><Hour>5</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>1</Day><Hour>23</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37658072</ArticleId><ArticleId IdType="pmc">PMC10474035</ArticleId><ArticleId IdType="doi">10.1038/s41598-023-40198-2</ArticleId><ArticleId IdType="pii">10.1038/s41598-023-40198-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>James SL, Lucchesi LR, Bisignano C, Castle CD, Dingels ZV, Fox JT, et al. Epidemiology of injuries from fire, heat and hot substances: Global, regional and national morbidity and mortality estimates from the Global Burden of Disease 2017 study. Inj. Prev. 2019 doi: 10.1136/injuryprev-2019-043299.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/injuryprev-2019-043299</ArticleId><ArticleId IdType="pmc">PMC7571358</ArticleId><ArticleId IdType="pubmed">31857422</ArticleId></ArticleIdList></Reference><Reference><Citation>Smolle C, Cambiaso-Daniel J, Forbes AA, Wurzer P, Hundeshagen G, Branski LK, et al. Recent trends in burn epidemiology worldwide: A systematic review. Burns. 2017 doi: 10.1016/j.burns.2016.08.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.08.013</ArticleId><ArticleId IdType="pmc">PMC5616188</ArticleId><ArticleId IdType="pubmed">27600982</ArticleId></ArticleIdList></Reference><Reference><Citation>Haikonen K, Lillsunde PM, Vuola J. Inpatient costs of fire-related injuries in Finland. Burns. 2014 doi: 10.1016/j.burns.2014.03.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.03.016</ArticleId><ArticleId IdType="pubmed">24742781</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger E, Kowal S, Pinar Bilir S, Han E, Foster K. Relationship between patient characteristics and number of procedures as well as length of stay for patients surviving severe burn injuries: Analysis of the american burn association national burn repository. J. Burn Care Res. 2020;41:1037&#x2013;1044. doi: 10.1093/jbcr/iraa040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/iraa040</ArticleId><ArticleId IdType="pmc">PMC7510847</ArticleId><ArticleId IdType="pubmed">32221517</ArticleId></ArticleIdList></Reference><Reference><Citation>Guilabert P, Us&#xfa;a G, Mart&#xed;n N, Abarca L, Barret JP, Colomina MJ. Fluid resuscitation management in patients with burns: Update. Br. J. Anaesth. 2016;117:284&#x2013;296. doi: 10.1093/bja/aew266.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/bja/aew266</ArticleId><ArticleId IdType="pubmed">27543523</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xc5;kerlund E, Huss FRM, Sj&#xf6;berg F. Burns in Sweden: An analysis of 24 538 cases during the period 1987&#x2013;2004. Burns. 2007;33:31&#x2013;36. doi: 10.1016/j.burns.2006.10.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2006.10.002</ArticleId><ArticleId IdType="pubmed">17223486</ArticleId></ArticleIdList></Reference><Reference><Citation>Dokter J, Vloemans AF, Beerthuizen GIJM, van der Vlies CH, Boxma H, Breederveld R, et al. Epidemiology and trends in severe burns in the Netherlands. Burns. 2014;40:1406&#x2013;1414. doi: 10.1016/j.burns.2014.03.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.03.003</ArticleId><ArticleId IdType="pubmed">24703338</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederer IA, Hacker S, Sternat N, Waldmann A, Salameh O, Radtke C, et al. Gender has no influence on mortality after burn injuries: A 20-year single center study with 839 patients. Burns. 2019;45:205&#x2013;212. doi: 10.1016/j.burns.2018.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.08.012</ArticleId><ArticleId IdType="pubmed">30170774</ArticleId></ArticleIdList></Reference><Reference><Citation>M&#xfc;ller M, Moser EM, Pfortmueller CA, Olariu R, Lehmann B, Exadaktylos AK. Aetiology of adult burns treated from 2000 to 2012 in a Swiss University Hospital. Burns. 2016;42:919&#x2013;925. doi: 10.1016/j.burns.2016.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.03.005</ArticleId><ArticleId IdType="pubmed">27061890</ArticleId></ArticleIdList></Reference><Reference><Citation>Onarheim H, Jensen SA, Rosenberg BE, Guttormsen AB. The epidemiology of patients with burn injuries admitted to Norwegian hospitals in 2007. Burns. 2009 doi: 10.1016/j.burns.2009.06.191.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2009.06.191</ArticleId><ArticleId IdType="pubmed">19748742</ArticleId></ArticleIdList></Reference><Reference><Citation>Pieptu V, Moscalu R, Mihai A, Moscalu M, Pieptu D, Azoic&#x103;i D. Epidemiology of hospitalized burns in Romania: A 10-year study on 92,333 patients. Burns. 2021 doi: 10.1016/j.burns.2021.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2021.05.020</ArticleId><ArticleId IdType="pubmed">34670711</ArticleId></ArticleIdList></Reference><Reference><Citation>Schiefer JL, Perbix W, Grigutsch D, Zinser M, Demir E, Fuchs PC, et al. Etiology, incidence and gender-specific patterns of severe burns in a German Burn Center&#x2014;Insights of 25 years. Burns. 2016;42:687&#x2013;696. doi: 10.1016/j.burns.2015.10.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2015.10.031</ArticleId><ArticleId IdType="pubmed">26708237</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanttula K, Haikonen K, Vuola J. Hospitalized burns in Finland: 36 305 cases from 1980&#x2013;2010. Burns. 2018;44:651&#x2013;657. doi: 10.1016/j.burns.2017.09.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.09.001</ArticleId><ArticleId IdType="pubmed">29029854</ArticleId></ArticleIdList></Reference><Reference><Citation>Theodorou P, Xu W, Weinand C, Perbix W, Maegele M, Lefering R, et al. Incidence and treatment of burns: A twenty-year experience from a single center in Germany. Burns. 2013;39:49&#x2013;54. doi: 10.1016/j.burns.2012.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.05.003</ArticleId><ArticleId IdType="pubmed">22673118</ArticleId></ArticleIdList></Reference><Reference><Citation>van Yperen DT, van Lieshout EMM, Verhofstad MHJ, van der Vlies CH. Epidemiology of burn patients admitted in the Netherlands: A nationwide registry study investigating incidence rates and hospital admission from 2014 to 2018. Eur. J. Trauma Emerg. Surg. 2021 doi: 10.1007/s00068-021-01777-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-021-01777-y</ArticleId><ArticleId IdType="pmc">PMC9192419</ArticleId><ArticleId IdType="pubmed">34463772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zayakova Y, Vajarov I, Stanev A, Nenkova N, Hristov H. Epidemiological analysis of burn patients in East Bulgaria. Burns. 2014;40:683&#x2013;688. doi: 10.1016/j.burns.2013.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2013.08.016</ArticleId><ArticleId IdType="pubmed">24035580</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Pinto R, Kraft R, Nathens AB, Finnerty CC, Gamelli RL, et al. Morbidity and survival probability in burn patients in modern burn care. Crit. Care Med. 2015;43:808&#x2013;815. doi: 10.1097/CCM.0000000000000790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000790</ArticleId><ArticleId IdType="pmc">PMC4359665</ArticleId><ArticleId IdType="pubmed">25559438</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlin L, Stanford L, Moore D, Cairns B, Charles A. The measured effect magnitude of co-morbidities on burn injury mortality. Burns. 2016;42:1433&#x2013;1438. doi: 10.1016/j.burns.2016.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.03.007</ArticleId><ArticleId IdType="pmc">PMC5278667</ArticleId><ArticleId IdType="pubmed">27593340</ArticleId></ArticleIdList></Reference><Reference><Citation>Low ZK, Ng WY, Fook-Chong S, Tan BK, Chong SJ, Hwee J, et al. Comparison of clinical outcomes in diabetic and non-diabetic burns patients in a national burns referral centre in southeast Asia: A 3-year retrospective review. Burns. 2017;43:436&#x2013;444. doi: 10.1016/j.burns.2016.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.06.004</ArticleId><ArticleId IdType="pubmed">28159150</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayampanathan AA. Systematic review and meta-analysis of complications and outcomes of obese patients with burns. Burns. 2016;42:1634&#x2013;1643. doi: 10.1016/j.burns.2016.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.05.008</ArticleId><ArticleId IdType="pubmed">27268011</ArticleId></ArticleIdList></Reference><Reference><Citation>Barret JP, Gomez P, Solano I, Gonzalez-Dorrego M, Crisol FJ. Epidemiology and mortality of adult burns in Catalonia 1999. Burns. 1999;25:325&#x2013;329. doi: 10.1016/S0305-4179(98)00190-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(98)00190-9</ArticleId><ArticleId IdType="pubmed">10431980</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, Gamelli RL, Palmieri TL, Horton JW, et al. American burn association consensus conference to define sepsis and infection in burns. J. Burn Care Res. 2007;28:776&#x2013;790. doi: 10.1097/BCR.0b013e3181599bc9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Putra ON, Saputro ID, Diana D. Rifle criteria for acute kidney injury in burn patients: prevalence and risk factors. Ann. Burns Fire Disasters. 2021;34:252.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534303</ArticleId><ArticleId IdType="pubmed">34744541</ArticleId></ArticleIdList></Reference><Reference><Citation>Cartotto R, Li Z, Hanna S, Spano S, Wood D, Chung K, et al. The Acute Respiratory Distress Syndrome (ARDS) in mechanically ventilated burn patients: An analysis of risk factors, clinical features, and outcomes using the Berlin ARDS definition. Burns. 2016;42:1423&#x2013;1432. doi: 10.1016/j.burns.2016.01.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.01.031</ArticleId><ArticleId IdType="pubmed">27520712</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez JLA, Bastida JL, Mart&#xed;nez MM, Moreno JMM, Chamorro JJ. Socio-economic cost and health-related quality of life of burn victims in Spain. Burns. 2008;34:975&#x2013;981. doi: 10.1016/j.burns.2007.12.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2007.12.011</ArticleId><ArticleId IdType="pubmed">18472221</ArticleId></ArticleIdList></Reference><Reference><Citation>Sousa D, Ceniceros A, Galeiras R, P&#xe9;rtega-D&#xed;az S, Guti&#xe9;rrez-Urb&#xf3;n JM, Rodr&#xed;guez-Mayo M, et al. Microbiology in burns patients with blood stream infections: Trends over time and during the course of hospitalization. Infect. Dis. 2018;50:289&#x2013;296. doi: 10.1080/23744235.2017.1397738.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/23744235.2017.1397738</ArticleId><ArticleId IdType="pubmed">29105600</ArticleId></ArticleIdList></Reference><Reference><Citation>Brusselaers N, Monstrey S, Vogelaers D, Hoste E, Blot S. Severe burn injury in Europe: A systematic review of the incidence, etiology, morbidity, and mortality. Crit. Care. 2010 doi: 10.1186/cc9300.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9300</ArticleId><ArticleId IdType="pmc">PMC3219295</ArticleId><ArticleId IdType="pubmed">20958968</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke J, Wood F, Semmens J, Edgar DW, Spilsbury K, Hendrie D, et al. A study of burn hospitalizations for children younger than 5 years of age: 1983&#x2013;2008. Pediatrics. 2011 doi: 10.1542/peds.2010-3136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2010-3136</ArticleId><ArticleId IdType="pubmed">21382945</ArticleId></ArticleIdList></Reference><Reference><Citation>Harats M, Peleg K, Givon A, Kornhaber R, Goder M, Jaeger M, et al. Burns in Israel, comparative study: Demographic, etiologic and clinical trends 1997&#x2013;2003 versus 2004&#x2013;2010. Burns. 2016;42:500&#x2013;507. doi: 10.1016/j.burns.2015.05.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2015.05.023</ArticleId><ArticleId IdType="pubmed">26410362</ArticleId></ArticleIdList></Reference><Reference><Citation>Hop MJ, Wijnen BFM, Nieuwenhuis MK, Dokter J, Middelkoop E, Polinder S, et al. Economic burden of burn injuries in the Netherlands: A 3 months follow-up study. Injury. 2016;47:203&#x2013;210. doi: 10.1016/j.injury.2015.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2015.09.009</ArticleId><ArticleId IdType="pubmed">26454627</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios Garc&#xed;a P, Pacheco Compa&#xf1;a FJ, Rodr&#xed;guez P&#xe9;rez E, Bugallo Sanz JI, Fern&#xe1;ndez-Quinto A, Avellaneda-Oviedo EM. Trends in burn injuries in Galicia (Spain): An epidemiological study. Int. Wound J. 2020;17:1717&#x2013;1724. doi: 10.1111/iwj.13456.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iwj.13456</ArticleId><ArticleId IdType="pmc">PMC7949175</ArticleId><ArticleId IdType="pubmed">32662941</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JM, Rea S, Boyd JH, Randall SM, Wood FM. Mortality after burn injury in children: A 33-year population-based study. Pediatrics. 2015;135:e903&#x2013;e910. doi: 10.1542/peds.2014-3140.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2014-3140</ArticleId><ArticleId IdType="pubmed">25802351</ArticleId></ArticleIdList></Reference><Reference><Citation>Zavlin D, Chegireddy V, Boukovalas S, Nia AM, Branski LK, Friedman JD, et al. Multi-institutional analysis of independent predictors for burn mortality in the United States. Burns Trauma. 2018 doi: 10.1186/s41038-018-0127-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-018-0127-y</ArticleId><ArticleId IdType="pmc">PMC6103989</ArticleId><ArticleId IdType="pubmed">30151396</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Wang S, Tan J, Zhou J, Wu J, Luo G. Epidemiology of pediatric burns in southwest China from 2011 to 2015. Burns. 2017;43:1306&#x2013;1317. doi: 10.1016/j.burns.2017.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.03.004</ArticleId><ArticleId IdType="pubmed">28372828</ArticleId></ArticleIdList></Reference><Reference><Citation>Armstrong M, Wheeler KK, Shi J, Thakkar RK, Fabia RB, Groner JI, et al. Epidemiology and trend of US pediatric burn hospitalizations, 2003&#x2013;2016. Burns. 2021;47:551&#x2013;559. doi: 10.1016/j.burns.2020.05.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2020.05.021</ArticleId><ArticleId IdType="pubmed">33781634</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson EL, Maguire S, Holl&#xe9;n LI, Nuttall D, Rea D, Kemp AM. Agents, mechanisms and clinical features of non-scald burns in children: A prospective UK study. Burns. 2017;43:1218&#x2013;1226. doi: 10.1016/j.burns.2017.01.036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.036</ArticleId><ArticleId IdType="pubmed">28645715</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanyaolu L, Javed MU, Eales M, Hemington-Gorse S. A 10 year epidemiological study of paediatric burns at the Welsh Centre for burns and plastic surgery. Burns. 2017;43:632&#x2013;637. doi: 10.1016/j.burns.2016.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.10.004</ArticleId><ArticleId IdType="pubmed">27816410</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S, Li D, Shen C, Chai J, Zhu H, Lin Y, et al. Epidemiology of burns in pediatric patients of Beijing City. BMC Pediatr. 2016 doi: 10.1186/s12887-016-0686-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12887-016-0686-7</ArticleId><ArticleId IdType="pmc">PMC5070381</ArticleId><ArticleId IdType="pubmed">27756257</ArticleId></ArticleIdList></Reference><Reference><Citation>Kendrick D, Young B, Mason-Jones AJ, Ilyas N, Achana FA, Cooper NJ, et al. Home safety education and provision of safety equipment for injury prevention. Cochrane Database of Syst. Rev. 2012 doi: 10.1002/14651858.CD005014.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005014.pub3</ArticleId><ArticleId IdType="pmc">PMC9758703</ArticleId><ArticleId IdType="pubmed">22972081</ArticleId></ArticleIdList></Reference><Reference><Citation>Prokopenko M, Reed AJM, Chicco M, Issa F. Preventable burns from domestic tap water. Eur. Burn J. 2022;3:362&#x2013;369. doi: 10.3390/ebj3020031.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ebj3020031</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos JV, Viana J, Oliveira A, Ramalho A, Sousa-Teixeira J, Duke J, et al. Hospitalisations with burns in children younger than five years in Portugal, 2011&#x2013;2015. Burns. 2019;45:1223&#x2013;1230. doi: 10.1016/j.burns.2019.01.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.01.003</ArticleId><ArticleId IdType="pubmed">30686698</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen SH, Chen YC, Chen TJ, Ma H. Epidemiology of burns in Taiwan: A nationwide report including inpatients and outpatients. Burns. 2014;40:1397&#x2013;1405. doi: 10.1016/j.burns.2014.01.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2014.01.014</ArticleId><ArticleId IdType="pubmed">24518304</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng W, Wang S, Shen C, Zhao D, Li D, Shang Y. Epidemiology of hospitalized burn patients in China: A systematic review. Burns Open. 2018;2:8&#x2013;16. doi: 10.1016/j.burnso.2017.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burnso.2017.10.003</ArticleId></ArticleIdList></Reference><Reference><Citation>Fan X, Ma B, Zeng D, Fang X, Li H, Xiao S, et al. Burns in a major burns center in East China from 2005 to 2014: Incidence and outcome. Burns. 2017;43:1586&#x2013;1595. doi: 10.1016/j.burns.2017.01.033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.033</ArticleId><ArticleId IdType="pubmed">28855061</ArticleId></ArticleIdList></Reference><Reference><Citation>Wasiak J, Spinks A, Ashby K, Clapperton A, Cleland H, Gabbe B. The epidemiology of burn injuries in an Australian setting, 2000&#x2013;2006. Burns. 2009;35:1124&#x2013;1132. doi: 10.1016/j.burns.2009.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2009.04.016</ArticleId><ArticleId IdType="pubmed">19482430</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L, He X, Xian J, Liao J, Chen X, Luo Y, et al. Development of a framework for managing severe burns through a 17-year retrospective analysis of burn epidemiology and outcomes. Sci. Rep. 2021 doi: 10.1038/s41598-021-88507-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-88507-x</ArticleId><ArticleId IdType="pmc">PMC8087787</ArticleId><ArticleId IdType="pubmed">33931691</ArticleId></ArticleIdList></Reference><Reference><Citation>Cleland H, Fernando DT, Gabbe BJ. Trends in Victorian burn injuries 2008&#x2013;2017. Burns. 2021 doi: 10.1016/j.burns.2021.06.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2021.06.007</ArticleId><ArticleId IdType="pubmed">34304930</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogura A, Tsurumi A, Que YA, Almpani M, Zheng H, Tompkins RG, et al. Associations between clinical characteristics and the development of multiple organ failure after severe burns in adult patients. Burns. 2019;45:1775&#x2013;1782. doi: 10.1016/j.burns.2019.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.02.014</ArticleId><ArticleId IdType="pubmed">31690472</ArticleId></ArticleIdList></Reference><Reference><Citation>Brink C, Isaacs Q, Scriba MF, Nathire MEH, Rode H, Martinez R. Infant burns: A single institution retrospective review. Burns. 2019;45:1518&#x2013;1527. doi: 10.1016/j.burns.2018.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.11.005</ArticleId><ArticleId IdType="pubmed">30638666</ArticleId></ArticleIdList></Reference><Reference><Citation>Knowlin L, Reid T, Williams F, Cairns B, Charles A. Burn mortality in patients with preexisting cardiovascular disease. Burns. 2017;43:949&#x2013;955. doi: 10.1016/j.burns.2017.01.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.026</ArticleId><ArticleId IdType="pmc">PMC5912170</ArticleId><ArticleId IdType="pubmed">28189352</ArticleId></ArticleIdList></Reference><Reference><Citation>Observatorio Espa&#xf1;ol de las Drogas y las Adicciones. Informe 2021. Alcohol, tabaco y drogas ilegales en Espa&#xf1;a. Madrid: Ministerio de Sanidad. Delegaci&#xf3;n del Gobierno para el Plan Nacional sobre Drogas. 243 p. (2021).</Citation></Reference><Reference><Citation>Eiroa-Orosa FJ, Giannoni-Pastor A, Fidel-Kinori SG, Arg&#xfc;ello JM. Substance use and misuse in burn patients: Testing the classical hypotheses of the interaction between post-traumatic symptomatology and substance use. J. Addict. Dis. 2016;35:194&#x2013;204. doi: 10.1080/10550887.2015.1127717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/10550887.2015.1127717</ArticleId><ArticleId IdType="pubmed">26670348</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xe9;rez-Rodrigo C, Herv&#xe1;s B&#xe1;rbara G, Gianzo Citores M, Aranceta-Bartrina J. Prevalence of obesity and associated cardiovascular risk factors in the Spanish population: The ENPE study. Revista Espa&#xf1;ola de Cardiolog&#xed;a (English Edition) 2021 doi: 10.1016/j.rec.2020.12.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rec.2020.12.020</ArticleId><ArticleId IdType="pubmed">33773941</ArticleId></ArticleIdList></Reference><Reference><Citation>Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of Obesity and Severe Obesity Among Adults: United States, 2017-2018 Key findings Data from the National Health and Nutrition Examination Survey. 2017.</Citation></Reference><Reference><Citation>Mild Obesity Is Protective After Severe Burn Injury n.d.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3963145</ArticleId><ArticleId IdType="pubmed">23877367</ArticleId></ArticleIdList></Reference><Reference><Citation>Clark A, Neyra JA, Madni T, Imran J, Phelan H, Arnoldo B, et al. Acute kidney injury after burn. Burns. 2017;43:898&#x2013;908. doi: 10.1016/j.burns.2017.01.023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2017.01.023</ArticleId><ArticleId IdType="pubmed">28412129</ArticleId></ArticleIdList></Reference><Reference><Citation>Demsey D, Mordhorst A, Griesdale DEG, Papp A. Improved outcomes of renal injury following burn trauma. Burns. 2019;45:1024&#x2013;1030. doi: 10.1016/j.burns.2019.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.04.001</ArticleId><ArticleId IdType="pubmed">31054958</ArticleId></ArticleIdList></Reference><Reference><Citation>Folkestad T, Brurberg KG, Nordhuus KM, Tveiten CK, Guttormsen AB, Os I, et al. Acute kidney injury in burn patients admitted to the intensive care unit: A systematic review and meta-analysis. Crit. Care. 2020 doi: 10.1186/s13054-019-2710-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-019-2710-4</ArticleId><ArticleId IdType="pmc">PMC6941386</ArticleId><ArticleId IdType="pubmed">31898523</ArticleId></ArticleIdList></Reference><Reference><Citation>Witkowski W, Kawecki M, Surowiecka-Pastewka A, Klimm W, Szamotulska K, Niemczyk S. Early and late acute kidney injury in severely burned patients. Med. Sci. Monit. 2016;22:3755&#x2013;3763. doi: 10.12659/MSM.895875.</Citation><ArticleIdList><ArticleId IdType="doi">10.12659/MSM.895875</ArticleId><ArticleId IdType="pmc">PMC5070618</ArticleId><ArticleId IdType="pubmed">27746455</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu G, Xiao Y, Wang C, Hong X, Sun Y, Ma B, et al. Risk factors for acute kidney injury in patients with burn injury: A meta-analysis and systematic review. J. Burn Care Res. 2017;38:271&#x2013;282. doi: 10.1097/BCR.0000000000000438.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0000000000000438</ArticleId><ArticleId IdType="pubmed">27617407</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuo G, Yang SY, Chuang SS, Fan PC, Chang CH, Hsiao YC, et al. Using acute kidney injury severity and scoring systems to predict outcome in patients with burn injury. J. Formos. Med. Assoc. 2016;115:1046&#x2013;1052. doi: 10.1016/j.jfma.2016.10.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2016.10.012</ArticleId><ArticleId IdType="pubmed">27923537</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan Chor Lip H, Tan JH, Thomas M, Imran FH, Azmah Tuan Mat TN. Survival analysis and mortality predictors of hospitalized severe burn victims in a Malaysian burns intensive care unit. Burns Trauma. 2019 doi: 10.1186/s41038-018-0140-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-018-0140-1</ArticleId><ArticleId IdType="pmc">PMC6348617</ArticleId><ArticleId IdType="pubmed">30705904</ArticleId></ArticleIdList></Reference><Reference><Citation>Duke JM, Randall SM, Wood FM, Boyd JH, Fear MW. Burns and long-term infectious disease morbidity: A population-based study. Burns. 2017;43:273&#x2013;281. doi: 10.1016/j.burns.2016.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.10.020</ArticleId><ArticleId IdType="pubmed">28041752</ArticleId></ArticleIdList></Reference><Reference><Citation>Raz-Pasteur A, Hussein K, Finkelstein R, Ullmann Y, Egozi D. Blood stream infections (BSI) in severe burn patients-early and late BSI: A 9-year study. Burns. 2013 doi: 10.1016/j.burns.2012.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2012.09.015</ArticleId><ArticleId IdType="pubmed">23159703</ArticleId></ArticleIdList></Reference><Reference><Citation>Costescu Strachinaru DI, Gallez JL, Fran&#xe7;ois PM, Baekelandt D, Paridaens MS, Pirnay JP, et al. Epidemiology and etiology of blood stream infections in a Belgian burn wound center. Acta Clin. Belg. Int. J. Clin. Lab. Med. 2021 doi: 10.1080/17843286.2021.1872309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17843286.2021.1872309</ArticleId><ArticleId IdType="pubmed">33432871</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand&#xe3;o C. The role of comorbidities on outcome prediction in acute burn patients place des comorbidit&#xe9;s dans les crit&#xe8;res pronostiques des patients br&#xfb;l&#xe9;s. Ann. Burns Fire Disasters. 2021;34:323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8717902</ArticleId><ArticleId IdType="pubmed">35035325</ArticleId></ArticleIdList></Reference><Reference><Citation>Forster NA, Zingg M, Haile SR, K&#xfc;nzi W, Giovanoli P, Guggenheim M. 30 years later&#x2014;Does the ABSI need revision? Burns. 2011;37:958&#x2013;963. doi: 10.1016/j.burns.2011.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2011.03.009</ArticleId><ArticleId IdType="pubmed">21493008</ArticleId></ArticleIdList></Reference><Reference><Citation>Palomar M, &#xc1;lvarez-Lerma F, Riera A, D&#xed;az MT, Torres F, Agra Y, et al. Impact of a national multimodal intervention to prevent catheter-related bloodstream infection in the ICU: The Spanish experience. Crit. Care Med. 2013;41:2364&#x2013;2372. doi: 10.1097/CCM.0b013e3182923622.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3182923622</ArticleId><ArticleId IdType="pubmed">23939352</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SF, Bessey PQ, Schurr MJ, Browning SM, Jeng JC, Caruso DM, et al. National burn repository 2005: A ten-year review. J. Burn Care Res. 2006;27:411&#x2013;436. doi: 10.1097/01.BCR.0000226260.17523.22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BCR.0000226260.17523.22</ArticleId><ArticleId IdType="pubmed">16819343</ArticleId></ArticleIdList></Reference><Reference><Citation>Kallinen O, Maisniemi K, B&#xf6;hling T, Tukiainen E, Koljonen V. Multiple organ failure as a cause of death in patients with severe burns. J. Burn Care Res. 2012;33:206&#x2013;211. doi: 10.1097/BCR.0b013e3182331e73.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3182331e73</ArticleId><ArticleId IdType="pubmed">21979843</ArticleId></ArticleIdList></Reference><Reference><Citation>Nickel KJ, Omeis T, Papp A. Demographics and clinical outcomes of adult burn patients admitted to a single provincial burn centre: A 40-year review. Burns. 2020;46:1958&#x2013;1967. doi: 10.1016/j.burns.2020.06.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2020.06.020</ArticleId><ArticleId IdType="pubmed">32660831</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang T, Nie C, Zhang H, Zeng X, Yu H, Wei Z, et al. Epidemiological characteristics and factors affecting length of hospital stay for children and adults with burns in Zunyi, China: A retrospective study. PeerJ. 2018 doi: 10.7717/peerj.5740.</Citation><ArticleIdList><ArticleId IdType="doi">10.7717/peerj.5740</ArticleId><ArticleId IdType="pmc">PMC6173946</ArticleId><ArticleId IdType="pubmed">30310756</ArticleId></ArticleIdList></Reference><Reference><Citation>Blom L, Klingberg A, Laflamme L, Wallis L, Hasselberg M. Gender differences in burns: A study from emergency centres in the Western Cape, South Africa. Burns. 2016;42:1600&#x2013;1608. doi: 10.1016/j.burns.2016.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2016.05.003</ArticleId><ArticleId IdType="pubmed">27262931</ArticleId></ArticleIdList></Reference><Reference><Citation>Toppi J, Cleland H, Gabbe B. Severe burns in Australian and New Zealand adults: Epidemiology and burn centre care. Burns. 2019;45:1456&#x2013;1461. doi: 10.1016/j.burns.2019.04.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2019.04.006</ArticleId><ArticleId IdType="pubmed">31053412</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta K, Arega H, Smith NL, Li K, Gause E, Lee J, et al. Gender-based disparities in burn injuries, care and outcomes: A World Health Organization (WHO) Global Burn Registry cohort study. Am. J. Surg. 2021 doi: 10.1016/j.amjsurg.2021.07.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjsurg.2021.07.041</ArticleId><ArticleId IdType="pmc">PMC8688305</ArticleId><ArticleId IdType="pubmed">34330521</ArticleId></ArticleIdList></Reference><Reference><Citation>Obed D, Schroeter A, Gruber L, Bucher F, Salim M, Bingoel AS, et al. Epidemiology and outcome analysis of 1359 intensive care burn patients: A 13-year retrospective study in a major burn center in Germany. Burns. 2022 doi: 10.1016/j.burns.2022.08.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2022.08.022</ArticleId><ArticleId IdType="pubmed">36195487</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurczyk K, Chrisco LP, di Corpo M, Nizamani R, Sljivic S, Calvert CT, et al. Work-Related burn injuries in a tertiary care burn center, 2013 to 2018. J. Burn Care Res. 2020;41:1009&#x2013;1014. doi: 10.1093/jbcr/iraa105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jbcr/iraa105</ArticleId><ArticleId IdType="pubmed">32598473</ArticleId></ArticleIdList></Reference><Reference><Citation>McInnes JA, Cleland H, Tracy LM, Darton A, Wood FM, Perrett T, et al. Epidemiology of work-related burn injuries presenting to burn centres in Australia and New Zealand. Burns. 2019;45:484&#x2013;493. doi: 10.1016/j.burns.2018.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.09.011</ArticleId><ArticleId IdType="pubmed">30274814</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34970680</PMID><DateCompleted><Year>2022</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1098-4275</ISSN><JournalIssue CitedMedium="Internet"><Volume>149</Volume><Issue>1 Suppl 1</Issue><PubDate><Year>2022</Year><Month>Jan</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatrics</Title><ISOAbbreviation>Pediatrics</ISOAbbreviation></Journal><ArticleTitle>Gastrointestinal Dysfunction Criteria in Critically Ill Children: The PODIUM Consensus Conference.</ArticleTitle><Pagination><StartPage>S53</StartPage><EndPage>S58</EndPage><MedlinePgn>S53-S58</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1542/peds.2021-052888H</ELocationID><Abstract><AbstractText Label="CONTEXT">Prior criteria to define pediatric multiple organ dysfunction syndrome (MODS) did not include gastrointestinal dysfunction.</AbstractText><AbstractText Label="OBJECTIVES">Our objective was to evaluate current evidence and to develop consensus criteria for gastrointestinal dysfunction in critically ill children.</AbstractText><AbstractText Label="DATA SOURCES">Electronic searches of PubMed and EMBASE were conducted from January 1992 to January 2020, using medical subject heading terms and text words to define gastrointestinal dysfunction, pediatric critical illness, and outcomes.</AbstractText><AbstractText Label="STUDY SELECTION">Studies were included if they evaluated critically ill children with gastrointestinal dysfunction, performance characteristics of assessment/scoring tools to screen for gastrointestinal dysfunction, and assessed outcomes related to mortality, functional status, organ-specific outcomes, or other patient-centered outcomes. Studies of adults or premature infants, animal studies, reviews/commentaries, case series with sample size &#x2264;10, and non-English language studies with inability to determine eligibility criteria were excluded.</AbstractText><AbstractText Label="DATA EXTRACTION">Data were abstracted from each eligible study into a standard data extraction form along with risk of bias assessment by a task force member.</AbstractText><AbstractText Label="RESULTS">The systematic review supports the following criteria for severe gastrointestinal dysfunction: 1a) bowel perforation, 1b) pneumatosis intestinalis, or 1c) bowel ischemia, present on plain abdominal radiograph, computed tomography (CT) scan, magnetic resonance imaging (MRI), or gross surgical inspection, or 2) rectal sloughing of gut mucosa.</AbstractText><AbstractText Label="LIMITATIONS">The validity of the consensus criteria for gastrointestinal dysfunction are limited by the quantity and quality of current evidence.</AbstractText><AbstractText Label="CONCLUSIONS">Understanding the role of gastrointestinal dysfunction in the pathophysiology and outcomes of MODS is important in pediatric critical illness.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the American Academy of Pediatrics.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri V</ForeName><Initials>KV</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and the Steele Children's Research Center, University of Arizona College of Medicine, Tucson, Arizona.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Irving</LastName><ForeName>Sharon Y</ForeName><Initials>SY</Initials><AffiliationInfo><Affiliation>Department of Family and Community Health, University of Pennsylvania School of Nursing, Philadelphia, Pennsylvania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prince</LastName><ForeName>Jose M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Zucker School of Medicine at Hofstra/Northwell, Hempstead, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pathan</LastName><ForeName>Nazima</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Paediatrics, University of Cambridge and Kings College, Cambridge, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Ann-Marie</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Nell Hodgson Woodruff School of Nursing, Emory University, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Children's Healthcare of Atlanta, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Pediatric Organ Dysfunction Information Update Mandate (PODIUM) Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>K23 DK106462</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PG/09/084/27993</GrantID><Acronym>BHF_</Acronym><Agency>British Heart Foundation</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatrics</MedlineTA><NlmUniqueID>0376422</NlmUniqueID><ISSNLinking>0031-4005</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D041981" MajorTopicYN="N">Gastrointestinal Tract</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>FINANCIAL DISCLOSURES: The authors have indicated they have no financial relationships relevant to this article to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Bembea</LastName><ForeName>Melania M</ForeName><Initials>MM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agus</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akcan-Arikan</LastName><ForeName>Ayse</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Alexander</LastName><ForeName>Peta</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Basu</LastName><ForeName>Rajit</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohn</LastName><ForeName>Desmond</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brand&#xe3;o</LastName><ForeName>Leonardo R</ForeName><Initials>LR</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carcillo</LastName><ForeName>Joseph A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Checchia</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheifetz</LastName><ForeName>Ira M</ForeName><Initials>IM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cornell</LastName><ForeName>Timothy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Eckerle</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Erickson</LastName><ForeName>Simon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Farris</LastName><ForeName>Reid W D</ForeName><Initials>RWD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Faustino</LastName><ForeName>E Vincent S</ForeName><Initials>EVS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie C</ForeName><Initials>JC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fuhrman</LastName><ForeName>Dana Y</ForeName><Initials>DY</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giuliano</LastName><ForeName>John S</ForeName><Initials>JS</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Guilliams</LastName><ForeName>Kristin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaies</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorga</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson</LastName><ForeName>Sheila J</ForeName><Initials>SJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hassinger</LastName><ForeName>Amanda B</ForeName><Initials>AB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jeffries</LastName><ForeName>Howard</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jouvet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kannan</LastName><ForeName>Sujatha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karam</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khemani</LastName><ForeName>Robinder G</ForeName><Initials>RG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kissoon</LastName><ForeName>Niranjan</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Laussen</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leclerc</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Jan Hau</ForeName><Initials>JH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>Stephane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lobner</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKiernan</LastName><ForeName>Patrick J</ForeName><Initials>PJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monagle</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Odetola</LastName><ForeName>Folafoluwa</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Parker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pierce</LastName><ForeName>Richard W</ForeName><Initials>RW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pineda</LastName><ForeName>Jose</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robinson</LastName><ForeName>Karen A</ForeName><Initials>KA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rowan</LastName><ForeName>Courtney M</ForeName><Initials>CM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryerson</LastName><ForeName>Lindsay M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schlapbach</LastName><ForeName>Luregn J</ForeName><Initials>LJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Selewski</LastName><ForeName>David T</ForeName><Initials>DT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shekerdemian</LastName><ForeName>Lara S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Simon</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Lincoln S</ForeName><Initials>LS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squires</LastName><ForeName>James E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Squires</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sutherland</LastName><ForeName>Scott M</ForeName><Initials>SM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellette</LastName><ForeName>Yves</ForeName><Initials>Y</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spaeder</LastName><ForeName>Michael C</ForeName><Initials>MC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Srinivasan</LastName><ForeName>Vijay</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tasker</LastName><ForeName>Robert C</ForeName><Initials>RC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thiagarajan</LastName><ForeName>Ravi</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Neal</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tissieres</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Traube</LastName><ForeName>Chani</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wainwright</LastName><ForeName>Mark S</ForeName><Initials>MS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Shan L</ForeName><Initials>SL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Watson</LastName><ForeName>R Scott</ForeName><Initials>RS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whitney</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willson</LastName><ForeName>Doug</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wynn</LastName><ForeName>James L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Yehya</LastName><ForeName>Nadir</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jerry J</ForeName><Initials>JJ</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>9</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>9</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>1</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34970680</ArticleId><ArticleId IdType="mid">NIHMS1843068</ArticleId><ArticleId IdType="pmc">PMC9662164</ArticleId><ArticleId IdType="doi">10.1542/peds.2021-052888H</ArticleId><ArticleId IdType="pii">184292</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Klingensmith NJ, Coopersmith CM. The Gut as the Motor of Multiple Organ Dysfunction in Critical Illness. Crit Care Clin. 2016;32(2):203&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4808565</ArticleId><ArticleId IdType="pubmed">27016162</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner JR. Intestinal mucosal barrier function in health and disease. NatRevImmunol. 2009;9(11):799&#x2013;809.</Citation><ArticleIdList><ArticleId IdType="pubmed">19855405</ArticleId></ArticleIdList></Reference><Reference><Citation>Reintam A, Parm P, Kitus R, Starkopf J, Kern H. Gastrointestinal failure score in critically ill patients: a prospective observational study. Crit Care. 2008;12(4):R90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575570</ArticleId><ArticleId IdType="pubmed">18625051</ArticleId></ArticleIdList></Reference><Reference><Citation>Asrani VM, Brown A, Huang W, Bissett I, Windsor JA. Gastrointestinal Dysfunction in Critical Illness: A Review of Scoring Tools. JPEN J Parenter Enteral Nutr. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">31350771</ArticleId></ArticleIdList></Reference><Reference><Citation>Eveleens RD, Joosten KFM, de Koning BAE, Hulst JM, Verbruggen S. Definitions, predictors and outcomes of feeding intolerance in critically ill children: A systematic review. Clin Nutr. 2019.</Citation><ArticleIdList><ArticleId IdType="pubmed">30962102</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Larmonier CB, Deschenes J, Redford D, Kiela PR, Ghishan FK. Clinical characteristics associated with postoperative intestinal epithelial barrier dysfunction in children with congenital heart disease. Pediatr Crit Care Med. 2015;16(1):37&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4286428</ArticleId><ArticleId IdType="pubmed">25162512</ArticleId></ArticleIdList></Reference><Reference><Citation>Derikx JP, Bijker EM, Vos GD, et al. Gut mucosal cell damage in meningococcal sepsis in children: relation with clinical outcome. Crit Care Med. 2010;38(1):133&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pubmed">19730255</ArticleId></ArticleIdList></Reference><Reference><Citation>Tume LN, Bickerdike A, Latten L, et al. Routine gastric residual volume measurement and energy target achievement in the PICU: a comparison study. Eur J Pediatr. 2017;176(12):1637&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5682857</ArticleId><ArticleId IdType="pubmed">28921175</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, McAleer D, Hamilton S, et al. Challenges to optimal enteral nutrition in a multidisciplinary pediatric intensive care unit. JPEN JParenterEnteral Nutr. 2010;34(1):38&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4902117</ArticleId><ArticleId IdType="pubmed">19903872</ArticleId></ArticleIdList></Reference><Reference><Citation>Kurbegov AC, Sondheimer JM. Pneumatosis intestinalis in non-neonatal pediatric patients. Pediatrics. 2001;108(2):402&#x2013;406.</Citation><ArticleIdList><ArticleId IdType="pubmed">11483806</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO. Gastrointestinal complications associated with the surgical treatment of heart disease in children. J Pediatr Surg. 2017;52(3):414&#x2013;419.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916446</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang YJ, Yan DC, Lai JY, et al. Strangulated small bowel obstruction in children. J Pediatr Surg. 2017;52(8):1313&#x2013;1317.</Citation><ArticleIdList><ArticleId IdType="pubmed">28318600</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehghani SM, Nikeghbalian S, Kazemi K, et al. Outcome of bowel perforation after pediatric liver transplantation. Pediatr Transplant. 2008;12(2):146&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">18307662</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanada Y, Mizuta K, Wakiya T, et al. Bowel perforation after pediatric living donor liver transplantation. Pediatr Surg Int. 2011;27(1):23&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pubmed">20848288</ArticleId></ArticleIdList></Reference><Reference><Citation>Shaked A, Vargas J, Csete ME, et al. Diagnosis and treatment of bowel perforation following pediatric orthotopic liver transplantation. Arch Surg. 1993;128(9):994&#x2013;998; discussion 998&#x2013;999.</Citation><ArticleIdList><ArticleId IdType="pubmed">8368937</ArticleId></ArticleIdList></Reference><Reference><Citation>Balakrishnan B, Dasgupta M, Gajewski K, et al. Low near infrared spectroscopic somatic oxygen saturation at admission is associated with need for lifesaving interventions among unplanned admissions to the pediatric intensive care unit. J Clin Monit Comput. 2018;32(1):89&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">28258341</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulueta JL, Vida VL, Perisinotto E, Pittarello D, Stellin G. Role of intraoperative regional oxygen saturation using near infrared spectroscopy in the prediction of low output syndrome after pediatric heart surgery. J Card Surg. 2013;28(4):446&#x2013;452.</Citation><ArticleIdList><ArticleId IdType="pubmed">23734582</ArticleId></ArticleIdList></Reference><Reference><Citation>Mikhailov TA, Kuhn EM, Manzi J, et al. Early enteral nutrition is associated with lower mortality in critically ill children. JPEN J Parenter Enteral Nutr. 2014;38(4):459&#x2013;466.</Citation><ArticleIdList><ArticleId IdType="pubmed">24403379</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, Bechard LJ, Cahill N, et al. Nutritional practices and their relationship to clinical outcomes in critically ill children--an international multicenter cohort study*. Crit Care Med. 2012;40(7):2204&#x2013;2211.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3704225</ArticleId><ArticleId IdType="pubmed">22564954</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta NM, Skillman HE, Irving SY, et al. Guidelines for the Provision and Assessment of Nutrition Support Therapy in the Pediatric Critically Ill Patient: Society of Critical Care Medicine and American Society for Parenteral and Enteral Nutrition. JPEN J Parenter Enteral Nutr. 2017;41(5):706&#x2013;742.</Citation><ArticleIdList><ArticleId IdType="pubmed">28686844</ArticleId></ArticleIdList></Reference><Reference><Citation>Chisti MJ, Shahid AS, Shahunja KM, et al. Ileus in children presenting with diarrhea and severe acute malnutrition: A chart review. PLoS Negl Trop Dis. 2017;11(5):e0005603.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5441652</ArticleId><ArticleId IdType="pubmed">28493871</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaibou M, Tucci M, Dugas MA, Farrell CA, Proulx F, Lacroix J. Clinically significant upper gastrointestinal bleeding acquired in a pediatric intensive care unit: a prospective study. Pediatrics. 1998;102(4 Pt 1):933&#x2013;938.</Citation><ArticleIdList><ArticleId IdType="pubmed">9755268</ArticleId></ArticleIdList></Reference><Reference><Citation>Je BK, Kim HK, Horn PS. Abdominal Compartment Syndrome in Children: Clinical and Imaging Features. AJR Am J Roentgenol. 2019;212(3):655&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">30645165</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Bougmiza IM, Chehab MS, Bafaqih HA, AlMohaimeed SA, Malbrain ML. Incidence, Risk Factors, and Prognosis of Intra-Abdominal Hypertension in Critically Ill Children: A Prospective Epidemiological Study. J Intensive Care Med. 2016;31(6):403&#x2013;408.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922384</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, et al. Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med. 2013;39(7):1190&#x2013;1206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680657</ArticleId><ArticleId IdType="pubmed">23673399</ArticleId></ArticleIdList></Reference><Reference><Citation>Horoz OO, Yildizdas D, Sari Y, Unal I, Ekinci F, Petmezci E. The relationship of abdominal perfusion pressure with mortality in critically ill pediatric patients. J Pediatr Surg. 2019;54(9):1731&#x2013;1735.</Citation><ArticleIdList><ArticleId IdType="pubmed">30638664</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers MB, Firek B, Shi M, et al. Disruption of the microbiota across multiple body sites in critically ill children. Microbiome. 2016;4(1):66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5200963</ArticleId><ArticleId IdType="pubmed">28034303</ArticleId></ArticleIdList></Reference><Reference><Citation>Wijeyesekera A, Wagner J, De Goffau M, et al. Multi-Compartment Profiling of Bacterial and Host Metabolites Identifies Intestinal Dysbiosis and Its Functional Consequences in the Critically Ill Child. Crit Care Med. 2019;47(9):e727&#x2013;e734.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6699985</ArticleId><ArticleId IdType="pubmed">31169619</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimizu K, Ogura H, Hamasaki T, et al. Altered gut flora are associated with septic complications and death in critically ill patients with systemic inflammatory response syndrome. Dig Dis Sci. 2011;56(4):1171&#x2013;1177.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3059822</ArticleId><ArticleId IdType="pubmed">20931284</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoseph BP, Klingensmith NJ, Liang Z, et al. Mechanisms of Intestinal Barrier Dysfunction in Sepsis. Shock. 2016;46(1):52&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4910519</ArticleId><ArticleId IdType="pubmed">27299587</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26862016</PMID><DateCompleted><Year>2017</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2025</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1432-1238</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Intensive care medicine</Title><ISOAbbreviation>Intensive Care Med</ISOAbbreviation></Journal><ArticleTitle>Antithrombin&#xa0;III for critically ill patients: a systematic review with meta-analysis and trial sequential analysis.</ArticleTitle><Pagination><StartPage>505</StartPage><EndPage>520</EndPage><MedlinePgn>505-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00134-016-4225-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Antithrombin III (AT III) is an anticoagulant with anti-inflammatory properties. We assessed the benefits and harms of AT III in critically ill patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We searched from inception to 27 August 2015 in CENTRAL, MEDLINE, EMBASE, CAB, BIOSIS and CINAHL. We included randomized controlled trials (RCTs) irrespective of publication status, date of publication, blinding status, outcomes published or language.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We included 30 RCTs with a total of 3933 participants. The majority of included trials were at high risk of bias. Combining all trials, regardless of bias, showed no statistically significant effect of AT III on mortality (RR 0.95, 95% CI 0.88-1.03, I (2) = 0%, fixed-effect model, 29 trials, 3882 participants). Among those with severe sepsis and disseminated intravascular coagulation (DIC), AT III showed no impact on mortality (RR 0.95, 95% Cl 0.88-1.03, I (2) = 0%, fixed-effect model, 12 trials, 2858 participants). We carried out multiple subgroup and sensitivity analyses to assess the benefits and harms of AT III and to examine the impact of risk of bias. AT III significantly increased bleeding events (RR 1.58, 95% CI 1.35-1.84, I (2) = 0%, fixed-effect model, 11 trials, 3019 participants). However, for all other outcome measures and analyses, the results did not reach statistical significance.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">There is insufficient evidence to support AT III substitution in any category of critically ill participants including those with sepsis and DIC. AT III did not show an impact on mortality, but increased the risk of bleeding.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Allingstrup</LastName><ForeName>Mikkel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Anaesthesia, K&#xf8;ge Sygehus, Copenhagen University Hospital, Copenhagen, Denmark. mikkel.allingstrup@gmail.com.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. mikkel.allingstrup@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetterslev</LastName><ForeName>J&#xf8;rn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Department 7812, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ravn</LastName><ForeName>Frederikke B</ForeName><Initials>FB</Initials><AffiliationInfo><Affiliation>Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>M&#xf8;ller</LastName><ForeName>Ann Merete</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group, University of Copenhagen Herlev Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>Arash</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group, University of Copenhagen Herlev Hospital, Herlev, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>02</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Intensive Care Med</MedlineTA><NlmUniqueID>7704851</NlmUniqueID><ISSNLinking>0342-4642</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000991">Antithrombins</NameOfSubstance></Chemical><Chemical><RegistryNumber>9000-94-6</RegistryNumber><NameOfSubstance UI="D000990">Antithrombin III</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000990" MajorTopicYN="N">Antithrombin III</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000991" MajorTopicYN="N">Antithrombins</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004211" MajorTopicYN="N">Disseminated Intravascular Coagulation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Antithrombin&#xa0;III</Keyword><Keyword MajorTopicYN="N">Bleeding</Keyword><Keyword MajorTopicYN="N">DIC</Keyword><Keyword MajorTopicYN="N">Multi organ failure</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Septic shock</Keyword></KeywordList><CoiStatement>Mikkel Allingstrup, Frederikke B. Ravn, Ann Merete M&#xf8;ller and Arash Afshari declare that there are no conflicts of interest. J&#xf8;rn Wetterslev declares that he is a member of the task force on TSA at Copenhagen Trial Unit developing and programming TSA.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>1</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>2</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>3</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26862016</ArticleId><ArticleId IdType="pmc">PMC7095103</ArticleId><ArticleId IdType="doi">10.1007/s00134-016-4225-7</ArticleId><ArticleId IdType="pii">10.1007/s00134-016-4225-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wunsch H, Angus D, Harrison D, et al. Variation in critical care services across North America and Western Europe. Crit Care Med. 2008;36:2787&#x2013;2793. doi: 10.1097/CCM.0b013e318186aec8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318186aec8</ArticleId><ArticleId IdType="pubmed">18766102</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M, De Jonge E, Van der Poll T. New treatment strategies for disseminated intravascular coagulation based on current understanding of the pathophysiology. Ann Med. 2004;36:41&#x2013;49. doi: 10.1080/07853890310017251.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/07853890310017251</ArticleId><ArticleId IdType="pubmed">15000346</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayr F, Yende S, Angus D. Epidemiology of severe sepsis. Virulence. 2014;5:4&#x2013;11. doi: 10.4161/viru.27372.</Citation><ArticleIdList><ArticleId IdType="doi">10.4161/viru.27372</ArticleId><ArticleId IdType="pmc">PMC3916382</ArticleId><ArticleId IdType="pubmed">24335434</ArticleId></ArticleIdList></Reference><Reference><Citation>Periti P. Current treatment of sepsis and endotoxaemia. Expert Opin Pharmacother. 2000;1:1203&#x2013;1217. doi: 10.1517/14656566.1.6.1203.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.1.6.1203</ArticleId><ArticleId IdType="pubmed">11249488</ArticleId></ArticleIdList></Reference><Reference><Citation>Polderman KH, Girbes ARJ. Drug intervention trials in sepsis: divergent results. Lancet. 2004;363:1721&#x2013;1723. doi: 10.1016/S0140-6736(04)16259-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(04)16259-4</ArticleId><ArticleId IdType="pubmed">15158636</ArticleId></ArticleIdList></Reference><Reference><Citation>Becker BF, Heindl B, Kupatt C, Zahler S. Endothelial function and hemostasis. Z Kardiol. 2000;89:160&#x2013;167.</Citation><ArticleIdList><ArticleId IdType="pubmed">10798271</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz R, Moffett BS, Karabinas S, et al. Antithrombin concentrate use in children receiving unfractionated heparin for acute thrombosis. J Pediatr. 2015;167:645&#x2013;649. doi: 10.1016/j.jpeds.2015.06.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpeds.2015.06.006</ArticleId><ArticleId IdType="pubmed">26148660</ArticleId></ArticleIdList></Reference><Reference><Citation>Opal SM, Kessler CM, Roemisch J, Knaub S. Antithrombin, heparin, and heparan sulfate. Crit Care Med. 2002;30:325&#x2013;331. doi: 10.1097/00003246-200205001-00024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200205001-00024</ArticleId><ArticleId IdType="pubmed">12004255</ArticleId></ArticleIdList></Reference><Reference><Citation>Rublee D, Opal SM, Schramm W, et al. Quality of life effects of antithrombin&#xa0;III in sepsis survivors: results from the KyberSept trial. Crit Care. 2002;6:349&#x2013;356. doi: 10.1186/cc1529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc1529</ArticleId><ArticleId IdType="pmc">PMC125322</ArticleId><ArticleId IdType="pubmed">12225612</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarychanski R, Abou-Setta AM, Kanji S, et al. The efficacy and safety of heparin in patients with sepsis: a systematic review and metaanalysis. Crit Care Med. 2015;43:511&#x2013;518. doi: 10.1097/CCM.0000000000000763.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000763</ArticleId><ArticleId IdType="pubmed">25493972</ArticleId></ArticleIdList></Reference><Reference><Citation>Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, Sch&#xfc;nemann HJ. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924&#x2013;926. doi: 10.1136/bmj.39489.470347.AD.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.39489.470347.AD</ArticleId><ArticleId IdType="pmc">PMC2335261</ArticleId><ArticleId IdType="pubmed">18436948</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535. doi: 10.1136/bmj.b2535.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.b2535</ArticleId><ArticleId IdType="pmc">PMC2714657</ArticleId><ArticleId IdType="pubmed">19622551</ArticleId></ArticleIdList></Reference><Reference><Citation>Higgins JPT, Green S (2011) Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration. http://www.cochrane-handbook.org. Accessed March 2011</Citation></Reference><Reference><Citation>Afshari A, Wetterslev J, Brok J, M&#xf8;ller A. Antithrombin&#xa0;III for critically ill patients. Cochrane Database Syst Rev. 2008;16(3):5370.</Citation><ArticleIdList><ArticleId IdType="pubmed">18646125</ArticleId></ArticleIdList></Reference><Reference><Citation>The Cochrane Collaboration (2014) Review Manager (RevMan), version 5.3.5. The Nordic Cochrane Centre, Copenhagen</Citation></Reference><Reference><Citation>Thorlund K, Engstr&#xf8;m J, Wetterslev J, Brok J, Imberger G, Gluud C (2011) User manual for trial sequential analysis (TSA). Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark, pp 1&#x2013;115. http://www.ctu.dk/tsa/files/tsa_manual.pdf</Citation></Reference><Reference><Citation>Albert J, Blomqvist H, Gardlund B, et al. Effect of antithrombin concentrate on haemostatic variables in critically ill patients. Acta Anaesthesiol Scand. 1992;36:745&#x2013;752. doi: 10.1111/j.1399-6576.1992.tb03557.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.1992.tb03557.x</ArticleId><ArticleId IdType="pubmed">1466208</ArticleId></ArticleIdList></Reference><Reference><Citation>Balk RA, Bedrosian C, McCormick L, et al. Prospective double blind placebo-controlled trial of ATIII substitution in sepsis. Intensive Care Med. 1995;21:17.</Citation></Reference><Reference><Citation>Baudo F, DeGasperi A, De Cataldo F, et al. Antithrombin&#xa0;III supplementation during orthotopic liver transplantation in cirrhotic patients: a randomized trial. Thromb Res. 1992;68:409&#x2013;416. doi: 10.1016/0049-3848(92)90099-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(92)90099-V</ArticleId><ArticleId IdType="pubmed">1290169</ArticleId></ArticleIdList></Reference><Reference><Citation>Baudo F, Caimi TM, De Cataldo F, et al. Antithrombin&#xa0;III (ATIII) replacement therapy in patients with severe sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med. 1998;24:336&#x2013;342. doi: 10.1007/s001340050576.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050576</ArticleId><ArticleId IdType="pubmed">9609411</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauhut B, Kramar H, Vinazzer H, Bergmann H. Substitution of antithrombin&#xa0;III in shock and DIC: a randomized study. Thromb Res. 1985;39:81&#x2013;89. doi: 10.1016/0049-3848(85)90123-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(85)90123-9</ArticleId><ArticleId IdType="pubmed">4035650</ArticleId></ArticleIdList></Reference><Reference><Citation>Diaz-Cremades JM, Lorenzo R, S&#xe1;nchez M, et al. Use of antithrombin&#xa0;III in critical patients. Intensive Care Med. 1994;20:577&#x2013;580. doi: 10.1007/BF01705725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01705725</ArticleId><ArticleId IdType="pubmed">7706571</ArticleId></ArticleIdList></Reference><Reference><Citation>Eisele B, Lamy M, Thijs LG, et al. Antithrombin&#xa0;III in patients with severe sepsis. A randomized, placebo-controlled, double-blind multicenter trial plus a meta-analysis on all randomized, placebo-controlled, double-blind trials with antithrombin&#xa0;III in severe sepsis. Intensive Care Med. 1998;24:663&#x2013;672. doi: 10.1007/s001340050642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050642</ArticleId><ArticleId IdType="pubmed">9722035</ArticleId></ArticleIdList></Reference><Reference><Citation>Fourrier F, Chopin C, Huart JJ, et al. Double-blind, placebo-controlled trial of antithrombin&#xa0;III concentrates in septic shock with disseminated intravascular coagulation. Chest. 1993;104:882&#x2013;888. doi: 10.1378/chest.104.3.882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.104.3.882</ArticleId><ArticleId IdType="pubmed">8365305</ArticleId></ArticleIdList></Reference><Reference><Citation>Fulia F, Cordaro S, Meo P, et al. Can the administration of antithrombin&#xa0;III decrease the risk of cerebral hemorrhage in premature infants. Biol Neonate. 2003;83:1&#x2013;5. doi: 10.1159/000067005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000067005</ArticleId><ArticleId IdType="pubmed">12566675</ArticleId></ArticleIdList></Reference><Reference><Citation>Gando S, Saitoh D, Ishikura H, et al. A randomized, controlled, multicenter trial of the effects of antithrombin on disseminated intravascular coagulation in patients with sepsis. Crit Care. 2013;17:297. doi: 10.1186/cc13163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc13163</ArticleId><ArticleId IdType="pmc">PMC4057033</ArticleId><ArticleId IdType="pubmed">24342495</ArticleId></ArticleIdList></Reference><Reference><Citation>Grenander A, Bredbacka S, Rydvall A, et al. Antithrombin treatment in patients with traumatic brain injury: a pilot study. J Neurosurg Anesthesiol. 2001;13:49&#x2013;56. doi: 10.1097/00008506-200101000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00008506-200101000-00010</ArticleId><ArticleId IdType="pubmed">11145479</ArticleId></ArticleIdList></Reference><Reference><Citation>Haire WD, Ruby EI, Stephens LC, et al. A prospective randomized double-blind trial of antithrombin&#xa0;III concentrate in the treatment of multiple-organ dysfunction syndrome during hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 1998;4:142&#x2013;150. doi: 10.1016/S1083-8791(98)50003-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1083-8791(98)50003-1</ArticleId><ArticleId IdType="pubmed">9923412</ArticleId></ArticleIdList></Reference><Reference><Citation>Harper PL, Williamson L, Park G, et al. A pilot study of antithrombin replacement in intensive care management: the effects on mortality, coagulation and renal function. Transfus Med. 1991;1:121&#x2013;128. doi: 10.1111/j.1365-3148.1991.tb00020.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-3148.1991.tb00020.x</ArticleId><ArticleId IdType="pubmed">9259838</ArticleId></ArticleIdList></Reference><Reference><Citation>Inthorn D, Hoffmann JN, Hartl WH, et al. Antithrombin&#xa0;III supplementation in severe sepsis: beneficial effects on organ dysfunction. Shock. 1997;8:328&#x2013;334. doi: 10.1097/00024382-199711000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-199711000-00003</ArticleId><ArticleId IdType="pubmed">9361342</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi T, Terao T, Ikenoue T, et al. Treatment of severe preeclampsia with antithrombin concentrate: results of a prospective feasibility study. Semin Thromb Hemost. 2003;29:645&#x2013;652. doi: 10.1055/s-2004-815632.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2004-815632</ArticleId><ArticleId IdType="pubmed">14719181</ArticleId></ArticleIdList></Reference><Reference><Citation>Langley PG, Hughes RD, Forbes A, et al. Controlled trial of antithrombin&#xa0;III supplementation in fulminant hepatic failure. J Hepatol. 1993;17:326&#x2013;331. doi: 10.1016/S0168-8278(05)80213-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0168-8278(05)80213-2</ArticleId><ArticleId IdType="pubmed">8315261</ArticleId></ArticleIdList></Reference><Reference><Citation>Lavrentieva A, Kontakiotis T, Bitzani M, et al. The efficacy of antithrombin administration in the acute phase of burn injury. Thromb Haemost. 2008;100:286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">18690349</ArticleId></ArticleIdList></Reference><Reference><Citation>Maki M, Kobayashi T, Terao T, et al. Antithrombin therapy for severe preeclampsia: results of a double-blind, randomized, placebo-controlled trial. Thromb Haemost. 2000;84:583&#x2013;590.</Citation><ArticleIdList><ArticleId IdType="pubmed">11057854</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitchell L, Andrew M, Hanna K, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study. Thromb Haemost. 2003;90:235&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pubmed">12888870</ArticleId></ArticleIdList></Reference><Reference><Citation>Muntean W, Rossegger H. Antithrombin&#xa0;III concentrate in preterm infants with IRDS: an open, controlled, randomized clinical trial (abstract) Thromb Haemost. 1989;62:288.</Citation></Reference><Reference><Citation>Neporada E, Vorobyeva N, Nedashkovsky E. Antithrombin III deficiency correction in patients with disseminated intravascular coagulation. Obshaya Reanimatol. 2008;5:49&#x2013;54. doi: 10.15360/1813-9779-2008-5-49.</Citation><ArticleIdList><ArticleId IdType="doi">10.15360/1813-9779-2008-5-49</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiyama T, Kohno Y, Koishi K. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study. Am J Emerg Med. 2012;30:1219&#x2013;1223. doi: 10.1016/j.ajem.2011.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajem.2011.06.003</ArticleId><ArticleId IdType="pubmed">22204993</ArticleId></ArticleIdList></Reference><Reference><Citation>Palareti G, Legnani C, Coccheri S, et al. Laboratory effects of antithrombin-III (ATIII) replacement in patients with sepsis and or postsurgical complications requiring hemodynamic and or respiratory support&#x2014;a controlled, double-blind, randomized multicenter study. Thromb Haemost. 1995;73:1251.</Citation></Reference><Reference><Citation>Schmidt B, Gillie P, Mitchell L, et al. A placebo-controlled randomized trial of antithrombin therapy in neonatal respiratory distress syndrome. Am J Respir Crit Care Med. 1998;158:470&#x2013;476. doi: 10.1164/ajrccm.158.2.9712116.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.158.2.9712116</ArticleId><ArticleId IdType="pubmed">9700123</ArticleId></ArticleIdList></Reference><Reference><Citation>Schorr M, Siebeck M, Zugel N, et al. Antithrombin&#xa0;III and local serum application: adjuvant therapy in peritonitis. Eur J Clin Invest. 2000;30:359&#x2013;366. doi: 10.1046/j.1365-2362.2000.00630.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2362.2000.00630.x</ArticleId><ArticleId IdType="pubmed">10759886</ArticleId></ArticleIdList></Reference><Reference><Citation>Schuster HP, Eisele B, Keinecke HO, et al. S-AT&#xa0;III study: antithrombin&#xa0;III in patients with sepsis. Intensive Care Med. 1997;23(Suppl 1):76.</Citation><ArticleIdList><ArticleId IdType="pubmed">9722035</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith-Erichsen N, Aasen AO, Kongsgaard UE, et al. The effect of antithrombin&#xa0;III substitution therapy on components of the plasma protease systems in surgical patients. Clin Intensive Care. 1996;7:291&#x2013;296. doi: 10.3109/tcic.7.6.291.296.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/tcic.7.6.291.296</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobyeva N, Neporada E, Turundaevskaia O, Mel&#x2019;nikova G. Place of antithrombin&#xa0;III concentrate in the intensive care of disseminated intravascular coagulation. Anesteziol Reanimatol. 2007;2:42&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">17563999</ArticleId></ArticleIdList></Reference><Reference><Citation>Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin&#xa0;III in severe sepsis, a randomized controlled trial. JAMA. 2001;286:1869&#x2013;1878. doi: 10.1001/jama.286.15.1869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.286.15.1869</ArticleId><ArticleId IdType="pubmed">11597289</ArticleId></ArticleIdList></Reference><Reference><Citation>Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High-dose antithrombin&#xa0;III treatment of severely injured patients: results of a prospective study. J Trauma. 1998;45:931&#x2013;940. doi: 10.1097/00005373-199811000-00015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199811000-00015</ArticleId><ArticleId IdType="pubmed">9820705</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Angelo A, Valsecchi L (2015) High-dose antithrombin supplementation in early pre-eclampsia: a double-blind, placebo controlled study (on behalf of the AT&#xa0;III-EPAS study group). http://abstract.mci-group.com/cgi-bin/mc/printabs.pl?APP=ISTH2009ABS-abstract&amp;TEMPLATE=&amp;keyf=0771&amp;showHide=show&amp;client. Accessed 21 April 2015</Citation></Reference><Reference><Citation>Gotzsche PC. Why we need a broad perspective on meta-analysis. It may be crucially important for patients. BMJ. 2000;321:585&#x2013;586. doi: 10.1136/bmj.321.7261.585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.321.7261.585</ArticleId><ArticleId IdType="pmc">PMC1118486</ArticleId><ArticleId IdType="pubmed">10977820</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25444751</PMID><DateCompleted><Year>2015</Year><Month>10</Month><Day>05</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3492</ISSN><JournalIssue CitedMedium="Internet"><Volume>440</Volume><PubDate><Year>2015</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Clinica chimica acta; international journal of clinical chemistry</Title><ISOAbbreviation>Clin Chim Acta</ISOAbbreviation></Journal><ArticleTitle>Novel markers predict death and organ failure following hemorrhagic shock.</ArticleTitle><Pagination><StartPage>87</StartPage><EndPage>92</EndPage><MedlinePgn>87-92</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cca.2014.10.045</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0009-8981(14)00492-6</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">ADAMTS 13, sP-Selectin and HSP27 have been investigated as potential prognostic markers in patients with hemorrhagic shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This study was part of a double-blind, randomized, parallel-group, controlled trial and included seventeen trauma patients presented to ED with severe hemorrhagic. The sera for testing were collected from these patients at the time of admission. Investigators and laboratory personnel performing testing were blinded to the patients' identity and clinical course.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The prognostic value of ADAMTS13, sP-Selectin, and HSP27 was compared to prognostic value of systolic blood pressure (SBP), base deficit estimation (BD), heart rate (HR), shock index (SI) and tissue oxygen saturation (StO2) by constructing the receiver operation characteristics (ROC). The area under the curve (AUC) of the ROC for HSP27 (0.92) was greater than for SBP (0.45), BD (0.89), HR (0.61), SI (0.45) and StO2 (0.46). AUC for sP-Selectin (0.86) and for ADAMTS13 antigen (0.74) were comparable with BD one, but greater than for the rest of currently used tests.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Serum concentrations of ADAMTS13, HSP27 and sP-Selectin measured during the admission, appear to be comparable to or better than SBP, BD, SI, HR and StO2 in predicting MODS and death after hemorrhage from trauma. These potential new markers deserve further investigation.</AbstractText><CopyrightInformation>Copyright &#xa9; 2014 Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Furmaga</LastName><ForeName>Wieslaw</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States. Electronic address: furmaga@uthscsa.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prihoda</LastName><ForeName>Thomas J</ForeName><Initials>TJ</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muir</LastName><ForeName>Mark T</ForeName><Initials>MT</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mikhailov</LastName><ForeName>Valery</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarthy</LastName><ForeName>Janet</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arar</LastName><ForeName>Yousef</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pathology, University Texas Health Science Center at San Antonio, 7704 Floyd Curl Drive, San Antonio, TX, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>11</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Clin Chim Acta</MedlineTA><NlmUniqueID>1302422</NlmUniqueID><ISSNLinking>0009-8981</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055551">HSP27 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C057725">HSPB1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006360">Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018832">Molecular Chaperones</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019007">P-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.-</RegistryNumber><NameOfSubstance UI="D051722">ADAM Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="D000071120">ADAMTS13 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.87</RegistryNumber><NameOfSubstance UI="C099604">ADAMTS13 protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051722" MajorTopicYN="N">ADAM Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000071120" MajorTopicYN="N">ADAMTS13 Protein</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019540" MajorTopicYN="N">Area Under Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="Y">analysis</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055551" MajorTopicYN="N">HSP27 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="N">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006360" MajorTopicYN="N">Heat-Shock Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018832" MajorTopicYN="N">Molecular Chaperones</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019007" MajorTopicYN="N">P-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ADAMTS13</Keyword><Keyword MajorTopicYN="N">HSP27</Keyword><Keyword MajorTopicYN="N">Hemorrhagic shock</Keyword><Keyword MajorTopicYN="N">Hemorrhagic shock markers</Keyword><Keyword MajorTopicYN="N">Multi-organ failure</Keyword><Keyword MajorTopicYN="N">sP-Selectin</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>10</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>12</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>10</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25444751</ArticleId><ArticleId IdType="doi">10.1016/j.cca.2014.10.045</ArticleId><ArticleId IdType="pii">S0009-8981(14)00492-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32035159</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1097-6825</ISSN><JournalIssue CitedMedium="Internet"><Volume>145</Volume><Issue>6</Issue><PubDate><Year>2020</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of allergy and clinical immunology</Title><ISOAbbreviation>J Allergy Clin Immunol</ISOAbbreviation></Journal><ArticleTitle>RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness.</ArticleTitle><Pagination><StartPage>1673</StartPage><EndPage>1680.e11</EndPage><MedlinePgn>1673-1680.e11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jaci.2020.01.040</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0091-6749(20)30179-2</ELocationID><Abstract><AbstractText Label="BACKGROUND">Decreased TNF-&#x3b1; production in whole blood after ex&#xa0;vivo LPS stimulation indicates suppression of the Toll-like receptor (TLR)4 pathway. This is associated with increased mortality in pediatric influenza critical illness. Whether antiviral immune signaling pathways are also suppressed in these patients is unclear.</AbstractText><AbstractText Label="OBJECTIVES">We sought to evaluate suppression of the TLR4 and the antiviral retinoic acid-inducible gene-I (RIG-I) pathways with clinical outcomes in children with severe influenza infection.</AbstractText><AbstractText Label="METHODS">In this 24-center, prospective, observational cohort study of children with confirmed influenza infection, blood was collected within 72 hours of intensive care unit admission. Ex&#xa0;vivo whole blood stimulations were performed with matched controls using the viral ligand polyinosinic-polycytidylic acid-low-molecular-weight/LyoVec and LPS to evaluate IFN-&#x3b1; and TNF-&#x3b1; production capacities (RIG-I and TLR4 pathways, respectively).</AbstractText><AbstractText Label="RESULTS">Suppression of either IFN-&#x3b1; or TNF-&#x3b1; production capacity was associated with longer duration of mechanical ventilation and hospitalization, and increased organ dysfunction. Children with suppression of both RIG-I and TLR4 pathways (n&#xa0;= 33 of 103 [32%]) were more likely to have prolonged (&#x2265;7 days) multiple-organ dysfunction syndrome (30.3% vs 8.6%; P&#xa0;= .004) or prolonged hypoxemic respiratory failure (39.4% vs 11.4%; P&#xa0;= .001) compared with those with single- or no pathway suppression.</AbstractText><AbstractText Label="CONCLUSIONS">Suppression of both RIG-I and TLR4 signaling pathways, essential for respective antiviral and antibacterial responses, is common in previously immunocompetent children with influenza-related critical illness and is associated with bacterial coinfection and adverse outcomes. Prospective testing of both pathways may aid in risk-stratification and in immune monitoring.</AbstractText><CopyrightInformation>Copyright &#xa9; 2020 American Academy of Allergy, Asthma &amp; Immunology. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Novak</LastName><ForeName>Tanya</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass; Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass; Department of Anesthesia, Harvard Medical School, Boston.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital, Division of Critical Care Medicine, Department of Pediatrics, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McDonald</LastName><ForeName>Douglas R</ForeName><Initials>DR</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Division of Immunology and Harvard Medical School Department of Pediatrics, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newhams</LastName><ForeName>Margaret M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mistry</LastName><ForeName>Anushay J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Panoskaltsis-Mortari</LastName><ForeName>Angela</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cytokine Reference Laboratory, Department of Pediatrics, University of Minnesota, Minneapolis, Minn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mourani</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Section of Critical Care Medicine, Department of Pediatrics, University of Colorado School of Medicine and Children's Hospital Colorado, Aurora, Colo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Loftis</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials><AffiliationInfo><Affiliation>Section of Critical Care Medicine, Department of Pediatrics, Texas Children's Hospital, Houston, Tex.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, Philadelphia, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tarquinio</LastName><ForeName>Keiko M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Children's Healthcare of Atlanta at Egleston, Department of Pediatrics, Emory University School of Medicine, Atlanta, Ga.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology Critical Care Medicine, Children's Hospital Los Angeles, Los Angeles, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, St Louis Children's Hospital, St Louis, Mo.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Children's Hospital of Orange County, Orange, Calif.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Junger</LastName><ForeName>Wolfgang G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Mass.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Randolph</LastName><ForeName>Adrienne G</ForeName><Initials>AG</Initials><AffiliationInfo><Affiliation>Boston Children's Hospital, Department of Anesthesiology, Critical Care and Pain Medicine, Boston, Mass; Department of Anesthesia, Harvard Medical School, Boston. Electronic address: adrienne.randolph@childrens.harvard.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>PALISI Pediatric Intensive Care Influenza (PICFLU) Network Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 GM103702</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R56 AI084011</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD095228</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R35 GM136429</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HD098363</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI084011</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM116162</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>02</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Allergy Clin Immunol</MedlineTA><NlmUniqueID>1275002</NlmUniqueID><ISSNLinking>0091-6749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016898">Interferon-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011971">Receptors, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C495345">TLR4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D051197">Toll-Like Receptor 4</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.1.-</RegistryNumber><NameOfSubstance UI="C452820">RIGI protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="N">DEAD Box Protein 58</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016898" MajorTopicYN="N">Interferon-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011971" MajorTopicYN="N">Receptors, Immunologic</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051197" MajorTopicYN="N">Toll-Like Receptor 4</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">IFN-&#x3b1;</Keyword><Keyword MajorTopicYN="N">LPS</Keyword><Keyword MajorTopicYN="N">Polyinosinic:polycytidylic acid</Keyword><Keyword MajorTopicYN="N">TNF-&#x3b1;</Keyword><Keyword MajorTopicYN="N">Toll-like receptor 4</Keyword><Keyword MajorTopicYN="N">critical care</Keyword><Keyword MajorTopicYN="N">influenza</Keyword><Keyword MajorTopicYN="N">pediatric</Keyword><Keyword MajorTopicYN="N">retinoic acid&#x2013;inducible gene-I</Keyword><Keyword MajorTopicYN="N">suppression</Keyword></KeywordList><CoiStatement><b>COI Statement:</b> Dr. Novak reports grants from NIH and Boston
Children&#x2019;s Hospital during the conduct of the study; Dr. Hall reports
grants from NIH during the conduct of the study; personal fees from LaJolla
Pharmaceuticals and personal fees from Bristol Myers-Squibb outside the
submitted work; Dr. Randolph reports grants from NIH during the conduct of the
study and grants from Genentech Inc. outside the submitted work and personal
fees from LaJolla Pharmaceuticals; Dr. Junger reports grants from NIH during the
conduct of the study; Dr. Mourani reports grants from NIH during the conduct of
the study; Dr. Panoskaltsis-Mortari reports grants from NIH during the conduct
of the study; Dr. Weiss reports grants from NIGMS outside the submitted work;
All other authors have no COI to disclose.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Sanders</LastName><ForeName>Ronald C</ForeName><Initials>RC</Initials><Suffix>Jr</Suffix></Investigator><Investigator ValidYN="Y"><LastName>Irby</LastName><ForeName>Olivia K</ForeName><Initials>OK</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hefley</LastName><ForeName>Glenda</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tellez</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flori</LastName><ForeName>Heidi</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cvijanovich</LastName><ForeName>Natalie</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anas</LastName><ForeName>Nick</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas-Shiraishi</LastName><ForeName>Ofelia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapru</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillen</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Czaja</LastName><ForeName>Angela</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mourani</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paden</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tarquinio</LastName><ForeName>Keiko</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stone</LastName><ForeName>Cheryl L</ForeName><Initials>CL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wardenburg</LastName><ForeName>Juliane Bubeck</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pinto</LastName><ForeName>Neethi</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montgomery</LastName><ForeName>Vicki</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Janice E</ForeName><Initials>JE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Randolph</LastName><ForeName>Adrienne G</ForeName><Initials>AG</Initials></Investigator><Investigator ValidYN="Y"><LastName>Agan</LastName><ForeName>Anna A</ForeName><Initials>AA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ash</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mistry</LastName><ForeName>Anushay</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Newhams</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kurachek</LastName><ForeName>Stephen C</ForeName><Initials>SC</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartman</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Truemper</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mahapatra</LastName><ForeName>Sidharth</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dawson</LastName><ForeName>Machelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ackerman</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Daugherty</LastName><ForeName>L Eugene</ForeName><Initials>LE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nofziger</LastName><ForeName>Ryan</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shein</LastName><ForeName>Steve</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steele</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson-Huber</LastName><ForeName>Lisa</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Thomas</LastName><ForeName>Neal J</ForeName><Initials>NJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spear</LastName><ForeName>Debra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bush</LastName><ForeName>Jenny L</ForeName><Initials>JL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graham</LastName><ForeName>Kathryn</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Higgerson</LastName><ForeName>Renee</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Christie</LastName><ForeName>LeeAnn</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loftis</LastName><ForeName>Laura L</ForeName><Initials>LL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaimon</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gedeit</LastName><ForeName>Rainer</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Murkowski</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>9</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32035159</ArticleId><ArticleId IdType="mid">NIHMS1573421</ArticleId><ArticleId IdType="pmc">PMC7323584</ArticleId><ArticleId IdType="doi">10.1016/j.jaci.2020.01.040</ArticleId><ArticleId IdType="pii">S0091-6749(20)30179-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Coffin SE, Zaoutis TE, Rosenquist AB, Heydon K, Herrera G, Bridges CB, et al. Incidence, complications, and risk factors for prolonged stay in children hospitalized with community-acquired influenza. Pediatrics. 2007;119(4):740&#x2013;748. DOI: 10.1542/peds.2006-2679.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2006-2679</ArticleId><ArticleId IdType="pubmed">17403845</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang BM, Feng CG, McLean AS. Understanding the role of host response in influenza pneumonitis. Intensive Care Med. 2019;45(7):1012&#x2013;1014. DOI: 10.1007/s00134-019-05582-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-019-05582-5</ArticleId><ArticleId IdType="pubmed">31020362</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchieri G. Type I interferon: friend or foe? J Exp Med. 2010;207(10):2053&#x2013;2063. DOI: 10.1084/jem.20101664.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20101664</ArticleId><ArticleId IdType="pmc">PMC2947062</ArticleId><ArticleId IdType="pubmed">20837696</ArticleId></ArticleIdList></Reference><Reference><Citation>Decker T, Muller M, Stockinger S. The yin and yang of type I interferon activity in bacterial infection. Nat Rev Immunol. 2005;5(9):675&#x2013;687. DOI: 10.1038/nri1684.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1684</ArticleId><ArticleId IdType="pubmed">16110316</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson S, Crotta S, McCabe TM, Wack A. Pathogenic potential of interferon alphabeta in acute influenza infection. Nat Commun. 2014;5:3864 DOI: 10.1038/ncomms4864.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms4864</ArticleId><ArticleId IdType="pmc">PMC4033792</ArticleId><ArticleId IdType="pubmed">24844667</ArticleId></ArticleIdList></Reference><Reference><Citation>Huys L, Van Hauwermeiren F, Dejager L, Dejonckheere E, Lienenklaus S, Weiss S, et al. Type I interferon drives tumor necrosis factor-induced lethal shock. J Exp Med. 2009;206(9):1873&#x2013;1882. DOI: 10.1084/jem.20090213.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20090213</ArticleId><ArticleId IdType="pmc">PMC2737160</ArticleId><ArticleId IdType="pubmed">19687227</ArticleId></ArticleIdList></Reference><Reference><Citation>Li W, Moltedo B, Moran TM. Type I interferon induction during influenza virus infection increases susceptibility to secondary Streptococcus pneumoniae infection by negative regulation of gammadelta T cells. J Virol. 2012;86(22):12304&#x2013;12312. DOI: 10.1128/JVI.01269-12.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01269-12</ArticleId><ArticleId IdType="pmc">PMC3486468</ArticleId><ArticleId IdType="pubmed">22951826</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakamura S, Davis KM, Weiser JN. Synergistic stimulation of type I interferons during influenza virus coinfection promotes Streptococcus pneumoniae colonization in mice. J Clin Invest. 2011;121(9):3657&#x2013;3665. DOI: 10.1172/JCI57762.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57762</ArticleId><ArticleId IdType="pmc">PMC3163966</ArticleId><ArticleId IdType="pubmed">21841308</ArticleId></ArticleIdList></Reference><Reference><Citation>Caskey M, Lefebvre F, Filali-Mouhim A, Cameron MJ, Goulet JP, Haddad EK, et al. Synthetic double-stranded RNA induces innate immune responses similar to a live viral vaccine in humans. J Exp Med. 2011;208(12):2357&#x2013;2366. DOI: 10.1084/jem.20111171.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111171</ArticleId><ArticleId IdType="pmc">PMC3256967</ArticleId><ArticleId IdType="pubmed">22065672</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong JP, Saravolac EG, Sabuda D, Levy HB, Kende M. Prophylactic and therapeutic efficacies of poly(IC.LC) against respiratory influenza A virus infection in mice. Antimicrob Agents Chemother. 1995;39(11):2574&#x2013;2576.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC162988</ArticleId><ArticleId IdType="pubmed">8585749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J, Huang S, Zhao X, Chen M, Lin Y, Xia Y, et al. Poly(I:C) treatment leads to interferon-dependent clearance of hepatitis B virus in a hydrodynamic injection mouse model. J Virol. 2014;88(18):10421&#x2013;10431. DOI: 10.1128/JVI.00996-14.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00996-14</ArticleId><ArticleId IdType="pmc">PMC4178898</ArticleId><ArticleId IdType="pubmed">24920792</ArticleId></ArticleIdList></Reference><Reference><Citation>Baum A, Garcia-Sastre A. Differential recognition of viral RNA by RIG-I. Virulence. 2011;2(2):166&#x2013;169.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3100765</ArticleId><ArticleId IdType="pubmed">21422808</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H, Takeuchi O, Mikamo-Satoh E, Hirai R, Kawai T, Matsushita K, et al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J Exp Med. 2008;205(7):1601&#x2013;1610. DOI: 10.1084/jem.20080091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20080091</ArticleId><ArticleId IdType="pmc">PMC2442638</ArticleId><ArticleId IdType="pubmed">18591409</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Geyer SM, Guo CY, Panoskaltsis-Mortari A, Jouvet P, Ferdinands J, et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med. 2013;41(1):224&#x2013;236. DOI: 10.1097/CCM.0b013e318267633c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318267633c</ArticleId><ArticleId IdType="pmc">PMC3705720</ArticleId><ArticleId IdType="pubmed">23222256</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph AG, Agan AA, Flanagan RF, Meece JK, Fitzgerald JC, Loftis LL, et al. Optimizing Virus Identification in Critically Ill Children Suspected of Having an Acute Severe Viral Infection. Pediatr Crit Care Med. 2016;17(4):279&#x2013;286. DOI: 10.1097/PCC.0000000000000661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000661</ArticleId><ArticleId IdType="pubmed">26895562</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiore-Gartland A, Panoskaltsis-Mortari A, Agan AA, Mistry AJ, Thomas PG, Matthay MA, et al. Cytokine Profiles of Severe Influenza Virus-Related Complications in Children. Front Immunol. 2017;8:1423 DOI: 10.3389/fimmu.2017.01423.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01423</ArticleId><ArticleId IdType="pmc">PMC5681736</ArticleId><ArticleId IdType="pubmed">29163498</ArticleId></ArticleIdList></Reference><Reference><Citation>Postal M, Sinicato NA, Pelicari KO, Marini R, Lavras Costallat LT, Appenzeller S. Clinical and serological manifestations associated with interferon-alpha levels in childhood-onset systemic lupus erythematosus. Clinics (Sao Paulo). 2012;67(2):157&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3275113</ArticleId><ArticleId IdType="pubmed">22358241</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HO, Kim HS, Youn JC, Shin EC, Park S. Serum cytokine profiles in healthy young and elderly population assessed using multiplexed bead-based immunoassays. J Transl Med. 2011;9:113 DOI: 10.1186/1479-5876-9-113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1479-5876-9-113</ArticleId><ArticleId IdType="pmc">PMC3146842</ArticleId><ArticleId IdType="pubmed">21774806</ArticleId></ArticleIdList></Reference><Reference><Citation>Bocci V. Roles of interferon produced in physiological conditions. A speculative review. Immunology. 1988;64(1):1&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1385178</ArticleId><ArticleId IdType="pubmed">2454881</ArticleId></ArticleIdList></Reference><Reference><Citation>Shahin D, El-Refaey AM, El-Hawary AK, Salam AA, Machaly S, Abousamra N, et al. Serum interferon-alpha level in first degree relatives of systemic lupus erythematosus patients: Correlation with autoantibodies titers. Egyptian Journal of Medical Human Genetics. 2011;12(2):139&#x2013;146. DOI: 10.1016/j.ejmhg.2011.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejmhg.2011.06.009</ArticleId></ArticleIdList></Reference><Reference><Citation>Cornell TT, Sun L, Hall MW, Gurney JG, Ashbrook MJ, Ohye RG, et al. Clinical implications and molecular mechanisms of immunoparalysis after cardiopulmonary bypass. J Thorac Cardiovasc Surg. 2012;143(5):1160&#x2013;1166 e1161 DOI: 10.1016/j.jtcvs.2011.09.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2011.09.011</ArticleId><ArticleId IdType="pmc">PMC3262077</ArticleId><ArticleId IdType="pubmed">21996297</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Knatz NL, Vetterly C, Tomarello S, Wewers MD, Volk HD, et al. Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525&#x2013;532. DOI: 10.1007/s00134-010-2088-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2088-x</ArticleId><ArticleId IdType="pmc">PMC5224706</ArticleId><ArticleId IdType="pubmed">21153402</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszynski JA, Nofziger R, Moore-Clingenpeel M, Greathouse K, Anglim L, Steele L, et al. Early Immune Function and Duration of Organ Dysfunction in Critically III Children with Sepsis. Am J Respir Crit Care Med. 2018;198(3):361&#x2013;369. DOI: 10.1164/rccm.201710-2006OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201710-2006OC</ArticleId><ArticleId IdType="pmc">PMC6835060</ArticleId><ArticleId IdType="pubmed">29470918</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Paul F, Pellegrini S, Uze G. IFNA2: The prototypic human alpha interferon. Gene. 2015;567(2):132&#x2013;137. DOI: 10.1016/j.gene.2015.04.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.gene.2015.04.087</ArticleId><ArticleId IdType="pmc">PMC5629289</ArticleId><ArticleId IdType="pubmed">25982860</ArticleId></ArticleIdList></Reference><Reference><Citation>Reder AT, Feng X. Aberrant Type I Interferon Regulation in Autoimmunity: Opposite Directions in MS and SLE, Shaped by Evolution and Body Ecology. Front Immunol. 2013;4:281 DOI: 10.3389/fimmu.2013.00281.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00281</ArticleId><ArticleId IdType="pmc">PMC3775461</ArticleId><ArticleId IdType="pubmed">24062747</ArticleId></ArticleIdList></Reference><Reference><Citation>Alsharifi M, Regner M, Blanden R, Lobigs M, Lee E, Koskinen A, et al. Exhaustion of type I interferon response following an acute viral infection. J Immunol. 2006;177(5):3235&#x2013;3241.</Citation><ArticleIdList><ArticleId IdType="pubmed">16920963</ArticleId></ArticleIdList></Reference><Reference><Citation>Furuya Y, Mullbacher A. Type I IFN exhaustion is a host defence protecting against secondary bacterial infections. Scand J Immunol. 2013;78(5):395&#x2013;400. DOI: 10.1111/sji.12107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/sji.12107</ArticleId><ArticleId IdType="pmc">PMC7169485</ArticleId><ArticleId IdType="pubmed">24006947</ArticleId></ArticleIdList></Reference><Reference><Citation>Tian X, Xu F, Lung WY, Meyerson C, Ghaffari AA, Cheng G, et al. Poly I:C enhances susceptibility to secondary pulmonary infections by gram-positive bacteria. PLoS One. 2012;7(9):e41879 DOI: 10.1371/journal.pone.0041879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0041879</ArticleId><ArticleId IdType="pmc">PMC3433467</ArticleId><ArticleId IdType="pubmed">22962579</ArticleId></ArticleIdList></Reference><Reference><Citation>Randolph AG, Vaughn F, Sullivan R, Rubinson L, Thompson BT, Yoon G, et al. Critically ill children during the 2009&#x2013;2010 influenza pandemic in the United States. Pediatrics. 2011;128(6):e1450&#x2013;1458. DOI: 10.1542/peds.2011-0774.</Citation><ArticleIdList><ArticleId IdType="doi">10.1542/peds.2011-0774</ArticleId><ArticleId IdType="pmc">PMC3387899</ArticleId><ArticleId IdType="pubmed">22065262</ArticleId></ArticleIdList></Reference><Reference><Citation>Warnking K, Klemm C, Loffler B, Niemann S, van Kruchten A, Peters G, et al. Super-infection with Staphylococcus aureus inhibits influenza virus-induced type I IFN signalling through impaired STAT1-STAT2 dimerization. Cell Microbiol. 2015;17(3):303&#x2013;317. DOI: 10.1111/cmi.12375.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cmi.12375</ArticleId><ArticleId IdType="pubmed">25293394</ArticleId></ArticleIdList></Reference><Reference><Citation>Chu M, Zhou M, Jiang C, Chen X, Guo L, Zhang M, et al. Staphylococcus aureus Phenol-Soluble Modulins alpha1-alpha3 Act as Novel Toll-Like Receptor (TLR) 4 Antagonists to Inhibit HMGB1/TLR4/NF-kappaB Signaling Pathway. Front Immunol. 2018;9:862 DOI: 10.3389/fimmu.2018.00862.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.00862</ArticleId><ArticleId IdType="pmc">PMC5996891</ArticleId><ArticleId IdType="pubmed">29922279</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28275227</PMID><DateCompleted><Year>2019</Year><Month>07</Month><Day>25</Day></DateCompleted><DateRevised><Year>2019</Year><Month>07</Month><Day>25</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1827-1596</ISSN><JournalIssue CitedMedium="Internet"><Volume>83</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>Minerva anestesiologica</Title><ISOAbbreviation>Minerva Anestesiol</ISOAbbreviation></Journal><ArticleTitle>Halogenated volatile anesthetics in the intensive care unit: current knowledge on an upcoming practice.</ArticleTitle><Pagination><StartPage>737</StartPage><EndPage>748</EndPage><MedlinePgn>737-748</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.23736/S0375-9393.17.11735-9</ELocationID><Abstract><AbstractText>The aim of this narrative review was to highlight key points of volatile anesthetics administration in the intensive care unit (ICU), including AnaConDa&#xae; and Mirus&#xae; devices characteristics and the reported findings on clinical outcomes in critically ill patients. Intravenous sedation in the ICU is associated with issues, such as over- and under-sedation. Halogenated compounds, which can be safely administered by inserting a device in any ICU ventilation circuit, have interesting pharmacodynamic and pharmacokinetic profiles for patients with multi-organ failure. Moreover, analysis of the concentration of exhaled volatile compounds could help evaluation of sedation depth. A recent meta-analysis confirmed that rapid washout of the volatile anesthetics improved both extubation readiness and quality of awakening when compared to intravenous sedation. When administered for a long period, volatile anesthetics improved sedation stability with fewer dose adjustments. Pre- and post-conditioning properties of halogenated compounds are interesting and long-term exposition to this compound is investigated for a potential impact on mortality rate and ICU/hospital length of stay. For now, psychomotor side effects have been reported, mostly in infants, but there were no hepatic or renal injuries. Findings regarding hemodynamic stability are conflicting. Apart from sedation, volatile anesthetics were therapeutic in case reports of status asthmaticus and epilepticus and data are cumulating for benefits in cases of acute respiratory distress syndrome. According to current literature, they should be withheld in cerebral injury. To summarize, the use of volatile anesthetics for sedation is yet only approved by German guidelines, but could spread due to its potential benefits.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Laferriere-Langlois</LastName><ForeName>Pascal</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Medicine and Health Sciences Faculty, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada - pascal.laferriere-langlois@usherbrooke.ca.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>d'ARAGON</LastName><ForeName>Frederick</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Medicine and Health Sciences Faculty, Centre Hospitalier Universitaire de Sherbrooke (CHUS), Sherbrooke, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Manzanares</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Intensive Care, Faculty of Medicine, UDELAR, Hospital de Cl&#xed;nicas (H&#xf4;pital Universitaire), Montevideo, Uruguay.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>03</Month><Day>08</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Minerva Anestesiol</MedlineTA><NlmUniqueID>0375272</NlmUniqueID><ISSNLinking>0375-9393</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018685">Anesthetics, Inhalation</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006219">Halogens</NameOfSubstance></Chemical></ChemicalList><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Minerva Anestesiol. 2017 Jul;83(7):679-681. doi: 10.23736/S0375-9393.17.12141-3.</RefSource><PMID Version="1">28528539</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000769" MajorTopicYN="N">Anesthesia, Inhalation</DescriptorName><QualifierName UI="Q000295" MajorTopicYN="N">instrumentation</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018685" MajorTopicYN="N">Anesthetics, Inhalation</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D054810" MajorTopicYN="N">Deep Sedation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004867" MajorTopicYN="N">Equipment Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006219" MajorTopicYN="N">Halogens</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014835" MajorTopicYN="N">Volatilization</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>7</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>3</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28275227</ArticleId><ArticleId IdType="doi">10.23736/S0375-9393.17.11735-9</ArticleId><ArticleId IdType="pii">S0375-9393.17.11735-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32780121</PMID><DateCompleted><Year>2020</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2574-3805</ISSN><JournalIssue CitedMedium="Internet"><Volume>3</Volume><Issue>8</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>JAMA network open</Title><ISOAbbreviation>JAMA Netw Open</ISOAbbreviation></Journal><ArticleTitle>Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children.</ArticleTitle><Pagination><StartPage>e209271</StartPage><MedlinePgn>e209271</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e209271</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamanetworkopen.2020.9271</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Multiple organ dysfunction syndrome (MODS) is a dynamic and heterogeneous process associated with high morbidity and mortality in critically ill children.</AbstractText><AbstractText Label="OBJECTIVE">To determine whether data-driven phenotypes of MODS based on the trajectories of 6 organ dysfunctions have prognostic and therapeutic relevance in critically ill children.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">This cohort study included 20&#x202f;827 pediatric intensive care encounters among 14&#x202f;285 children admitted to 2 large academic pediatric intensive care units (PICUs) between January 2010 and August 2016. Patients were excluded if they were older than 21 years or had undergone cardiac surgery. The 6 subscores of the pediatric Sequential Organ Failure Assessment (pSOFA) score were calculated for the first 3 days, including the subscores for respiratory, cardiovascular, coagulation, hepatic, neurologic, and renal dysfunctions. MODS was defined as a pSOFA subscore of at least 2 in at least 2 organs. Encounters were split in a 80:20 ratio for derivation and validation, respectively. The trajectories of the 6 subscores were used to derive a set of data-driven phenotypes of MODS using subgraph-augmented nonnegative matrix factorization in the derivation set. Data analysis was conducted from March to October 2019.</AbstractText><AbstractText Label="EXPOSURES">The primary exposure was phenotype membership. In the subset of patients with vasoactive-dependent shock, the interaction between hydrocortisone and phenotype membership and its association with outcomes were examined in a matched cohort.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome was in-hospital mortality. Secondary outcomes included persistent MODS on day 7, and vasoactive-free, ventilator-free, and hospital-free days. Regression analysis was used to adjust for age, severity of illness, immunocompromised status, and study site.</AbstractText><AbstractText Label="RESULTS">There were 14&#x202f;285 patients with 20&#x202f;827 encounters (median [interquartile range] age 5.2 years [1.5-12.7] years; 11&#x202f;409 [54.8%; 95% CI, 54.1%-55.5%] male patients). Of these, 5297 encounters (25.4%; 95% CI, 24.8%-26.0%) were with patients who had MODS, of which 5054 (95.4%) met the subgraph count threshold and were included in the analysis. Subgraph augmented nonnegative matrix factorization uncovered 4 data-driven phenotypes of MODS, characterized by a combination of neurologic, respiratory, coagulation, and cardiovascular dysfunction, as follows: phenotype 1, severe, persistent encephalopathy (1019 patients [19.2%]); phenotype 2, moderate, resolving hypoxemia (1828 patients [34.5%]); phenotype 3, severe, persistent hypoxemia and shock (1012 patients [19.1%]); and phenotype 4, moderate, persistent thrombocytopenia and shock (1195 patients [22.6%]). These phenotypes were reproducible in a validation set of encounters, had distinct clinical characteristics, and were independently associated with outcomes. For example, using phenotype 2 as reference, the adjusted hazard ratios (aHRs) for death by 28 days were as follows: phenotype 1, aHR of 3.0 (IQR, 2.1-4.3); phenotype 3, aHR of 2.8 (IQR, 2.0-4.1); and phenotype 4, aHR of 1.8 (IQR, 1.2-2.6). Interaction analysis in a matched cohort of patients with vasoactive-dependent shock revealed that hydrocortisone had differential treatment association with vasoactive-free days across phenotypes. For example, patients in phenotype 3 who received hydrocortisone had more vasoactive-free days than those who did not (23 days vs 18 days; P for interaction&#x2009;&lt;&#x2009;.001), whereas patients in other phenotypes who received hydrocortisone either had no difference or had less vasoactive-free days.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">In this study, data-driven phenotyping in critically ill children with MODS uncovered 4 distinct and reproducible phenotypes with prognostic relevance and possible therapeutic relevance. Further validation and characterization of these phenotypes is warranted.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Critical Care, Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Health and Biomedical Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Driskill Graduate Program, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pendergrast</LastName><ForeName>Tricia</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pinto</LastName><ForeName>Neethi</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Section of Critical Care, Department of Pediatrics, The University of Chicago, Chicago, Illinois.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Health and Biomedical Informatics, Department of Preventive Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 LM012203</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 LM012618</GrantID><Acronym>LM</Acronym><Agency>NLM NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD096402</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Netw Open</MedlineTA><NlmUniqueID>101729235</NlmUniqueID><ISSNLinking>2574-3805</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="Y">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> None reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32780121</ArticleId><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.9271</ArticleId><ArticleId IdType="pii">2769144</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Tamburro RF, Jenkins TL. Multiple organ dysfunction syndrome: a challenge for the pediatric critical care community. Pediatr Crit Care Med. 2017;18(3_suppl)(suppl 1):S1-S3.</Citation><ArticleIdList><ArticleId IdType="pubmed">28248828</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Pinto NP, Sanchez-Pinto LN. Association of organ dysfunction scores and functional outcomes following pediatric critical illness. Pediatr Crit Care Med. 2019;20(8):722-727. doi:10.1097/PCC.0000000000001999</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001999</ArticleId><ArticleId IdType="pubmed">31398181</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F; Groupe Francophone de R&#xe9;animation et d&#x2019;Urgences P&#xe9;diatriques (GFRUP) . PELOD-2: an update of the Pediatric Logistic Organ Dysfunction score. Crit Care Med. 2013;41(7):1761-1773. doi:10.1097/CCM.0b013e31828a2bbd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, et al. ; Sepsis Prevalence, Outcomes, and Therapy Study Investigators . New or progressive multiple organ dysfunction syndrome in pediatric severe sepsis: a sepsis phenotype with higher morbidity and mortality. Pediatr Crit Care Med. 2017;18(1):8-16. doi:10.1097/PCC.0000000000000978</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000978</ArticleId><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Deken V, Lacroix J, Leclerc F; Groupe Francophone de R&#xe9;animation et Urgences P&#xe9;diatriques . Daily estimation of the severity of organ dysfunctions in critically ill children by using the PELOD-2 score. Crit Care. 2015;19:324. doi:10.1186/s13054-015-1054-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-1054-y</ArticleId><ArticleId IdType="pmc">PMC4570178</ArticleId><ArticleId IdType="pubmed">26369662</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Gavrilin MA, Knatz NL, Duncan MD, Fernandez SA, Wewers MD. Monocyte mRNA phenotype and adverse outcomes from pediatric multiple organ dysfunction syndrome. Pediatr Res. 2007;62(5):597-603. doi:10.1203/PDR.0b013e3181559774</Citation><ArticleIdList><ArticleId IdType="doi">10.1203/PDR.0b013e3181559774</ArticleId><ArticleId IdType="pubmed">17805202</ArticleId></ArticleIdList></Reference><Reference><Citation>Upperman JS, Lacroix J, Curley MA, et al. . Specific etiologies associated with the multiple organ dysfunction syndrome in children: part 1. Pediatr Crit Care Med. 2017;18(3_suppl)(suppl 1):S50-S57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333126</ArticleId><ArticleId IdType="pubmed">28248834</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Podd B, Aneja R, et al. . Pathophysiology of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017;18(3_suppl)(suppl 1):S32-S45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333491</ArticleId><ArticleId IdType="pubmed">28248832</ArticleId></ArticleIdList></Reference><Reference><Citation>Seely AJ, Christou NV. Multiple organ dysfunction syndrome: exploring the paradigm of complex nonlinear systems. Crit Care Med. 2000;28(7):2193-2200. doi:10.1097/00003246-200007000-00003</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200007000-00003</ArticleId><ArticleId IdType="pubmed">10921540</ArticleId></ArticleIdList></Reference><Reference><Citation>An G, Nieman G, Vodovotz Y. Computational and systems biology in trauma and sepsis: current state and future perspectives. Int J Burns Trauma. 2012;2(1):1-10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415970</ArticleId><ArticleId IdType="pubmed">22928162</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Sherwood ER. Immunology: getting sepsis therapy right. Science. 2015;347(6227):1201-1202. doi:10.1126/science.aaa8334</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.aaa8334</ArticleId><ArticleId IdType="pmc">PMC4398343</ArticleId><ArticleId IdType="pubmed">25766219</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. . Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015;191(3):309-315. doi:10.1164/rccm.201410-1864OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201410-1864OC</ArticleId><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Berg RA, Wessel D, et al. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network . A multicenter network assessment of three inflammation phenotypes in pediatric sepsis-induced multiple organ failure. Pediatr Crit Care Med. 2019;20(12):1137-1146. doi:10.1097/PCC.0000000000002105</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000002105</ArticleId><ArticleId IdType="pmc">PMC8121153</ArticleId><ArticleId IdType="pubmed">31568246</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Kennedy JN, Wang S, et al. . Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003-2017. doi:10.1001/jama.2019.5791</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.5791</ArticleId><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox DB, Lanspa MJ, Kuttler KG, Brewer SC, Brown SM. Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. Intensive Care Med. 2015;41(5):814-822. doi:10.1007/s00134-015-3764-7</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-3764-7</ArticleId><ArticleId IdType="pmc">PMC4607311</ArticleId><ArticleId IdType="pubmed">25851384</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee CS, Delucchi K, Parsons PE, Thompson BT, Ware LB, Matthay MA; NHLBI ARDS Network . Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014;2(8):611-620. doi:10.1016/S2213-2600(14)70097-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(14)70097-9</ArticleId><ArticleId IdType="pmc">PMC4154544</ArticleId><ArticleId IdType="pubmed">24853585</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweeney TE, Azad TD, Donato M, et al. . Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters. Crit Care Med. 2018;46(6):915-925. doi:10.1097/CCM.0000000000003084</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000003084</ArticleId><ArticleId IdType="pmc">PMC5953807</ArticleId><ArticleId IdType="pubmed">29537985</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gomez H, Chang CH, et al. . Precision medicine for all? challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21(1):257. doi:10.1186/s13054-017-1836-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-017-1836-5</ArticleId><ArticleId IdType="pmc">PMC5648512</ArticleId><ArticleId IdType="pubmed">29047353</ArticleId></ArticleIdList></Reference><Reference><Citation>Saria S, Goldenberg A. Subtyping: what it is and its role in precision medicine. IEEE Intell Syst. 2015;30(4):70-75. doi:10.1109/MIS.2015.60</Citation><ArticleIdList><ArticleId IdType="doi">10.1109/MIS.2015.60</ArticleId></ArticleIdList></Reference><Reference><Citation>Schulam P, Wigley F, Saria S Clustering longitudinal clinical marker trajectories from electronic health data: applications to phenotyping and endotype discovery. Paper presented at: 29th Conference on Artificial Intelligence; January 25-30, 2015; Austin, TX.</Citation></Reference><Reference><Citation>Luo Y, Xin Y, Joshi R, Celi LA, Szolovits P Predicting ICU mortality risk by grouping temporal trends from a multivariate panel of physiologic measurements. Paper presented at: 30th AAAI Conference; February 12-17, 2016; Phoenix, AZ.</Citation></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019;200(3):327-335. doi:10.1164/rccm.201806-1197OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201806-1197OC</ArticleId><ArticleId IdType="pmc">PMC6680307</ArticleId><ArticleId IdType="pubmed">30789749</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno R, Vincent J-L, Matos R, et al. . The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care: results of a prospective, multicentre study, Working Group on Sepsis-Related Problems of the ESICM. Intensive Care Med. 1999;25(7):686-696. doi:10.1007/s001340050931</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340050931</ArticleId><ArticleId IdType="pubmed">10470572</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Sanchez-Pinto LN. Adaptation and validation of a pediatric Sequential Organ Failure Assessment score and evaluation of the Sepsis-3 definitions in critically ill children. JAMA Pediatr. 2017;171(10):e172352. doi:10.1001/jamapediatrics.2017.2352</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapediatrics.2017.2352</ArticleId><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated Pediatric Risk of Mortality score. Crit Care Med. 1996;24(5):743-752. doi:10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14(1):199. doi:10.1186/1471-2431-14-199</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2431-14-199</ArticleId><ArticleId IdType="pmc">PMC4134331</ArticleId><ArticleId IdType="pubmed">25102958</ArticleId></ArticleIdList></Reference><Reference><Citation>Borgelt C, Meinl T, Berthold M. MoSS: a program for molecular substructure mining. Proc First Int Workshop on Open Source Data Mining. 2005:6-15. doi:10.1145/1133905.1133908</Citation><ArticleIdList><ArticleId IdType="doi">10.1145/1133905.1133908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaujoux R, Seoighe C. A flexible R package for nonnegative matrix factorization. BMC Bioinformatics. 2010;11(1):367. doi:10.1186/1471-2105-11-367</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2105-11-367</ArticleId><ArticleId IdType="pmc">PMC2912887</ArticleId><ArticleId IdType="pubmed">20598126</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33(7):1484-1491. doi:10.1097/01.CCM.0000170943.23633.47</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000170943.23633.47</ArticleId><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, et al. . Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making. 1999;19(4):399-410. doi:10.1177/0272989X9901900408</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9901900408</ArticleId><ArticleId IdType="pubmed">10520678</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. . Endotype transitions during the acute phase of pediatric septic shock reflect changing risk and treatment response. Crit Care Med. 2018;46(3):e242-e249. doi:10.1097/CCM.0000000000002932</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002932</ArticleId><ArticleId IdType="pmc">PMC5825261</ArticleId><ArticleId IdType="pubmed">29252929</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Renault A, Brun-Buisson C, et al. ; CRICS-TRIGGERSEP Network . Hydrocortisone plus fludrocortisone for adults with septic shock. N Engl J Med. 2018;378(9):809-818. doi:10.1056/NEJMoa1705716</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705716</ArticleId><ArticleId IdType="pubmed">29490185</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon K, McNally JD. Corticosteroids in pediatric septic shock are helpful. Crit Care Med. 2018;46(4):635-636. doi:10.1097/CCM.0000000000002979</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002979</ArticleId><ArticleId IdType="pubmed">29360665</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon K, McNally JD, Choong K, et al. . A survey of stated physician practices and beliefs on the use of steroids in pediatric fluid and/or vasoactive infusion-dependent shock. Pediatr Crit Care Med. 2013;14(5):462-466. doi:10.1097/PCC.0b013e31828a7287</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31828a7287</ArticleId><ArticleId IdType="pubmed">23628832</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprung CL, Annane D, Keh D, et al. ; CORTICUS Study Group . Hydrocortisone therapy for patients with septic shock. N Engl J Med. 2008;358(2):111-124. doi:10.1056/NEJMoa071366</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa071366</ArticleId><ArticleId IdType="pubmed">18184957</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesh B, Finfer S, Cohen J, et al. ; ADRENAL Trial Investigators and the Australian&#x2013;New Zealand Intensive Care Society Clinical Trials Group . Adjunctive glucocorticoid therapy in patients with septic shock. N Engl J Med. 2018;378(9):797-808. doi:10.1056/NEJMoa1705835</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1705835</ArticleId><ArticleId IdType="pubmed">29347874</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP; STROBE Initiative . The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med. 2007;147(8):573-577. doi:10.7326/0003-4819-147-8-200710160-00010</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-147-8-200710160-00010</ArticleId><ArticleId IdType="pubmed">17938396</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, S&#xe9;bille V, Bellissant E; Ger-Inf-05 Study Group . Effect of low doses of corticosteroids in septic shock patients with or without early acute respiratory distress syndrome. Crit Care Med. 2006;34(1):22-30. doi:10.1097/01.CCM.0000194723.78632.62</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000194723.78632.62</ArticleId><ArticleId IdType="pubmed">16374152</ArticleId></ArticleIdList></Reference><Reference><Citation>Tongyoo S, Permpikul C, Mongkolpun W, et al. . Hydrocortisone treatment in early sepsis-associated acute respiratory distress syndrome: results of a randomized controlled trial. Crit Care. 2016;20(1):329. doi:10.1186/s13054-016-1511-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1511-2</ArticleId><ArticleId IdType="pmc">PMC5065699</ArticleId><ArticleId IdType="pubmed">27741949</ArticleId></ArticleIdList></Reference><Reference><Citation>Kochanek PM, Tasker RC, Carney N, et al. . Guidelines for the management of pediatric severe traumatic brain injury, third edition: update of the Brain Trauma Foundation guidelines. Pediatr Crit Care Med. 2019;20(3S)(suppl 1):S1-S82. doi:10.1097/PCC.0000000000001735</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001735</ArticleId><ArticleId IdType="pubmed">30829890</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald JC, Weiss SL, Maude SL, et al. . Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med. 2017;45(2):e124-e131. doi:10.1097/CCM.0000000000002053</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000002053</ArticleId><ArticleId IdType="pmc">PMC5452983</ArticleId><ArticleId IdType="pubmed">27632680</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall MW, Knatz NL, Vetterly C, et al. . Immunoparalysis and nosocomial infection in children with multiple organ dysfunction syndrome. Intensive Care Med. 2011;37(3):525-532. doi:10.1007/s00134-010-2088-x</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-010-2088-x</ArticleId><ArticleId IdType="pmc">PMC5224706</ArticleId><ArticleId IdType="pubmed">21153402</ArticleId></ArticleIdList></Reference><Reference><Citation>Shakoory B, Carcillo JA, Chatham WW, et al. . Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of the macrophage activation syndrome: re-analysis of a prior phase III trial. Crit Care Med. 2016;44(2):275-281. doi:10.1097/CCM.0000000000001402</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001402</ArticleId><ArticleId IdType="pmc">PMC5378312</ArticleId><ArticleId IdType="pubmed">26584195</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37272946</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>29</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1529-7535</ISSN><JournalIssue CitedMedium="Internet"><Volume>24</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title><ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Derivation, Validation, and Clinical Relevance of a Pediatric Sepsis Phenotype With Persistent Hypoxemia, Encephalopathy, and Shock.</ArticleTitle><Pagination><StartPage>795</StartPage><EndPage>806</EndPage><MedlinePgn>795-806</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0000000000003292</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Untangling the heterogeneity of sepsis in children and identifying clinically relevant phenotypes could lead to the development of targeted therapies. Our aim was to analyze the organ dysfunction trajectories of children with sepsis-associated multiple organ dysfunction syndrome (MODS) to identify reproducible and clinically relevant sepsis phenotypes and determine if they are associated with heterogeneity of treatment effect (HTE) to common therapies.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Multicenter observational cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Thirteen PICUs in the United States.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Patients admitted with suspected infections to the PICU between 2012 and 2018.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">We used subgraph-augmented nonnegative matrix factorization to identify candidate trajectory-based phenotypes based on the type, severity, and progression of organ dysfunction in the first 72 hours. We analyzed the candidate phenotypes to determine reproducibility as well as prognostic, therapeutic, and biological relevance. Overall, 38,732 children had suspected infection, of which 15,246 (39.4%) had sepsis-associated MODS with an in-hospital mortality of 10.1%. We identified an organ dysfunction trajectory-based phenotype (which we termed persistent hypoxemia, encephalopathy, and shock) that was highly reproducible, had features of systemic inflammation and coagulopathy, and was independently associated with higher mortality. In a propensity score-matched analysis, patients with persistent hypoxemia, encephalopathy, and shock phenotype appeared to have HTE and benefit from adjuvant therapy with hydrocortisone and albumin. When compared with other high-risk clinical syndromes, the persistent hypoxemia, encephalopathy, and shock phenotype only overlapped with 50%-60% of patients with septic shock, moderate-to-severe pediatric acute respiratory distress syndrome, or those in the top tier of organ dysfunction burden, suggesting that it represents a nonsynonymous clinical phenotype of sepsis-associated MODS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">We derived and validated the persistent hypoxemia, encephalopathy, and shock phenotype, which is highly reproducible, clinically relevant, and associated with HTE to common adjuvant therapies in children with sepsis.</AbstractText><CopyrightInformation>Copyright &#xa9; 2023 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University Feinberg School of Medicine and Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bennett</LastName><ForeName>Tellen D</ForeName><Initials>TD</Initials><AffiliationInfo><Affiliation>Departments of Biomedical Informatics and Pediatrics, University of Colorado School of Medicine, Aurora, CO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stroup</LastName><ForeName>Emily K</ForeName><Initials>EK</Initials><AffiliationInfo><Affiliation>Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atreya</LastName><ForeName>Mihir</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bubeck Wardenburg</LastName><ForeName>Juliane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Washington University School of Medicine, St. Louis, MO.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Geva</LastName><ForeName>Alon</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, Critical Care, and Pain Medicine, Boston Children's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Computational Health Informatics Program, Boston Children's Hospital, Boston, MA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anaesthesia, Harvard Medical School, Boston, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Faustino</LastName><ForeName>E Vincent S</ForeName><Initials>EVS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Yale School of Medicine, New Haven, CT.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Farris</LastName><ForeName>Reid W</ForeName><Initials>RW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Washington and Seattle Children's Hospital, Seattle, WA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hall</LastName><ForeName>Mark W</ForeName><Initials>MW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, The Ohio State University and Nationwide Children's Hospital, Columbus, OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rogerson</LastName><ForeName>Colin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shah</LastName><ForeName>Sareen S</ForeName><Initials>SS</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Cohen Children's Medical Center, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, NY.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weiss</LastName><ForeName>Scott L</ForeName><Initials>SL</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care, Children's Hospital of Philadelphia, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khemani</LastName><ForeName>Robinder G</ForeName><Initials>RG</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology and Critical Care Medicine, Children's Hospital of Los Angeles, Los Angeles, CA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD105939</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD096402</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 TR001863</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>06</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Crit Care Med</MedlineTA><NlmUniqueID>100954653</NlmUniqueID><ISSNLinking>1529-7535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000092522" MajorTopicYN="N">Clinical Relevance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="Y">Shock, Septic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010641" MajorTopicYN="N">Phenotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001927" MajorTopicYN="Y">Brain Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000860" MajorTopicYN="N">Hypoxia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>Drs. Sanchez-Pinto, Bennett, and Shah&#x2019;s institutions received funding from the National Institute of Child Health and Human Development. Dr. Sanchez-Pinto&#x2019;s institution received funding from the National Institute of General Medical Sciences. Drs. Sanchez-Pinto, Bennett, Luo, Bubeck-Wardenburg, Faustino, Hall, Rogerson, Shah, Weiss, and Khemani received support for article research from the National Institutes of Health (NIH). Dr. Bennett&#x2019;s institution received funding from the National Center for Advancing Translational Sciences and the National Heart, Lung, and Blood Institute. Drs. Luo, Bubeck-Wardenburg, Faustino, Hall, Rogerson, Weiss, and Khemani&#x2019;s institutions received funding from the NIH. Dr. Bubeck-Wardenburg&#x2019;s institution received funding from the National Institute of Allergy and Infectious Diseases; she disclosed that she has a financial relationship with Aridis Pharmaceuticals related to intellectual property owned by the University of Chicago. Dr. Hall received funding from Abbvie, Kiadis, and the American Board of Pediatrics. Dr. Khemani received funding from OrangeMed and Bayer. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>29</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>13</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>6</Month><Day>5</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>9</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37272946</ArticleId><ArticleId IdType="mid">NIHMS1899354</ArticleId><ArticleId IdType="pmc">PMC10540758</ArticleId><ArticleId IdType="doi">10.1097/PCC.0000000000003292</ArticleId><ArticleId IdType="pii">00130478-990000000-00218</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Matics TJ, Sanchez-Pinto LN: Adaptation and validation of a pediatric Sequential Organ Failure Assessment score and evaluation of the sepsis-3 definitions in critically ill children. JAMA Pediatr. 2017; 171:e172352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Balamuth F, Hensley J, et al. : The epidemiology of hospital death following pediatric severe sepsis: when, why, and how children with sepsis die. Pediatr Crit Care Med. 2017; 18:823&#x2013;830</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5581233</ArticleId><ArticleId IdType="pubmed">28549024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Stroup EK, Pendergrast T, et al. : Derivation and validation of novel phenotypes of multiple organ dysfunction syndrome in critically ill children. JAMA Netw Open. 2020; 3:e209271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="pubmed">32780121</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, et al. : New or progressive multiple organ dysfunction syndrome in pediatric severe sepsis. Pediatr Crit Care Med. 2017; 18:8&#x2013;16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, et al. ; Sepsis Prevalence, Outcomes, and Therapies (SPROUT) Study Investigators and Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network: Global epidemiology of pediatric severe sepsis: The sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015; 191:1147&#x2013;1157</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Rudd KE, Johnson SC, Agesa KM, et al. : Global, regional, and national sepsis incidence and mortality, 1990-2017: Analysis for the Global Burden of Disease Study. Lancet. 2020; 395:200&#x2013;211</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6970225</ArticleId><ArticleId IdType="pubmed">31954465</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. : Developing a clinically feasible personalized medicine approach to pediatric septic shock. Am J Respir Crit Care Med. 2015; 191:309&#x2013;315</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Berg RA, Wessel D, et al. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network: A multicenter network assessment of three inflammation phenotypes in pediatric sepsis-induced multiple organ failure. Pediatr Crit Care Med. 2019; 20:1137&#x2013;1146</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121153</ArticleId><ArticleId IdType="pubmed">31568246</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah FA, Meyer NJ, Angus DC, et al. : A research agenda for precision medicine in sepsis and acute respiratory distress syndrome: An Official American Thoracic Society Research Statement. Am J Respir Crit Care Med. 2021; 204:891&#x2013;901</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8534611</ArticleId><ArticleId IdType="pubmed">34652268</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z, Mao C, Su C, et al. : Sepsis subphenotyping based on organ dysfunction trajectory. Crit Care. 2022; 26:197.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9250715</ArticleId><ArticleId IdType="pubmed">35786445</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. : Endotype transitions during the acute phase of pediatric septic shock reflect changing risk and treatment response. Crit Care Med. 2018; 46:e242&#x2013;e249</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5825261</ArticleId><ArticleId IdType="pubmed">29252929</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Kennedy JN, Wang S, et al. : Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019; 321:2003&#x2013;2017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Knox DB, Lanspa MJ, Kuttler KG, et al. : Phenotypic clusters within sepsis-associated multiple organ dysfunction syndrome. Intensive Care Med. 2015; 41:814&#x2013;822</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4607311</ArticleId><ArticleId IdType="pubmed">25851384</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, et al. : Identifying novel sepsis subphenotypes using temperature trajectories. Am J Respir Crit Care Med. 2019; 200:327&#x2013;335</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680307</ArticleId><ArticleId IdType="pubmed">30789749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Semler M, Qian ET, et al. : Development and validation of novel sepsis subphenotypes using trajectories of vital signs. Intensive Care Med. 2022;48:1582&#x2013;1592</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9510534</ArticleId><ArticleId IdType="pubmed">36152041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Wolfe KS, Hrusch CL, et al. : Temperature trajectory subphenotypes correlate with immune responses in patients with sepsis. Crit Care Med. 2020; 48:1645&#x2013;1653</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7837282</ArticleId><ArticleId IdType="pubmed">32947475</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Balamuth F, Chilutti M, et al. : Identification of pediatric sepsis for epidemiologic surveillance using electronic clinical data. Pediatr Crit Care Med. 2020; 21:113&#x2013;121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008717</ArticleId><ArticleId IdType="pubmed">32032262</ArticleId></ArticleIdList></Reference><Reference><Citation>Scott HF, Brilli RJ, Paul R, et al. ; Improving Pediatric Sepsis Outcomes (IPSO) Collaborative Investigators: Evaluating pediatric sepsis definitions designed for electronic health record extraction and multicenter quality improvement. Crit Care Med. 2020; 48:e916&#x2013;e926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7677030</ArticleId><ArticleId IdType="pubmed">32931197</ArticleId></ArticleIdList></Reference><Reference><Citation>von Elm E, Altman DG, Egger M, et al. : The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. PLoS Med. 2007; 4:e296.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2020495</ArticleId><ArticleId IdType="pubmed">17941714</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno R, Vincent JL, Matos R, et al. : The use of maximum SOFA score to quantify organ dysfunction/failure in intensive care. Results of a Prospective, Multicentre STUDY. Working group on sepsis related problems of the ESICM. Intensive Care Med. 1999; 25:686&#x2013;696</Citation><ArticleIdList><ArticleId IdType="pubmed">10470572</ArticleId></ArticleIdList></Reference><Reference><Citation>Raith EP, Udy AA, Bailey M, et al. ; Australian and New Zealand Intensive Care Society (ANZICS) Centre for Outcomes and Resource Evaluation (CORE): Prognostic Accuracy of the SOFA Score, SIRS Criteria, and qSOFA score for in-hospital mortality among adults with suspected infection admitted to the intensive care unit. JAMA. 2017; 317:290&#x2013;300</Citation><ArticleIdList><ArticleId IdType="pubmed">28114553</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Liu VX, Iwashyna TJ, et al. : Assessment of clinical criteria for sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315:762&#x2013;774</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5433435</ArticleId><ArticleId IdType="pubmed">26903335</ArticleId></ArticleIdList></Reference><Reference><Citation>Moons KGM, Altman DG, Reitsma JB, et al. : Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis (TRIPOD): Explanation and elaboration. Ann Intern Med. 2015; 162:W1&#x2013;73</Citation><ArticleIdList><ArticleId IdType="pubmed">25560730</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMerle KM, Angus DC, Baillie JK, et al. : Sepsis subclasses: A framework for development and interpretation. Crit Care Med. 2021; 49:748&#x2013;759</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627188</ArticleId><ArticleId IdType="pubmed">33591001</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruse N, Kooistra EJ, Jansen A, et al. : Clinical sepsis phenotypes in critically ill COVID-19 patients. Crit Care. 2022; 26:244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9361232</ArticleId><ArticleId IdType="pubmed">35945618</ArticleId></ArticleIdList></Reference><Reference><Citation>Calfee CS, Delucchi K, Parsons PE, et al. ; NHLBI ARDS Network: Subphenotypes in acute respiratory distress syndrome: Latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014; 2:611&#x2013;620</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4154544</ArticleId><ArticleId IdType="pubmed">24853585</ArticleId></ArticleIdList></Reference><Reference><Citation>Dahmer MK, Yang G, Zhang M, et al. ; RESTORE and BALI study investigators: Identification of phenotypes in paediatric patients with acute respiratory distress syndrome: A latent class analysis. Lancet Respir Med. 2022; 10:289&#x2013;297</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8897230</ArticleId><ArticleId IdType="pubmed">34883088</ArticleId></ArticleIdList></Reference><Reference><Citation>Sinha P, Delucchi KL, Chen Y, et al. : Latent class analysis-derived subphenotypes are generalisable to observational cohorts of acute respiratory distress syndrome: A prospective study. Thorax. 2022; 77:13&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8688287</ArticleId><ArticleId IdType="pubmed">34253679</ArticleId></ArticleIdList></Reference><Reference><Citation>Alipanah N, Calfee CS: Phenotyping in acute respiratory distress syndrome: State of the art and clinical implications. Curr Opin Crit Care. 2022; 28:1&#x2013;8</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8782441</ArticleId><ArticleId IdType="pubmed">34670998</ArticleId></ArticleIdList></Reference><Reference><Citation>Famous KR, Delucchi K, Ware LB, et al. ; ARDS Network: Acute respiratory distress syndrome subphenotypes respond differently to randomized fluid management strategy. Am J Respir Crit Care Med. 2017; 195:331&#x2013;338</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5328179</ArticleId><ArticleId IdType="pubmed">27513822</ArticleId></ArticleIdList></Reference><Reference><Citation>Perizes EN, Chong G, Sanchez-Pinto LN: Derivation and validation of vasoactive inotrope score trajectory groups in critically ill children with shock. Pediatr Crit Care Med. 2022; 23:1017&#x2013;1026</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722555</ArticleId><ArticleId IdType="pubmed">36053068</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Kernan KK, Horvat CM, et al. : Why and how is hyperferritinemic sepsis different from sepsis without hyperferritinemia? Pediatr Crit Care Med. 2020; 21:509&#x2013;512</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8121152</ArticleId><ArticleId IdType="pubmed">32358338</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Halstead ES, Hall MW, et al. ; Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network Investigators: Three hypothetical inflammation pathobiology phenotypes and pediatric sepsis-induced multiple organ failure outcome. Pediatr Crit Care Med. 2017; 18:513&#x2013;523</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5457354</ArticleId><ArticleId IdType="pubmed">28410274</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin Y, Kernan KF, Fan Z, et al. : Machine learning derivation of four computable 24-h pediatric sepsis phenotypes to facilitate enrollment in early personalized anti-inflammatory clinical trials. Crit Care. 2022; 26:128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9077858</ArticleId><ArticleId IdType="pubmed">35526000</ArticleId></ArticleIdList></Reference><Reference><Citation>Horvat CM, Fabio A, Nagin DS, et al. ; on behalf of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Collaborative Pediatric Critical Care Research Network: Mortality risk in pediatric sepsis based on C-reactive protein and ferritin levels. Pediatr Crit Care Med. 2022; 23:968&#x2013;979</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9722561</ArticleId><ArticleId IdType="pubmed">36178701</ArticleId></ArticleIdList></Reference><Reference><Citation>Herold S, Steinmueller M, von Wulffen W, et al. : Lung epithelial apoptosis in influenza virus pneumonia: The role of macrophage-expressed TNF-related apoptosis-inducing ligand. J Exp Med. 2008; 205:3065&#x2013;3077</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2605231</ArticleId><ArticleId IdType="pubmed">19064696</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin KL, Suzuki Y, Nakano H, et al. : CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. J Immunol. 2008; 180:2562&#x2013;2572</Citation><ArticleIdList><ArticleId IdType="pubmed">18250467</ArticleId></ArticleIdList></Reference><Reference><Citation>Coates BM, Staricha KL, Koch CM, et al. : Inflammatory monocytes drive influenza a virus-mediated lung injury in juvenile mice. J Immunol. 2018; 200:2391&#x2013;2404</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5860989</ArticleId><ArticleId IdType="pubmed">29445006</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar V: Pulmonary innate immune response determines the outcome of inflammation during pneumonia and sepsis-associated acute lung injury. Front Immunol. 2020; 11: 1722.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7417316</ArticleId><ArticleId IdType="pubmed">32849610</ArticleId></ArticleIdList></Reference><Reference><Citation>Villar J, Ferrando C, Mart&#xed;nez D, et al. ; dexamethasone in ARDS network: Dexamethasone treatment for the acute respiratory distress syndrome: A multicentre, randomised controlled trial. Lancet Respir Med. 2020; 8:267&#x2013;276</Citation><ArticleIdList><ArticleId IdType="pubmed">32043986</ArticleId></ArticleIdList></Reference><Reference><Citation>Menon K, Schlapbach LJ, Akech S, et al. ; Pediatric Sepsis Definition Taskforce of the Society of Critical Care Medicine: Criteria for pediatric sepsis&#x2014;a systematic review and meta-analysis by the pediatric sepsis definition taskforce. Crit Care Med. 2022; 50:21&#x2013;36</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8670345</ArticleId><ArticleId IdType="pubmed">34612847</ArticleId></ArticleIdList></Reference><Reference><Citation>Maddali MV, Churpek M, Pham T, et al. ; LUNG SAFE Investigators and the ESICM Trials Group: Validation and utility of ARDS subphenotypes identified by machine-learning models using clinical data: An observational, multicohort, retrospective analysis. Lancet Respir Med. 2022; 10:367&#x2013;377</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8976729</ArticleId><ArticleId IdType="pubmed">35026177</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlton EF, McHugh WM, McDonough K, et al. : Markers of endothelial dysfunction and cytokines in high-risk pediatric patients with severe sepsis. Am J Respir Crit Care Med. 2020; 201:380&#x2013;384</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6999097</ArticleId><ArticleId IdType="pubmed">31597044</ArticleId></ArticleIdList></Reference><Reference><Citation>Badke CM, Carroll MS, Weese-Mayer DE, et al. : Association between heart rate variability and inflammatory biomarkers in critically ill children. Pediatr Crit Care Med. 2022; 23:e289&#x2013;e294</Citation><ArticleIdList><ArticleId IdType="pubmed">35293369</ArticleId></ArticleIdList></Reference><Reference><Citation>Badke CM, Marsillio LE, Carroll MS, et al. : Development of a heart rate variability risk score to predict organ dysfunction and death in critically ill children. Pediatr Crit Care Med. 2021; 22:e437&#x2013;e447</Citation><ArticleIdList><ArticleId IdType="pubmed">33710071</ArticleId></ArticleIdList></Reference><Reference><Citation>Kreif N: Learning from an association analysis using propensity scores. Pediatr Crit Care Med. 2021; 22:108810881092&#x2013;108810881092</Citation><ArticleIdList><ArticleId IdType="pubmed">34690327</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">27762438</PMID><DateCompleted><Year>2018</Year><Month>12</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1365-2044</ISSN><JournalIssue CitedMedium="Internet"><Volume>72</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Month>Jan</Month></PubDate></JournalIssue><Title>Anaesthesia</Title><ISOAbbreviation>Anaesthesia</ISOAbbreviation></Journal><ArticleTitle>The effect of inhaled nitric oxide in acute respiratory distress syndrome in children and adults: a Cochrane Systematic Review with trial sequential analysis.</ArticleTitle><Pagination><StartPage>106</StartPage><EndPage>117</EndPage><MedlinePgn>106-117</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/anae.13628</ELocationID><Abstract><AbstractText>Acute respiratory distress syndrome is associated with high mortality and morbidity. Inhaled nitric oxide has been used to improve oxygenation but its role remains controversial. Our primary objective in this systematic review was to examine the effects of inhaled nitric oxide administration on mortality in adults and children with acute respiratory distress syndrome. We included all randomised, controlled trials, irrespective of date of publication, blinding status, outcomes reported or language. Our primary outcome measure was all-cause mortality. We performed several subgroup and sensitivity analyses to assess the effect of inhaled nitric oxide. There was no statistically significant effect of inhaled nitric oxide on longest follow-up mortality (inhaled nitric oxide group 250/654 deaths (38.2%) vs. control group 221/589 deaths (37.5%; relative risk (95% CI) 1.04 (0.9-1.19)). We found a significant improvement in PaO<sub>2</sub> /F<sub>I</sub> O<sub>2</sub> ratio at 24 h (mean difference (95% CI) 15.91 (8.25-23.56)), but not at 48 h or 72 h, while four trials indicated improved oxygenation in the inhaled nitric oxide group at 96 h (mean difference (95% CI) 14.51 (3.64-25.38)). There were no statistically significant differences in ventilator-free days, duration of mechanical ventilation, resolution of multi-organ failure, quality of life, length of stay in intensive care unit or hospital, cost-benefit analysis and methaemoglobin and nitrogen dioxide levels. There was an increased risk of renal impairment (risk ratio (95% CI) 1.59 (1.17-2.16)) with inhaled nitric oxide. In conclusion, there is insufficient evidence to support inhaled nitric oxide in any category of critically ill patients with acute respiratory distress syndrome despite a transient improvement in oxygenation, since mortality is not reduced and it may induce renal impairment.</AbstractText><CopyrightInformation>&#xa9; 2016 The Association of Anaesthetists of Great Britain and Ireland.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Karam</LastName><ForeName>O</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0001-6606-1736</Identifier><AffiliationInfo><Affiliation>Paediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gebistorf</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Paediatric Intensive Care Unit, Geneva University Hospital, Geneva, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wetterslev</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Copenhagen Trial Unit, Centre for Clinical Intervention Research, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afshari</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>The Cochrane Anaesthesia, Critical and Emergency Care Group and Copenhagen Trial Unit and Department of Paediatric and Obstetric Anaesthesia, Rigshospitalet, Copenhagen, Denmark.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D000078182">Systematic Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Anaesthesia</MedlineTA><NlmUniqueID>0370524</NlmUniqueID><ISSNLinking>0003-2409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001993">Bronchodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>31C4KY9ESH</RegistryNumber><NameOfSubstance UI="D009569">Nitric Oxide</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D055371" MajorTopicYN="N">Acute Lung Injury</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000280" MajorTopicYN="N">Administration, Inhalation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015982" MajorTopicYN="N">Bias</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001993" MajorTopicYN="N">Bronchodilator Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009569" MajorTopicYN="N">Nitric Oxide</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">nitric oxide</Keyword><Keyword MajorTopicYN="N">systematic review</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>7</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>12</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27762438</ArticleId><ArticleId IdType="doi">10.1111/anae.13628</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">40259139</PMID><DateCompleted><Year>2025</Year><Month>07</Month><Day>29</Day></DateCompleted><DateRevised><Year>2025</Year><Month>09</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1573-2614</ISSN><JournalIssue CitedMedium="Internet"><Volume>39</Volume><Issue>4</Issue><PubDate><Year>2025</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Journal of clinical monitoring and computing</Title><ISOAbbreviation>J Clin Monit Comput</ISOAbbreviation></Journal><ArticleTitle>Heart rate variability as a marker of multiple organ dysfunction syndromes: a systematic review.</ArticleTitle><Pagination><StartPage>717</StartPage><EndPage>729</EndPage><MedlinePgn>717-729</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s10877-025-01296-w</ELocationID><Abstract><AbstractText>Multiple organ dysfunction syndrome (MODS) can be caused by many factors. Assessments of the severity of MODS are currently based on occasional measurements of several clinical variables (laboratory data, vital signs, etc.). The analysis of heart rate variability (HRV) as a guide to autonomic nervous system activity might be of value in the continuous assessment of the severity of MODS. We systematically reviewed publications on the value of HRV variables for the diagnosis of MODS in patients of any age admitted to the ICU. Two investigators independently searched the PubMed, Embase, Cochrane and Science Direct databases for articles in English or French published between 2004 and 2024. Ten studies were included and rated for endpoint bias (MODS or mortality), using the revised Quality Assessment of Diagnostic Accuracy Studies. Nine studies assessed MODS, and six assessed mortality. All the studies evidenced low HRV in patients with MODS and in non-survivors. The results of our review show that HRV indices are influenced by the severity of MODS and might serve as a tool for predicting mortality in patients with MODS. However, patient characteristics, and treatments and HRV processing methods must be taken into account when interpreting the results. In order to clarify the impact of MODS on HRV variables, methodologically rigorous studies are now needed.</AbstractText><CopyrightInformation>&#xa9; 2025. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wojtanowski</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC IT 1403, 59000, Lille, France. anne.wojtanowski@chu-lille.fr.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 2694 METRICS, 59000, Lille, France. anne.wojtanowski@chu-lille.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hureau</LastName><ForeName>Maxence</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Department, CHU Lille, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 7365 GRITA, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeanne</LastName><ForeName>Mathieu</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC IT 1403, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anesthesia and Intensive Care Department, CHU Lille, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 7365 GRITA, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bureau</LastName><ForeName>C&#xf4;me</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>CHU Lille, Service de M&#xe9;decine Intensive-R&#xe9;animation, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Recher</LastName><ForeName>Morgan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Univ. Lille, ULR 2694 METRICS, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, CHU Lille, 59000, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>De Jonckheere</LastName><ForeName>Julien</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CHU Lille, CIC IT 1403, 59000, Lille, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Univ. Lille, ULR 2694 METRICS, 59000, Lille, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078182">Systematic Review</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2025</Year><Month>04</Month><Day>21</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>J Clin Monit Comput</MedlineTA><NlmUniqueID>9806357</NlmUniqueID><ISSNLinking>1387-1307</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006339" MajorTopicYN="Y">Heart Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001341" MajorTopicYN="N">Autonomic Nervous System</DescriptorName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autonomic nervous system</Keyword><Keyword MajorTopicYN="N">Heart rate variability</Keyword><Keyword MajorTopicYN="N">Intensive care unit</Keyword><Keyword MajorTopicYN="N">Mortality</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword></KeywordList><CoiStatement>Declarations. Competing interests: Mathieu Jeanne is a member of the editorial board of the Journal of Clinical Monitoring and Computing. Other authors have no relevant financial or non-financial interests to disclose. Ethical Standards: Not applicable. Informed Consent: This paper concerns a systematic review of already published studies. This research doesn't involve human subjects and doesn't require informed consent.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2025</Year><Month>3</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2025</Year><Month>4</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2025</Year><Month>7</Month><Day>29</Day><Hour>18</Hour><Minute>31</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2025</Year><Month>4</Month><Day>22</Day><Hour>0</Hour><Minute>26</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2025</Year><Month>4</Month><Day>21</Day><Hour>23</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>4</Month><Day>21</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">40259139</ArticleId><ArticleId IdType="pmc">PMC12304018</ArticleId><ArticleId IdType="doi">10.1007/s10877-025-01296-w</ArticleId><ArticleId IdType="pii">10.1007/s10877-025-01296-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Gourd NM, Nikitas N. Multiple organ dysfunction syndrome. J Intensive Care Med. 2020;35(12):1564&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">31455133</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendon&#xe7;a A, Bruining H, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine (see contributors to the project in the appendix). Intensive Care Med. 1996;22(7):707&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985;13(10):818&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">3928249</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23(10):1638&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F. PELOD-2: an update of the PEdiatric Logistic Organ Dysfunction Score. Crit Care Med. 2013;41(7):1761&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Butruille L, Blouin A, De Jonckheere J, Mur S, Margez T, Rakza T, et al. Impact of skin-to-skin contact on the autonomic nervous system in the preterm infant and his mother. Infant Behav Dev. 2017;49:83&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">28777974</ArticleId></ArticleIdList></Reference><Reference><Citation>Rommel D, Nandrino JL, De Jonckheere J, Swierczek M, Dodin V, Logier R. Maintenance of parasympathetic inhibition following emotional induction in patients with restrictive type anorexia nervosa. Psychiatry Res. 2015;225(3):651&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pubmed">25500345</ArticleId></ArticleIdList></Reference><Reference><Citation>Heart rate variability: standards of measurement, physiological interpretation and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Circulation. 1996;93(5):1043&#x2013;65.</Citation><ArticleIdList><ArticleId IdType="pubmed">8598068</ArticleId></ArticleIdList></Reference><Reference><Citation>Adam J, Rupprecht S, K&#xfc;nstler ECS, Hoyer D. Heart rate variability as a marker and predictor of inflammation, nosocomial infection, and sepsis&#x2014;a systematic review. Auton Neurosci Basic Clin. 2023;249: 103116.</Citation><ArticleIdList><ArticleId IdType="pubmed">37651781</ArticleId></ArticleIdList></Reference><Reference><Citation>Arag&#xf3;n-Bened&#xed; C, Oliver-Forni&#xe9;s P, Galluccio F, Yamak Altinpulluk E, Ergonenc T, El Sayed AA, et al. Is the heart rate variability monitoring using the analgesia nociception index a predictor of illness severity and mortality in critically ill patients with COVID-19? A pilot study. PLoS ONE. 2021;16(3): e0249128.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7990300</ArticleId><ArticleId IdType="pubmed">33760875</ArticleId></ArticleIdList></Reference><Reference><Citation>de Castilho FM, Ribeiro ALP, Nobre V, Barros G, de Sousa MR. Heart rate variability as predictor of mortality in sepsis: a systematic review. PLoS ONE. 2018;13(9): e0203487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6133362</ArticleId><ArticleId IdType="pubmed">30204803</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021;372: n71.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8005924</ArticleId><ArticleId IdType="pubmed">33782057</ArticleId></ArticleIdList></Reference><Reference><Citation>Whiting PF, Rutjes AWS, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med. 2011;155(8):529&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pubmed">22007046</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, M&#xfc;ller-Werdan U, Hoffmann T, Francis DP, Piepoli MF, Rauchhaus M, et al. Autonomic dysfunction predicts mortality in patients with multiple organ dysfunction syndrome of different age groups*. Crit Care Med. 2005;33(9):1994&#x2013;2002.</Citation><ArticleIdList><ArticleId IdType="pubmed">16148471</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer D, Friedrich H, Zwiener U, Pompe B, Baranowski R, Werdan K, et al. Prognostic impact of autonomic information flow in multiple organ dysfunction syndrome patients. Int J Cardiol. 2006;108(3):359&#x2013;69.</Citation><ArticleIdList><ArticleId IdType="pubmed">15979171</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer D, Frank B, G&#xf6;tze C, Schmidt H, Baranowski R, &#x17b;ebrowski JJ, et al. Complex autonomic dysfunction in cardiovascular, intensive care, and schizophrenic patients assessed by autonomic information flow. Biomed Tech Eng. 2006;51(4):182&#x2013;5.</Citation><ArticleIdList><ArticleId IdType="pubmed">17061934</ArticleId></ArticleIdList></Reference><Reference><Citation>Papaioannou VE, Maglaveras N, Houvarda I, Antoniadou E, Vretzakis G. Investigation of altered heart rate variability, nonlinear properties of heart rate signals, and organ dysfunction longitudinally over time in intensive care unit patients. J Crit Care. 2006;21(1):95&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">16616632</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Hoyer D, Hennen R, Heinroth K, Rauchhaus M, Prondzinsky R, et al. Autonomic dysfunction predicts both 1- and 2-month mortality in middle-aged patients with multiple organ dysfunction syndrome*. Crit Care Med. 2008;36(3):967&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pubmed">18431287</ArticleId></ArticleIdList></Reference><Reference><Citation>Green GC, Bradley B, Bravi A, Seely AJE. Continuous multiorgan variability analysis to track severity of organ failure in critically ill patients. J Crit Care. 2013;28(5):879.e1-879.e11.</Citation><ArticleIdList><ArticleId IdType="pubmed">23726387</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt H, Lotze U, Ghanem A, Anker SD, Said SM, Braun-Dullaeus R, et al. Relation of impaired interorgan communication and parasympathetic activity in chronic heart failure and multiple-organ dysfunction syndrome. J Crit Care. 2014;29(3):367&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">24529299</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Zhou J, Ke L, Nie Y, Tong Z, Li W, et al. Role of heart rate variability in predicting the severity of severe acute pancreatitis. Dig Dis Sci. 2014;59(10):2557&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">24821463</ArticleId></ArticleIdList></Reference><Reference><Citation>Badke CM, Marsillio LE, Carroll MS, Weese-Mayer DE, Sanchez-Pinto LN. Development of a heart rate variability risk score to predict organ dysfunction and death in critically Ill children. Pediatr Crit Care Med. 2021;22(8):e437&#x2013;47.</Citation><ArticleIdList><ArticleId IdType="pubmed">33710071</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo X, Gao H, Yu X, Jiang Z, Yang W. Spectral analysis of heart rate variability for trauma outcome prediction: an analysis of 210 ICU multiple trauma patients. Eur J Trauma Emerg Surg. 2021;47(1):153&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">31209555</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoyer D, Friedrich H, Frank B, Pompe B, Baranowski R, Zebrowski JJ, et al. Autonomic information flow improves prognostic impact of task force HRV monitoring. Comput Methods Programs Biomed. 2006;81(3):246&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pubmed">16483685</ArticleId></ArticleIdList></Reference><Reference><Citation>Pontet J, Contreras P, Curbelo A, Medina J, Noveri S, Bentancourt S, et al. Heart rate variability as early marker of multiple organ dysfunction syndrome in septic patients. J Crit Care. 2003;18(3):156&#x2013;63.</Citation><ArticleIdList><ArticleId IdType="pubmed">14595568</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrard CS, Kontoyannis DA, Piepoli M. Spectral analysis of heart rate variability in the sepsis syndrome. Clin Auton Res Off J Clin Auton Res Soc. 1993;3(1):5&#x2013;13.</Citation><ArticleIdList><ArticleId IdType="pubmed">8386574</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin MP, O&#x2019;Shea TM, Bissonette EA, Harrell FE, Lake DE, Moorman JR. Abnormal heart rate characteristics preceding neonatal sepsis and sepsis-like illness. Pediatr Res. 2003;53(6):920&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12646726</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin MP, Moorman JR. Toward the early diagnosis of neonatal sepsis and sepsis-like illness using novel heart rate analysis. Pediatrics. 2001;107(1):97&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">11134441</ArticleId></ArticleIdList></Reference><Reference><Citation>Norris PR, Ozdas A, Cao H, Williams AE, Harrell FE, Jenkins JM, et al. Cardiac uncoupling and heart rate variability stratify ICU patients by mortality: a study of 2088 trauma patients. Ann Surg. 2006;243(6):804&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1570581</ArticleId><ArticleId IdType="pubmed">16772784</ArticleId></ArticleIdList></Reference><Reference><Citation>Bradley BD, Green G, Ramsay T, Seely AJE. Impact of sedation and organ failure on continuous heart and respiratory rate variability monitoring in critically ill patients: a pilot study*. Crit Care Med. 2013;41(2):433&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pubmed">23263615</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebert TJ, Muzi M, Berens R, Goff D, Kampine JP. Sympathetic responses to induction of anesthesia in humans with propofol or etomidate. Anesthesiology. 1992;76(5):725&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">1575340</ArticleId></ArticleIdList></Reference><Reference><Citation>Bari V, Vaini E, Pistuddi V, Fantinato A, Cairo B, De Maria B, et al. Comparison of causal and non-causal strategies for the assessment of baroreflex sensitivity in predicting acute kidney dysfunction after coronary artery bypass grafting. Front Physiol. 2019;10:1319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6813722</ArticleId><ArticleId IdType="pubmed">31681021</ArticleId></ArticleIdList></Reference><Reference><Citation>Huhle R, Burghardt M, Zaunseder S, Wessel N, Koch T, Malberg H, et al. Effects of awareness and nociception on heart rate variability during general anaesthesia. Physiol Meas. 2012;33(2):207&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pubmed">22260880</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">37210541</PMID><DateCompleted><Year>2023</Year><Month>12</Month><Day>17</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>May</Month><Day>20</Day></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Biomarker-based risk model to predict persistent multiple organ dysfunctions after congenital heart surgery: a prospective observational cohort study.</ArticleTitle><Pagination><StartPage>193</StartPage><MedlinePgn>193</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">193</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13054-023-04494-7</ELocationID><Abstract><AbstractText Label="BACKGROUND">Multiple organ dysfunction syndrome (MODS) is an important cause of post-operative morbidity and mortality for children undergoing cardiac surgery requiring cardiopulmonary bypass (CPB). Dysregulated inflammation is widely regarded as a key contributor to bypass-related MODS pathobiology, with considerable overlap of pathways associated with septic shock. The pediatric sepsis biomarker risk model (PERSEVERE) is comprised of seven protein biomarkers of inflammation and reliably predicts baseline risk of mortality and organ dysfunction among critically ill children with septic shock. We aimed to determine if PERSEVERE biomarkers and clinical data could be combined to derive a new model to assess the risk of persistent CPB-related MODS in the early post-operative period.</AbstractText><AbstractText Label="METHODS">This study included 306 patients&#x2009;&lt;&#x2009;18&#xa0;years old admitted to a pediatric cardiac ICU after surgery requiring cardiopulmonary bypass (CPB) for congenital heart disease. Persistent MODS, defined as dysfunction of two or more organ systems on postoperative day 5, was the primary outcome. PERSEVERE biomarkers were collected 4 and 12&#xa0;h after CPB. Classification and regression tree methodology were used to derive a model to assess the risk of persistent MODS.</AbstractText><AbstractText Label="RESULTS">The optimal model containing interleukin-8 (IL-8), chemokine ligand 3 (CCL3), and age as predictor variables had an area under the receiver operating characteristic curve (AUROC) of 0.86 (0.81-0.91) for differentiating those with or without persistent MODS and a negative predictive value of 99% (95-100). Ten-fold cross-validation of the model yielded a corrected AUROC of 0.75 (0.68-0.84).</AbstractText><AbstractText Label="CONCLUSIONS">We present a novel risk prediction model to assess the risk for development of multiple organ dysfunction after pediatric cardiac surgery requiring CPB. Pending prospective validation, our model may facilitate identification of a high-risk cohort to direct interventions and studies aimed at improving outcomes via mitigation of post-operative organ dysfunction.</AbstractText><CopyrightInformation>&#xa9; 2023. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benscoter</LastName><ForeName>Alexis L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA. alexis.benscoter@cchmc.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alten</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atreya</LastName><ForeName>Mihir R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati College of Medicine, 3333 Burnet Ave, MLC 2003, Cincinnati, OH, 45229, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrnes</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>Division of Cardiology, Department of Pediatrics, University of Alabama at Birmingham, Birmingham, AL, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Kentucky, Lexington, KY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollberding</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>Division of Biostatistics and Epidemiology, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Hector R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Cincinnati Children's Hospital Medical Center, University of Cincinnati, Cincinnati, OH, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35GM126943</GrantID><Agency>National Institution of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="UpdateOf"><RefSource>Res Sq. 2023 Jan 27:rs.3.rs-2488327. doi: 10.21203/rs.3.rs-2488327/v1.</RefSource><PMID Version="1">36747744</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002315" MajorTopicYN="Y">Cardiopulmonary Bypass</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006330" MajorTopicYN="Y">Heart Defects, Congenital</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012772" MajorTopicYN="N">Shock, Septic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Biomarkers</Keyword><Keyword MajorTopicYN="N">Cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction</Keyword><Keyword MajorTopicYN="N">Pediatric cardiac critical care</Keyword><Keyword MajorTopicYN="N">Risk stratification</Keyword></KeywordList><CoiStatement>During the time of this study and manuscript preparation, H.R.W. and the Cincinnati Children&#x2019;s Hospital Research Foundation hold US patents for the PERSEVERE biomarkers.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>5</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>5</Month><Day>22</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>5</Month><Day>21</Day><Hour>1</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>5</Month><Day>20</Day><Hour>23</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>20</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37210541</ArticleId><ArticleId IdType="pmc">PMC10199562</ArticleId><ArticleId IdType="doi">10.1186/s13054-023-04494-7</ArticleId><ArticleId IdType="pii">10.1186/s13054-023-04494-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1&#x2014;mechanisms of pathogenesis. J Card Vasc Anesth. 2009;23:223&#x2013;231. doi: 10.1053/j.jvca.2008.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.jvca.2008.08.007</ArticleId><ArticleId IdType="pubmed">18930659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybdahl B, Wahba A, Lien E, et al. The inflammatory response after open heart surgery release of heat-shock protein 70 and signaling through toll-like receptor 4. Circ. 2002;105:685&#x2013;690. doi: 10.1161/hc0602.103617.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/hc0602.103617</ArticleId><ArticleId IdType="pubmed">11839622</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Visvanathan K, et al. Cardiopulmonary bypass elicits a prominent innate immune response in children with congenital heart disease. J Thorac Cardiovasc Surg. 2004;127:1523&#x2013;1525. doi: 10.1016/j.jtcvs.2003.11.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2003.11.027</ArticleId><ArticleId IdType="pubmed">15116021</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Horton SB, et al. The influence of bypass temperature on the systemic inflammatory response and organ injury after pediatric open surgery: a randomized trial. J Thorac Cardiovasc Surg. 2011;142:174&#x2013;180. doi: 10.1016/j.jtcvs.2011.01.059.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2011.01.059</ArticleId><ArticleId IdType="pubmed">21420106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahle WT, Matthews E, Kanter KR, et al. Inflammatory response after neonatal cardiac surgery and its relationship to clinical outcomes. Ann Thorac Surg. 2014;97:950&#x2013;956. doi: 10.1016/j.athoracsur.2013.10.069.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2013.10.069</ArticleId><ArticleId IdType="pubmed">24424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan CK, Newburger JW, McGrath E, et al. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg. 2010;111:1244&#x2013;1251. doi: 10.1213/ANE.0b013e3181f333aa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1213/ANE.0b013e3181f333aa</ArticleId><ArticleId IdType="pubmed">20829561</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC. The clinical implications of the systemic inflammatory reaction related to cardiac operations in children. Cardiol Young. 2003;13:228&#x2013;239. doi: 10.1017/S1047951103000465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1017/S1047951103000465</ArticleId><ArticleId IdType="pubmed">12903869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubicki R, Grohmann J, Siepe M, et al. Early prediction of capillary leak syndrome in infants after cardiopulmonary bypass. Eur J Cardiothorac Surg. 2013;44:275&#x2013;281. doi: 10.1093/ejcts/ezt028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezt028</ArticleId><ArticleId IdType="pubmed">23389476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Jeffries HE, Zimmerman JJ, et al. Sepsis in the pediatric cardiac intensive care unit. World J Pediatr Congenit Heart Surg. 2011;2:393&#x2013;39912. doi: 10.1177/2150135111403781.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2150135111403781</ArticleId><ArticleId IdType="pmc">PMC3277844</ArticleId><ArticleId IdType="pubmed">22337571</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartmann ME, et al. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017;18(3):S4&#x2013;S16. doi: 10.1097/PCC.0000000000001047.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001047</ArticleId><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Lacroix JR. Monitoring severity of multiple organ dysfunction syndrome: new and progressive multiple organ dysfunction syndrome, scoring systems. Pediatr Crit Care Med. 2017;18(3):S17&#x2013;S23. doi: 10.1097/PCC.0000000000001049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001049</ArticleId><ArticleId IdType="pubmed">28248830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich N, Allen GL, et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med. 2009;37:1558&#x2013;1566. doi: 10.1097/CCM.0b013e31819fcc08.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819fcc08</ArticleId><ArticleId IdType="pmc">PMC2747356</ArticleId><ArticleId IdType="pubmed">19325468</ArticleId></ArticleIdList></Reference><Reference><Citation>Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther. 2011;9:71&#x2013;79. doi: 10.1586/eri.10.154.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/eri.10.154</ArticleId><ArticleId IdType="pmc">PMC3033193</ArticleId><ArticleId IdType="pubmed">21171879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med. 2011;12:165&#x2013;173. doi: 10.1097/PCC.0b013e3181e28876.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181e28876</ArticleId><ArticleId IdType="pmc">PMC2924462</ArticleId><ArticleId IdType="pubmed">20473243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Salsibury S, Xiao Q, et al. The pediatric sepsis biomarker risk model. Crit Care. 2012;16:R147&#x2013;R183. doi: 10.1186/cc11652.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc11652</ArticleId><ArticleId IdType="pmc">PMC3682273</ArticleId><ArticleId IdType="pubmed">23025259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Caldwell JT, Cvijanovich NZ, et al. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model. Sci Transl Med. 2019;11(518):eaax9000. doi: 10.1126/scitranslmed.aax9000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax9000</ArticleId><ArticleId IdType="pmc">PMC7720682</ArticleId><ArticleId IdType="pubmed">31723040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Genetics and genomics in pediatric septic shock. Crit Care Med. 2012;40:1618&#x2013;1626. doi: 10.1097/CCM.0b013e318246b546.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318246b546</ArticleId><ArticleId IdType="pmc">PMC3329642</ArticleId><ArticleId IdType="pubmed">22511139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Weiss SL, Giuliano JS, Jr, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS ONE. 2014;9:e86242. doi: 10.1371/journal.pone.0086242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086242</ArticleId><ArticleId IdType="pmc">PMC3906040</ArticleId><ArticleId IdType="pubmed">24489704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. AJRCCM. 2014 doi: 10.1164/rccm.201410-1864OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201410-1864OC</ArticleId><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Lindsell CJ, Pettila V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med. 2014;42:781&#x2013;789. doi: 10.1097/CCM.0000000000000106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000000106</ArticleId><ArticleId IdType="pmc">PMC4620515</ArticleId><ArticleId IdType="pubmed">24335447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Sawa Y, Fukuyama N, et al. Preoperative glutamine administration induces heat-shock protein 70 expression and attenuates cardiopulmonary bypass-induced inflammatory response by regulating nitric oxide synthase activity. Circulation. 2002;106(20):260&#x2013;267. doi: 10.1161/01.CIR.0000035651.72240.07.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000035651.72240.07</ArticleId><ArticleId IdType="pubmed">12427658</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Warszawska JM, Schenk P, et al. Intraoperative ventilation strategy during cardiopulmonary bypass attenuates the release of matrix metalloproteinases and improves oxygenation. J Surg Res. 2015;195(1):294&#x2013;302. doi: 10.1016/j.jss.2014.12.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2014.12.022</ArticleId><ArticleId IdType="pubmed">25577145</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Szerafin T, Mitterbauer A, et al. Low tidal volume ventilation during cardiopulmonary bypass reduces postoperative chemokine serum concentrations. Thorac Cardiovasc Surg. 2014;62(8):677&#x2013;682. doi: 10.1055/s-0034-1387824.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1387824</ArticleId><ArticleId IdType="pubmed">25226360</ArticleId></ArticleIdList></Reference><Reference><Citation>Khabar KSA, ElBarbary MA, Khouqeer F, et al. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clin Immunol Immunopathol. 1997;85(1):97&#x2013;103. doi: 10.1006/clin.1997.4413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/clin.1997.4413</ArticleId><ArticleId IdType="pubmed">9325075</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhok AB, Ojamaa K, Haridas V, et al. Cytokine response in children undergoing surgery for congenital heart disease. Pediatr Cardiol. 2006;27:408&#x2013;413. doi: 10.1007/s00246-006-0934-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00246-006-0934-y</ArticleId><ArticleId IdType="pubmed">16830075</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona F, Manso PH, Vincente WVA, et al. Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine. 2008;42(3):317&#x2013;324. doi: 10.1016/j.cyto.2008.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.03.005</ArticleId><ArticleId IdType="pubmed">18417355</ArticleId></ArticleIdList></Reference><Reference><Citation>deFontnouvelle CA, Greenberg JH, Thiessen-Philbrook HR, et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury after pediatric surgery. Ann Thorac Surg. 2017;104:2072&#x2013;2079. doi: 10.1016/j.athoracsur.2017.04.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2017.04.038</ArticleId><ArticleId IdType="pmc">PMC5696070</ArticleId><ArticleId IdType="pubmed">28821332</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien SM, Clarke DR, Jacobs JP, et al. An empirically based tool for analyzing mortality associated with congenital heart disease. J Thorac Cardiovasc Surg. 2009;138(5):1139&#x2013;1153. doi: 10.1016/j.jtcvs.2009.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.03.071</ArticleId><ArticleId IdType="pubmed">19837218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JP, O'Brien SM, Pasquali SK, et al. Variation in outcomes for risk-stratified pediatric cardiac surgical operations: as analysis of the STS Congenital Heart Surgery Database. Ann Thorac Surg. 2012;94(2):564&#x2013;571. doi: 10.1016/j.athoracsur.2012.01.105.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2012.01.105</ArticleId><ArticleId IdType="pmc">PMC4006082</ArticleId><ArticleId IdType="pubmed">22704799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM. Intensive Care Med. 2002;28:204&#x2013;207. doi: 10.1007/s00134-001-1185-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-001-1185-2</ArticleId><ArticleId IdType="pubmed">11907665</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6:2&#x2013;8. doi: 10.1097/01.PCC.0000149131.72248.E6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell RA, Ghanayem NS, Kuhn EM, et al. Relationship between risk-adjustment tools and the pediatric logistic organ dysfunction score. World J Pediatr Congenit Heart Surg. 2014;15:16&#x2013;21. doi: 10.1177/2150135113510008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/2150135113510008</ArticleId><ArticleId IdType="pubmed">24403350</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, et al. PELOD-2: an update of the Pediatric logistic organ dysfunction score. Crit Care Med. 2013;41:1761&#x2013;1773. doi: 10.1097/CCM.0b013e31828a2bbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Umsted TM, Lu CK, Freeman WM, et al. The kinetics of cardiopulmonary bypass: a dual-platform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Artif Organs. 2012;36(1):E1&#x2013;E20. doi: 10.1111/j.1525-1594.2011.01412.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1525-1594.2011.01412.x</ArticleId><ArticleId IdType="pubmed">22250822</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller R, Mockel M. Logistic regression and CART in the analysis of multimarker studies. Clin Chim Acta. 2008;394:1&#x2013;6. doi: 10.1016/j.cca.2008.04.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2008.04.007</ArticleId><ArticleId IdType="pubmed">18455512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout D, Pagel C, et al. Incidence and risk factors for important early morbidities associated with pediatric cardiac surgery in a UK population. J Thorac Cardiovasc Surg. 2019;158(4):1185&#x2013;1196.e736. doi: 10.1016/j.jtcvs.2019.03.139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2019.03.139</ArticleId><ArticleId IdType="pubmed">31353100</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med. 2003;31:28&#x2013;33. doi: 10.1097/00003246-200301000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200301000-00004</ArticleId><ArticleId IdType="pubmed">12544989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11(2):234&#x2013;238. doi: 10.1097/PCC.0b013e3181b806fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b806fc</ArticleId><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Jeffries HE, Niebler RA, et al. Vasoactive-inotropic score is associated with outcome after infant cardiact surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System registries. Pediatr Crit Care Med. 2014;15(6):529&#x2013;537. doi: 10.1097/PCC.0000000000000153.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000153</ArticleId><ArticleId IdType="pmc">PMC4159673</ArticleId><ArticleId IdType="pubmed">24777300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessler P, Pfenninger J, Pfammatter JP, et al. Plasma levels of interleukin-8 and expression of interleukin-8 receptors on circulating neutrophils and monocytes after cardiopulmonary bypass in children. J Thorac Cardiovasc Surg. 2003;126(3):718&#x2013;725. doi: 10.1016/S0022-5223(03)00685-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-5223(03)00685-8</ArticleId><ArticleId IdType="pubmed">14502144</ArticleId></ArticleIdList></Reference><Reference><Citation>Drennan SE, Burge KY, Szyld EG, et al. Clinical and laboratory predictors for the development of low cardiac output syndrome in infants undergoing cardiopulmonary bypass: a pilot study. J Clin Med. 2021;10(4):712. doi: 10.3390/jcm10040712.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10040712</ArticleId><ArticleId IdType="pmc">PMC7916966</ArticleId><ArticleId IdType="pubmed">33670210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorjipour F, Totonchi Z, Dehaki MG, et al. Serum levels of interleukin-6, interleukin-8, interleukin-10 and tumor necrosis factor-&#x3b1;, renal function biochemical parameters and clinical outcomes in pediatric cardiopulmonary bypass surgery. Perfusion. 2019;34(8):651&#x2013;659. doi: 10.1177/0267659119842470.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0267659119842470</ArticleId><ArticleId IdType="pubmed">31027462</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KD, Altmann C, Smits G, et al. Serum interleukin-6 and interleukin-8 are early predictors of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care. 2009;13(4):R104. doi: 10.1186/cc7940.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7940</ArticleId><ArticleId IdType="pmc">PMC2750143</ArticleId><ArticleId IdType="pubmed">19570208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenburger M, Tjan TDT, Schneider M, et al. The impact of the pro- and anti-inflammatory immune response on ventilation time after cardiac surgery. Cytometry B Clin Cytom. 2003;53(1):70&#x2013;74. doi: 10.1002/cyto.b.10027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cyto.b.10027</ArticleId><ArticleId IdType="pubmed">12717694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavasar I, Miller CS, Al-Sabbagh M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. Gen Methods Biomark Res Appl 2015;223&#x2013;249.</Citation></Reference><Reference><Citation>Wolpe SD, Davatelis G, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med. 1988;167(2):570&#x2013;581. doi: 10.1084/jem.167.2.570.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.167.2.570</ArticleId><ArticleId IdType="pmc">PMC2188834</ArticleId><ArticleId IdType="pubmed">3279154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Lindsell CJ, et al. PERSEVERE II: Redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med. 2016;44(11):2010&#x2013;2017. doi: 10.1097/CCM.0000000000001852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001852</ArticleId><ArticleId IdType="pmc">PMC5201138</ArticleId><ArticleId IdType="pubmed">27513537</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyata H, Murakami A, Tomotaki A, et al. Predictors of 90-day mortality after congenital heart surgery: the first report of risk models from a Japanese database. J Thorac Cardiovasc Surg. 2014;148:2201&#x2013;2206. doi: 10.1016/j.jtcvs.2013.01.053.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2013.01.053</ArticleId><ArticleId IdType="pubmed">25444193</ArticleId></ArticleIdList></Reference><Reference><Citation>Hill KD, Kannankeril PJ, Jacobs JP, et al., for the STRESS Network Investigators. Methylprednisolone for heart surgery in infants&#x2014;a randomized, controlled trial. N Engl J Med. 2022;387:2138&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9843240</ArticleId><ArticleId IdType="pubmed">36342116</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasser WC, Dabal RJ, Askenazi DJ, et al. Prophylactic peritoneal dialysis following cardiopulmonary bypass in children is associated with decreased inflammation and improved clinical outcomes. Congenit Heart Dis. 2014;9(2):106&#x2013;115. doi: 10.1111/chd.12072.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/chd.12072</ArticleId><ArticleId IdType="pubmed">23647999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37808065</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2666-2736</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>JTCVS open</Title><ISOAbbreviation>JTCVS Open</ISOAbbreviation></Journal><ArticleTitle>Effect of red blood cell storage time in pediatric cardiac surgery patients: A subgroup analysis of a randomized controlled trial.</ArticleTitle><Pagination><StartPage>454</StartPage><EndPage>467</EndPage><MedlinePgn>454-467</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.xjon.2023.04.022</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="UNASSIGNED">This study aimed to determine whether or not transfusion of fresh red blood cells (RBCs) reduced the incidence of new or progressive multiple organ dysfunction syndrome compared with standard-issue RBCs in pediatric patients undergoing cardiac surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">Preplanned secondary analysis of the Age of Blood in Children in Pediatric Intensive Care Unit study, an international randomized controlled trial. This study included children enrolled in the Age of Blood in Children in Pediatric Intensive Care Unit trial and admitted to a pediatric intensive care unit after cardiac surgery with cardiopulmonary bypass. Patients were randomized to receive either fresh (stored &#x2264;7&#xa0;days) or standard-issue RBCs. The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured up to 28&#xa0;days postrandomization or at pediatric intensive care unit discharge, or death.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">One hundred seventy-eight patients (median age, 0.6&#xa0;years; interquartile range, 0.3-2.6 years) were included with 89 patients randomized to the fresh RBCs group (median length of storage, 5&#xa0;days; interquartile range, 4-6&#xa0;days) and 89 to the standard-issue RBCs group (median length of storage, 18&#xa0;days; interquartile range, 13-22&#xa0;days). There were no statistically significant differences in new or progressive multiple organ dysfunction syndrome between fresh (43 out of 89 [48.3%]) and standard-issue RBCs groups (38 out of 88 [43.2%]), with a relative risk of 1.12 (95% CI, 0.81 to 1.54; <i>P</i>&#xa0;=&#xa0;.49) and an unadjusted absolute risk difference of 5.1% (95% CI, -9.5% to 19.8%; <i>P</i>&#xa0;=&#xa0;.49).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">In neonates and children undergoing cardiac surgery with cardiopulmonary bypass, the use of fresh RBCs did not reduce the incidence of new or progressive multiple organ dysfunction syndrome compared with the standard-issue RBCs. A larger trial is needed to confirm these results.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Sophie M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spinella</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Departments of Surgery and Critical Care Medicine, Pittsburgh University, Pittsburgh, Pa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Unit&#xe9; de recherche clinique appliqu&#xe9;e, Centre Hospitalier Universitaire Sainte-Justine, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Clinical Epidemiology Program, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Freed</LastName><ForeName>Darren H</ForeName><Initials>DH</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care Medicine, Department of Pediatrics, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poirier</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of Cardiac Surgery, Sainte Justine and Montreal Heart Institute, University of Montreal, Montreal, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivarajan</LastName><ForeName>Venkatesan B</ForeName><Initials>VB</Initials><AffiliationInfo><Affiliation>Pediatric Cardiac Intensive Care, Department of Pediatrics, Stollery Children's Hospital, University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Divisions of Hematology/Oncology and Critical Care, Department of Pediatrics, University of Minnesota, Minneapolis, Minn.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Willems</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Intensive Care, Leiden University Hospital, Leiden, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia Guerra</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care, Department of Pediatrics, Alberta Children's Hospital; University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Age of Blood in Children in Pediatric Intensive Care Unit Trial Investigators</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Canadian Critical Care Trials Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Pediatric Acute Lung Injury and Sepsis Investigators Network</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>BloodNet Pediatric Critical Care Blood Research Network</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Groupe Francophone de R&#xe9;animation et Urgences P&#xe9;diatriques</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL116383</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>05</Month><Day>31</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>JTCVS Open</MedlineTA><NlmUniqueID>101768541</NlmUniqueID><ISSNLinking>2666-2736</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">cardiopulmonary bypass</Keyword><Keyword MajorTopicYN="N">critical care medicine</Keyword><Keyword MajorTopicYN="N">erythrocyte</Keyword><Keyword MajorTopicYN="N">length of storage</Keyword><Keyword MajorTopicYN="N">pediatric cardiac surgery</Keyword><Keyword MajorTopicYN="N">red blood cell</Keyword><Keyword MajorTopicYN="N">transfusion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>4</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>6</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>9</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>5</Month><Day>31</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37808065</ArticleId><ArticleId IdType="pmc">PMC10556812</ArticleId><ArticleId IdType="doi">10.1016/j.xjon.2023.04.022</ArticleId><ArticleId IdType="pii">S2666-2736(23)00116-X</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Spinella P.C., Dressler A., Tucci M., Carroll C.L., Rosen R.S., Hume H., et al. Survey of transfusion policies at US and Canadian children&#x2019;s hospitals in 2008 and 2009. Transfusion. 2010;50:2328&#x2013;2335. doi: 10.1111/j.1537-2995.2010.02708.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02708.x</ArticleId><ArticleId IdType="pubmed">20529008</ArticleId></ArticleIdList></Reference><Reference><Citation>Flegel W.A., Natanson C., Klein H.G. Does prolonged storage of red blood cells cause harm? Br J Haematol. 2014;165:3&#x2013;16. doi: 10.1111/bjh.12747.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12747</ArticleId><ArticleId IdType="pmc">PMC5515544</ArticleId><ArticleId IdType="pubmed">24460532</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella P.C., Tucci M., Fergusson D.A., Lacroix J., H&#xe9;bert P.C., Leteurtre S., et al. Effect of fresh vs standard-issue red blood cell transfusions on multiple organ dysfunction syndrome in critically ill pediatric patients: a randomized clinical trial. JAMA. 2019;322:2179&#x2013;2190. doi: 10.1001/jama.2019.17478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2019.17478</ArticleId><ArticleId IdType="pmc">PMC7081749</ArticleId><ArticleId IdType="pubmed">31821429</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D.A., H&#xe9;bert P., Hogan D.L., LeBel L., Rouvinez-Bouali N., Smyth J.A., et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308:1443&#x2013;1451. doi: 10.1001/2012.jama.11953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2012.jama.11953</ArticleId><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabangi A., Ainomugisha B., Cserti-Gazdewich C., Ddungu H., Kyeyune D., Musisi E., et al. Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial. JAMA. 2015;314:2514&#x2013;2523. doi: 10.1001/jama.2015.13977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.13977</ArticleId><ArticleId IdType="pubmed">26637812</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholette J.M., Willems A., Valentine S.L., Bateman S.T., Schwartz S.M. Recommendations on RBC transfusion in infants and children with acquired and congenital heart disease from the pediatric critical care transfusion and anemia expertise initiative. Pediatr Crit Care Med. 2018;19:S137&#x2013;S148. doi: 10.1097/PCC.0000000000001603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001603</ArticleId><ArticleId IdType="pmc">PMC6126364</ArticleId><ArticleId IdType="pubmed">30161069</ArticleId></ArticleIdList></Reference><Reference><Citation>Baltsavias I., Faraoni D., Willems A., El Kenz H., Melot C., De Hert S., et al. Blood storage duration and morbidity and mortality in children undergoing cardiac surgery. A retrospective analysis. Eur J Anaesthesiol. 2014;31:310&#x2013;316. doi: 10.1097/EJA.0000000000000024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EJA.0000000000000024</ArticleId><ArticleId IdType="pubmed">24492183</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawase H., Egi M., Kanazawa T., Shimizu K., Toda Y., Iwasaki T., et al. Storage duration of transfused red blood cells is not significantly associated with postoperative adverse events in pediatric cardiac surgery patients. Transfus Apher Sci. 2016;54:111&#x2013;116. doi: 10.1016/j.transci.2016.01.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transci.2016.01.027</ArticleId><ArticleId IdType="pubmed">26856639</ArticleId></ArticleIdList></Reference><Reference><Citation>Bishnoi A.K., Garg P., Patel K., Ananthanarayanan C., Shah R., Solanki A., et al. Effect of red blood cell storage duration on outcome after paediatric cardiac surgery: a prospective observational study. Heart Lung Circ. 2019;28:784&#x2013;791. doi: 10.1016/j.hlc.2018.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.hlc.2018.03.012</ArticleId><ArticleId IdType="pubmed">29706495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholette J.M., Pietropaoli A.P., Henrichs K.F., Alfieris G.M., Powers K.S., Phipps R., et al. Longer RBC storage duration is associated with increased postoperative infections in pediatric cardiac surgery. Pediatr Crit Care Med. 2015;16:227&#x2013;235. doi: 10.1097/PCC.0000000000000320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000000320</ArticleId><ArticleId IdType="pmc">PMC4351137</ArticleId><ArticleId IdType="pubmed">25607740</ArticleId></ArticleIdList></Reference><Reference><Citation>Manlhiot C., McCrindle B.W., Menjak I.B., Yoon H., Holtby H.M., Brand&#xe3;o L.R., et al. Longer blood storage is associated with suboptimal outcomes in high-risk pediatric cardiac surgery. Ann Thorac Surg. 2012;93:1563&#x2013;1569. doi: 10.1016/j.athoracsur.2011.08.075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.athoracsur.2011.08.075</ArticleId><ArticleId IdType="pubmed">22137242</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner M.E., Ness P.M., Assmann S.F., Triulzi D.J., Sloan S.R., Delaney M., et al. Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015;372:1419&#x2013;1429. doi: 10.1056/NEJMoa1414219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="pubmed">25853746</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch C.G., Sessler D.I., Duncan A.E., Mascha E.J., Li L., Yang D., et al. Effect of red blood cell storage duration on major postoperative complications in cardiac surgery: a randomized trial. J Thorac Cardiovasc Surg. 2020;160:1505&#x2013;1514.e3. doi: 10.1016/j.jtcvs.2019.09.165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2019.09.165</ArticleId><ArticleId IdType="pubmed">31813538</ArticleId></ArticleIdList></Reference><Reference><Citation>Heddle N.M., Cook R.J., Arnold D.M., Liu Y., Barty R., Crowther M.A., et al. Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016;375:1937&#x2013;1945. doi: 10.1056/NEJMoa1609014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609014</ArticleId><ArticleId IdType="pubmed">27775503</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M., Lacroix J., Fergusson D., Doctor A., H&#xe9;bert P., Berg R.A., et al. The age of blood in pediatric intensive care units (ABC PICU): study protocol for a randomized controlled trial. Trials. 2018;19:404. doi: 10.1186/s13063-018-2809-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-018-2809-y</ArticleId><ArticleId IdType="pmc">PMC6064163</ArticleId><ArticleId IdType="pubmed">30055634</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., H&#xe9;bert P., Fergusson D., Tinmouth A., Blajchman M.A., Callum J., et al. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev. 2011;25:197&#x2013;205. doi: 10.1016/j.tmrv.2011.03.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2011.03.001</ArticleId><ArticleId IdType="pubmed">21550205</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F., Fayon M., Farrell C.A., Lacroix J., Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109:1033&#x2013;1037. doi: 10.1378/chest.109.4.1033.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., H&#xe9;bert P.C., Hutchison J.S., Hume H.A., Tucci M., Ducruet T., et al. Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356:1609&#x2013;1619. doi: 10.1056/NEJMoa066240.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066240</ArticleId><ArticleId IdType="pubmed">17442904</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S., Duhamel A., Salleron J., Grandbastien B., Lacroix J., Leclerc F. PELOD-2: an update of the Pediatric Logistic Organ Dysfunction Score. Crit Care Med. 2013;41:1761&#x2013;1773. doi: 10.1097/CCM.0b013e31828a2bbd.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas N.J., Shaffer M.L., Willson D.F., Shih M.C., Curley M.A. Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med. 2010;11:12&#x2013;17. doi: 10.1097/PCC.0b013e3181b0653d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b0653d</ArticleId><ArticleId IdType="pmc">PMC2936504</ArticleId><ArticleId IdType="pubmed">19561556</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard G.R., Artigas A., Brigham K.L., Carlet J., Falke K., Hudson L., et al. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149:818&#x2013;824. doi: 10.1164/ajrccm.149.3.7509706.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.149.3.7509706</ArticleId><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies M.G., Gurney J.G., Yen A.H., Napoli M.L., Gajarski R.J., Ohye R.G., et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11:234&#x2013;238. doi: 10.1097/PCC.0b013e3181b806fc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b806fc</ArticleId><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien S.M., Clarke D.R., Jacobs J.P., Jacobs M.L., Lacour-Gayet F.G., Pizarro C., et al. An empirically based tool for analyzing mortality associated with congenital heart surgery. J Thorac Cardiovasc Surg. 2009;138:1139&#x2013;1153. doi: 10.1016/j.jtcvs.2009.03.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jtcvs.2009.03.071</ArticleId><ArticleId IdType="pubmed">19837218</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B., Giroir B., Randolph A. International Consensus Conference on&#xa0;Pediatric Sepsis. International Pediatric Sepsis Consensus Conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit&#xa0;Care Med. 2005;6:2&#x2013;8. doi: 10.1097/01.PCC.0000149131.72248.E6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J., Gauvin F., Skippen P., Cox P., Langley J.M., Matlow A.G. Nosocomial infections in the pediatric intensive care unit: epidemiology and control. Pediatr Crit Care. 2006;103:1394&#x2013;1421.</Citation></Reference><Reference><Citation>CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis. 1989;139:1058&#x2013;1059. doi: 10.1164/ajrccm/139.4.1058.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/139.4.1058</ArticleId><ArticleId IdType="pubmed">2539031</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandra T., Cohen J. International Sepsis Forum definition of infection in the ICUCC. The International Sepsis Forum Consensus Conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538&#x2013;1548. doi: 10.1097/01.ccm.0000168253.91200.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccm.0000168253.91200.83</ArticleId><ArticleId IdType="pubmed">16003060</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper D.J., McQuilten Z.K., Nichol A., Ady B., Aubron C., Bailey M., et al. Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377:1858&#x2013;1867. doi: 10.1056/NEJMoa1707572.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707572</ArticleId><ArticleId IdType="pubmed">28952891</ArticleId></ArticleIdList></Reference><Reference><Citation>Redlin M., Habazettl H., Schoenfeld H., Kukucka M., Boettcher W., Kuppe H., et al. Red blood cell storage duration is associated with various clinical outcomes in pediatric cardiac surgery. Transfus Med Hemother. 2014;41:146&#x2013;151. doi: 10.1159/000357998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000357998</ArticleId><ArticleId IdType="pmc">PMC4025050</ArticleId><ArticleId IdType="pubmed">24847191</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Carlucci C., Isgr&#xf2; G., Boncilli A., De Benedetti D., De la Torre T., et al. Duration of red blood cell storage and outcomes in pediatric cardiac surgery: an association found for pump prime blood. Crit Care. 2009;13:R207. doi: 10.1186/cc8217.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8217</ArticleId><ArticleId IdType="pmc">PMC2811896</ArticleId><ArticleId IdType="pubmed">20025760</ArticleId></ArticleIdList></Reference><Reference><Citation>Cholette JM, Henrichs KF, Alfieris GM, Powers K.S., Phipps R., Spinelli S.L., et al. Washing red blood cells and platelets transfused in cardiac surgery reduces postoperative inflammation and number of transfusions: results of a prospective, randomized, controlled clinical trial. Pediatr Crit Care Med. 2012;13:290&#x2013;299.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3839819</ArticleId><ArticleId IdType="pubmed">21926663</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexander P.E., Barty R., Fei Y., Vandvik P.O., Pai M., Siemieniuk R.A., et al. Transfusion of fresher vs older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood. 2016;127:400&#x2013;410. doi: 10.1182/blood-2015-09-670950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2015-09-670950</ArticleId><ArticleId IdType="pubmed">26626995</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">36747744</PMID><DateRevised><Year>2023</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2693-5015</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2023</Year><Month>Jan</Month><Day>27</Day></PubDate></JournalIssue><Title>Research square</Title><ISOAbbreviation>Res Sq</ISOAbbreviation></Journal><ArticleTitle>Biomarker-based risk model to predict persistent multiple organ dysfunctions after congenital heart surgery &#xe2;&#x20ac;" A prospective observational cohort study.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">rs.3.rs-2488327</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.21203/rs.3.rs-2488327/v1</ELocationID><Abstract><AbstractText><b>Background:</b> Multiple organ dysfunction syndrome (MODS) is an important cause of post-operative morbidity and mortality for children undergoing cardiac surgery requiring cardiopulmonary bypass (CPB). Dysregulated inflammation is widely regarded as a key contributor to bypass-related MODS pathobiology, with considerable overlap of pathways associated with septic shock. The pediatric sepsis biomarker risk model (PERSEVERE) is comprised of seven protein biomarkers of inflammation, and reliably predicts baseline risk of mortality and organ dysfunction among critically ill children with septic shock. We aimed to determine if PERSEVERE biomarkers and clinical data could be combined to derive a new model to assess the risk of persistent CPB-related MODS in the early post-operative period. <b>Methods:</b> This study included 306 patients &lt;18 years old admitted to a pediatric cardiac ICU after surgery requiring cardiopulmonary bypass (CPB) for congenital heart disease. Persistent MODS, defined as dysfunction of two or more organ systems on postoperative day 5, was the primary outcome. PERSEVERE biomarkers were collected 4 and 12 hours after CPB. Classification and Regression Tree methodology was used to derive a model to assess the risk of persistent MODS. <b>Results:</b> The optimal model containing interleukin-8 (IL-8), chemokine ligand 3 (CCL3), and age as predictor variables, had an area under the receiver operating characteristic curve (AUROC) of 0.86 (0.81-0.91) for differentiating those with or without persistent MODS, and a negative predictive value of 99% (95-100). Ten-fold cross-validation of the model yielded a corrected AUROC of 0.75. <b>Conclusions:</b> We present a novel risk prediction model to assess the risk for development of multiple organ dysfunction after pediatric cardiac surgery requiring CPB. Pending prospective validation, our model may facilitate identification of a high-risk cohort to direct interventions and studies aimed at improving outcomes via mitigation of post-operative organ dysfunction. <b>Clinical Trial Registration Number:</b> This study does not meet criteria for a clinical trial per the WHO International Clinical Trials Registry Platform as no intervention was performed.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Benscoter</LastName><ForeName>Alexis L</ForeName><Initials>AL</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alten</LastName><ForeName>Jeffrey A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Atreya</LastName><ForeName>Mihir R</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>University of Cincinnati, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cooper</LastName><ForeName>David S</ForeName><Initials>DS</Initials><AffiliationInfo><Affiliation>University of Cincinnati College of Medicine, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Byrnes</LastName><ForeName>Jonathan W</ForeName><Initials>JW</Initials><AffiliationInfo><Affiliation>University of Alabama at Birmingham.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nelson</LastName><ForeName>David P</ForeName><Initials>DP</Initials><AffiliationInfo><Affiliation>University of Kentucky.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ollberding</LastName><ForeName>Nicholas J</ForeName><Initials>NJ</Initials><AffiliationInfo><Affiliation>University of Cincinnati, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Hector R</ForeName><Initials>HR</Initials><AffiliationInfo><Affiliation>University of Cincinnati, Cincinnati Children's Hospital Medical Center.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R35 GM126943</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D000076942">Preprint</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Res Sq</MedlineTA><NlmUniqueID>101768035</NlmUniqueID><ISSNLinking>2693-5015</ISSNLinking></MedlineJournalInfo><CommentsCorrectionsList><CommentsCorrections RefType="UpdateIn"><RefSource>Crit Care. 2023 May 20;27(1):193. doi: 10.1186/s13054-023-04494-7.</RefSource><PMID Version="1">37210541</PMID></CommentsCorrections></CommentsCorrectionsList><CoiStatement>Competing interests. During the time of this study and manuscript preparation, H.R.W. and the Cincinnati Children&#x2019;s Hospital Research Foundation hold U.S. patents for the PERSEVERE biomarkers.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>2</Month><Day>7</Day><Hour>1</Hour><Minute>57</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36747744</ArticleId><ArticleId IdType="pmc">PMC9901021</ArticleId><ArticleId IdType="doi">10.21203/rs.3.rs-2488327/v1</ArticleId><ArticleId IdType="pii">rs.3.rs-2488327</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Warren OJ, Smith AJ, Alexiou C, et al. The inflammatory response to cardiopulmonary bypass: part 1&#x2014;mechanisms of pathogenesis. J Card Vasc Anesth 2009,23:223&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">18930659</ArticleId></ArticleIdList></Reference><Reference><Citation>Dybdahl B, Wahba A, Lien E. et al. The inflammatory response after open heart surgery release of heat-shock protein 70 and signaling through toll-like receptor 4. Circ 2002,105:685&#x2013;690.</Citation><ArticleIdList><ArticleId IdType="pubmed">11839622</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Visvanathan K, et al. Cardiopulmonary bypass elicits a prominent innate immune response in children with congenital heart disease. J Thorac Cardiovasc Surg 2004,127:1523&#x2013;1525.</Citation><ArticleIdList><ArticleId IdType="pubmed">15116021</ArticleId></ArticleIdList></Reference><Reference><Citation>Stocker CF, Shekerdemian LS, Horton SB, et al. The influence of bypass temperature on the systemic inflammatory response and organ injury after pediatric open surgery: a randomized trial. J Thorac Cardiovasc Surg 2011,142:174&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">21420106</ArticleId></ArticleIdList></Reference><Reference><Citation>Mahle WT, Matthews E, Kanter KR, et al. Inflammatory response after neonatal cardiac surgery and its relationship to clinical outcomes. Ann Thorac Surg 2014,97:950&#x2013;956.</Citation><ArticleIdList><ArticleId IdType="pubmed">24424015</ArticleId></ArticleIdList></Reference><Reference><Citation>Allan CK, Newburger JW, McGrath E, et al. The relationship between inflammatory activation and clinical outcome after infant cardiopulmonary bypass. Anesth Analg 2010,111:1244&#x2013;1251.</Citation><ArticleIdList><ArticleId IdType="pubmed">20829561</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC. The clinical implications of the systemic inflammatory reaction related to cardiac operations in children. Cardiol Young 2003, 13:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pubmed">12903869</ArticleId></ArticleIdList></Reference><Reference><Citation>Kubicki R, Grohmann J, Siepe M, et al. Early prediction of capillary leak syndrome in infants after cardiopulmonary bypass. Eur J Cardiothorac Surg 2013,44:275&#x2013;281.</Citation><ArticleIdList><ArticleId IdType="pubmed">23389476</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Jeffries HE, Zimmerman JJ, et al. Sepsis in the pediatric cardiac intensive care unit. World J Pediatr Congenit Heart Surg 2011,2:393&#x2013;39912.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3277844</ArticleId><ArticleId IdType="pubmed">22337571</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartmann ME, et al. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med 2017,18(3):S4&#x2013;S16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Lacroix JR. Monitoring severity of multiple organ dysfunction syndrome: new and progressive multiple organ dysfunction syndrome, scoring systems. Pediatr Crit Care Med 2017,18(3)S17&#x2013;S23.</Citation><ArticleIdList><ArticleId IdType="pubmed">28248830</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich N, Allen GL, et al. Genomic expression profiling across the pediatric systemic inflammatory response syndrome, sepsis, and septic shock spectrum. Crit Care Med 2009,37:1558&#x2013;1566.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2747356</ArticleId><ArticleId IdType="pubmed">19325468</ArticleId></ArticleIdList></Reference><Reference><Citation>Standage SW, Wong HR. Biomarkers for pediatric sepsis and septic shock. Expert Rev Anti Infect Ther 2011,9:71&#x2013;79.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3033193</ArticleId><ArticleId IdType="pubmed">21171879</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaplan JM, Wong HR. Biomarker discovery and development in pediatric critical care medicine. Pediatr Crit Care Med 2011,12:165&#x2013;173.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2924462</ArticleId><ArticleId IdType="pubmed">20473243</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Salsibury S, Qiang Xiao, et al. The pediatric sepsis biomarker risk model. Critical Care 2012,16:R147&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3682273</ArticleId><ArticleId IdType="pubmed">23025259</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Caldwell JT, Cvijanovich NZ, et al. Prospective clinical testing and experimental validation of the Pediatric Sepsis Biomarker Risk Model. Sci Transl Med 2019,11(518): eaax9000. doi: 10.1126/scitranslmed.aax9000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.aax9000</ArticleId><ArticleId IdType="pmc">PMC7720682</ArticleId><ArticleId IdType="pubmed">31723040</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR. Genetics and genomics in pediatric septic shock. Crit Care Med 2012,40:1618&#x2013;1626</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3329642</ArticleId><ArticleId IdType="pubmed">22511139</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Weiss SL, Giuliano JS Jr, et al. Testing the prognostic accuracy of the updated pediatric sepsis biomarker risk model. PLoS ONE 2014,9:e86242. doi:10.1371/journal.pone.0086242</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0086242</ArticleId><ArticleId IdType="pmc">PMC3906040</ArticleId><ArticleId IdType="pubmed">24489704</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Anas N, et al. Developing a clinically feasible personalized medicine approach to pediatric septic shock. AJRCCM Articles in Press 2014,doi:10.1164/rccm.201410-1864OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201410-1864OC</ArticleId><ArticleId IdType="pmc">PMC4351580</ArticleId><ArticleId IdType="pubmed">25489881</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Lindsell CJ, Pettila V, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 2014,42:781&#x2013;789.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4620515</ArticleId><ArticleId IdType="pubmed">24335447</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayashi Y, Sawa Y, Fukuyama N, et al. Preoperative glutamine administration induces heat-shock protein 70 expression and attenuates cardiopulmonary bypass-induced inflammatory response by regulating nitric oxide synthase activity. Circ 2002,106(20):260&#x2013;267.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427658</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Warszawska JM, Schenk P, et al. Intraoperative ventilation strategy during cardiopulmonary bypass attenuates the release of matrix metalloproteinases and improves oxygenation. J Surg Research 2015,195(1):294&#x2013;302.</Citation><ArticleIdList><ArticleId IdType="pubmed">25577145</ArticleId></ArticleIdList></Reference><Reference><Citation>Beer L, Szerafin T, Mitterbauer A, et al. Low tidal volume ventilation during cardiopulmonary bypass reduces postoperative chemokine serum concentrations. Thorac Cardiovasc Surg 2014. 62(8):677&#x2013;682.</Citation><ArticleIdList><ArticleId IdType="pubmed">25226360</ArticleId></ArticleIdList></Reference><Reference><Citation>Khabar KSA, ElBarbary MA, Khouqeer F, et al. Circulating endotoxin and cytokines after cardiopulmonary bypass: differential correlation with duration of bypass and systemic inflammatory response/multiple organ dysfunction syndromes. Clinical Immunology and Immunopathology 1997,85(1):97&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">9325075</ArticleId></ArticleIdList></Reference><Reference><Citation>Madhok AB, Ojamaa K, Haridas V, et al. Cytokine response in children undergoing surgery for congenital heart disease. Pediatri Cardiol 2006, 27:408&#x2013;413.</Citation><ArticleIdList><ArticleId IdType="pubmed">16830075</ArticleId></ArticleIdList></Reference><Reference><Citation>Carmona F, Manso PH, Vincente WVA, et al. Risk stratification in neonates and infants submitted to cardiac surgery with cardiopulmonary bypass: a multimarker approach combining inflammatory mediators, N-terminal pro-B-type natriuretic peptide and troponin I. Cytokine 2008,42(3):317&#x2013;324.</Citation><ArticleIdList><ArticleId IdType="pubmed">18417355</ArticleId></ArticleIdList></Reference><Reference><Citation>deFontnouvelle CA, Greenberg JH, Thiessen-Philbrook HR, et al. Interleukin-8 and tumor necrosis factor predict acute kidney injury after pediatric surgery. Ann Thorac Surg 2017,104:2072&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5696070</ArticleId><ArticleId IdType="pubmed">28821332</ArticleId></ArticleIdList></Reference><Reference><Citation>O&#x2019;Brien SM, Clarke DR, Jacobs JP, et al. An empirically based tool for analyzing mortality associated with congenital heart disease. J Thorac Cardiovasc Surg 2009, 138(5): 1139&#x2013;1153.</Citation><ArticleIdList><ArticleId IdType="pubmed">19837218</ArticleId></ArticleIdList></Reference><Reference><Citation>Jacobs JP, O&#x2019;Brien SM, Pasquali SK, et al. Variation in outcomes for risk-stratified pediatric cardiac surgical operations: as analysis of the STS Congenital Heart Surgery Database. Ann Thorac Surg 2012,94(2):564&#x2013;571.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4006082</ArticleId><ArticleId IdType="pubmed">22704799</ArticleId></ArticleIdList></Reference><Reference><Citation>Gemke RJ, van Vught J. Scoring systems in pediatric intensive care: PRISM III versus PIM. Intensive Care Med 2002,28:204&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pubmed">11907665</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med 2005,6:2&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Russell RA, Ghanayem NS, Kuhn EM, et al. Relationship between risk-adjustment tools and the pediatric logistic organ dysfunction score. World J Pediatr Congenit Heart Surg 2014,15:16&#x2013;21</Citation><ArticleIdList><ArticleId IdType="pubmed">24403350</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, et al. PELOD-2: an update of the Pediatric logistic organ dysfunction score. Crit Care Med 2013,41:1761&#x2013;1773.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Umsted TM, Lu CK, Freeman WM, et al. The kinetics of cardiopulmonary bypass: a dual-platform proteomics study of plasma biomarkers in pediatric patients undergoing cardiopulmonary bypass. Artificial Organs 2012,36(1):E1&#x2013;E20.</Citation><ArticleIdList><ArticleId IdType="pubmed">22250822</ArticleId></ArticleIdList></Reference><Reference><Citation>Muller R, Mockel M. Logistic regression and CART in the analysis of multimarker studies. Clinica Chimica Acta 2008,394_1&#x2013;6.</Citation><ArticleIdList><ArticleId IdType="pubmed">18455512</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout D, Pagel C, et al. Incidence and risk factors for important early morbidities associated with pediatric cardiac surgery in a UK population. J Thorac Cardiovasc Surg 2019, 158(4):1185&#x2013;1196.e736.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353100</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KL, Ridout DA, Goldman AP, et al. Risk factors for long intensive care unit stay after cardiopulmonary bypass in children. Crit Care Med 2003, 31:28&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">12544989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med 2010,11(2):234&#x2013;238.37.</Citation><ArticleIdList><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Jeffries HE, Niebler RA, et al. Vasoactive-inotropic score is associated with outcome after infant cardiact surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System registries. Pediatr Crit Care Med 2014,15(6):529&#x2013;537.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159673</ArticleId><ArticleId IdType="pubmed">24777300</ArticleId></ArticleIdList></Reference><Reference><Citation>Gessler P, Pfenninger J, Pfammatter JP, et al. Plasma levels of interleukin-8 and expression of interleukin-8 receptors on circulating neutrophils and monocytes after cardiopulmonary bypass in children. J Thorac Cardiovasc Surg 2003,126(3):718&#x2013;725.</Citation><ArticleIdList><ArticleId IdType="pubmed">14502144</ArticleId></ArticleIdList></Reference><Reference><Citation>Drennan SE, Burge KY, Szyld EG, et al. Clinical and laboratory predictors for the development of low cardiac output syndrome in infants undergoing cardiopulmonary bypass: A pilot study. J Clin Med 2021,10(4)712.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7916966</ArticleId><ArticleId IdType="pubmed">33670210</ArticleId></ArticleIdList></Reference><Reference><Citation>Gorjipour F, Totonchi Z, Dehaki MG, et al. Serum levels of interleukin-6, interleukin-8, interleukin-10 and tumor necrosis factor-a, renal function biochemical parameters and clinical outcomes in pediatric cardiopulmonary bypass surgery. Perfusion 2019,34(8):651&#x2013;659.</Citation><ArticleIdList><ArticleId IdType="pubmed">31027462</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu KD, Altmann C, Smits G, et al. Serum interleukin-6 and interleukin-8 are early predictors of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care 2009,13(4)R104.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2750143</ArticleId><ArticleId IdType="pubmed">19570208</ArticleId></ArticleIdList></Reference><Reference><Citation>Rothenburger M, Tjan TDT, Schneider M, et al. The impact of the pro- and anti-inflammatory immune response on ventilation time after cardiac surgery. Cytometry B Clin Cytom 2003,53(1):70&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">12717694</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavasar I, Miller CS, Al-Sabbagh M. Macrophage inflammatory protein-1 alpha (MIP-1 alpha)/CCL3: as a biomarker. General Methods in Biomarker Research and their Applications 2015. 223&#x2013;249.</Citation></Reference><Reference><Citation>Wolpe SD, Davatelis G, Sherry B, et al. Macrophages secrete a novel heparin-binding protein with inflammatory and neutrophil chemokinetic properties. J Exp Med 1988,167(2):570&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2188834</ArticleId><ArticleId IdType="pubmed">3279154</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Cvijanovich NZ, Lindsell CJ, et al. PERSEVERE II: Redefining the pediatric sepsis biomarker risk model with septic shock phenotype. Crit Care Med 2016,44(11):2010&#x2013;2017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5201138</ArticleId><ArticleId IdType="pubmed">27513537</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasser WC, Dabal RJ, Askenazi DJ, et al. Prophylactic peritoneal dialysis following cardiopulmonary bypass in children is associated with decreased inflammation and improved clinical outcomes. Congenit Heart Dis 2014,9(2):106&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">23647999</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36053068</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>05</Day></DateCompleted><DateRevised><Year>2023</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1529-7535</ISSN><JournalIssue CitedMedium="Internet"><Volume>23</Volume><Issue>12</Issue><PubDate><Year>2022</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title><ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Derivation and Validation of Vasoactive Inotrope Score Trajectory Groups in Critically Ill Children With Shock.</ArticleTitle><Pagination><StartPage>1017</StartPage><EndPage>1026</EndPage><MedlinePgn>1017-1026</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0000000000003070</ELocationID><Abstract><AbstractText Label="OBJECTIVES">To determine whether there are clinically relevant and reproducible Vasoactive Inotrope Score (VIS) trajectories in children with shock during the acute phase of critical illness.</AbstractText><AbstractText Label="DESIGN">Retrospective, observational cohort study.</AbstractText><AbstractText Label="SETTING">Two tertiary, academic PICUs.</AbstractText><AbstractText Label="PATIENTS">Children (&lt; 18 yr old) who required vasoactive infusions within 24 hours of admission to the PICU. Those admitted post cardiac surgery were excluded.</AbstractText><AbstractText Label="INTERVENTIONS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">An hourly VIS was calculated for the first 72 hours after initiation of vasoactives. Group-based trajectory modeling (GBTM) was applied to a derivation set (75% of encounters) and compared with the trajectories in a validation set (25% of encounters) using the same variables. The primary outcome was in-hospital mortality, and the secondary outcome was multiple organ dysfunction syndrome (MODS) on day 7. A total of 1,828 patients met inclusion criteria, and 309 (16.9%) died. GBTM identified four subgroups that were reproducible in the validation set: "Mild, fast resolving shock" ( n = 853 [47%]; mortality 9%), "Moderate, slow resolving shock" ( n = 422 [23%]; mortality 15%), "Moderate, prolonged shock" ( n = 312 [17%]; mortality 21%), and "Severe, prolonged shock" ( n = 241 [13%]; mortality 40%). There was a significant difference in mortality, MODS on day 7, and suspected infection ( p &lt; 0.001) across groups. The "Mild, fast resolving shock" and "Severe, prolonged shock" groups were identifiable within the first 24 hours. The "Moderate, slow resolving" and "Moderate, prolonged shock" groups were indistinguishable in the first 24 hours after initiation of vasoactives but differed in in-hospital mortality and MODS on day 7. Hydrocortisone administration was independently associated with poor outcomes in the "Mild, fast resolving shock" group.</AbstractText><AbstractText Label="CONCLUSIONS">We uncovered four distinct and reproducible VIS trajectory groups that were associated with different risk factors, response to therapy, and outcomes in children with shock. Characterizing VIS trajectory groups in the acute phase of critical illness may enable better prognostication and more targeted management.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 by the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Perizes</LastName><ForeName>Elitsa N</ForeName><Initials>EN</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chong</LastName><ForeName>Grace</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Critical Care, University of Chicago Medicine Comer Children's Hospital, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, University of Chicago Pritzker School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Pinto</LastName><ForeName>L Nelson</ForeName><Initials>LN</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Ann &amp; Robert H. Lurie Children's Hospital of Chicago, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Preventive Medicine (Health and Biomedical Informatics), Northwestern University Feinberg School of Medicine, Chicago, IL., Current affiliation for Dr. Perizes: Division of Critical Care Medicine, Helen DeVos Children's Hospital, Grand Rapids, MI.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01 HD105939</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R21 HD096402</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Crit Care Med</MedlineTA><NlmUniqueID>100954653</NlmUniqueID><ISSNLinking>1529-7535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>Dr. Sanchez-Pinto&#x2019;s institution received funding from National Institutes of Health (NIH) grant R01HD105939 and R21HD096402, and he received support for article research from the NIH. The remaining authors have disclosed that they do not have any potential conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>2</Day><Hour>9</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>12</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36053068</ArticleId><ArticleId IdType="mid">NIHMS1825960</ArticleId><ArticleId IdType="pmc">PMC9722555</ArticleId><ArticleId IdType="doi">10.1097/PCC.0000000000003070</ArticleId><ArticleId IdType="pii">00130478-202212000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hartman ME, Linde-Zwirble WT, Angus DC, Watson RS. Trends in the epidemiology of pediatric severe sepsis*. Pediatr Crit Care Med. 2013;14(7):686&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pubmed">23897242</ArticleId></ArticleIdList></Reference><Reference><Citation>Balamuth F, Weiss SL, Neuman MI, Scott H, Brady PW, Paul R, et al. Pediatric severe sepsis in U.S. children&#x2019;s hospitals. Pediatr Crit Care Med. 2014;15(9):798&#x2013;805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4221502</ArticleId><ArticleId IdType="pubmed">25162514</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015;191(10):1147&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Peters MJ, Alhazzani W, Agus MSD, Flori HR, Inwald DP, et al. Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children. Pediatr Crit Care Med. 2020;21(2):e52&#x2013;e106.</Citation><ArticleIdList><ArticleId IdType="pubmed">32032273</ArticleId></ArticleIdList></Reference><Reference><Citation>Bellazzi R, Zupan B. Predictive data mining in clinical medicine: current issues and guidelines. Int J Med Inform. 2008;77(2):81&#x2013;97.</Citation><ArticleIdList><ArticleId IdType="pubmed">17188928</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Kennedy JN, Wang S, Chang C-CH, Elliott CF, Xu Z, et al. Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis. JAMA. 2019;321(20):2003&#x2013;17.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6537818</ArticleId><ArticleId IdType="pubmed">31104070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children. JAMA Netw Open. 2020;3(8):e209271-e.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="pubmed">32780121</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gomez H, Chang C-CH, Clermont G, Kellum JA, Kennedy J, et al. Precision medicine for all? Challenges and opportunities for a precision medicine approach to critical illness. Crit Care. 2017;21(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5648512</ArticleId><ArticleId IdType="pubmed">29047353</ArticleId></ArticleIdList></Reference><Reference><Citation>Jha RM, Elmer J, Zusman BE, Desai S, Puccio AM, Okonkwo DO, et al. Intracranial Pressure Trajectories: A Novel Approach to Informing Severe Traumatic Brain Injury Phenotypes. Crit Care Med. 2018;46(11):1792&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6185785</ArticleId><ArticleId IdType="pubmed">30119071</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhavani SV, Carey KA, Gilbert ER, Afshar M, Verhoef PA, Churpek MM. Identifying Novel Sepsis Subphenotypes Using Temperature Trajectories. Am J Respir Crit Care Med. 2019;200(3):327&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6680307</ArticleId><ArticleId IdType="pubmed">30789749</ArticleId></ArticleIdList></Reference><Reference><Citation>Wernovsky G, Mayer JE Jr, Jonas RA, Hanley FL, Blackstone EH, Kirklin JW, et al. Factors influencing early and late outcome of the arterial switch operation for transposition of the great arteries. J Thorac Cardiovasc Surg. 1995;109(2):289&#x2013;301; discussion &#x2212;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">7853882</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Gurney JG, Yen AH, Napoli ML, Gajarski RJ, Ohye RG, et al. Vasoactive-inotropic score as a predictor of morbidity and mortality in infants after cardiopulmonary bypass. Pediatr Crit Care Med. 2010;11(2):234&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">19794327</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaies MG, Jeffries HE, Niebler RA, Pasquali SK, Donohue JE, Yu S, et al. Vasoactive-inotropic score is associated with outcome after infant cardiac surgery: an analysis from the Pediatric Cardiac Critical Care Consortium and Virtual PICU System Registries. Pediatr Crit Care Med. 2014;15(6):529&#x2013;37.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4159673</ArticleId><ArticleId IdType="pubmed">24777300</ArticleId></ArticleIdList></Reference><Reference><Citation>McIntosh AM, Tong S, Deakyne SJ, Davidson JA, Scott HF. Validation of the Vasoactive-Inotropic Score in Pediatric Sepsis. Pediatr Crit Care Med. 2017;18(8):750&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5548505</ArticleId><ArticleId IdType="pubmed">28486385</ArticleId></ArticleIdList></Reference><Reference><Citation>Von Elm E, Altman DG, Egger M, Pocock SJ, G&#xf8;tzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bulletin of the World Health Organization. 2007;85:867&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2636253</ArticleId><ArticleId IdType="pubmed">18038077</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembea MM, Agus M, Akcan-Arikan A, Alexander P, Basu R, Bennett TD, et al. Pediatric organ dysfunction information update mandate (PODIUM) contemporary organ dysfunction criteria: executive summary. Pediatrics. 2022;149(Supplement_1):S1&#x2013;S12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9599725</ArticleId><ArticleId IdType="pubmed">34970673</ArticleId></ArticleIdList></Reference><Reference><Citation>Feudtner C, Feinstein JA, Zhong W, Hall M, Dai D. Pediatric complex chronic conditions classification system version 2: updated for ICD-10 and complex medical technology dependence and transplantation. BMC Pediatr. 2014;14(1):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4134331</ArticleId><ArticleId IdType="pubmed">25102958</ArticleId></ArticleIdList></Reference><Reference><Citation>Sanchez-Pinto LN, Stroup EK, Pendergrast T, Pinto N, Luo Y. Derivation and Validation of Novel Phenotypes of Multiple Organ Dysfunction Syndrome in Critically Ill Children. JAMA Netw Open. 2020;3(8):e209271.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7420303</ArticleId><ArticleId IdType="pubmed">32780121</ArticleId></ArticleIdList></Reference><Reference><Citation>Matics TJ, Sanchez-Pinto LN. Adaptation and Validation of a Pediatric Sequential Organ Failure Assessment Score and Evaluation of the Sepsis-3 Definitions in Critically Ill Children. JAMA Pediatr. 2017:e172352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6583375</ArticleId><ArticleId IdType="pubmed">28783810</ArticleId></ArticleIdList></Reference><Reference><Citation>Khanna A, English SW, Wang XS, Ham K, Tumlin J, Szerlip H, et al. Angiotensin II for the treatment of vasodilatory shock. New England Journal of Medicine. 2017;377(5):419&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">28528561</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson J, Nelson D, Holst A, Hellgren E, Friman O, Oldner A. Temporal patterns of organ dysfunction after severe trauma. Critic Care. 2021;25(1):1&#x2013;11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8101241</ArticleId><ArticleId IdType="pubmed">33952314</ArticleId></ArticleIdList></Reference><Reference><Citation>Roberts RJ, Miano TA, Hammond DA, Patel GP, Chen J-T, Phillips KM, et al. Evaluation of Vasopressor Exposure and Mortality in Patients With Septic Shock. Crit Care Med. 2020;48(10):1445&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">32706559</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#xfc;nser MW, Ruokonen E, Pettil&#xe4; V, Ulmer H, Torgersen C, Schmittinger CA, et al. Association of arterial blood pressure and vasopressor load with septic shock mortality: a post hoc analysis of a multicenter trial. Crit Care. 2009;13(6):1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2811945</ArticleId><ArticleId IdType="pubmed">19917106</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong HR, Atkinson SJ, Cvijanovich NZ, Anas N, Allen GL, Thomas NJ, et al. Combining prognostic and predictive enrichment strategies to identify children with septic shock responsive to corticosteroids. Crit Care Med. 2016;44(10):e1000.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5026540</ArticleId><ArticleId IdType="pubmed">27270179</ArticleId></ArticleIdList></Reference><Reference><Citation>Alobaidi R, Morgan C, Basu RK, Stenson E, Featherstone R, Majumdar SR, et al. Association between fluid balance and outcomes in critically ill children: a systematic review and meta-analysis. JAMA Pediatr. 2018;172(3):257&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5885847</ArticleId><ArticleId IdType="pubmed">29356810</ArticleId></ArticleIdList></Reference><Reference><Citation>Arikan AA, Zappitelli M, Goldstein SL, Naipaul A, Jefferson LS, Loftis LL. Fluid overload is associated with impaired oxygenation and morbidity in critically ill children. Pediatr Crit Care Med. 2012;13(3):253&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">21760565</ArticleId></ArticleIdList></Reference><Reference><Citation>Valentine SL, Sapru A, Higgerson RA, Spinella PC, Flori HR, Graham DA, et al. Fluid balance in critically ill children with acute lung injury. Crit Care Med. 2012;40(10):2883.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3455114</ArticleId><ArticleId IdType="pubmed">22824936</ArticleId></ArticleIdList></Reference><Reference><Citation>Abulebda K, Cvijanovich NZ, Thomas NJ, Allen GL, Anas N, Bigham MT, et al. Post-intensive care unit admission fluid balance and pediatric septic shock outcomes: A risk-stratified analysis. Crit Care Med. 2014;42(2):397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3947064</ArticleId><ArticleId IdType="pubmed">24145842</ArticleId></ArticleIdList></Reference><Reference><Citation>DeMerle KM, Angus DC, Baillie JK, Brant E, Calfee CS, Carcillo J, et al. Sepsis Subclasses: A Framework for Development and Interpretation. Crit Care Med. 2021. May 1;49(5):748&#x2013;759.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8627188</ArticleId><ArticleId IdType="pubmed">33591001</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33931112</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>22</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2047-783X</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Apr</Month><Day>30</Day></PubDate></JournalIssue><Title>European journal of medical research</Title><ISOAbbreviation>Eur J Med Res</ISOAbbreviation></Journal><ArticleTitle>The potential of adipokines in identifying multiple trauma patients at risk of developing multiple organ dysfunction syndrome.</ArticleTitle><Pagination><StartPage>38</StartPage><MedlinePgn>38</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">38</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s40001-021-00511-z</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Multiple organ dysfunction syndrome (MODS) and the consecutive multiple organ failure (MOF) are severe and dreaded complications with a high mortality in multiple trauma patients. The aim of this study was to investigate the potential of the adipokines leptin, resistin, interleukin-17A and interleukin-33 as possible biomarkers in the early posttraumatic inflammatory response and for identifying severely traumatized patients at risk of developing MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In total, 14 multiple trauma patients with an injury severity score (ISS)&#x2009;&#x2265;&#x2009;16 as well as a control group of 14 non-multiple trauma patients were included in this study and blood samples were taken at the time points 0, 6, 24, 48 and 72&#xa0;h after admission. For the trauma patients, the SIRS and Denver MOF score were determined daily. The quantitative measurement of the plasma concentrations of the adipokines was performed using ELISA.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the statistical analysis, the multiple trauma patients showed statistically significant higher plasma concentrations of leptin, resistin, IL-17A and IL-33 compared to the control group. In addition, there was a statistically significant positive correlation between the concentrations of resistin, IL-17A and IL-33 and the corresponding SIRS scores and between the concentrations of resistin, IL-17A and IL-33 and the corresponding Denver MOF scores. Finally, ROC curve analysis revealed that the adipokines leptin and IL-17A are suitable diagnostic markers for the discrimination between multiple trauma patients with and without MOF.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Leptin and IL-17A could be suitable diagnostic markers to identify severely injured patients with a developing SIRS and MOF earlier, to adjust surgical therapy planning and intensive care.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Haupt</LastName><ForeName>Julian</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-2608-3444</Identifier><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany. julian1haupt@bundeswehr.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bundeswehr Institute of Radiobiology affiliated to the University Ulm, Neuherbergstrasse 11, 80937, Munich, Germany. julian1haupt@bundeswehr.org.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krysiak</LastName><ForeName>Niels</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Unger</LastName><ForeName>Marina</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bogner-Flatz</LastName><ForeName>Viktoria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Hospital Munich, Ludwig-Maximilians-University, Nussbaumstrasse 20, 80336, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hanschen</LastName><ForeName>Marc</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>Martijn</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Cell Biology-Inspired Tissue Engineering (cBITE), MERLN Institute for Technology-Inspired Regenerative Medicine, Maastricht University, Universiteitssingel 40, 6229 ER, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Haug</LastName><ForeName>Alexander T</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Experimental Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Trauma Surgery, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopedics and Sports Orthopedics, Klinikum rechts der Isar, Technical University of Munich, Ismaninger Strasse 22, 81675, Munich, Germany.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>04</Month><Day>30</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Med Res</MedlineTA><NlmUniqueID>9517857</NlmUniqueID><ISSNLinking>0949-2321</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D054392">Adipokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D054392" MajorTopicYN="N">Adipokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012372" MajorTopicYN="N">ROC Curve</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Adipokines</Keyword><Keyword MajorTopicYN="N">Interleukin-17A</Keyword><Keyword MajorTopicYN="N">Interleukin-33</Keyword><Keyword MajorTopicYN="N">Leptin</Keyword><Keyword MajorTopicYN="N">Multiple organ dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Multiple organ failure</Keyword><Keyword MajorTopicYN="N">Multiple trauma</Keyword><Keyword MajorTopicYN="N">Resistin</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>4</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>1</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>4</Month><Day>30</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33931112</ArticleId><ArticleId IdType="pmc">PMC8086117</ArticleId><ArticleId IdType="doi">10.1186/s40001-021-00511-z</ArticleId><ArticleId IdType="pii">10.1186/s40001-021-00511-z</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wick M, Ekkernkamp A, Muhr G. The epidemiology of multiple trauma. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen. 1997. 68(11):1053&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9518193</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R. Das schwere Trauma. Notfall+ Rettungsmedizin. 2008;11(6):373&#x2013;6.</Citation></Reference><Reference><Citation>Ornato JP, Craren EJ, Nelson NM, Kimball KF. Impact of improved emergency medical services and emergency trauma care on the reduction in mortality from trauma. J Trauma. 1985;25(7):575&#x2013;579. doi: 10.1097/00005373-198507000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198507000-00001</ArticleId><ArticleId IdType="pubmed">4009762</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker CC. Epidemiology of trauma: the civilian perspective. Ann Emerg Med. 1986;15(12):1389&#x2013;1391. doi: 10.1016/S0196-0644(86)80921-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0196-0644(86)80921-0</ArticleId><ArticleId IdType="pubmed">3777610</ArticleId></ArticleIdList></Reference><Reference><Citation>Regel G, Lobenhoffer P, Grotz M, Pape H, Lehmann U, Tscherne H. Treatment results of patients with multiple trauma: an analysis of 3406 cases treated between 1972 and 1991 at a German Level I Trauma Center. J Trauma Acute Care Surg. 1995;38(1):70&#x2013;78. doi: 10.1097/00005373-199501000-00020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199501000-00020</ArticleId><ArticleId IdType="pubmed">7745664</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36(6):691&#x2013;709. doi: 10.1016/j.injury.2004.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.12.037</ArticleId><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>van Griensven M, Krettek C, Pape H-C. Immune Reactions afterTrauma. Eur J Trauma. 2003;29(4):181&#x2013;192. doi: 10.1007/s00068-001-1324-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-001-1324-z</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Lezotte DC. Early risk factors for postinjury multiple organ failure. World J Surg. 1996;20(4):392&#x2013;400. doi: 10.1007/s002689900062.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s002689900062</ArticleId><ArticleId IdType="pubmed">8662125</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore EE, Johnson JL, Ciesla DJ, Biffl WL, Banerjee A. Validation of postinjury multiple organ failure scores. Shock (Augusta, Ga) 2009;31(5):438. doi: 10.1097/SHK.0b013e31818ba4c6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31818ba4c6</ArticleId><ArticleId IdType="pmc">PMC4324473</ArticleId><ArticleId IdType="pubmed">18838942</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewar D, Moore FA, Moore EE, Balogh Z. Postinjury multiple organ failure. Injury. 2009;40(9):912&#x2013;918. doi: 10.1016/j.injury.2009.05.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2009.05.024</ArticleId><ArticleId IdType="pubmed">19541301</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest. 1992;101(6):1644&#x2013;1655. doi: 10.1378/chest.101.6.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Ouchi N, Parker JL, Lugus JJ, Walsh K. Adipokines in inflammation and metabolic disease. Nat Rev Immunol. 2011;11(2):85&#x2013;97. doi: 10.1038/nri2921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2921</ArticleId><ArticleId IdType="pmc">PMC3518031</ArticleId><ArticleId IdType="pubmed">21252989</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg AH, Scherer PE. Adipose tissue, inflammation, and cardiovascular disease. Circ Res. 2005;96(9):939&#x2013;949. doi: 10.1161/01.RES.0000163635.62927.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.RES.0000163635.62927.34</ArticleId><ArticleId IdType="pubmed">15890981</ArticleId></ArticleIdList></Reference><Reference><Citation>Javier C, Morena S, Rodolfo G, Ver&#xf3;nica L, Jes&#xfa;s GRJ, Francisca L, et al. Adipokines: Biofactors from white adipose tissue A complex hub among inflammation, metabolism, and immunity. BioFactors. 2011;37(6):413&#x2013;420. doi: 10.1002/biof.185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/biof.185</ArticleId><ArticleId IdType="pubmed">22038756</ArticleId></ArticleIdList></Reference><Reference><Citation>Fantuzzi G, Faggioni R. Leptin in the regulation of immunity, inflammation, and hematopoiesis. J Leukoc Biol. 2000;68(4):437&#x2013;446.</Citation><ArticleIdList><ArticleId IdType="pubmed">11037963</ArticleId></ArticleIdList></Reference><Reference><Citation>La Cava A, Matarese G. The weight of leptin in immunity. Nat Rev Immunol. 2004;4(5):371&#x2013;379. doi: 10.1038/nri1350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri1350</ArticleId><ArticleId IdType="pubmed">15122202</ArticleId></ArticleIdList></Reference><Reference><Citation>Finck BN, Johnson RW. Tumor necrosis factor (TNF)-&#x3b1; induces leptin production through the p55 TNF receptor. Am J Physiol Regulatory Integrative Comparative Physiol. 2000;278(2):R537&#x2013;R543. doi: 10.1152/ajpregu.2000.278.2.R537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpregu.2000.278.2.R537</ArticleId><ArticleId IdType="pubmed">10666158</ArticleId></ArticleIdList></Reference><Reference><Citation>Santos-Alvarez J, Goberna R, S&#xe1;nchez-Margalet V. Human leptin stimulates proliferation and activation of human circulating monocytes. Cell Immunol. 1999;194(1):6&#x2013;11. doi: 10.1006/cimm.1999.1490.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cimm.1999.1490</ArticleId><ArticleId IdType="pubmed">10357875</ArticleId></ArticleIdList></Reference><Reference><Citation>Negrin LL, Jahn A, van Griensven M. Leptin protects against mortality and organ dysfunction in a two-hit trauma/sepsis model and is IL-6-dependent. Shock. 2017;48(1):130&#x2013;137. doi: 10.1097/SHK.0000000000000837.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000837</ArticleId><ArticleId IdType="pubmed">28114167</ArticleId></ArticleIdList></Reference><Reference><Citation>Steppan CM, Brown EJ, Wright CM, Bhat S, Banerjee RR, Dai CY, et al. A family of tissue-specific resistin-like molecules. Proc Natl Acad Sci USA. 2001;98(2):502&#x2013;506. doi: 10.1073/pnas.98.2.502.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.98.2.502</ArticleId><ArticleId IdType="pmc">PMC14616</ArticleId><ArticleId IdType="pubmed">11209052</ArticleId></ArticleIdList></Reference><Reference><Citation>Patel L, Buckels AC, Kinghorn IJ, Murdock PR, Holbrook JD, Plumpton C, et al. Resistin is expressed in human macrophages and directly regulated by PPAR gamma activators. Biochem Biophys Res Commun. 2003;300(2):472&#x2013;476. doi: 10.1016/S0006-291X(02)02841-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(02)02841-3</ArticleId><ArticleId IdType="pubmed">12504108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaser S, Kaser A, Sandhofer A, Ebenbichler CF, Tilg H, Patsch JR. Resistin messenger-RNA expression is increased by proinflammatory cytokines in vitro. Biochem Biophys Res Commun. 2003;309(2):286&#x2013;290. doi: 10.1016/j.bbrc.2003.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2003.07.003</ArticleId><ArticleId IdType="pubmed">12951047</ArticleId></ArticleIdList></Reference><Reference><Citation>Bokarewa M, Nagaev I, Dahlberg L, Smith U, Tarkowski A. Resistin, an adipokine with potent proinflammatory properties. J Immunol. 2005;174(9):5789&#x2013;5795. doi: 10.4049/jimmunol.174.9.5789.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.174.9.5789</ArticleId><ArticleId IdType="pubmed">15843582</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwakura Y, Ishigame H, Saijo S, Nakae S. Functional specialization of interleukin-17 family members. Immunity. 2011;34(2):149&#x2013;162. doi: 10.1016/j.immuni.2011.02.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.02.012</ArticleId><ArticleId IdType="pubmed">21349428</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaffen SL. An overview of IL-17 function and signaling. Cytokine. 2008;43(3):402&#x2013;407. doi: 10.1016/j.cyto.2008.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2008.07.017</ArticleId><ArticleId IdType="pmc">PMC2582446</ArticleId><ArticleId IdType="pubmed">18701318</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabat R, Witte E, Witte K, Wolk K. IL-22 and IL-17: An Overview. In: Quesniaux V, Ryffel B, Padova F, editors. IL-17, IL-22 and Their Producing Cells: Role in Inflammation and Autoimmunity. Basel: Springer Basel; 2013. pp. 11&#x2013;35.</Citation></Reference><Reference><Citation>Mitsdoerffer M, Lee Y, J&#xe4;ger A, Kim H-J, Korn T, Kolls JK, et al. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc Natl Acad Sci. 2010;107(32):14292&#x2013;14297. doi: 10.1073/pnas.1009234107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1009234107</ArticleId><ArticleId IdType="pmc">PMC2922571</ArticleId><ArticleId IdType="pubmed">20660725</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmitz J, Owyang A, Oldham E, Song Y, Murphy E, McClanahan TK, et al. IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. Immunity. 2005;23(5):479&#x2013;490. doi: 10.1016/j.immuni.2005.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.09.015</ArticleId><ArticleId IdType="pubmed">16286016</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood IS, Wang B, Trayhurn P. IL-33, a recently identified interleukin-1 gene family member, is expressed in human adipocytes. Biochem Biophys Res Commun. 2009;384(1):105&#x2013;109. doi: 10.1016/j.bbrc.2009.04.081.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbrc.2009.04.081</ArticleId><ArticleId IdType="pubmed">19393621</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamkanfi M, Dixit VM. IL-33 raises alarm. Immunity. 2009;31(1):5&#x2013;7. doi: 10.1016/j.immuni.2009.06.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.06.011</ArticleId><ArticleId IdType="pubmed">19604486</ArticleId></ArticleIdList></Reference><Reference><Citation>Komai-Koma M, Xu D, Li Y, McKenzie AN, McInnes IB, Liew FY. IL-33 is a chemoattractant for human Th2 cells. Eur J Immunol. 2007;37(10):2779&#x2013;2786. doi: 10.1002/eji.200737547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200737547</ArticleId><ArticleId IdType="pubmed">17853410</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherry WB, Yoon J, Bartemes KR, Iijima K, Kita H. A novel IL-1 family cytokine, IL-33, potently activates human eosinophils. J Allergy Clin Immunol. 2008;121(6):1484&#x2013;1490. doi: 10.1016/j.jaci.2008.04.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2008.04.005</ArticleId><ArticleId IdType="pmc">PMC2821937</ArticleId><ArticleId IdType="pubmed">18539196</ArticleId></ArticleIdList></Reference><Reference><Citation>Gennarelli T, Wodzin E, Barrington I. Association for the Advancement of Automotive Medicine: The Abbreviated Injury Scale 2005. Update. 2008.</Citation></Reference><Reference><Citation>Keller WK, Dillihunt R, Fenner H, Jolley F, Keeney A, Weygandt P, et al. Rating the severity of tissue damage: I The abbreviated injury scale. JAMA. 1971;215(2):277&#x2013;280. doi: 10.1001/jama.1971.03180150059012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.1971.03180150059012</ArticleId><ArticleId IdType="pubmed">5107365</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, O'Neill B, Haddon W, Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma Acute Care Surg. 1974;14(3):187&#x2013;196. doi: 10.1097/00005373-197403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197403000-00001</ArticleId><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker S, O'Neill B. The injury severity score: an update. J Trauma Acute Care Surg. 1976;16(11):882&#x2013;885. doi: 10.1097/00005373-197611000-00006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197611000-00006</ArticleId><ArticleId IdType="pubmed">994270</ArticleId></ArticleIdList></Reference><Reference><Citation>Sektion Notfall- &amp; Intensivmedizin, Schwerverletztenversorgung (NIS) der Deutschen Gesellschaft f&#xfc;r Unfallchirurgie (DGU). TraumaRegister Jahresbericht 2015. 2015.</Citation></Reference><Reference><Citation>Fr&#xf6;hlich M, Lefering R, Probst C, Paffrath T, Schneider MM, Maegele M, et al. Epidemiology and risk factors of multiple-organ failure after multiple trauma: an analysis of 31,154 patients from the TraumaRegister DGU. J Trauma Acute Care Surg. 2014;76(4):921&#x2013;928. doi: 10.1097/TA.0000000000000199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000199</ArticleId><ArticleId IdType="pubmed">24662853</ArticleId></ArticleIdList></Reference><Reference><Citation>Grotz M, van Griensven M, Stalp M, Kaufmann U, Hildebrand F, Pape H. Scoring des Multiorganversagens nach schwerem Trauma Vergleich des Goris- Marshall-und Moore-Scores Der Chirurg. 2001;72(6):723&#x2013;730.</Citation><ArticleIdList><ArticleId IdType="pubmed">11469095</ArticleId></ArticleIdList></Reference><Reference><Citation>Hutchings L, Watkinson P, Young JD, Willett K. Defining multiple organ failure after major trauma: a comparison of the Denver, Sequential Organ Failure Assessment and Marshall scoring systems. J Trauma Acute Care Surg. 2017;82(3):534. doi: 10.1097/TA.0000000000001328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000001328</ArticleId><ArticleId IdType="pmc">PMC5328408</ArticleId><ArticleId IdType="pubmed">28030507</ArticleId></ArticleIdList></Reference><Reference><Citation>Chachkhiani I, Gurlich R, Maruna P, Frasko R, Lindner J. The postoperative stress response and its reflection in cytokine network and leptin plasma levels. Physiol Res. 2005;54(3):279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">15588161</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura F, Shimizu H, Yoshidome H, Ohtsuka M, Kato A, Yoshitomi H, et al. Circulating cytokines, chemokines, and stress hormones are increased in patients with organ dysfunction following liver resection. J Surg Res. 2006;133(2):102&#x2013;112. doi: 10.1016/j.jss.2005.10.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2005.10.025</ArticleId><ArticleId IdType="pubmed">16386757</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef AAAM, Amr YM, Suliman GA. The diagnostic value of serum leptin monitoring and its correlation with tumor necrosis factor-&#x3b1; in critically ill patients: a prospective observational study. Crit Care. 2010;14(2):R33. doi: 10.1186/cc8911.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8911</ArticleId><ArticleId IdType="pmc">PMC2887140</ArticleId><ArticleId IdType="pubmed">20230641</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace AM, Sattar N, Mcmillan DC. The co-ordinated cytokine/hormone response to acute injury incorporates leptin. Cytokine. 2000;12(7):1042&#x2013;1045. doi: 10.1006/cyto.2000.0674.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.2000.0674</ArticleId><ArticleId IdType="pubmed">10880250</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong X-Q, Yang S-B, Zhu F-L, Lv Q-W, Zhang G-H, Huang H-B. Resistin is associated with mortality in patients with traumatic brain injury. Crit Care. 2010;14(5):R190. doi: 10.1186/cc9307.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9307</ArticleId><ArticleId IdType="pmc">PMC3219297</ArticleId><ArticleId IdType="pubmed">21029428</ArticleId></ArticleIdList></Reference><Reference><Citation>Wade CE, Mora AG, Shields BA, Pidcoke HF, Baer LA, Chung KK, et al. Signals from fat after injury: plasma adipokines and ghrelin concentrations in the severely burned. Cytokine. 2013;61(1):78&#x2013;83. doi: 10.1016/j.cyto.2012.08.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2012.08.031</ArticleId><ArticleId IdType="pmc">PMC3505238</ArticleId><ArticleId IdType="pubmed">23021431</ArticleId></ArticleIdList></Reference><Reference><Citation>Sund&#xe9;n-Cullberg J, Nystr&#xf6;m T, Lee ML, Mullins GE, Tokics L, Andersson J, et al. Pronounced elevation of resistin correlates with severity of disease in severe sepsis and septic shock. Crit Care Med. 2007;35(6):1536&#x2013;1542. doi: 10.1097/01.CCM.0000266536.14736.03.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000266536.14736.03</ArticleId><ArticleId IdType="pubmed">17452927</ArticleId></ArticleIdList></Reference><Reference><Citation>Abboud A, Namas RA, Ramadan M, Mi Q, Almahmoud K, Abdul-Malak O, et al. Computational analysis supports an early, type 17 cell-associated divergence of blunt trauma survival and mortality. Crit Care Med. 2016;44(11):e1074. doi: 10.1097/CCM.0000000000001951.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001951</ArticleId><ArticleId IdType="pmc">PMC5201164</ArticleId><ArticleId IdType="pubmed">27513538</ArticleId></ArticleIdList></Reference><Reference><Citation>Hefele F, Ditsch A, Krysiak N, Caldwell C, Biberthaler P, van Griensven M, et al. Trauma induces interleukin-17A expression on Th17 Cells and CD4+ regulatory T cells as well as platelet dysfunction. Front Immunol. 2019;10:2389. doi: 10.3389/fimmu.2019.02389.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.02389</ArticleId><ArticleId IdType="pmc">PMC6797820</ArticleId><ArticleId IdType="pubmed">31681282</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelkader A, El-Sayed M, Eladawy A, Elsayed R, Mukhtar A, Hammimy W. Interleukin-17a as a predictor of occurrence of sepsis in polytrauma patients: a prospective observational study. Intensive Care Med Exp. 2015;3(1):A790. doi: 10.1186/2197-425X-3-S1-A790.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/2197-425X-3-S1-A790</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirsiger S, Simmen H-P, Werner CM, Wanner GA, Rittirsch D. Danger signals activating the immune response after trauma. Mediators of inflammation. 2012;2012.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388465</ArticleId><ArticleId IdType="pubmed">22778496</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J, Guardado J, Hoffman R, Xu H, Namas R, Vodovotz Y, et al. IL33-mediated ILC2 activation and neutrophil IL5 production in the lung response after severe trauma: A reverse translation study from a human cohort to a mouse trauma model. PLoS Med. 2017;14(7):e1002365. doi: 10.1371/journal.pmed.1002365.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1002365</ArticleId><ArticleId IdType="pmc">PMC5526517</ArticleId><ArticleId IdType="pubmed">28742815</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">34686556</PMID><DateCompleted><Year>2021</Year><Month>11</Month><Day>03</Day></DateCompleted><DateRevised><Year>2021</Year><Month>11</Month><Day>11</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2044-6055</ISSN><JournalIssue CitedMedium="Internet"><Volume>11</Volume><Issue>10</Issue><PubDate><Year>2021</Year><Month>Oct</Month><Day>22</Day></PubDate></JournalIssue><Title>BMJ open</Title><ISOAbbreviation>BMJ Open</ISOAbbreviation></Journal><ArticleTitle>Multicentre, longitudinal, observational cohort study to examine the relationship between neutrophil function and sepsis in adults and children with severe thermal injuries: a protocol for the Scientific Investigation of the Biological Pathways Following Thermal Injury-2 (SIFTI-2) study.</ArticleTitle><Pagination><StartPage>e052035</StartPage><MedlinePgn>e052035</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e052035</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/bmjopen-2021-052035</ELocationID><Abstract><AbstractText Label="INTRODUCTION">Burn-induced changes in the phenotype and function of neutrophils, cells which provide front-line protection against rapidly dividing bacterial infections, are emerging as potential biomarkers for the early prediction of sepsis. In a longitudinal study of adult burns patients, we recently demonstrated that a combined measurement of neutrophil phagocytic capacity, immature granulocyte (IG) count and plasma cell-free DNA (cfDNA) levels on the day of injury gave good discriminatory power for the prediction of later sepsis development. However, limited by a small sample size, single-centre design and focus on adult burns patients, these biomarkers require prospective validation in a larger patient cohort. The Scientific Investigation of the Biological Pathways Following Thermal Injury-2 study aims to prospectively validate neutrophil phagocytic activity, IG count and plasma cfDNA levels as early prognostic biomarkers of sepsis in thermally injured adult and paediatric patients.</AbstractText><AbstractText Label="METHODS AND ANALYSIS">This multicentre, longitudinal, observational cohort study will enrol 245 paediatric and adult patients with moderate to severe burns within 24 hours of injury. Blood samples will be obtained at 19 postinjury time points (days 1-14, day 28, months 3, 6, 12 and 24) and analysed for neutrophil phagocytic activity, IG count and cfDNA levels. Patients will be screened daily for sepsis using the 2007 American Burn Association diagnostic criteria for sepsis. In addition, daily multiple organ dysfunction syndrome and Sequential Organ Failure Assessment Scores will be recorded relationships between neutrophil phagocytic activity, IG count and plasma cfDNA levels on day 1 of injury and the development of sepsis will be examined using logistic regression models.</AbstractText><AbstractText Label="ETHICS AND DISSEMINATION">This study received ethics approval from the West Midlands, Coventry and Warwickshire Research Ethics Committee (REC reference:16/WM/0217). Findings will be presented at national and international conferences, and submitted for publication in peer-reviewed journals.</AbstractText><AbstractText Label="TRIAL REGISTRATION NUMBER">NCT04693442.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazeldine</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4280-4889</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McGee</LastName><ForeName>Kirsty C</ForeName><Initials>KC</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Tarrah</LastName><ForeName>Khaled</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hassouna</LastName><ForeName>Tarek</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Patel</LastName><ForeName>Krupali</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Imran</LastName><ForeName>Rizwana</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-1641-2478</Identifier><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Jonathan R B</ForeName><Initials>JRB</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bamford</LastName><ForeName>Amy</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barnes</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>St Andrews Centre for Plastic Surgery and Burns, Mid and South Essex NHS Foundation Trust, Essex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wilson</LastName><ForeName>Yvonne</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Birmingham Children's Hospital NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0003-1030-6786</Identifier><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham College of Medical and Dental Sciences, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Moiemen</LastName><ForeName>Naiem S</ForeName><Initials>NS</Initials><AffiliationInfo><Affiliation>National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, University of Birmingham, Birmingham, UK naiem.moiemen2@nhs.net.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham, UK.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04693442</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>10</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ Open</MedlineTA><NlmUniqueID>101552874</NlmUniqueID><ISSNLinking>2044-6055</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="Y">Burns</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008137" MajorTopicYN="N">Longitudinal Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015337" MajorTopicYN="N">Multicenter Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D064887" MajorTopicYN="N">Observational Studies as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">adult intensive &amp; critical care</Keyword><Keyword MajorTopicYN="N">immunology</Keyword><Keyword MajorTopicYN="N">paediatric intensive &amp; critical care</Keyword></KeywordList><CoiStatement>Competing interests: None declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>23</Day><Hour>5</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>11</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>10</Month><Day>22</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34686556</ArticleId><ArticleId IdType="pmc">PMC8543641</ArticleId><ArticleId IdType="doi">10.1136/bmjopen-2021-052035</ArticleId><ArticleId IdType="pii">bmjopen-2021-052035</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Jackson PC, Hardwicke J, Bamford A, et al. . Revised estimates of mortality from the Birmingham burn centre, 2001-2010: a continuing analysis over 65 years. Ann Surg 2014;259:979&#x2013;84. 10.1097/SLA.0b013e31829160ca</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31829160ca</ArticleId><ArticleId IdType="pubmed">23598383</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;lhan B, Kan&#x131;k Y&#xfc;ksek S, Hayran M, et al. . Infections in pediatric burn patients: an analysis of one hundred eighty-one patients. Surg Infect 2020;21:357&#x2013;62. 10.1089/sur.2019.010</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/sur.2019.010</ArticleId><ArticleId IdType="pubmed">31589562</ArticleId></ArticleIdList></Reference><Reference><Citation>Holl&#xe9;n L, Hughes R, Dodds N, et al. . Use of procalcitonin as a biomarker for sepsis in moderate to major paediatric burns. Trauma 2019;21:192&#x2013;200. 10.1177/1460408618760940</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1460408618760940</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramakrishnan KM, Jayaraman V, Mathivanan T, et al. . Profile of burn sepsis challenges and outcome in an exclusive children's hospital in Chennai, India. Ann Burns Fire Disasters 2012;25:13&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3431721</ArticleId><ArticleId IdType="pubmed">23012610</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann EA, Baun MM, Meininger JC, et al. . Comparison of mortality associated with sepsis in the burn, trauma, and general intensive care unit patient: a systematic review of the literature. Shock 2012;37:4&#x2013;16. 10.1097/SHK.0b013e318237d6bf</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318237d6bf</ArticleId><ArticleId IdType="pubmed">21941222</ArticleId></ArticleIdList></Reference><Reference><Citation>Singer M, Deutschman CS, Seymour CW, et al. . The third International consensus definitions for sepsis and septic shock (sepsis-3). JAMA 2016;315:801&#x2013;10. 10.1001/jama.2016.0287</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2016.0287</ArticleId><ArticleId IdType="pmc">PMC4968574</ArticleId><ArticleId IdType="pubmed">26903338</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams FN, Herndon DN, Hawkins HK, et al. . The leading causes of death after burn injury in a single pediatric burn center. Crit Care 2009;13:R183. 10.1186/cc8170</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8170</ArticleId><ArticleId IdType="pmc">PMC2811947</ArticleId><ArticleId IdType="pubmed">19919684</ArticleId></ArticleIdList></Reference><Reference><Citation>Farina JA, Rosique MJ, Rosique RG. Curbing inflammation in burn patients. Int J Inflam 2013;2013:1&#x2013;9. 10.1155/2013/715645</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2013/715645</ArticleId><ArticleId IdType="pmc">PMC3671671</ArticleId><ArticleId IdType="pubmed">23762773</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh DG, Saffle JR, Holmes JH, et al. . American burn association consensus conference to define sepsis and infection in burns. J Burn Care Res 2007;28:776&#x2013;90. 10.1097/BCR.0b013e3181599bc9</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/BCR.0b013e3181599bc9</ArticleId><ArticleId IdType="pubmed">17925660</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, et al. . Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992;101:1644&#x2013;55. 10.1378/chest.101.6.1644</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Nunez Lopez O, Cambiaso-Daniel J, Branski LK, et al. . Predicting and managing sepsis in burn patients: current perspectives. Ther Clin Risk Manag 2017;13:1107&#x2013;17. 10.2147/TCRM.S119938</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/TCRM.S119938</ArticleId><ArticleId IdType="pmc">PMC5584891</ArticleId><ArticleId IdType="pubmed">28894374</ArticleId></ArticleIdList></Reference><Reference><Citation>Neely AN, Fowler LA, Kagan RJ, et al. . Procalcitonin in pediatric burn patients: an early indicator of sepsis? J Burn Care Rehabil 2004;25:76&#x2013;80. 10.1097/01.BCR.0000105095.94766.89</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.BCR.0000105095.94766.89</ArticleId><ArticleId IdType="pubmed">14726743</ArticleId></ArticleIdList></Reference><Reference><Citation>Bargues L, Chancerelle Y, Catineau J, et al. . Evaluation of serum procalcitonin concentration in the ICU following severe burn. Burns 2007;33:860&#x2013;4. 10.1016/j.burns.2006.10.401</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2006.10.401</ArticleId><ArticleId IdType="pubmed">17532575</ArticleId></ArticleIdList></Reference><Reference><Citation>Seymour CW, Gesten F, Prescott HC, et al. . Time to treatment and mortality during mandated emergency care for sepsis. N Engl J Med 2017;376:2235&#x2013;44. 10.1056/NEJMoa1703058</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1703058</ArticleId><ArticleId IdType="pmc">PMC5538258</ArticleId><ArticleId IdType="pubmed">28528569</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones CN, Moore M, Dimisko L, et al. . Spontaneous neutrophil migration patterns during sepsis after major burns. PLoS One 2014;9:e114509. 10.1371/journal.pone.0114509</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0114509</ArticleId><ArticleId IdType="pmc">PMC4260850</ArticleId><ArticleId IdType="pubmed">25489947</ArticleId></ArticleIdList></Reference><Reference><Citation>Butler KL, Ambravaneswaran V, Agrawal N, et al. . Burn injury reduces neutrophil directional migration speed in microfluidic devices. PLoS One 2010;5:e11921. 10.1371/journal.pone.0011921</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0011921</ArticleId><ArticleId IdType="pmc">PMC2912851</ArticleId><ArticleId IdType="pubmed">20689600</ArticleId></ArticleIdList></Reference><Reference><Citation>Arturson G. Neutrophil granulocyte functions in severely burned patients. Burns Incl Therm Inj 1985;11:309&#x2013;19. 10.1016/0305-4179(85)90093-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0305-4179(85)90093-2</ArticleId><ArticleId IdType="pubmed">4027746</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson P, Dinsdale RJ, Wearn CM, et al. . Neutrophil dysfunction, immature granulocytes, and cell-free DNA are early biomarkers of sepsis in burn-injured patients: a prospective observational cohort study. Ann Surg 2017;265:1241&#x2013;9. 10.1097/SLA.0000000000001807</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001807</ArticleId><ArticleId IdType="pubmed">27232244</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjerknes R, Vindenes H, Laerum OD. Altered neutrophil functions in patients with large burns. Blood Cells 1990;16:127&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">2190644</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinsdale RJ, Devi A, Hampson P, et al. . Changes in novel haematological parameters following thermal injury: a prospective observational cohort study. Sci Rep 2017;7:3211. 10.1038/s41598-017-03222-w</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-017-03222-w</ArticleId><ArticleId IdType="pmc">PMC5468303</ArticleId><ArticleId IdType="pubmed">28607467</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffith R. What is gillick competence? Hum Vaccin Immunother 2016;12:244&#x2013;7. 10.1080/21645515.2015.1091548</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21645515.2015.1091548</ArticleId><ArticleId IdType="pmc">PMC4962726</ArticleId><ArticleId IdType="pubmed">26619366</ArticleId></ArticleIdList></Reference><Reference><Citation>. DOI.Jeschke MG, Chinkes DL, Finnerty CC, et al. . Pathophysiologic response to severe burn injury. Ann Surg 2008;248:387&#x2013;401. 10.1097/SLA.0b013e3181856241</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181856241</ArticleId><ArticleId IdType="pmc">PMC3905467</ArticleId><ArticleId IdType="pubmed">18791359</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnerty CC, Jeschke MG, Herndon DN, et al. . Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med 2008;14:553&#x2013;60. 10.2119/2007-00132.Finnerty</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/2007-00132.Finnerty</ArticleId><ArticleId IdType="pmc">PMC2424320</ArticleId><ArticleId IdType="pubmed">18548133</ArticleId></ArticleIdList></Reference><Reference><Citation>Mulder PPG, Vlig M, Boekema BKHL, et al. . Persistent systemic inflammation in patients with severe burn injury is accompanied by influx of immature neutrophils and shifts in T cell subsets and cytokine profiles. Front Immunol 2020;11:621222. 10.3389/fimmu.2020.621222</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.621222</ArticleId><ArticleId IdType="pmc">PMC7879574</ArticleId><ArticleId IdType="pubmed">33584717</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergquist M, H&#xe4;stbacka J, Glaumann C, et al. . The time-course of the inflammatory response to major burn injury and its relation to organ failure and outcome. Burns 2019;45:354&#x2013;63. 10.1016/j.burns.2018.09.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.burns.2018.09.001</ArticleId><ArticleId IdType="pubmed">30274808</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Kulp GA, et al. . Long-term persistance of the pathophysiologic response to severe burn injury. PLoS One 2011;6:e21245. 10.1371/journal.pone.0021245</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0021245</ArticleId><ArticleId IdType="pmc">PMC3138751</ArticleId><ArticleId IdType="pubmed">21789167</ArticleId></ArticleIdList></Reference><Reference><Citation>Dehne MG, Sablotzki A, Hoffmann A, et al. . Alterations of acute phase reaction and cytokine production in patients following severe burn injury. Burns 2002;28:535&#x2013;42. 10.1016/S0305-4179(02)00050-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0305-4179(02)00050-5</ArticleId><ArticleId IdType="pubmed">12220910</ArticleId></ArticleIdList></Reference><Reference><Citation>Hur J, Yang HT, Chun W, et al. . Inflammatory cytokines and their prognostic ability in cases of major burn injury. Ann Lab Med 2015;35:105&#x2013;10. 10.3343/alm.2015.35.1.105</Citation><ArticleIdList><ArticleId IdType="doi">10.3343/alm.2015.35.1.105</ArticleId><ArticleId IdType="pmc">PMC4272939</ArticleId><ArticleId IdType="pubmed">25553289</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BZ, McAlister S, McGuire HM, et al. . Pediatric burn survivors have long-term immune dysfunction with diminished vaccine response. Front Immunol 2020;11:1481. 10.3389/fimmu.2020.01481</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01481</ArticleId><ArticleId IdType="pmc">PMC7385079</ArticleId><ArticleId IdType="pubmed">32793203</ArticleId></ArticleIdList></Reference><Reference><Citation>Fear VS, Boyd JH, Rea S, et al. . Burn injury leads to increased long-term susceptibility to respiratory infection in both mouse models and population studies. PLoS One 2017;12:e0169302. 10.1371/journal.pone.0169302</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0169302</ArticleId><ArticleId IdType="pmc">PMC5221812</ArticleId><ArticleId IdType="pubmed">28068397</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft R, Herndon DN, Finnerty CC, et al. . Occurrence of multiorgan dysfunction in pediatric burn patients: incidence and clinical outcome. Ann Surg 2014;259:381&#x2013;7. 10.1097/SLA.0b013e31828c4d04</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828c4d04</ArticleId><ArticleId IdType="pmc">PMC3731402</ArticleId><ArticleId IdType="pubmed">23511841</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">24589345</PMID><DateCompleted><Year>2014</Year><Month>11</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1757-7241</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><PubDate><Year>2014</Year><Month>Mar</Month><Day>03</Day></PubDate></JournalIssue><Title>Scandinavian journal of trauma, resuscitation and emergency medicine</Title><ISOAbbreviation>Scand J Trauma Resusc Emerg Med</ISOAbbreviation></Journal><ArticleTitle>Interleukin-6 as inflammatory marker referring to multiple organ dysfunction syndrome in severely injured children.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1757-7241-22-16</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Despite the suggestion that the inflammatory response in traumatized children is functionally unique, prognostic markers predicting pediatric multiple organ failure are lacking. We intended to verify whether Interleukin-6 (IL-6) displays a pivotal role in pediatric trauma similar to adults.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Traumatized children less than 18 years of age with an Injury Severity Score &gt;9 points and consecutive admission to the hospital's pediatric intensive care unit were included. Organ function was evaluated according to the score by Marshall et al. while IL-6 levels were measured repetitively every morning.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">59 traumatized children were included (8.4 &#xb1; 4.4 years; 57.6% male gender). Incidence of MODS was 11.9%. No differences were found referring to age, gender, injury distribution or overall injury severity between children with and without MODS. Increased IL-6 levels during hospital admission were associated with injury severity (Spearman correlation: r = 0.522, p &lt; 0.001), while an inconsistent association towards the development of MODS was proven at that time point (Spearman correlation: r = 0.180, p = 0.231; Pearson's correlation: r = 0.297, p = 0.045). However, increased IL-6 levels during the first two days were no longer associated with the injury severity but a significant correlation to MODS was measured.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The presented prospective study is the first providing evidence for a correlation of IL-6 levels with injury severity and the incidence of MODS in traumatized children.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Andruszkow</LastName><ForeName>Hagen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Fischer</LastName><ForeName>Janika</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Sasse</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Brunnemer</LastName><ForeName>Ulf</ForeName><Initials>U</Initials></Author><Author ValidYN="Y"><LastName>Andruszkow</LastName><ForeName>Julia Helga Karla</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>G&#xe4;nsslen</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Frink</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department for Trauma, Hand and Reconstructive Surgery, University Medical Center Marburg, Baldingerstr, 35043 Marburg, Germany. frink@med.uni-marburg.de.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>03</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Trauma Resusc Emerg Med</MedlineTA><NlmUniqueID>101477511</NlmUniqueID><ISSNLinking>1757-7241</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>11</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>3</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>11</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2014</Year><Month>3</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24589345</ArticleId><ArticleId IdType="pmc">PMC3942614</ArticleId><ArticleId IdType="doi">10.1186/1757-7241-22-16</ArticleId><ArticleId IdType="pii">1757-7241-22-16</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Valadka S, Poenaru D, Dueck A. Long-term disability after trauma in children. J Pediatr Surg. 2000;35:684&#x2013;687. doi: 10.1053/jpsu.2000.5943.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jpsu.2000.5943</ArticleId><ArticleId IdType="pubmed">10813323</ArticleId></ArticleIdList></Reference><Reference><Citation>Schalamon J, V Bismarck S, Schober PH, Hollwarth ME. Multiple trauma in pediatric patients. Pediatr Surg Int. 2003;19:417&#x2013;423. doi: 10.1007/s00383-003-0954-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00383-003-0954-0</ArticleId><ArticleId IdType="pubmed">12861420</ArticleId></ArticleIdList></Reference><Reference><Citation>Moulton SL. Early management of the child with multiple injuries. Clin Orthop Relat Res. 2000;376:6&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">10906852</ArticleId></ArticleIdList></Reference><Reference><Citation>Musgrave DS, Mendelson SA. Pediatric orthopedic trauma: principles in management. Crit Care Med. 2002;30:S431&#x2013;S443. doi: 10.1097/00003246-200211001-00008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200211001-00008</ArticleId><ArticleId IdType="pubmed">12528785</ArticleId></ArticleIdList></Reference><Reference><Citation>Abdelgawad AA, Kanlic EM. Orthopedic management of children with multiple injuries. J Trauma. 2011;70:1568&#x2013;1574. doi: 10.1097/TA.0b013e318204eafc.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318204eafc</ArticleId><ArticleId IdType="pubmed">21817996</ArticleId></ArticleIdList></Reference><Reference><Citation>Letts M, Davidson D, Lapner P. Multiple trauma in children: predicting outcome and long-term results. Can J Surg. 2002;45:126&#x2013;131.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3686935</ArticleId><ArticleId IdType="pubmed">11939656</ArticleId></ArticleIdList></Reference><Reference><Citation>Calkins CM, Bensard DD, Moore EE, McIntyre RC, Silliman CC, Biffl W, Harken AH, Partrick DA, Offner PJ. The injured child is resistant to multiple organ failure: a different inflammatory response? J Trauma. 2002;53:1058&#x2013;1063. doi: 10.1097/00005373-200212000-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200212000-00005</ArticleId><ArticleId IdType="pubmed">12478028</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, Glass NL, Yeh TS. Outcome of pediatric patients with multiple organ system failure. Crit Care Med. 1986;14:271&#x2013;274. doi: 10.1097/00003246-198604000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-198604000-00002</ArticleId><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Joyal JS, Mariscalco MM, Leteurtre S, Leclerc F, Lacroix J. The pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2009;10:12&#x2013;22. doi: 10.1097/PCC.0b013e31819370a9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31819370a9</ArticleId><ArticleId IdType="pubmed">19057438</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JH, Partrick DA, Johnston RB Jr. The inflammatory response to injury in children. Curr Opin Pediatr. 2010;22:315&#x2013;320. doi: 10.1097/MOP.0b013e328338da48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MOP.0b013e328338da48</ArticleId><ArticleId IdType="pubmed">20386451</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med. 1994;22:1025&#x2013;1031. doi: 10.1097/00003246-199406000-00023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199406000-00023</ArticleId><ArticleId IdType="pubmed">8205810</ArticleId></ArticleIdList></Reference><Reference><Citation>Moore FA, Moore EE. Evolving concepts in the pathogenesis of postinjury multiple organ failure. Surg Clin North Am. 1995;75:257&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">7899997</ArticleId></ArticleIdList></Reference><Reference><Citation>Keel M, Trentz O. Pathophysiology of polytrauma. Injury. 2005;36:691&#x2013;709. doi: 10.1016/j.injury.2004.12.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2004.12.037</ArticleId><ArticleId IdType="pubmed">15910820</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25:1789&#x2013;1795. doi: 10.1097/00003246-199711000-00014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199711000-00014</ArticleId><ArticleId IdType="pubmed">9366759</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Sir Isaac Newton, sepsis, SIRS, and CARS. Crit Care Med. 1996;24:1125&#x2013;1128. doi: 10.1097/00003246-199607000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199607000-00010</ArticleId><ArticleId IdType="pubmed">8674323</ArticleId></ArticleIdList></Reference><Reference><Citation>Partrick DA, Moore FA, Moore EE, Biffl WL, Sauaia A, Barnett CC Jr, Jack A. Barney resident research award winner: the inflammatory profile of interleukin-6, interleukin-8, and soluble intercellular adhesion molecule-1 in postinjury multiple organ failure. Am J Surg. 1996;172:425&#x2013;429. doi: 10.1016/S0002-9610(96)00252-8. discussed 429-431.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(96)00252-8</ArticleId><ArticleId IdType="pubmed">8942538</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, Minei J, Moore EE, O&#x2019;Keefe G, Sperry J, Remick D, Tompkins R, Maier RV. Inflammation and the HOST Response to Injury Collaborative Research Program: Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock. 2010;34:346&#x2013;351. doi: 10.1097/SHK.0b013e3181d8e687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181d8e687</ArticleId><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135:291&#x2013;295. doi: 10.1001/archsurg.135.3.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.135.3.291</ArticleId><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Jawa RS, Anillo S, Huntoon K, Baumann H, Kulaylat M. Interleukin-6 in surgery, trauma, and critical care part II: clinical implications. J Intensive Care Med. 2011;26:73&#x2013;87. doi: 10.1177/0885066610384188.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0885066610384188</ArticleId><ArticleId IdType="pmc">PMC6223019</ArticleId><ArticleId IdType="pubmed">21464062</ArticleId></ArticleIdList></Reference><Reference><Citation>Andruszkow H, Lefering R, Frink M, Mommsen P, Zeckey C, Rahe K, Krettek C, Hildebrand F. Survival benefit of helicopter emergency medical services compared to ground emergency medical services in traumatized patients. Crit Care. 2013;17:R124. doi: 10.1186/cc12796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc12796</ArticleId><ArticleId IdType="pmc">PMC4056624</ArticleId><ArticleId IdType="pubmed">23799905</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Paffrath T, Linker R, Bouillon B, Neugebauer EA. Deutsche Gesellschaft fur Unfallchirurgie/German Society for Trauma S. Head injury and outcome&#x2013;what influence do concomitant injuries have? J Trauma. 2008;65:1036&#x2013;1043. doi: 10.1097/TA.0b013e318184ee48. discussion 1043-1034.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318184ee48</ArticleId><ArticleId IdType="pubmed">19001971</ArticleId></ArticleIdList></Reference><Reference><Citation>Baker SP, O&#x2019;Neill B, Haddon W Jr, Long WB. The injury severity score: a method for describing patients with multiple injuries and evaluating emergency care. J Trauma. 1974;14:187&#x2013;196. doi: 10.1097/00005373-197403000-00001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-197403000-00001</ArticleId><ArticleId IdType="pubmed">4814394</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Seghaye MC, Engelhardt W, Grabitz RG, Faymonville ME, Hornchen H, Messmer BJ, von Bernuth G. Multiple system organ failure after open heart surgery in infants and children. Thorac Cardiovasc Surg. 1993;41:49&#x2013;53. doi: 10.1055/s-2007-1013820.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-2007-1013820</ArticleId><ArticleId IdType="pubmed">8367856</ArticleId></ArticleIdList></Reference><Reference><Citation>Feickert HJ, Schepers AK, Rodeck B, Geerlings H, Hoyer PF. Incidence, impact on survival, and risk factors for multi-organ system failure in children following liver transplantation. Pediatr Transplant. 2001;5:266&#x2013;273. doi: 10.1034/j.1399-3046.2001.005004266.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1034/j.1399-3046.2001.005004266.x</ArticleId><ArticleId IdType="pubmed">11472605</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Bratton SL, Martin LD, Crawford SW, Weiss NS. Outcome of children who require mechanical ventilatory support after bone marrow transplantation. Crit Care Med. 2000;28:830&#x2013;835. doi: 10.1097/00003246-200003000-00036.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200003000-00036</ArticleId><ArticleId IdType="pubmed">10752837</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas NJ, Lucking SE, Dillon PW, Cilley RE. Is the injured child different or just treated differently with respect to the development of multiple organ dysfunction syndrome? J Trauma. 2003;55:181&#x2013;182. author repy 183-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855903</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyons WS, Calkins CM, Moore EE, Bensard DD, Partrick DA, McIntyre RC, Harken AH. &#x201c;Resistance&#x201d; to the inflammatory response and multiple organ failure in children. J Trauma. 2003;55:182&#x2013;184. author reply 183-184.</Citation><ArticleIdList><ArticleId IdType="pubmed">12855904</ArticleId></ArticleIdList></Reference><Reference><Citation>Zingarelli B, Hake PW, O&#x2019;Connor M, Burroughs TJ, Wong HR, Solomkin JS, Lentsch AB. Lung injury after hemorrhage is age dependent: role of peroxisome proliferator-activated receptor gamma. Crit Care Med. 2009;37:1978&#x2013;1987. doi: 10.1097/CCM.0b013e31819feb4d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31819feb4d</ArticleId><ArticleId IdType="pmc">PMC2765201</ArticleId><ArticleId IdType="pubmed">19384226</ArticleId></ArticleIdList></Reference><Reference><Citation>Finnerty CC, Jeschke MG, Herndon DN, Gamelli R, Gibran N, Klein M, Silver G, Arnoldo B, Remick D, Tompkins RG. Temporal cytokine profiles in severely burned patients: a comparison of adults and children. Mol Med. 2008;14:553&#x2013;560.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2424320</ArticleId><ArticleId IdType="pubmed">18548133</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, Carles M, Howard M, Pittet JF. Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care. 2009;13:R174. doi: 10.1186/cc8152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma. 2008;65:646&#x2013;652. doi: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181820d48</ArticleId><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Lausevic M, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiaretti A, Genovese O, Aloe L, Antonelli A, Piastra M, Polidori G, Di Rocco C. Interleukin 1beta and interleukin 6 relationship with paediatric head trauma severity and outcome. Childs Nerv Syst. 2005;21:185&#x2013;193. doi: 10.1007/s00381-004-1032-1. discussion 194.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00381-004-1032-1</ArticleId><ArticleId IdType="pubmed">15455248</ArticleId></ArticleIdList></Reference><Reference><Citation>McClain C, Cohen D, Phillips R, Ott L, Young B. Increased plasma and ventricular fluid interleukin-6 levels in patients with head injury. J Lab Clin Med. 1991;118:225&#x2013;231.</Citation><ArticleIdList><ArticleId IdType="pubmed">1919295</ArticleId></ArticleIdList></Reference><Reference><Citation>Saissy JM, Cellard-Peyle F, Vitris M, Demaziere J, Gaye M, Poli L, Trossaert M, Dieye A, Sarthou JL. Severe malaria in an African seasonal endemic area: comparison of aspects in adults and children and prognostic value of cytokines. Presse Med. 1994;23:1426&#x2013;1430.</Citation><ArticleIdList><ArticleId IdType="pubmed">7824455</ArticleId></ArticleIdList></Reference><Reference><Citation>From the bench to the bedside: the future of sepsis research. Executive summary of an American College of Chest Physicians, National Institute of Allergy and Infectious Disease, and National Heart, Lung, and Blood Institute Workshop. Chest. 1997;111:744&#x2013;753.</Citation><ArticleIdList><ArticleId IdType="pubmed">9118716</ArticleId></ArticleIdList></Reference><Reference><Citation>Strecker W, Gebhard F, Perl M, Rager J, Buttenschon K, Kinzl L, Beck A. Biochemical characterization of individual injury pattern and injury severity. Injury. 2003;34:879&#x2013;887. doi: 10.1016/S0020-1383(03)00022-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0020-1383(03)00022-6</ArticleId><ArticleId IdType="pubmed">14636727</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauaia A, Moore FA, Moore EE, Haenel JB, Read RA, Lezotte DC. Early predictors of postinjury multiple organ failure. Arch Surg. 1994;129:39&#x2013;45. doi: 10.1001/archsurg.1994.01420250051006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.1994.01420250051006</ArticleId><ArticleId IdType="pubmed">8279939</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, Willatts S, De Mendonca A, Bruining H, Reinhart CK, Suter PM, Thijs LG. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure: on behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22:707&#x2013;710. doi: 10.1007/BF01709751.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF01709751</ArticleId><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Gauvin F, Grandbastien B, Nam TV, Proulx F, Lacroix J, Leclerc F. Development of a pediatric multiple organ dysfunction score: use of two strategies. Med Decis Making. 1999;19:399&#x2013;410. doi: 10.1177/0272989X9901900408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0272989X9901900408</ArticleId><ArticleId IdType="pubmed">10520678</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33:1484&#x2013;1491. doi: 10.1097/01.CCM.0000170943.23633.47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000170943.23633.47</ArticleId><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33546739</PMID><DateCompleted><Year>2021</Year><Month>02</Month><Day>19</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>07</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>22</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Feb</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.</ArticleTitle><Pagination><StartPage>116</StartPage><MedlinePgn>116</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">116</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-021-05072-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Baricitinib is supposed to have a double effect on SARS-CoV2 infection. Firstly, it reduces the inflammatory response through the inhibition of the Januse-Kinase signalling transducer and activator of transcription (JAK-STAT) pathway. Moreover, it reduces the receptor mediated viral endocytosis by AP2-associated protein kinase 1 (AAK1) inhibition. We propose the use of baricinitib to prevent the progression of the respiratory insufficiency in SARS-CoV2 pneumonia in onco-haematological patients. In this phase Ib/II study, the primary objective in the safety cohort is to describe the incidence of severe adverse events associated with baricitinib administration. The primary objective of the randomized phase (baricitinib cohort versus standard of care cohort) is to evaluate the number of patients who did not require mechanical oxygen support since start of therapy until day +14 or discharge (whichever it comes first). The secondary objectives of the study (only randomized phase of the study) are represented by the comparison between the two arms of the study in terms of mortality and toxicity at day+30. Moreover, a description of the immunological related changes between the two arms of the study will be reported.</AbstractText><AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">The trial is a phase I/II study with a safety run-in cohort (phase 1) followed by an open label phase II randomized controlled trial with an experimental arm compared to a standard of care arm.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">The study will be performed at the Institut Catal&#xe0; d'Oncologia, a tertiary level oncological referral center in the Catalonia region (Spain). The eligibility criteria are: patients &gt; 18 years affected by oncological diseases; ECOG performance status &lt; 2 (Karnofsky score &gt; 60%); a laboratory confirmed infection with SARS-CoV-2 by means of real -time PCR; radiological signs of low respiratory tract disease; absence of organ dysfunction (a total bilirubin within normal institutional limits, AST/ALT&#x2264;2.5 X institutional upper limit of normal, alkaline phosphatase &#x2264;2.5 X institutional upper limit of normal, coagulation within normal institutional limits, creatinine clearance &gt;30 mL/min/1.73 m<sup>2</sup> for patients with creatinine levels above institutional normal); absence of HIV infection; no active or latent HBV or HCV infection. The exclusion criteria are: patients with oncological diseases who are not candidates to receive any active oncological treatment; hemodynamic instability at time of study enrollment; impossibility to receive oral medication; medical history of recent or active pulmonary embolism or deep venous thrombosis or patients at high-risk of suffering them (surgical intervention, immobilization); multi organ failure, rapid worsening of respiratory function with requirement of fraction of inspired oxygen (FiO<sub>2</sub>) &gt; 50% or high-flow nasal cannula before initiation of study treatment; uncontrolled intercurrent illness (ongoing or severe active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements); allergy to one or more of study treatments; pregnant or breastfeeding women; positive pregnancy test in a pre-dose examination. Patients should have the ability to understand, and the willingness to sign, a written informed consent document; the willingness to accept randomization to any assigned treatment arm; and must agree not to enroll in another study of an investigational agent prior to completion of Day +28 of study. An electronic Case Report Form in the Research Electronic Data Capture (REDCap) platform will be used to collect the data of the trial. Removal from the study will apply in case of unacceptable adverse event(s), development of an intercurrent illness, condition or procedural complication, which could interfere with the patient's continued participation and voluntary patient withdrawal from study treatment (all patients are free to withdraw from participation in this study at any time, for any reasons, specified or unspecified, and without prejudice).</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">Treatment will be administered on an inpatient basis. We will compare the experimental treatment with baricitinib plus the institutional standard of care compared with the standard of care alone. During the phase I, we will define the dose-limiting toxicity of baricitinib and the dose to be used in the phase 2 part of the study. The starting baricitinib dose will be an oral tablet 4 mg-once daily which can be reduced to 2 mg depending on the observed toxicity. The minimum duration of therapy will be 5 days and it can be extended to 7 days. The standard of care will include the following therapies. Antibiotics will be individualized based on clinical suspicion, including the management of febrile neutropenia. Prophylaxis of thromboembolic disease will be administered to all participants. Remdesivir administration will be considered only in patients with severe pneumonia (SatO<sub>2</sub> &lt;94%) with less than 7 days of onset of symptoms and with supplemental oxygen requirements but not using high-flow nasal cannula, non-invasive or invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO). In the randomized phase, tocilizumab or interferon will not be allowed in the experimental arm. Tocilizumab can be used in patients in the standard of care arm at the discretion of the investigator. If it is prescribed it will be used according to the following criteria: patients who, according to his baseline clinical condition, would be an ICU tributary, interstitial pneumonia with severe respiratory failure, patients who are not on mechanical ventilation or ECMO and who are still progressing with corticoid treatment or if they are not candidates for corticosteroids. Mild ARDS (PAFI &lt;300 mmHg) with radiological or blood gases deterioration that meets at least one of the following criteria: CRP &gt;100mg/L D-Dimer &gt;1,000&#x3bc;g/L LDH &gt;400U/L Ferritin &gt;700ng/ml Interleukin 6 &#x2265;40ng/L. The use of tocilizumab is not recommended if there are AST/ALT values greater than 10 times the upper limit of normal, neutrophils &lt;500 cells/mm3, sepsis due to other pathogens other than SARS-CoV-2, presence of comorbidity that can lead to a poor prognosis, complicated diverticulitis or intestinal perforation, ongoing skin infection. The dose will be that recommended by the Spanish Medicine Agency in patients &#x2265;75Kg: 600mg dose whereas in patients &lt;75kg: 400mg dose. Exceptionally, a second infusion can be assessed 12 hours after the first in those patients who experience a worsening of laboratory parameters after a first favourable response. The use of corticosteroids will be recommended in patients who have had symptoms for more than 7 days and who meet all the following criteria: need for oxygen support, non-invasive or invasive mechanical ventilation, acute respiratory failure or rapid deterioration of gas exchange, appearance or worsening of bilateral alveolar-interstitial infiltrates at the radiological level. In case of indication, it is recommended: dexamethasone 6mg/d p.o. or iv for 10 days or methylprednisolone 32mg/d orally or 30mg iv for 10 days or prednisone 40mg day p.o. for 10 days.</AbstractText><AbstractText Label="MAIN OUTCOMES" NlmCategory="RESULTS">Phase 1 part: to describe the toxicity profile of baricitinib in COVID19 oncological patients during the 5-7 day treatment period and until day +14 or discharge (whichever it comes first). Phase 2 part: to describe the number of patients in the experimental arm that will not require mechanical oxygen support compared to the standard of care arm until day +14 or discharge (whichever it comes first).</AbstractText><AbstractText Label="RANDOMISATION" NlmCategory="METHODS">For the phase 2 of the study, the allocation ratio will be 1:1. Randomization process will be carried out electronically through the REDcap platform ( https://www.project-redcap.org/ ) BLINDING (MASKING): This is an open label study. No blinding will be performed.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMISED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">The first part of the study (safety run-in cohort) will consist in the enrollment of 6 to 12 patients. In this population, we will test the toxicity of the experimental treatment. An incidence of severe adverse events grade 3-4 (graded by Common Terminology Criteria for Adverse Events v.5.0) inferior than 33% will be considered sufficient to follow with the next part of the study. The second part of the study we will perform an interim analysis of efficacy at first 64 assessed patients and a definitive one will analyze 128 assessed patients. Interim and definitive tests will be performed considering in both cases an alpha error of 0.05. We consider for the control arm this rate is expected to be 0.60 and for the experimental arm of 0.80. Considering this data, a superiority test to prove a difference of 0.20 with an overall alpha error of 0.10 and a beta error of 0.2 will be performed. Considering a 5% of dropout rate, it is expected that a total of 136 patients, 68 for each study arm, will be required to complete study accrual.</AbstractText><AbstractText Label="TRIAL STATUS" NlmCategory="METHODS">Version 5.0. 14<sup>th</sup> October 2020 Recruitment started on the 16<sup>th</sup> of December 2020. Expected end of recruitment is June 2021.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">AEMPs: 20-0356 EudraCT: 2020-001789-12, https://www.clinicaltrialsregister.eu/ctr-search/search (Not publically available as Phase I trial) Clinical trials: BARCOVID19, https://www.clinicaltrials.gov/ (In progress) FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol."</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moreno-Gonz&#xe1;lez</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain. gabriel.moreno@bellvitgehospital.cat.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mussetti</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Albasanz-Puig</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salvador</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Immunology Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sureda</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona University, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gudiol</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Spanish Network for Research in Infectious Disease (REIPI), Instituto de Salud Carlos III, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Barcelona University, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Salazar</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Oncology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marin</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Oncology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia</LastName><ForeName>M</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro</LastName><ForeName>V</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Trials Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Haba Vaca</LastName><ForeName>I</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Emergency Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Coma</LastName><ForeName>E</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Oncology Emergency Unit, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz-Linares</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hematology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dura</LastName><ForeName>X</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Disease Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fontanals</LastName><ForeName>S</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pharmacology Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serrano</LastName><ForeName>G</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palliative Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cruz</LastName><ForeName>C</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Palliative Department, Institut Catal&#xe0; d' Oncologia, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ma&#xf1;ez</LastName><ForeName>R</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Intensive Care Department, Hospital Universitari de Bellvitge, L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de LL., Barcelona, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>02</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001384">Azetidines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011720">Pyrazoles</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013449">Sulfonamides</NameOfSubstance></Chemical><Chemical><RegistryNumber>ISP4442I3Y</RegistryNumber><NameOfSubstance UI="C000596027">baricitinib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001384" MajorTopicYN="N">Azetidines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017321" MajorTopicYN="N">Clinical Trials, Phase I as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019337" MajorTopicYN="N">Hematologic Neoplasms</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010102" MajorTopicYN="N">Oxygen Inhalation Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011720" MajorTopicYN="N">Pyrazoles</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060888" MajorTopicYN="N">Real-Time Polymerase Chain Reaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012131" MajorTopicYN="N">Respiratory Insufficiency</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013449" MajorTopicYN="N">Sulfonamides</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID19</Keyword><Keyword MajorTopicYN="N">baricitinib</Keyword><Keyword MajorTopicYN="N">jak inhibitors</Keyword><Keyword MajorTopicYN="N">oncological patients</Keyword><Keyword MajorTopicYN="N">randomised controlled trial</Keyword><Keyword MajorTopicYN="N">respiratory insufficiency</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests in relation to the trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>1</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>2</Month><Day>6</Day><Hour>5</Hour><Minute>28</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>2</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>2</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>2</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33546739</ArticleId><ArticleId IdType="pmc">PMC7862837</ArticleId><ArticleId IdType="doi">10.1186/s13063-021-05072-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-021-05072-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38394174</PMID><DateCompleted><Year>2024</Year><Month>02</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>02</Month><Day>26</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1932-6203</ISSN><JournalIssue CitedMedium="Internet"><Volume>19</Volume><Issue>2</Issue><PubDate><Year>2024</Year></PubDate></JournalIssue><Title>PloS one</Title><ISOAbbreviation>PLoS One</ISOAbbreviation></Journal><ArticleTitle>Traditional herbal medicine use doubled the risk of multi-organ dysfunction syndrome in children: A prospective cohort study.</ArticleTitle><Pagination><StartPage>e0286233</StartPage><MedlinePgn>e0286233</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e0286233</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pone.0286233</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional herbal medicine (THM) is frequently used in pediatric populations in many low-income countries as a form of healthcare and has been associated with a range of adverse events, including liver toxicity, renal failure, and allergic reactions. Despite these concerns, its impact on multi-organ dysfunction syndrome (MODS) risk has not been thoroughly investigated.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">This study aimed to investigate the incidence and predictors of MODS in a pediatric intensive care unit (PICU) in Ethiopia, with a focus on the association between THM use and the risk of MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a single-center prospective cohort study conducted at a PICU in the university of Gondar Comprehensive Specialized hospital, Northwest Ethiopia. The study enrolled eligible patients aged one month to 18 years admitted to the PICU during the study period. Data on demographic characteristics, medical history, clinical and laboratory data, and outcome measures using standard case record forms, physical examination, and patient document reviews. The predictors of MODS were assessed using Cox proportional hazards models, with a focus on the association between traditional herbal medicine use and the risk of MODS.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 310 patients were included in the final analysis, with a median age of 48 months and a male-to-female ratio of 1.5:1. The proportion and incidence of MODS were 30.96% (95% CI:25.8, 36.6) and 7.71(95% CI: 6.10, 9.40) per 100-person-day observation respectively. Renal failure (17.74%), neurologic failure (15.16%), and heart failure (14.52%) were the leading organ failures identified. Nearly one-third of patients (32.9%) died in the PICU, of which 59.8% had MODS. The rate of mortality was higher in patients with MODS than in those without. The Cox proportional hazards model identified renal disease (AHR = 6.32 (95%CI: 3.17,12.61)), intake of traditional herbal medication (AHR = 2.45, 95% CI:1.29,4.65), modified Pediatric Index of Mortality 2 (mPIM 2) score (AHR = 1.54 (95% CI: 1.38,1.71), and critical illness diagnoses (AHR = 2.68 (95% CI: 1.77,4.07)) as predictors of MODS.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The incidence of MODS was high. Renal disease, THM use, mPIM 2 scores, and critical illness diagnoses were independent predictors of MODS. A more than twofold increase in the risk of MODS was seen in patients who used TMH. Healthcare providers should be aware of risks associated with THM, and educate caregivers about the potential harms of these products. Future studies with larger sample sizes and more comprehensive outcome measures are needed.</AbstractText><CopyrightInformation>Copyright: &#xa9; 2024 Teshager et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Teshager</LastName><ForeName>Nahom Worku</ForeName><Initials>NW</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Amare</LastName><ForeName>Ashenafi Tazebew</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Department of Pediatrics and Child Health, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamirat</LastName><ForeName>Koku Sisay</ForeName><Initials>KS</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zeleke</LastName><ForeName>Mulualem Endeshaw</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Anesthesia, School of Medicine, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Taddese</LastName><ForeName>Asefa Adimasu</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS One</MedlineTA><NlmUniqueID>101285081</NlmUniqueID><ISSNLinking>1932-6203</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D010936">Plant Extracts</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000139" MajorTopicYN="N">chemically induced</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051437" MajorTopicYN="Y">Renal Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010936" MajorTopicYN="N">Plant Extracts</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>There were no competing interests, and patients/public were not involved in the research.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>23</Day><Hour>13</Hour><Minute>55</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>23</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38394174</ArticleId><ArticleId IdType="pmc">PMC10889611</ArticleId><ArticleId IdType="doi">10.1371/journal.pone.0286233</ArticleId><ArticleId IdType="pii">PONE-D-23-14246</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: Definitions for sepsis and organ dysfunction in pediatrics. In: Pediatric Critical Care Medicine. 2005. doi: 10.1097/01.PCC.0000149131.72248.E6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109(4):1033&#x2013;7. doi: 10.1378/chest.109.4.1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Tantale&#xe1;n JA, Le&#xf3;n RJ, Santos AA, S&#xe1;nchez E. Multiple organ dysfunction syndrome in children. Pediatr Crit Care Med. 2003;4(2):181&#x2013;5. doi: 10.1097/01.PCC.0000059421.13161.88</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000059421.13161.88</ArticleId><ArticleId IdType="pubmed">12749649</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossetti E, Di Nardo M, Ricci Z. Multiple Organ Dysfunction in the Pediatric Intensive Care Unit. In: Critical Care Nephrology: Third Edition. 2017.</Citation></Reference><Reference><Citation>Typpo KV, Petersen NJ, Markovitz BP MM. Day one MODS is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatr Crit Care Med. 2009;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780005</ArticleId><ArticleId IdType="pubmed">19741445</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaugler M, Swinger N, Rahrig AL, Skiles J, Rowan CM. Multiple Organ Dysfunction and Critically Ill Children With Acute Myeloid Leukemia: Single-Center Retrospective Cohort Study. Pediatr Crit Care Med. 2022; doi: 10.1097/PCC.0000000000003153</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000003153</ArticleId><ArticleId IdType="pmc">PMC10081947</ArticleId><ArticleId IdType="pubmed">36728709</ArticleId></ArticleIdList></Reference><Reference><Citation>Hayes LW, Oster RA, Tofil NM, Tolwani AJ. Outcomes of critically ill children requiring continuous renal replacement therapy. J Crit Care. 2009; doi: 10.1016/j.jcrc.2008.12.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jcrc.2008.12.017</ArticleId><ArticleId IdType="pubmed">19327959</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson RS, Crow SS, Hartman ME, Lacroix J, Odetola FO. Epidemiology and outcomes of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017; doi: 10.1097/PCC.0000000000001047</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001047</ArticleId><ArticleId IdType="pmc">PMC5334773</ArticleId><ArticleId IdType="pubmed">28248829</ArticleId></ArticleIdList></Reference><Reference><Citation>Frenk J, G&#xf3;mez-Dant&#xe9;s O. The Triple Burden Disease in Developing Nations. Harvard Int Rev. 2011;</Citation></Reference><Reference><Citation>Berendes S, Heywood P, Oliver S, Garner P. Quality of private and public ambulatory health care in low and middle income countries: Systematic review of comparative studies. PLoS Med. 2011; doi: 10.1371/journal.pmed.1000433</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1000433</ArticleId><ArticleId IdType="pmc">PMC3075233</ArticleId><ArticleId IdType="pubmed">21532746</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Bestati N, Duhamel A, Proulx F, Grandbastien B, Lacroix J, et al.. 1218 Differences in Organ Dysfunctions Between Neonates and Other Children. Pediatr Res. 2010;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3219976</ArticleId><ArticleId IdType="pubmed">21062434</ArticleId></ArticleIdList></Reference><Reference><Citation>Fink EL, Kissoon N. Pediatric multiple organ dysfunction in resource limited settings. Pediatric Critical Care Medicine. 2017. doi: 10.1097/PCC.0000000000001045</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0000000000001045</ArticleId><ArticleId IdType="pubmed">28248837</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: An updated pediatric risk of mortality score. Crit Care Med. 1996; doi: 10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Wheeler DS, Wong HR, Shanley TP. Pediatric critical care medicine: Volume 1: Care of the critically ill or injured child, second edition. Pediatr Crit Care Med Vol 1 Care Crit Ill or Inj Child, Second Ed. 2014;1&#x2013;771.</Citation></Reference><Reference><Citation>Emr BM, Alcamo AM, Carcillo JA, Aneja RK, Mollen KP. Pediatric Sepsis Update: How Are Children Different? Surg Infect (Larchmt). 2018;</Citation><ArticleIdList><ArticleId IdType="pubmed">29394150</ArticleId></ArticleIdList></Reference><Reference><Citation>Ekor M. The growing use of herbal medicines: Issues relating to adverse reactions and challenges in monitoring safety. Frontiers in Neurology. 2014. doi: 10.3389/fphar.2013.00177</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2013.00177</ArticleId><ArticleId IdType="pmc">PMC3887317</ArticleId><ArticleId IdType="pubmed">24454289</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA, Steenkamp V, Stewart MJ. Acute renal failure associated with the use of traditional folk remedies in South Africa. Ren Fail. 2005;</Citation><ArticleIdList><ArticleId IdType="pubmed">15717633</ArticleId></ArticleIdList></Reference><Reference><Citation>Hillman L, Gottfried M, Whitsett M, Rakela J, Schilsky M, Lee WM, et al.. Corrigendum: Clinical Features and Outcomes of Complementary and Alternative Medicine Induced Acute Liver Failure and Injury. Am J Gastroenterol. 2016; doi: 10.1038/ajg.2016.349</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ajg.2016.349</ArticleId><ArticleId IdType="pmc">PMC5516923</ArticleId><ArticleId IdType="pubmed">27045922</ArticleId></ArticleIdList></Reference><Reference><Citation>K.A. O, I.O. S, O.F. N, A. S. Use of complementary and alternative medicines for children with chronic health conditions in Lagos, Nigeria. BMC Complementary and Alternative Medicine. 2008. doi: 10.1186/1472-6882-8-66</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1472-6882-8-66</ArticleId><ArticleId IdType="pmc">PMC2628640</ArticleId><ArticleId IdType="pubmed">19113999</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Gauthier M, Nadeau D, Lacroix J, Farrell CA. Timing and predictors of death in pediatric patients with multiple organ system failure. Crit Care Med. 1994; doi: 10.1097/00003246-199406000-00023</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199406000-00023</ArticleId><ArticleId IdType="pubmed">8205810</ArticleId></ArticleIdList></Reference><Reference><Citation>Khilnani P, Sarma D, Zimmerman J. Epidemiology and peculiarities of pediatric multiple organ dysfunction syndrome in New Delhi, India. Intensive Care Med. 2006; doi: 10.1007/s00134-006-0373-5</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-006-0373-5</ArticleId><ArticleId IdType="pubmed">16977482</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin JC, Spinella PC, Fitzgerald JC, Tucci M, Bush JL, Nadkarni VM, et al.. New or Progressive Multiple Organ Dysfunction Syndrome in Pediatric Severe Sepsis. Pediatr Crit Care Med. 2017;</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7261134</ArticleId><ArticleId IdType="pubmed">28060151</ArticleId></ArticleIdList></Reference><Reference><Citation>Kingma JG, Simard D, Rouleau JR, Drolet B, Simard C. The physiopathology of cardiorenal syndrome: A review of the potential contributions of inflammation. Journal of Cardiovascular Development and Disease. 2017. doi: 10.3390/jcdd4040021</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcdd4040021</ArticleId><ArticleId IdType="pmc">PMC5753122</ArticleId><ArticleId IdType="pubmed">29367550</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee SA, Cozzi M, Bush EL, Rabb H. Distant Organ Dysfunction in Acute Kidney Injury: A Review. American Journal of Kidney Diseases. 2018. doi: 10.1053/j.ajkd.2018.03.028</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ajkd.2018.03.028</ArticleId><ArticleId IdType="pmc">PMC6252108</ArticleId><ArticleId IdType="pubmed">29866457</ArticleId></ArticleIdList></Reference><Reference><Citation>Husain-Syed F, Rosner MH, Ronco C. Distant organ dysfunction in acute kidney injury. Acta Physiologica. 2020. doi: 10.1111/apha.13357</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/apha.13357</ArticleId><ArticleId IdType="pubmed">31379123</ArticleId></ArticleIdList></Reference><Reference><Citation>Panzarino V, Lesser J, Cassani FA. Pediatric Chronic Kidney Disease. Advances in Pediatrics. 2022. doi: 10.1016/j.yapd.2022.03.008</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yapd.2022.03.008</ArticleId><ArticleId IdType="pubmed">35985704</ArticleId></ArticleIdList></Reference><Reference><Citation>G&#xfc;n E, Akova B&#x15e;, Botan E, &#xc7;elik DB, Balaban B, &#xd6;zen H, et al.. Clinical features and outcomes of children admitted to the pediatric intensive care unit due to posterior reversible encephalopathy syndrome. Clin Neurol Neurosurg. 2022;</Citation><ArticleIdList><ArticleId IdType="pubmed">36265243</ArticleId></ArticleIdList></Reference><Reference><Citation>Price JF, Mott AR, Dickerson HA, Jefferies JL, Nelson DP, Chang AC, et al.. Worsening renal function in children hospitalized with decompensated heart failure: Evidence for a pediatric cardiorenal syndrome? Pediatr Crit Care Med. 2008; doi: 10.1097/PCC.0b013e31816c6ed1</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e31816c6ed1</ArticleId><ArticleId IdType="pubmed">18446113</ArticleId></ArticleIdList></Reference><Reference><Citation>Riley A J. Gebhard D, Akcan-Arikan A. Acute Kidney Injury in Pediatric Heart Failure. Curr Cardiol Rev. 2016; doi: 10.2174/1573403x12666151119165628</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1573403x12666151119165628</ArticleId><ArticleId IdType="pmc">PMC4861941</ArticleId><ArticleId IdType="pubmed">26585035</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PMF, de Carvalho ST, Fradico PF, Cazumb&#xe1; MLB, Campos RGB, Sim&#xf5;es e Silva AC. Hepatorenal syndrome in children: a review. Pediatric Nephrology. 2021. doi: 10.1007/s00467-020-04762-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-020-04762-6</ArticleId><ArticleId IdType="pmc">PMC7527294</ArticleId><ArticleId IdType="pubmed">33001296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sol&#xe9; C, Sol&#xe0; E, Huelin P, Carol M, Moreira R, Cereijo U, et al.. Characterization of inflammatory response in hepatorenal syndrome: Relationship with kidney outcome and survival. Liver Int. 2019; doi: 10.1111/liv.14037</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/liv.14037</ArticleId><ArticleId IdType="pmc">PMC6767546</ArticleId><ArticleId IdType="pubmed">30597709</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazory A, Ronco C. Hepatorenal Syndrome or Hepatocardiorenal Syndrome: Revisiting Basic Concepts in View of Emerging Data. CardioRenal Medicine. 2019. doi: 10.1159/000492791</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000492791</ArticleId><ArticleId IdType="pubmed">30223273</ArticleId></ArticleIdList></Reference><Reference><Citation>Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney International. 2013. doi: 10.1038/ki.2012.440</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ki.2012.440</ArticleId><ArticleId IdType="pubmed">23325079</ArticleId></ArticleIdList></Reference><Reference><Citation>Luyckx VA. Nephrotoxicity of Alternative Medicine Practice. Advances in Chronic Kidney Disease. 2012. doi: 10.1053/j.ackd.2012.04.005</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.ackd.2012.04.005</ArticleId><ArticleId IdType="pubmed">22578672</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen KC, Lu R, Iqbal U, Hsu KC, Chen BL, Nguyen PA, et al.. Interactions between traditional Chinese medicine and western drugs in Taiwan: A population-based study. Comput Methods Programs Biomed. 2015; doi: 10.1016/j.cmpb.2015.09.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmpb.2015.09.006</ArticleId><ArticleId IdType="pubmed">26470816</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakerink JA, Gospe SM, Dimand RJ, Eldridge MW. Multiple organ failure after ingestion of pennyroyal oil from herbal tea in two infants. Pediatrics. 1996;</Citation><ArticleIdList><ArticleId IdType="pubmed">8909490</ArticleId></ArticleIdList></Reference><Reference><Citation>Kam PCA, Liew S. Traditional Chinese herbal medicine and anaesthesia. Anaesthesia. 2002. doi: 10.1046/j.1365-2044.2002.02823.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2044.2002.02823.x</ArticleId><ArticleId IdType="pubmed">12392455</ArticleId></ArticleIdList></Reference><Reference><Citation>Akpan EE, Ekrikpo UE. Acute Renal Failure Induced by Chinese Herbal Medication in Nigeria. Case Rep Med. 2015; doi: 10.1155/2015/150204</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2015/150204</ArticleId><ArticleId IdType="pmc">PMC4496464</ArticleId><ArticleId IdType="pubmed">26199625</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan MZ, Saleh MA, Alkhayyat M, Roberts DE, Lindenmeyer CC. Multiorgan Dysfunction Related to Kratom Ingestion. ACG Case Reports J. 2021; doi: 10.14309/crj.0000000000000647</Citation><ArticleIdList><ArticleId IdType="doi">10.14309/crj.0000000000000647</ArticleId><ArticleId IdType="pmc">PMC8389947</ArticleId><ArticleId IdType="pubmed">34476274</ArticleId></ArticleIdList></Reference><Reference><Citation>Perazella MA. Renal vulnerability to drug toxicity. Clinical Journal of the American Society of Nephrology. 2009. doi: 10.2215/CJN.02050309</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.02050309</ArticleId><ArticleId IdType="pubmed">19520747</ArticleId></ArticleIdList></Reference><Reference><Citation>George P. Concerns regarding the safety and toxicity of medicinal plants&#x2014;An overview. J Appl Pharm Sci. 2011;</Citation></Reference><Reference><Citation>Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. Complementary and alternative medicine in chronic liver disease. Hepatology. 2001; doi: 10.1053/jhep.2001.27445</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/jhep.2001.27445</ArticleId><ArticleId IdType="pubmed">11526548</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayers SL, Kronenfeld JJ. Delays in seeking conventional medical care and complementary and alternative medicine utilization. Health Serv Res. 2012; doi: 10.1111/j.1475-6773.2012.01406.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1475-6773.2012.01406.x</ArticleId><ArticleId IdType="pmc">PMC3513619</ArticleId><ArticleId IdType="pubmed">22985034</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang WF, Wen KC, Hsiao ML. Adulteration by synthetic therapeutic substances of traditional Chinese medicines in Taiwan. J Clin Pharmacol. 1997; doi: 10.1002/j.1552-4604.1997.tb04312.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/j.1552-4604.1997.tb04312.x</ArticleId><ArticleId IdType="pubmed">9115061</ArticleId></ArticleIdList></Reference><Reference><Citation>Posadzki P, Watson L, Ernst E. Contamination and adulteration of herbal medicinal products (HMPs): An overview of systematic reviews. European Journal of Clinical Pharmacology. 2013. doi: 10.1007/s00228-012-1353-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00228-012-1353-z</ArticleId><ArticleId IdType="pubmed">22843016</ArticleId></ArticleIdList></Reference><Reference><Citation>Snyman T, Stewart MJ, Grove A, Steenkamp V. Adulteration of South African traditional herbal remedies. Ther Drug Monit. 2005; doi: 10.1097/00007691-200502000-00015</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00007691-200502000-00015</ArticleId><ArticleId IdType="pubmed">15665751</ArticleId></ArticleIdList></Reference><Reference><Citation>Calixto JB. Efficacy, safety, quality control, marketing and regulatory guidelines for herbal medicines (phytotherapeutic agents). Brazilian Journal of Medical and Biological Research. 2000. doi: 10.1590/s0100-879x2000000200004</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/s0100-879x2000000200004</ArticleId><ArticleId IdType="pubmed">10657057</ArticleId></ArticleIdList></Reference><Reference><Citation>Efferth T, Kaina B. Toxicities by Herbal Medicines with Emphasis to Traditional Chinese Medicine. Curr Drug Metab. 2011; doi: 10.2174/138920011798062328</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/138920011798062328</ArticleId><ArticleId IdType="pubmed">21892916</ArticleId></ArticleIdList></Reference><Reference><Citation>Goh AYT, Chan PWK, Lum LCS. Sepsis, severe sepsis and septic shock in paediatric multiple organ dysfunction syndrome. J Paediatr Child Health. 1999; doi: 10.1046/j.1440-1754.1999.355409.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1440-1754.1999.355409.x</ArticleId><ArticleId IdType="pubmed">10571765</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Fitzgerald JC, Pappachan J, Wheeler D, Jaramillo-Bustamante JC, Salloo A, et al.. Global epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study. Am J Respir Crit Care Med. 2015; doi: 10.1164/rccm.201412-2323OC</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.201412-2323OC</ArticleId><ArticleId IdType="pmc">PMC4451622</ArticleId><ArticleId IdType="pubmed">25734408</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfler A, Silvani P, Musicco M, Antonelli M, Salvo I. Incidence of and mortality due to sepsis, severe sepsis and septic shock in Italian Pediatric Intensive Care Units: A prospective national survey. Intensive Care Med. 2008; doi: 10.1007/s00134-008-1148-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-008-1148-y</ArticleId><ArticleId IdType="pubmed">18500425</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Proulx F, Grandbastien B, Cotting J, et al.. Validation of the paediatric logistic organ dysfunction (PELOD) score: Prospective, observational, multicentre study. Lancet. 2003; doi: 10.1016/S0140-6736(03)13908-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)13908-6</ArticleId><ArticleId IdType="pubmed">12885479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, Cotting J. Severity of illness and organ dysfunction scoring in children. Pediatric Critical Care Medicine. 2005. doi: 10.1097/01.PCC.0000161287.61028.D4</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000161287.61028.D4</ArticleId><ArticleId IdType="pubmed">15857545</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulla K, Sachdev A. Illness severity and organ dysfunction scoring in Pediatric Intensive Care Unit. Indian J Crit Care Med. 2016; doi: 10.4103/0972-5229.173685</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0972-5229.173685</ArticleId><ArticleId IdType="pmc">PMC4759990</ArticleId><ArticleId IdType="pubmed">26955214</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38062303</PMID><DateCompleted><Year>2024</Year><Month>06</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1556-0961</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Neurocritical care</Title><ISOAbbreviation>Neurocrit Care</ISOAbbreviation></Journal><ArticleTitle>Multiorgan Dysfunction Syndrome in Abusive and Accidental Pediatric Traumatic Brain Injury.</ArticleTitle><Pagination><StartPage>1099</StartPage><EndPage>1108</EndPage><MedlinePgn>1099-1108</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s12028-023-01887-y</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Abusive head trauma (AHT) is a mechanism of pediatric traumatic brain injury (TBI) with high morbidity and mortality. Multiorgan dysfunction syndrome (MODS), defined as organ dysfunction in two or more organ systems, is also associated with morbidity and mortality in critically ill children. Our objective was to compare the frequency of MODS and evaluate its association with outcome between AHT and accidental TBI (aTBI).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This was a single center, retrospective cohort study including children under 3 years old admitted to the pediatric intensive care unit with nonpenetrating TBI between 2014 and 2021. Presence or absence of MODS on days 1, 3, and 7 using the Pediatric Logistic Organ Dysfunction-2 score and new impairment status (Functional Status Scale score change&#x2009;&gt;&#x2009;1 compared with preinjury) at hospital discharge (HD), short-term timepoint, and long-term timepoint&#xa0;were abstracted from the electronic health record. Multiple logistic regression was performed to examine the association between MODS and TBI mechanism with new impairment status.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 576 children, 215 (37%) had AHT and 361 (63%) had aTBI. More children with AHT had MODS on days 1 (34% vs. 23%, p&#x2009;=&#x2009;0.003), 3 (28% vs. 6%, p&#x2009;&lt;&#x2009;0.001), and 7 (17% vs. 3%, p&#x2009;&lt;&#x2009;0.001) compared with those with aTBI. The most common organ failures were cardiovascular ([AHT] 66% vs. [aTBI] 66%, p&#x2009;=&#x2009;0.997), neurologic (33% vs. 16%, p&#x2009;&lt;&#x2009;0.001), and respiratory (34% vs. 15%, p&#x2009;&lt;&#x2009;0.001). MODS was associated with new impairment in multivariable logistic regression at HD (odds ratio 19.1 [95% confidence interval 9.8-38.6, p&#x2009;&lt;&#x2009;0.001]), short-term discharge (7.4 [3.7-15.2, p&#x2009;&lt;&#x2009;0.001]), and long-term discharge (4.3 [2.0-9.4, p&#x2009;&lt;&#x2009;0.001])]. AHT was also associated with new impairment at HD (3.4 [1.6-7.3, p&#x2009;=&#x2009;0.001]), short-term discharge (2.5 [1.3-4.7, p&#x2009;=&#x2009;0.005]), and long-term discharge (2.1 [1.1-4.1, p&#x2009;=&#x2009;0.036]).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Abusive head trauma as a mechanism was associated with MODS following TBI. Both AHT mechanism and MODS were associated with new impairment at all time points.</AbstractText><CopyrightInformation>&#xa9; 2023. Springer Science+Business Media, LLC, part of Springer Nature and Neurocritical Care Society.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>McNamara</LastName><ForeName>Caitlin R</ForeName><Initials>CR</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. mcnamaracr@upmc.edu.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Even</LastName><ForeName>Katelyn M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, Pennsylvania State University, State College, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kalinowski</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Horvat</LastName><ForeName>Christopher M</ForeName><Initials>CM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gaines</LastName><ForeName>Barbara A</ForeName><Initials>BA</Initials><AffiliationInfo><Affiliation>Division of Pediatric Surgery, Department of Surgery, University of Texas Southwestern, Dallas, TX, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Richardson</LastName><ForeName>Ward M</ForeName><Initials>WM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Surgery, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Simon</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kochanek</LastName><ForeName>Patrick M</ForeName><Initials>PM</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berger</LastName><ForeName>Rachel P</ForeName><Initials>RP</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fink</LastName><ForeName>Ericka L</ForeName><Initials>EL</Initials><AffiliationInfo><Affiliation>Department of Pediatric Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>T32 HD040686</GrantID><Acronym>HD</Acronym><Agency>NICHD NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5T32HD040686-22</GrantID><Agency>Foundation for the National Institutes of Health</Agency><Country/></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurocrit Care</MedlineTA><NlmUniqueID>101156086</NlmUniqueID><ISSNLinking>1541-6933</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000070642" MajorTopicYN="Y">Brain Injuries, Traumatic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002649" MajorTopicYN="Y">Child Abuse</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000081084" MajorTopicYN="N">Accidental Injuries</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Child abuse</Keyword><Keyword MajorTopicYN="N">Long-term effects</Keyword><Keyword MajorTopicYN="N">Multiorgan dysfunction syndrome</Keyword><Keyword MajorTopicYN="N">Pediatric intensive care units</Keyword><Keyword MajorTopicYN="N">Traumatic brain injury</Keyword></KeywordList><CoiStatement>Conflicts of interest. No authors have any personal or financial affiliations that could present a conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>10</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>6</Month><Day>4</Day><Hour>5</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>8</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>7</Day><Hour>23</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>6</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38062303</ArticleId><ArticleId IdType="mid">NIHMS1956554</ArticleId><ArticleId IdType="pmc">PMC11147737</ArticleId><ArticleId IdType="doi">10.1007/s12028-023-01887-y</ArticleId><ArticleId IdType="pii">10.1007/s12028-023-01887-y</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rebbe R, Mienko JA, Martinson ML. Incidence and risk factors for abusive head trauma: a population-based study. Child Abuse Rev. 2020;29(3):195&#x2013;207.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7567009</ArticleId><ArticleId IdType="pubmed">33071539</ArticleId></ArticleIdList></Reference><Reference><Citation>Shanahan ME, Zolotor AJ, Parrish JW, Barr RG, Runyan DK. National, regional, and state abusive head trauma: Application of the CDC algorithm. Pediatrics. 2013;132(6):e1546&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4074669</ArticleId><ArticleId IdType="pubmed">24276842</ArticleId></ArticleIdList></Reference><Reference><Citation>Araki T, Yokota H, Morita A. Pediatric traumatic brain injury: characteristic features, diagnosis, and management. Neurol Med Chir (Tokyo). 2017;57(2):82&#x2013;93.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5341344</ArticleId><ArticleId IdType="pubmed">28111406</ArticleId></ArticleIdList></Reference><Reference><Citation>Peterson C, Xu L, Florence C, Parks SE. Annual cost of US hospital visits for pediatric abusive head trauma. Child Maltreat. 2015;20(3):162&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4675617</ArticleId><ArticleId IdType="pubmed">25911437</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Runyan DK, Nocera M. Child outcomes and family characteristics 1 year after severe inflicted or noninflicted traumatic brain injury. Pediatrics. 2006;117(2):317&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2367124</ArticleId><ArticleId IdType="pubmed">16452349</ArticleId></ArticleIdList></Reference><Reference><Citation>Haviland J, Ross Russell RI. Outcome after severe non-accidental head injury. Arch Dis Child. 1997;77(6):504&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1717403</ArticleId><ArticleId IdType="pubmed">9496184</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson JE, Beres AL, Theodorou CM, Ugiliweneza B, Boakye M, Nu&#xf1;o M. Long-term impact of abusive head trauma in young children: Outcomes at 5 and 11 years old. J Pediatr Surg. 2021;56(12):2318&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8374003</ArticleId><ArticleId IdType="pubmed">33714452</ArticleId></ArticleIdList></Reference><Reference><Citation>Eismann EA, Theuerling J, Cassedy A, Curry PA, Colliers T, Makoroff KL. Early developmental, behavioral, and quality of life outcomes following abusive head trauma in infants. Child Abuse Negl. 2020;108:104643.</Citation><ArticleIdList><ArticleId IdType="pubmed">32739598</ArticleId></ArticleIdList></Reference><Reference><Citation>Keenan HT, Clark A, Holubkov R, Ewing-Cobbs L. Longitudinal Developmental Outcomes of Infants and Toddlers With Traumatic Brain Injury. JAMA Netw Open [Internet]. 2023;6(1):e2251195.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9856699</ArticleId><ArticleId IdType="pubmed">36648943</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller Ferguson N, Sarnaik A, Miles D, Shafi N, Peters MJ, Truemper E, et al. Abusive head trauma and mortality-an analysis from an international comparative effectiveness study of children with severe traumatic brain injury. Crit Care Med. 2017;45(8):1398&#x2013;407.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5511066</ArticleId><ArticleId IdType="pubmed">28430697</ArticleId></ArticleIdList></Reference><Reference><Citation>Paek D, Kwon DI. A review on four different paths to respiratory arrest from brain injury in children; implications for child abuse. J Forensic Leg Med. 2020;1:71.</Citation><ArticleIdList><ArticleId IdType="pubmed">32342908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, Glass NL, Yeh TS. Outcome of pediatric patients with multiple organ system failure. Crit Care Med [Internet]. 1986;14(4):271&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Glass NL, Kanter RK, Katz RW, Steinhart CM. Mortality associated with multiple organ system failure and sepsis in pediatric intensive care unit. J Pediatr. 1987;111(3):324&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">3625400</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanna K, Hamidi M, Vartanyan P, Henry M, Castanon L, Tang A, et al. Non-neurologic organ dysfunction plays a major role in predicting outcomes in pediatric traumatic brain injury &#x2606;. J Pediatr Surg [Internet]. 2020;55(8):1590&#x2013;5. 10.1016/j.jpedsurg.2020.01.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jpedsurg.2020.01.051</ArticleId><ArticleId IdType="pubmed">32081358</ArticleId></ArticleIdList></Reference><Reference><Citation>Typpo KV, Petersen NJ, Markovitz BPMMM. Day one MODS is associated with poor functional outcome and mortality in the pediatric intensive care unit. Pediatr Crit Care Med. 2009;10(5):562&#x2013;70.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2780005</ArticleId><ArticleId IdType="pubmed">19741445</ArticleId></ArticleIdList></Reference><Reference><Citation>Killien EY, Zahlan JM, Lad H, Watson RS, Vavilala MS, Huijsmans RLN, et al. Epidemiology and outcomes of multiple organ dysfunction syndrome following pediatric trauma. J Trauma Acute Care Surg [Internet]. 2022;93(6):829&#x2013;37. 10.1097/TA.0000000000003616.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003616</ArticleId><ArticleId IdType="pmc">PMC9525450</ArticleId><ArticleId IdType="pubmed">35358103</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown JB, Gestring ML, Leeper CM, Sperry JL, Peitzman AB, Billiar TR, et al. The value of the injury severity score in pediatric trauma: Time for a new definition of severe injury? J Trauma Acute Care Surg. 2017;82(6):995&#x2013;1001.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5464600</ArticleId><ArticleId IdType="pubmed">28328674</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F. PELOD-2: an update of the PEdiatric logistic organ dysfunction score. Crit Care Med. 2013;41(7):1761&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L, Wu Y, Huang H, Liu C, Cheng Y, Xu L, et al. Performance of PRISM III, PELOD-2, and P-MODS scores in two pediatric intensive care units in China. Front Pediatr. 2021;9:1&#x2013;7.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8113391</ArticleId><ArticleId IdType="pubmed">33996681</ArticleId></ArticleIdList></Reference><Reference><Citation>Zamalin D, Hamlin I, Shults J, Katherine Henry M, Campbell KA, Anderst JD, et al. (2023) Predictors of making a referral to child protective services prior to expert consultation. Acad Pediatr.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10638459</ArticleId><ArticleId IdType="pubmed">37178908</ArticleId></ArticleIdList></Reference><Reference><Citation>Wood JN, Henry MK, Berger RP, Lindberg DM, Anderst JD, Song L, et al. Use and utility of skeletal surveys to evaluate for occult fractures in young injured children. Acad Pediatr [Internet]. 2018. 10.1016/j.acap.2018.08.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.acap.2018.08.007</ArticleId><ArticleId IdType="pmc">PMC6377846</ArticleId><ArticleId IdType="pubmed">30121318</ArticleId></ArticleIdList></Reference><Reference><Citation>Petridou ET, Antonopoulos CN. Injury epidemiology. Int Encycloped Public Health. 2017;1:258&#x2013;74.</Citation></Reference><Reference><Citation>Pollack MM, Holubkov R. The functional status score (FSS): a new pediatric outcome measure. Pediatrics. 2009;124(1):1&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3191069</ArticleId><ArticleId IdType="pubmed">19564265</ArticleId></ArticleIdList></Reference><Reference><Citation>Kennedy JM, Ma J, Lyden ER, Haney SB. Abusive head trauma and a delay in presentation for care. Pediatr Emerg Care. 2020;38(1):e170&#x2013;2.</Citation><ArticleIdList><ArticleId IdType="pubmed">32675710</ArticleId></ArticleIdList></Reference><Reference><Citation>Sulhan S, Lyon KA, Shapiro LA, Huang JH. Neuroinflammation and blood&#x2013;brain barrier disruption following traumatic brain injury: pathophysiology and potential therapeutic targets. J Neurosci Res. 2020;98:19&#x2013;28.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6437022</ArticleId><ArticleId IdType="pubmed">30259550</ArticleId></ArticleIdList></Reference><Reference><Citation>Carcillo JA, Podd B, Aneja R, Weiss SL, Hall MW, Cornell TT, et al. Pathophysiology of pediatric multiple organ dysfunction syndrome. Pediatr Crit Care Med. 2017;18(3):S32&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5333491</ArticleId><ArticleId IdType="pubmed">28248832</ArticleId></ArticleIdList></Reference><Reference><Citation>Biswas A, Krishnan P, Albalkhi I, Mankad K, Shroff M. Imaging of Abusive Head Trauma in Children. W.B. Saunders: Neuroimaging Clinics of North America; 2023.</Citation><ArticleIdList><ArticleId IdType="pubmed">36965952</ArticleId></ArticleIdList></Reference><Reference><Citation>Dingman AL, Stence NV, O&#x2019;Neill BR, Sillau SH, Chapman KE. Seizure severity is correlated with severity of hypoxic-ischemic injury in abusive head trauma. Pediatr Neurol [Internet]. 2018;82:29&#x2013;35. 10.1016/j.pediatrneurol.2017.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pediatrneurol.2017.12.003</ArticleId><ArticleId IdType="pubmed">29625848</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh A, Olson LD, Chern JJ, Kim H. Clinical characteristics and nonconvulsive seizures in young children with abusive head trauma. J Child Neurol. 2019;34(12):713&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">31185789</ArticleId></ArticleIdList></Reference><Reference><Citation>Komisarow JM, Chen F, Vavilala MS, Laskowitz D, James ML, Krishnamoorthy V. Epidemiology and outcomes of acute respiratory distress syndrome following isolated severe traumatic brain injury. J Intensive Care Med. 2022;37(1):68&#x2013;74.</Citation><ArticleIdList><ArticleId IdType="pubmed">33191844</ArticleId></ArticleIdList></Reference><Reference><Citation>Humayun M, Premraj L, Shah V, Cho SM. Mechanical ventilation in acute brain injury patients with acute respiratory distress syndrome. Front Med (Lausanne) [Internet]. 2022;6:9. 10.3389/fmed.2022.999885/full.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2022.999885/full</ArticleId><ArticleId IdType="pmc">PMC9582443</ArticleId><ArticleId IdType="pubmed">36275802</ArticleId></ArticleIdList></Reference><Reference><Citation>Hollenberg SM, Singer M. Pathophysiology of sepsis-induced cardiomyopathy. Nat Rev Cardiol. 2021;18:424&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">33473203</ArticleId></ArticleIdList></Reference><Reference><Citation>Christiaans SC, Duhachek-Stapelman AL, Russell RT, Lisco SJ, Kerby JD, Pittet JF. Coagulopathy after severe pediatric trauma. Shock. 2014;41:476&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4024323</ArticleId><ArticleId IdType="pubmed">24569507</ArticleId></ArticleIdList></Reference><Reference><Citation>Almuqamam M, Novi B, Rossini CJ, Mammen A, DeSanti RL. Association of hyperchloremia and acute kidney injury in pediatric patients with moderate and severe traumatic brain injury. Child&#x2019;s Nervous Syst. 2023;39:1267&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">36595084</ArticleId></ArticleIdList></Reference><Reference><Citation>De Vlieger G, Meyfroidt G. Kidney dysfunction after traumatic brain injury: pathophysiology and general management, Neurocritical Care. Berlin: Springer; 2022.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9629888</ArticleId><ArticleId IdType="pubmed">36324003</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss SL, Carcillo JA, Leclerc F, Leteurtre S, Schlapbach LJ, Tissieres P, et al. Refining the Pediatric Multiple Organ Dysfunction Syndrome. Pediatrics. 2022;1:149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9084565</ArticleId><ArticleId IdType="pubmed">34970671</ArticleId></ArticleIdList></Reference><Reference><Citation>Radermacher P, Billiar TR, Ghezzi P, Martin L, Thiemermann C. Editorial: translational insights into mechanisms and therapy of organ dysfunction in sepsis and trauma. Front Immunol. 2020;11:1987.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7546816</ArticleId><ArticleId IdType="pubmed">33101267</ArticleId></ArticleIdList></Reference><Reference><Citation>. Asim M, Amin F, El-Menyar A. Multiple organ dysfunction syndrome: Contemporary insights on the clinicopathological spectrum. Qatar Med J. 2020;2020(2):22.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7884906</ArticleId><ArticleId IdType="pubmed">33628712</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson LW, Bass KD, Agyei JO, Naseem HUR, Borngraber E, Wang J, et al. Incidence of nonaccidental head trauma in infants: a call to revisit prevention strategies. J Neurosurg Pediatr [Internet]. 2019;24(6):689&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">31629317</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlapbach LJ, Weiss SL, Bembea MM, Carcillo JA, Leclerc F, Leteurtre S, et al. Scoring systems for organ dysfunction and multiple organ dysfunction: the PODIUM consensus conference. Pediatrics [Internet]. 2022;149:S23&#x2013;31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9703039</ArticleId><ArticleId IdType="pubmed">34970683</ArticleId></ArticleIdList></Reference><Reference><Citation>Bembea MM, Agus M, Akcan-Arikan A, Alexander P, Basu R, Bennett TD, et al. Pediatric organ dysfunction information update mandate (PODIUM) contemporary organ dysfunction criteria: executive summary. Pediatrics [Internet]. 2022;149:S1&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9599725</ArticleId><ArticleId IdType="pubmed">34970673</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">32091503</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>06</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>06</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1529-7535</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>4</Issue><PubDate><Year>2020</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies</Title><ISOAbbreviation>Pediatr Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Comparison of the Automated Pediatric Logistic Organ Dysfunction-2 Versus Manual Pediatric Logistic Organ Dysfunction-2 Score for Critically Ill Children.</ArticleTitle><Pagination><StartPage>e160</StartPage><EndPage>e169</EndPage><MedlinePgn>e160-e169</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/PCC.0000000000002235</ELocationID><Abstract><AbstractText Label="OBJECTIVES">The Pediatric Logistic Organ Dysfunction-2 is a validated score that quantifies organ dysfunction severity and requires complex data collection that is time-consuming and subject to errors. We hypothesized that a computer algorithm that automatically collects and calculates the Pediatric Logistic Organ Dysfunction-2 (aPELOD-2) score would be valid, fast and at least as accurate as a manual approach (mPELOD-2).</AbstractText><AbstractText Label="DESIGN">Retrospective cohort study.</AbstractText><AbstractText Label="SETTING">Single center tertiary medical and surgical pediatric critical care unit (Sainte-Justine Hospital, Montreal, Canada).</AbstractText><AbstractText Label="PATIENTS">Critically ill children participating in four clinical studies between January 2013 and August 2018, a period during which mPELOD-2 data were manually collected.</AbstractText><AbstractText Label="INTERVENTIONS">None.</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS">The aPELOD-2 was calculated for all consecutive admissions between 2013 and 2018 (n = 5,279) and had a good survival discrimination with an area under the receiver operating characteristic curve of 0.84 (95% CI, 0.81-0.88). We also collected data from four single-center studies in which mPELOD-2 was calculated (n = 796, 57% medical, 43% surgical) and compared these measurements to those of the aPELOD-2. For those patients, median age was 15 months (interquartile range, 3-73 mo), median ICU stay was 5 days (interquartile range, 3-9 d), mortality was 3.9% (n = 28). The intraclass correlation coefficient between mPELOD-2 and aPELOD-2 was 0.75 (95% CI, 0.73-0.77). The Bland-Altman showed a bias of 1.9 (95% CI, 1.7-2) and limits of agreement of -3.1 (95% CI, -3.4 to -2.8) to 6.8 (95% CI, 6.5-7.2). The highest agreement (Cohen's Kappa) of the Pediatric Logistic Organ Dysfunction-2 components was noted for lactate level (0.88), invasive ventilation (0.86), and creatinine level (0.82) and the lowest for the Glasgow Coma Scale (0.52). The proportion of patients with multiple organ dysfunction syndrome was higher for aPELOD-2 (78%) than mPELOD-2 (72%; p = 0.002). The aPELOD-2 had a better survival discrimination (area under the receiver operating characteristic curve, 0.81; 95% CI, 0.72-0.90) over mPELOD-2 (area under the receiver operating characteristic curve, 0.70; 95% CI, 0.59-0.82; p = 0.01).</AbstractText><AbstractText Label="CONCLUSIONS">We successfully created a freely available automatic algorithm to calculate the Pediatric Logistic Organ Dysfunction-2 score that is less labor intensive and has better survival discrimination than the manual calculation. Use of an automated system could greatly facilitate integration of the Pediatric Logistic Organ Dysfunction-2 score at the bedside and within clinical decision support systems.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sauthier</LastName><ForeName>Micha&#xeb;l</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landry-Hould</LastName><ForeName>Florence</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Univ. Lille, CHU Lille, EA 2694 - Sant&#xe9; Publique: &#xe9;pid&#xe9;miologie et qualit&#xe9; des soins, Service de r&#xe9;animation p&#xe9;diatrique, F-59000 Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kawaguchi</LastName><ForeName>Atsushi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Emeriaud</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouvet</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Sainte-Justine Hospital, Montreal, QC, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montreal, QC, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Pediatr Crit Care Med</MedlineTA><NlmUniqueID>100954653</NlmUniqueID><ISSNLinking>1529-7535</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Pediatr Crit Care Med. 2020 Apr;21(4):397-398. doi: 10.1097/PCC.0000000000002244.</RefSource><PMID Version="1">32251189</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="Y">Critical Illness</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="Y">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D063305" MajorTopicYN="N">Organ Dysfunction Scores</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>2</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32091503</ArticleId><ArticleId IdType="doi">10.1097/PCC.0000000000002235</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32743995</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>10</Day></DateCompleted><DateRevised><Year>2024</Year><Month>07</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1598-6357</ISSN><JournalIssue CitedMedium="Internet"><Volume>35</Volume><Issue>30</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>03</Day></PubDate></JournalIssue><Title>Journal of Korean medical science</Title><ISOAbbreviation>J Korean Med Sci</ISOAbbreviation></Journal><ArticleTitle>Clinical Course and Outcomes of 3,060 Patients with Coronavirus Disease 2019 in Korea, January-May 2020.</ArticleTitle><Pagination><StartPage>e280</StartPage><MedlinePgn>e280</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e280</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3346/jkms.2020.35.e280</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The fatality rate of patients with coronavirus disease 2019 (COVID-19) varies among countries owing to demographics, patient comorbidities, surge capacity of healthcare systems, and the quality of medical care. We assessed the clinical outcomes of patients with COVID-19 during the first wave of the epidemic in Korea.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Using a modified World Health Organization clinical record form, we obtained clinical data for 3,060 patients with COVID-19 treated at 55 hospitals in Korea. Disease severity scores were defined as: 1) no limitation of daily activities; 2) limitation of daily activities but no need for supplemental oxygen; 3) supplemental oxygen via nasal cannula; 4) supplemental oxygen via facial mask; 5) non-invasive mechanical ventilation; 6) invasive mechanical ventilation; 7) multi-organ failure or extracorporeal membrane oxygenation therapy; and 8) death. Recovery was defined as a severity score of 1 or 2, or discharge and release from isolation.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median age of the patients was 43 years of age; 43.6% were male. The median time from illness onset to admission was 5 days. Of the patients with a disease severity score of 3-4 on admission, 65 (71.5%) of the 91 patients recovered, and 7 (7.7%) died due to illness by day 28. Of the patients with disease severity scores of 5-7, 7 (19.5%) of the 36 patients recovered, and 8 (22.2%) died due to illness by day 28. None of the 1,324 patients who were &lt; 50 years of age died; in contrast, the fatality rate due to illness by day 28 was 0.5% (2/375), 0.9% (2/215), 5.8% (6/104), and 14.0% (7/50) for the patients aged 50-59, 60-69, 70-79, and &#x2265; 80 years of age, respectively.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In Korea, almost all patients of &lt; 50 years of age with COVID-19 recovered without supplemental oxygen. In patients of &#x2265; 50 years of age, the fatality rate increased with age, reaching 14% in patients of &#x2265; 80 years of age.</AbstractText><CopyrightInformation>&#xa9; 2020 The Korean Academy of Medical Sciences.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sung</LastName><ForeName>Ho Kyung</ForeName><Initials>HK</Initials><Identifier Source="ORCID">0000-0002-1207-0298</Identifier><AffiliationInfo><Affiliation>National Emergency Medical Center, National Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Jin Yong</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-4306-1597</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Incheon Medical Center, Incheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heo</LastName><ForeName>Jeonghun</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-9534-2921</Identifier><AffiliationInfo><Affiliation>Department of Pulmonology, Busan Medical Center, Busan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Seo</LastName><ForeName>Haesook</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-3554-6172</Identifier><AffiliationInfo><Affiliation>Department of Tuberculosis, Seoul Metropolitan Seobuk Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jang</LastName><ForeName>Young Soo</ForeName><Initials>YS</Initials><Identifier Source="ORCID">0000-0003-3586-9446</Identifier><AffiliationInfo><Affiliation>Department of Orthopedic Surgery, Seoul Metropolitan Seonam Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Hyewon</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0003-3491-1059</Identifier><AffiliationInfo><Affiliation>Department of Laboratory Medicine, Chungju Medical Center, Chungju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koh</LastName><ForeName>Bo Ram</ForeName><Initials>BR</Initials><Identifier Source="ORCID">0000-0002-8810-1417</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Gyeonggi Provincial Medical Center Ansung Hospital, Anseong, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jo</LastName><ForeName>Neungsun</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0003-4622-9655</Identifier><AffiliationInfo><Affiliation>Department of Infection Control, Chungcheongnam-do Gongju Medical Center, Gongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Hong Sang</ForeName><Initials>HS</Initials><Identifier Source="ORCID">0000-0002-4535-6305</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Armed Forces Capital Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baek</LastName><ForeName>Young Mi</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-8314-6317</Identifier><AffiliationInfo><Affiliation>Department of Infection Control, Chungcheongnam-do Seosan Medical Center, Seosan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Kyung Hwa</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0003-2836-6963</Identifier><AffiliationInfo><Affiliation>Department of Infectious Diseases, Chonnam National University Medical School, Gwangju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shon</LastName><ForeName>Jeung A</ForeName><Initials>JA</Initials><Identifier Source="ORCID">0000-0001-9515-7665</Identifier><AffiliationInfo><Affiliation>Department of Nursing, Yeongju Red Cross Hospital, Yeongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Min Chul</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-4410-5608</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Chung-Ang University Hospital, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kim</LastName><ForeName>Joon Ho</ForeName><Initials>JH</Initials><Identifier Source="ORCID">0000-0003-4127-2312</Identifier><AffiliationInfo><Affiliation>Department of Surgery, Gyeonggi Provincial Medical Center Uijeongbu Hospital, Uijeongbu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Hyun Ha</ForeName><Initials>HH</Initials><Identifier Source="ORCID">0000-0002-9405-2121</Identifier><AffiliationInfo><Affiliation>Division of Infectious Disease, Department of Internal Medicine, Kyungpook National University Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yukyung</ForeName><Initials>Y</Initials><Identifier Source="ORCID">0000-0002-0660-9867</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Korea Workers' Compensation &amp; Welfare Services Daegu Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kang</LastName><ForeName>Yu Min</ForeName><Initials>YM</Initials><Identifier Source="ORCID">0000-0002-4368-9878</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Myongji Hospital, Goyang, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0003-1179-1664</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Chungcheongnam-do Cheonan Medical Center, Cheonan, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Dong Hyun</ForeName><Initials>DH</Initials><Identifier Source="ORCID">0000-0002-9990-6042</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Hyun Jung</ForeName><Initials>HJ</Initials><Identifier Source="ORCID">0000-0003-4104-9583</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Jeonllanam-do Suncheon Medical Center, Suncheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Kyoung Ho</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-4517-3840</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Seoul National University Bundang Hospital, Seongnam, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Eun Kyoung</ForeName><Initials>EK</Initials><Identifier Source="ORCID">0000-0003-1104-268X</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Cheongju Medical Center, Cheongju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jeong</LastName><ForeName>Hyeongseok</ForeName><Initials>H</Initials><Identifier Source="ORCID">0000-0002-4539-079X</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Chungnam National University School of Medicine, Daejeon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lee</LastName><ForeName>Ji Yeon</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-2788-1392</Identifier><AffiliationInfo><Affiliation>Division of Infectious Diseases, Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ko</LastName><ForeName>Ja Young</ForeName><Initials>JY</Initials><Identifier Source="ORCID">0000-0002-1044-644X</Identifier><AffiliationInfo><Affiliation>Intensive Care Team, Gyeonggi Provincial Medical Center Paju Hospital, Paju, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Choi</LastName><ForeName>Jihee</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-5255-1352</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Gyeonggi Provincial Medical Center Icheon Hospital, Icheon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ryu</LastName><ForeName>Eun Hwa</ForeName><Initials>EH</Initials><Identifier Source="ORCID">0000-0001-5814-7636</Identifier><AffiliationInfo><Affiliation>Infection Control Team, Korea Worker's Compensation &amp; Welfare Service Changwon Hospital, Changwon, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chung</LastName><ForeName>Ki Hyun</ForeName><Initials>KH</Initials><Identifier Source="ORCID">0000-0002-7100-2519</Identifier><AffiliationInfo><Affiliation>National Medical Center, Seoul, Korea.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oh</LastName><ForeName>Myoung Don</ForeName><Initials>MD</Initials><Identifier Source="ORCID">0000-0002-2344-7695</Identifier><AffiliationInfo><Affiliation>Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Korea. mdohmd@snu.ac.kr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Korea National Committee for Clinical Management of COVID-19</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>4838-330-320-01</GrantID><Acronym>KCDC</Acronym><Agency>Korea Centers for Disease Control &amp; Prevention</Agency><Country>Korea</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>Korea (South)</Country><MedlineTA>J Korean Med Sci</MedlineTA><NlmUniqueID>8703518</NlmUniqueID><ISSNLinking>1011-8934</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>J Korean Med Sci. 2020 Sep 28;35(38):e353. doi: 10.3346/jkms.2020.35.e353.</RefSource><PMID Version="1">32989937</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018352" MajorTopicYN="N">Coronavirus Infections</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003625" MajorTopicYN="N">Data Collection</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005843" MajorTopicYN="N">Geography</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010356" MajorTopicYN="N">Patient Isolation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011024" MajorTopicYN="N">Pneumonia, Viral</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056910" MajorTopicYN="N" Type="Geographic">Republic of Korea</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055872" MajorTopicYN="N">Surge Capacity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014944" MajorTopicYN="N">World Health Organization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cohort Study</Keyword><Keyword MajorTopicYN="N">Korea</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword></KeywordList><CoiStatement>The authors have no potential conflicts of interest to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32743995</ArticleId><ArticleId IdType="pmc">PMC7402927</ArticleId><ArticleId IdType="doi">10.3346/jkms.2020.35.e280</ArticleId><ArticleId IdType="pii">35.e280</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. Coronavirus disease (COVID-2019) situation report-143.  [Updated 2020].  [Accessed 15 June, 2020].   https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports.</Citation></Reference><Reference><Citation>Kim JY, Choe PG, Oh Y, Oh KJ, Kim J, Park SJ, et al. The First Case of 2019 Novel Coronavirus Pneumonia Imported into Korea from Wuhan, China: Implication for Infection Prevention and Control Measures. J Korean Med Sci. 2020;35(5):e61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7008073</ArticleId><ArticleId IdType="pubmed">32030925</ArticleId></ArticleIdList></Reference><Reference><Citation>Korea Centers for Disease control and Prevention. Coronavirus disease-19 main website.  [Updated 2020].  [Accessed June 15, 2020].   http://ncov.mohw.go.kr/en.</Citation></Reference><Reference><Citation>Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in china: summary of a report of 72&#x202f;314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239&#x2013;1242.</Citation><ArticleIdList><ArticleId IdType="pubmed">32091533</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G, Zangrillo A, Zanella A, Antonelli M, Cabrini L, Castelli A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. JAMA. 2020;323(16):1574&#x2013;1581.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7136855</ArticleId><ArticleId IdType="pubmed">32250385</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020;369:m1966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7243801</ArticleId><ArticleId IdType="pubmed">32444366</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. I.S.A.R.E.I.C., Global COVID-19: clinical platform: novel coronavius (&#x200e;COVID-19)&#x200e;: rapid version. Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Korea Centers for Disease control and Prevention. Press release. Coronavirus disease-19, Republic of Korea.  [Updated 2020].  [Accessed June 12, 2020].   http://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&amp;brdGubun=125&amp;dataGubun=&amp;ncvContSeq=&amp;contSeq=&amp;board_idhttp://ncov.mohw.go.kr/en/tcmBoardList.do?brdId=12&amp;brdGubun=125&amp;dataGubun=&amp;ncvContSeq=&amp;contSeq=&amp;board_id=</Citation></Reference><Reference><Citation>WHO Working Group on the Clinical Characterisation and Management of COVID-19 Infection A minimal common outcome measure set for COVID-19 clinical research. Lancet Infect Dis. 2020 doi: 10.1016/S1473-3099(20)30483-7. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(20)30483-7</ArticleId><ArticleId IdType="pmc">PMC7292605</ArticleId><ArticleId IdType="pubmed">32539990</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: a preliminary report of the first 28 patients from the Korean cohort study on COVID-19. J Korean Med Sci. 2020;35(13):e142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7131901</ArticleId><ArticleId IdType="pubmed">32242348</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim NJ, Choe PG, Park SJ, Lim J, Lee WJ, Kang CK, et al. A cluster of tertiary transmissions of 2019 novel coronavirus (SARS-CoV-2) in the community from infectors with common cold symptoms. Korean J Intern Med. 2020;35(4):758&#x2013;764.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7373952</ArticleId><ArticleId IdType="pubmed">32506866</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. Report of the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19) Geneva: World Health Organization; 2020.</Citation></Reference><Reference><Citation>Verity R, Okell LC, Dorigatti I, Winskill P, Whittaker C, Imai N, et al. Estimates of the severity of coronavirus disease 2019: a model-based analysis. Lancet Infect Dis. 2020;20(6):669&#x2013;677.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7158570</ArticleId><ArticleId IdType="pubmed">32240634</ArticleId></ArticleIdList></Reference><Reference><Citation>Korean Society of Infectious Diseases; Korean Society of Pediatric Infectious Diseases; Korean Society of Epidemiology; Korean Society for Antimicrobial Therapy; Korean Society for Healthcare-associated Infection Control and Prevention; Korea Centers for Disease Control and Prevention. Report on the epidemiological features of coronavirus disease 2019 (COVID-19) outbreak in the Republic of Korea from January 19 to March 2, 2020. J Korean Med Sci. 2020;35(10):e112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7073313</ArticleId><ArticleId IdType="pubmed">32174069</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7177629</ArticleId><ArticleId IdType="pubmed">32320003</ArticleId></ArticleIdList></Reference><Reference><Citation>Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19 - Preliminary report. N Engl J Med. 2020 doi: 10.1056/NEJMoa2007764. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2007764</ArticleId><ArticleId IdType="pubmed">32649078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kang E, Lee SY, Jung H, Kim MS, Cho B, Kim YS. Operating protocols of a community treatment center for isolation of patients with coronavirus disease, South Korea. Emerging. Emerg Infect Dis. 2020 doi: 10.3201/eid2610.201460. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201460</ArticleId><ArticleId IdType="pmc">PMC7510742</ArticleId><ArticleId IdType="pubmed">32568665</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee YH, Hong CM, Kim DH, Lee TH, Lee J. Clinical course of asymptomatic and mildly symptomatic patients with coronavirus disease admitted to community treatment centers, South Korea. Emerg Infect Dis. 2020 doi: 10.3201/eid2610.201620. Forthcoming.</Citation><ArticleIdList><ArticleId IdType="doi">10.3201/eid2610.201620</ArticleId><ArticleId IdType="pmc">PMC7510714</ArticleId><ArticleId IdType="pubmed">32568662</ArticleId></ArticleIdList></Reference><Reference><Citation>Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, et al. Observational study of hydroxychloroquine in hospitalized patients with Covid-19. N Engl J Med. 2020;382(25):2411&#x2013;2418.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7224609</ArticleId><ArticleId IdType="pubmed">32379955</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19. N Engl J Med. 2020;382(19):1787&#x2013;1799.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7121492</ArticleId><ArticleId IdType="pubmed">32187464</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38409062</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>29</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2731-3786</ISSN><JournalIssue CitedMedium="Internet"><Volume>4</Volume><Issue>1</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>26</Day></PubDate></JournalIssue><Title>Journal of anesthesia, analgesia and critical care</Title><ISOAbbreviation>J Anesth Analg Crit Care</ISOAbbreviation></Journal><ArticleTitle>The use of extracorporeal blood purification therapies and sequential extracorporeal support in patients with septic shock (EROICASS): a study protocol for a national, non-interventional, observational multicenter, prospective study.</ArticleTitle><Pagination><StartPage>16</StartPage><MedlinePgn>16</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">16</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s44158-024-00153-7</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Septic shock, a critical condition characterized by organ failure, presents a substantial mortality risk in intensive care units (ICUs), with the 28-day mortality rate possibly reaching 40%. Conventional management of septic shock typically involves the administration of antibiotics, supportive care for organ dysfunction, and, if necessary, surgical intervention to address the source of infection. In recent decades, extracorporeal blood purification therapies (EBPT) have emerged as potential interventions aimed at modulating the inflammatory response and restoring homeostasis in patients with sepsis. Likewise, sequential extracorporeal therapy in sepsis (SETS) interventions offer comprehensive organ support in the setting of multiple organ dysfunction syndrome (MODS). The EROICASS study will assess and describe the utilization of EBPT in patients with septic shock. Additionally, we will evaluate the potential association between EBPT treatment utilization and 90-day mortality in septic shock cases in Italy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The EROICASS study is a national, non-interventional, multicenter observational prospective cohort study. All consecutive patients with septic shock at participating centers will be prospectively enrolled, with data collection extending from intensive care unit (ICU) admission to hospital discharge. Variables including patient demographics, clinical parameters, EBPT/SETS utilization, and outcomes will be recorded using a web-based data capture system. Statistical analyses will encompass descriptive statistics, hypothesis testing, multivariable regression models, and survival analysis to elucidate the associations between EBPT/SETS utilization and patient outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The EROICASS study provides valuable insights into the utilization and outcomes of EBPT and SETS in septic shock management. Through analysis of usage patterns and clinical data, this study aims to guide treatment decisions and enhance patient care. The implications of these findings may impact clinical guidelines, potentially improving survival rates and patient outcomes in septic shock cases.</AbstractText><CopyrightInformation>&#xa9; 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>De Rosa</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0001-8987-4596</Identifier><AffiliationInfo><Affiliation>Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy. silvia.derosa@unitn.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy. silvia.derosa@unitn.it.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy. silvia.derosa@unitn.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrari</LastName><ForeName>Fiorenza</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Intensive Care and Emergency, Fondazione IRRCS Ca' Granda Ospedale Maggiore Policlinico Milan, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Greco</LastName><ForeName>Massimiliano</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>IRCCS Humanitas Clinical and Research Center, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pota</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Woman, Child and General and Specialized Surgery, University of Campania "Luigi Vanvitelli", Naples, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Umbrello</LastName><ForeName>Michele</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Section of Resuscitation and Anesthesia, ASST Ovest Milanese, Ospedale Nuovo Di Legnano, Legnano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cotoia</LastName><ForeName>Antonella</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Medical and Surgical Sciences, Anesthesia and Intensive Care Unit, University of Foggia, Foggia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pasin</LastName><ForeName>Laura</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International Renal Research Institute of Vicenza (IRRV), Vicenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nalesso</LastName><ForeName>Federico</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nephrology, University Hospital, University of Padova, Padua, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paternoster</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Cardiac Resuscitation, Cardiovascular Anesthesia and Intensive Care, San Carlo Hospital, Potenza, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Villa</LastName><ForeName>Gianluca</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Health Sciences, Intensive Care and Pain Medicine Section of Anesthesia, University of Florence, Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lassola</LastName><ForeName>Sergio</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Miori</LastName><ForeName>Sara</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanna</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cantaluppi</LastName><ForeName>Vicenzo</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Translational Medicine, Nephrology and Kidney Transplantation Unit, "Maggiore Della Carit&#xe0;" University Hospital, University of Piemonte Orientale (UPO), Novara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marengo</LastName><ForeName>Marita</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Specialist Medicine, Nephrology and Dialysis Unit, Azienda Sanitaria Locale (ASL) CN1, Cuneo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Valente</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Nephrology and Dialysis, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fiorentino</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgical, Oncological, and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunori</LastName><ForeName>Giuliano</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Nephrology and Dialysis, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellani</LastName><ForeName>Giacomo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Centre for Medical Sciences (CISMed), University of Trento, 38122, Trento, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Anaesthesia and Intensive Care, Santa Chiara Regional Hospital, APSS, Trento, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giarratano</LastName><ForeName>Antonino</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgical, Oncological, and Oral Science (Di.Chir.On.S.), University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Anesthesia, Intensive Care, and Emergency, Policlinico Paolo Giaccone, University of Palermo, Palermo, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>J Anesth Analg Crit Care</MedlineTA><NlmUniqueID>9918591885906676</NlmUniqueID><ISSNLinking>2731-3786</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">EROICASS</Keyword><Keyword MajorTopicYN="N">Extracorporeal blood purification therapies</Keyword><Keyword MajorTopicYN="N">Sepsis</Keyword><Keyword MajorTopicYN="N">Sepsis-associated AKI</Keyword><Keyword MajorTopicYN="N">Sequential extracorporeal support</Keyword></KeywordList><CoiStatement>The authors declare that they have no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>1</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>26</Day><Hour>23</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38409062</ArticleId><ArticleId IdType="pmc">PMC10898122</ArticleId><ArticleId IdType="doi">10.1186/s44158-024-00153-7</ArticleId><ArticleId IdType="pii">10.1186/s44158-024-00153-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Rhodes A, Evans LE, Alhazzani W, Levy MM, Antonelli M, Ferrer R, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016. Intensive Care Med. 2017;43:304&#x2013;377. doi: 10.1007/s00134-017-4683-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-017-4683-6</ArticleId><ArticleId IdType="pubmed">28101605</ArticleId></ArticleIdList></Reference><Reference><Citation>Atan R, Crosbie D, Bellomo R. Techniques of extracorporeal cytokine removal: a systematic review of the literature. Blood Purif. 2012;33:88&#x2013;100. doi: 10.1159/000333845.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000333845</ArticleId><ArticleId IdType="pubmed">22248671</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A, Koyner JL, Gomez H, Pickkers P, Forni L, ADQI group. Sepsis-associated acute kidney injury - treatment standard. Nephrol Dial Transplant 2023:gfad142. 10.1093/ndt/gfad142.</Citation><ArticleIdList><ArticleId IdType="pubmed">37401137</ArticleId></ArticleIdList></Reference><Reference><Citation>Plataki M, Kashani K, Cabello-Garza J, Maldonado F, Kashyap R, Kor DJ, et al. Predictors of acute kidney injury in septic shock patients: an observational cohort study. Clin J Am Soc Nephrol. 2011;6:1744&#x2013;1751. doi: 10.2215/CJN.05480610.</Citation><ArticleIdList><ArticleId IdType="doi">10.2215/CJN.05480610</ArticleId><ArticleId IdType="pubmed">21734090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ostermann M, Chang RWS. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35:1837&#x2013;43; quiz 1852. 10.1097/01.CCM.0000277041.13090.0A.</Citation><ArticleIdList><ArticleId IdType="pubmed">17581483</ArticleId></ArticleIdList></Reference><Reference><Citation>Zarbock A, Nadim MK, Pickkers P, Gomez H, Bell S, Joannidis M, et al. Sepsis-associated acute kidney injury: consensus report of the 28th Acute Disease Quality Initiative workgroup. Nat Rev Nephrol. 2023;19:401&#x2013;417. doi: 10.1038/s41581-023-00683-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-023-00683-3</ArticleId><ArticleId IdType="pubmed">36823168</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Marengo M, Fiorentino M, Fanelli V, Brienza N, Fiaccadori E, et al. Extracorporeal blood purification therapies for sepsis-associated acute kidney injury in critically ill patients: expert opinion from the SIAARTI-SIN joint commission. J Nephrol. 2023 doi: 10.1007/s40620-023-01637-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40620-023-01637-5</ArticleId><ArticleId IdType="pmc">PMC10543830</ArticleId><ArticleId IdType="pubmed">37439963</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Cutuli SL, Lorenzin A, Zanella M. Sequential extracorporeal therapy in sepsis. Contrib Nephrol. 2023;200:1&#x2013;11. doi: 10.1159/000527573.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000527573</ArticleId><ArticleId IdType="pubmed">37290408</ArticleId></ArticleIdList></Reference><Reference><Citation>De Rosa S, Samoni S, Ronco C. Sequential extracorporeal therapy collaborative device and timely support for endotoxic, septic, and cardiac shock: a case report. Blood Purif. 2020;49:502&#x2013;508. doi: 10.1159/000505146.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000505146</ArticleId><ArticleId IdType="pubmed">31865323</ArticleId></ArticleIdList></Reference><Reference><Citation>Ilakovac V, Fister K, Marusic M, Marusic A. Reliability of disclosure forms of authors&#x2019; contributions. Can Med Assoc J. 2006;176:41&#x2013;46. doi: 10.1503/cmaj.060687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1503/cmaj.060687</ArticleId><ArticleId IdType="pmc">PMC1764586</ArticleId><ArticleId IdType="pubmed">17200389</ArticleId></ArticleIdList></Reference><Reference><Citation>Harris PA, Taylor R, Minor BL, Elliott V, Fernandez M, O&#x2019;Neal L, et al. The REDCap consortium: building an international community of software platform partners. J Biomed Inform. 2019;95:103208. doi: 10.1016/j.jbi.2019.103208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbi.2019.103208</ArticleId><ArticleId IdType="pmc">PMC7254481</ArticleId><ArticleId IdType="pubmed">31078660</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulfsohn MS, Tsiatis AA. A joint model for survival and longitudinal data measured with error. Biometrics. 1997;53:330&#x2013;339. doi: 10.2307/2533118.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2533118</ArticleId><ArticleId IdType="pubmed">9147598</ArticleId></ArticleIdList></Reference><Reference><Citation>Pant A, Mackraj I, Govender T. Advances in sepsis diagnosis and management: a paradigm shift towards nanotechnology. J Biomed Sci. 2021;28:6. doi: 10.1186/s12929-020-00702-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-020-00702-6</ArticleId><ArticleId IdType="pmc">PMC7790597</ArticleId><ArticleId IdType="pubmed">33413364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zhu J, Zhang C, Xiao J, Liu C, Wang S, et al. Non-invasive early prediction of septic acute kidney injury by Doppler-based renal resistive indexes combined with echocardiographic parameters: an experimental study. Front Med (Lausanne) 2021;8:723837. doi: 10.3389/fmed.2021.723837.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2021.723837</ArticleId><ArticleId IdType="pmc">PMC8671634</ArticleId><ArticleId IdType="pubmed">34926487</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19789443</PMID><DateCompleted><Year>2010</Year><Month>02</Month><Day>22</Day></DateCompleted><DateRevised><Year>2010</Year><Month>01</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0293</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2010</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Critical care medicine</Title><ISOAbbreviation>Crit Care Med</ISOAbbreviation></Journal><ArticleTitle>Comparison of two red-cell transfusion strategies after pediatric cardiac surgery: a subgroup analysis.</ArticleTitle><Pagination><StartPage>649</StartPage><EndPage>656</EndPage><MedlinePgn>649-56</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/CCM.0b013e3181bc816c</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To determine the impact of a restrictive vs. a liberal transfusion strategy on new or progressive multiple organ dysfunction syndrome in children post cardiac surgery. The optimal transfusion threshold after cardiac surgery in children is unknown.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Randomized, controlled trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Tertiary pediatric intensive care units.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Participants are a subgroup of pediatric patients post cardiac surgery from the TRIPICU (Transfusion Requirements in Pediatric Intensive Care Units) study. Exclusion criteria specific to the cardiac surgery subgroup included: age &lt;28 days and patients remaining cyanotic.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Critically ill children with a hemoglobin &lt; or = 95 g/L within 7 days of pediatric intensive care unit admission were randomized to receive prestorage leukocyte-reduced red-cell transfusion if their hemoglobin dropped either &lt;70 g/L (restrictive) or 95 g/L (liberal).</AbstractText><AbstractText Label="MEASUREMENTS AND MAIN RESULTS" NlmCategory="RESULTS">Postoperative cardiac patients (n = 125) from seven centers were enrolled. The restrictive (n = 63) and liberal (n = 62) groups were similar at baseline in age (mean +/- standard deviation = 31.4 +/- 38.1 mos vs. 26.4 +/- 39.1 mos), surgical procedure, severity of illness (Pediatric Risk of Mortality score = 3.4 +/- 3.2 vs. 3.2 +/- 3.2), multiple organ dysfunction syndrome (46% vs. 44%), mechanical ventilation (62% vs. 60%), and hemoglobin (83 vs. 80 g/L). Mean hemoglobin remained 21 g/L lower in the restrictive group after randomization. No significant difference was found in new or progressive multiple organ dysfunction syndrome (primary outcome) in the restrictive group vs. liberal group (12.7% vs. 6.5%; p = .36), pediatric intensive care unit length of stay (7.0 +/- 5.0 days vs. 7.4 +/- 6.4 days) or 28-day mortality (3.2% vs. 3.2%).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">In this subgroup analysis of cardiac surgery patients, a restrictive red-cell transfusion strategy, as compared with a liberal one, was not associated with any significant difference in new or progressive multiple organ dysfunction syndrome, but this evidence is not definitive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Willems</LastName><ForeName>Ariane</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Unit, Department of Pediatrics, Universit&#xe9; de Montr&#xe9;al, Montr&#xe9;al, QC, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrington</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Biarent</LastName><ForeName>Dominique</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Joffe</LastName><ForeName>Ari R</ForeName><Initials>AR</Initials></Author><Author ValidYN="Y"><LastName>Wensley</LastName><ForeName>David</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>TRIPICU investigators</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Canadian Critical Care Trials Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN37246456</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>130770</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>84300</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Crit Care Med</MedlineTA><NlmUniqueID>0355501</NlmUniqueID><ISSNLinking>0090-3493</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006454">Hemoglobins</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006454" MajorTopicYN="N">Hemoglobins</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><InvestigatorList><Investigator ValidYN="Y"><LastName>Cl&#xe9;ment de Cl&#xe9;ty</LastName><ForeName>S</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Biarent</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joffe</LastName><ForeName>A</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skippen</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wensley</LastName><ForeName>D</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchison</LastName><ForeName>J S</ForeName><Initials>JS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gottesman</LastName><ForeName>R</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Meert</LastName><ForeName>K</ForeName><Initials>K</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>10</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>2</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19789443</ArticleId><ArticleId IdType="doi">10.1097/CCM.0b013e3181bc816c</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31821429</PMID><DateCompleted><Year>2019</Year><Month>12</Month><Day>23</Day></DateCompleted><DateRevised><Year>2020</Year><Month>09</Month><Day>03</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1538-3598</ISSN><JournalIssue CitedMedium="Internet"><Volume>322</Volume><Issue>22</Issue><PubDate><Year>2019</Year><Month>Dec</Month><Day>10</Day></PubDate></JournalIssue><Title>JAMA</Title><ISOAbbreviation>JAMA</ISOAbbreviation></Journal><ArticleTitle>Effect of Fresh vs Standard-issue Red Blood Cell Transfusions on Multiple Organ Dysfunction Syndrome in Critically Ill Pediatric Patients: A Randomized Clinical Trial.</ArticleTitle><Pagination><StartPage>2179</StartPage><EndPage>2190</EndPage><MedlinePgn>2179-2190</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jama.2019.17478</ELocationID><Abstract><AbstractText Label="IMPORTANCE">The clinical consequences of red blood cell storage age for critically ill pediatric patients have not been examined in a large, randomized clinical trial.</AbstractText><AbstractText Label="OBJECTIVE">To determine if the transfusion of fresh red blood cells (stored &#x2264;7 days) reduced new or progressive multiple organ dysfunction syndrome compared with the use of standard-issue red blood cells in critically ill children.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">The Age of Transfused Blood in Critically-Ill Children trial was an international, multicenter, blinded, randomized clinical trial, performed between February 2014 and November 2018 in 50 tertiary care centers. Pediatric patients between the ages of 3 days and 16 years were eligible if the first red blood cell transfusion was administered within 7 days of intensive care unit admission. A total of 15&#x202f;568 patients were screened, and 13&#x202f;308 were excluded.</AbstractText><AbstractText Label="INTERVENTIONS">Patients were randomized to receive either fresh or standard-issue red blood cells. A total of 1538 patients were randomized with 768 patients in the fresh red blood cell group and 770 in the standard-issue group.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">The primary outcome measure was new or progressive multiple organ dysfunction syndrome, measured for 28 days or to discharge or death.</AbstractText><AbstractText Label="RESULTS">Among 1538 patients who were randomized, 1461 patients (95%) were included in the primary analysis (median age, 1.8 years; 47.3% girls), in which there were 728 patients randomized to the fresh red blood cell group and 733 to the standard-issue group. The median storage duration was 5 days (interquartile range [IQR], 4-6 days) in the fresh group vs 18 days (IQR, 12-25 days) in the standard-issue group (P&#x2009;&lt;&#x2009;.001). There were no significant differences in new or progressive multiple organ dysfunction syndrome between fresh (147 of 728 [20.2%]) and standard-issue red blood cell groups (133 of 732 [18.2%]), with an unadjusted absolute risk difference of 2.0% (95% CI, -2.0% to 6.1%; P&#x2009;=&#x2009;.33). The prevalence of sepsis was 25.8% (160 of 619) in the fresh group and 25.3% (154 of 608) in the standard-issue group. The prevalence of acute respiratory distress syndrome was 6.6% (41 of 619) in the fresh group and 4.8% (29 of 608) in the standard-issue group. Intensive care unit mortality was 4.5% (33 of 728) in the fresh group vs 3.5 % (26 of 732) in the standard-issue group (P&#x2009;=&#x2009;.34).</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">Among critically ill pediatric patients, the use of fresh red blood cells did not reduce the incidence of new or progressive multiple organ dysfunction syndrome (including mortality) compared with standard-issue red blood cells.</AbstractText><AbstractText Label="TRIAL REGISTRATION">ClinicalTrials.gov Identifier: NCT01977547.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Spinella</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Universit&#xe9; de Montr&#xe9;al and Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Ottawa Hospital Research Institute, Departments of Medicine &amp; Surgery, University of Ottawa School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care, Centre Hospitalier Universitaire (CHU) Sainte-Justine, Universit&#xe9; de Montr&#xe9;al and Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul C</ForeName><Initials>PC</Initials><AffiliationInfo><Affiliation>D&#xe9;partement de m&#xe9;decine, Centre de recherche du CHUM and Chaire de m&#xe9;decine transfusionnelle H&#xe9;ma-Qu&#xe9;bec-Bayer de l'Universit&#xe9; de Montr&#xe9;al, Centre hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Universit&#xe9; de Lille, EA 2694-Sant&#xe9; publique: &#xe9;pid&#xe9;miologie et qualit&#xe9; des soins, CHU Lille, R&#xe9;animation P&#xe9;diatrique, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Kenneth B</ForeName><Initials>KB</Initials><AffiliationInfo><Affiliation>Division of Biostatistics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Berg</LastName><ForeName>Robert A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>The Children's Hospital of Philadelphia, Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bockelmann</LastName><ForeName>Tina</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caro</LastName><ForeName>J Jaime</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>London School of Economics, London, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Evidera, Boston, Massachusetts.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Anesthesia and Critical Care, Bambino Ges&#xf9; Children's Hospital, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Clayton</LastName><ForeName>Lucy</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical, Department of Pediatrics, Centre Hospitalier Universitaire (CHU) Sainte-Justine Universit&#xe9; de Montr&#xe9;al and Centre de Recherche du Centre Hospitalier de l'Universit&#xe9; de Montr&#xe9;al, Montreal, Quebec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Division of Critical Care and Cardiology, Department of Pediatrics, University of Rochester Golisano Children's Hospital, Rochester, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guerra</LastName><ForeName>Gonzalo Garcia</ForeName><Initials>GG</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, University of Alberta, Edmonton, Canada.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Stollery Children's Hospital, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra D</ForeName><Initials>CD</Initials><AffiliationInfo><Affiliation>Departments of Pathology and Pediatrics, Emory University School of Medicine, Atlanta, Georgia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Transfusion, Tissue, Apheresis Services, Children's Healthcare of Atlanta, Atlanta, Georgia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Children's Hospital of Eastern Ontario, University of Ottawa, Ottawa, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muszynski</LastName><ForeName>Jennifer A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Division of Critical Care Medicine, Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nellis</LastName><ForeName>Marianne E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Pediatric Critical Care, Department of Pediatrics, Weill Cornell Medicine, New York, New York.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarpal</LastName><ForeName>Amrita</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Western University, Children's Hospital, London Health Sciences Centre, London, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Schafer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Critical Care, Department of Pediatrics, Washington University School of Medicine in St Louis, St Louis, Missouri.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Division of Pediatric Hematology and Oncology, Division of Pediatric Critical Care Medicine, Department of Pediatrics, University of Minnesota Medical School, Minneapolis.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Alexis F</ForeName><Initials>AF</Initials><AffiliationInfo><Affiliation>Research CHU de Qu&#xe9;bec-Universit&#xe9; Laval Centre, Population Health and Optimal Health Practices and Research Unit, Trauma, Emergency, Critical Care Medicine, Universit&#xe9; Laval and Department of Anesthesiology and Critical Care Medicine, Division of Critical Care Medicine, Faculty of Medicine, Universit&#xe9; Laval, Qu&#xe9;bec City, Qu&#xe9;bec, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>ABC-PICU Investigators, the Canadian Critical Care Trials Group, the Pediatric Acute Lung Injury and Sepsis Investigators Network, the BloodNet Pediatric Critical Care Blood Research Network, and the Groupe Francophone de R&#xe9;animation et Urgences P</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01977547</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K08 GM129763</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL116383</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA</MedlineTA><NlmUniqueID>7501160</NlmUniqueID><ISSNLinking>0098-7484</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA. 2019 Dec 10;322(22):2175-2176. doi: 10.1001/jama.2019.17476.</RefSource><PMID Version="1">31821418</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="Y">Blood Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016638" MajorTopicYN="N">Critical Illness</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D062072" MajorTopicYN="N">Patient Acuity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012127" MajorTopicYN="N">Respiratory Distress Syndrome, Newborn</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Spinella reported that he served as a consultant for Hemanext, that his institution received funding for the ABC PICU trial, has equity in KaloCyte, and received grants from KaloCyte, the National Heart, Lung, and Blood Institute (NHLBI), and the US Department of Defense (DOD). Dr Tucci reported that her institution received funding for the ABC-PICU trial. Dr Fergusson reported that his institution received funding data management and analysis for the ABC-PICU trial. Dr Lacroix reported that his institution received funding for the ABC-PICU trial. Dr Leteurtre reported that he received grants from Health French Ministry and GFRUP. Dr Schechtman reported that his institution received funding for the ABC-PICU trial. Dr Doctor reported that his institution received funding for the ABC-PICU trial; that he has equity in KaloCyte; received grants from KaloCyte, the National Institutes of Health (NIH), the NHLBI, the DOD, Entegrion; and that he received personal fees from Fresenius Kabi and Biogen. Dr Berg reported that she received grants from NIH. Ms Bockelmann reported that her institution received funding for the ABC-PICU trial. Dr Caro reported that he received support from Evidera and grants from EURO 2020. Ms Clayton reported that her institution received funding for the ABC-PICU trial. Dr Josephson reported that she has consulted for Octapharma and Immucor, received nonfinancial support from Sysmex, and received grants from Medtronics. Dr Muszynski reported that she received grants from the NIH. Ms Schafer reported that her institution received funding for the ABC-PICU trial. Dr Steiner reported that she received grants from NIH. No other disclosures were reported.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Spinella</LastName><ForeName>Philip</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bockelmann</LastName><ForeName>Tina</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berg</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Caro</LastName><ForeName>Jaime</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Turgeon</LastName><ForeName>Alexis</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hume</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Karam</LastName><ForeName>Oliver</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Javouhey</LastName><ForeName>&#xc9;tienne</ForeName><Initials>&#xc9;</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dean</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giroir</LastName><ForeName>Brett</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Klein</LastName><ForeName>Harvey</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Carson</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bellamy</LastName><ForeName>Abbie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brooks</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hoehn</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poitras</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Terrill</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jacobs</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramsay</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vo</LastName><ForeName>Dong</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>McGuire</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sabri</LastName><ForeName>Elham</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baty</LastName><ForeName>Jack</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gu</LastName><ForeName>Hongjie</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>H&#xe9;bert</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fergusson</LastName><ForeName>Dean</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Clayton</LastName><ForeName>Lucy</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>&#xc9;meriaud</LastName><ForeName>Guillaume</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Robitaille</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Blanchette</LastName><ForeName>Joannie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Haj-Moustafa</LastName><ForeName>Adnan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vincent</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lagu&#xeb;</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dumitrascu</LastName><ForeName>Mariana</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>French</LastName><ForeName>Mary-Ellen</ForeName><Initials>ME</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nait-Ladjemil</LastName><ForeName>Djouher</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ghamraoui</LastName><ForeName>Ali</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Grisoni</LastName><ForeName>Isabelle</ForeName><Initials>I</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bensaadi</LastName><ForeName>Kahina</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Girouard</LastName><ForeName>Anne-Marie</ForeName><Initials>AM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Garcia Guerra</LastName><ForeName>Gonzalo</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nahirniak</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>deMoissac</LastName><ForeName>Jodie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doepker</LastName><ForeName>Rosalyn</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Foster</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sarpal</LastName><ForeName>Amrita</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gunz</LastName><ForeName>Anna</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cameron</LastName><ForeName>Saoirse</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hsia</LastName><ForeName>Cyrus</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kinney</LastName><ForeName>Jeff</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hutchison</LastName><ForeName>Jamie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lau</LastName><ForeName>Wendy</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ferri</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Salehmohamed</LastName><ForeName>Hussein</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lazarro</LastName><ForeName>Sonny</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Menon</LastName><ForeName>Kusum</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leung</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>O&#x2019;Hearn</LastName><ForeName>Katie</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Labelle</LastName><ForeName>Roxane</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dugas</LastName><ForeName>Marc-Andr&#xe9;</ForeName><Initials>MA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ouellet</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gosselin</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belleau</LastName><ForeName>Annie</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gilfoyle</LastName><ForeName>Elaine</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shabani-Rad</LastName><ForeName>Meer-Taher</ForeName><Initials>MT</Initials></Investigator><Investigator ValidYN="Y"><LastName>Martin</LastName><ForeName>Dori-Ann</ForeName><Initials>DA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Dallas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nishi</LastName><ForeName>Sharon</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fontela</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whittemore</LastName><ForeName>Blair</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>O&#x2019;Donnell</LastName><ForeName>Shauna</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lamica</LastName><ForeName>Gail</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Choong</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chan</LastName><ForeName>Anthony</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hamilton</LastName><ForeName>Korinne</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wensley</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Au</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krahnm</LastName><ForeName>Gordon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Doctor</LastName><ForeName>Allan</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schechtman</LastName><ForeName>Ken</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schafer</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Remy</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steibel</LastName><ForeName>Jason</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cholette</LastName><ForeName>Jill</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Root Tallie</LastName><ForeName>Eileen</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henrichs</LastName><ForeName>Kelly</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fitzgerald</LastName><ForeName>Julie</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sesok-Pizzini</LastName><ForeName>Deborah</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leonard</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Muszynkski</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nicol</LastName><ForeName>Kathleen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hensley</LastName><ForeName>Josey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Marsillio</LastName><ForeName>Lauren</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shukla</LastName><ForeName>Avani</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McQuillen</LastName><ForeName>Patrick</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sapru</LastName><ForeName>Anil</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>McKenzie</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Schwarz</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vargas-Shiraishi</LastName><ForeName>Ofelia</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Flores</LastName><ForeName>Cathy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nellis</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Small</LastName><ForeName>Keshia</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cushing</LastName><ForeName>Melissa</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Avery</LastName><ForeName>Leslie</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kerrigan</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pelletier</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stidham</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mourani</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Deschenes</LastName><ForeName>Jendar</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wilkes</LastName><ForeName>Meredith</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hanson</LastName><ForeName>Sheila</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Woods</LastName><ForeName>Katherine</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Punzalan</LastName><ForeName>Rowena</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Typpo</LastName><ForeName>Katri</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kelley</LastName><ForeName>Connor</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Proytcheva</LastName><ForeName>Maria</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hobson</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hudgins</LastName><ForeName>Andrea</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vaught</LastName><ForeName>Heather</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Winkler</LastName><ForeName>Margaret</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kong</LastName><ForeName>Michele</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sewell</LastName><ForeName>Kate</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Markovitz</LastName><ForeName>Barry</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lomeli</LastName><ForeName>Mayra</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Perumbeti</LastName><ForeName>Ajay</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Loftis</LastName><ForeName>Laura</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jaimon</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bruzdoski</LastName><ForeName>Karen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kuo</LastName><ForeName>Kevin</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Kristen</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jayachandran</LastName><ForeName>Chaandini</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Willson</LastName><ForeName>Douglas</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Henderson</LastName><ForeName>Grace</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sanford</LastName><ForeName>Kim</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nerheim</LastName><ForeName>Dan</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dodge Zantek</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Statlets</LastName><ForeName>Erika</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Krallman</LastName><ForeName>Kelli</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Stoneman</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paden</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Skvarich</LastName><ForeName>Jane</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zimmerman</LastName><ForeName>Jerry</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Delaney</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Erin</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Luckett</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Noland</LastName><ForeName>Daniel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hupp</LastName><ForeName>Susan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ozment</LastName><ForeName>Caroline</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bandarenko</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>DeRidder</LastName><ForeName>Gustaaf</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Adu-Darko</LastName><ForeName>Michelle</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Fang</LastName><ForeName>Gary</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gorham</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Quaid</LastName><ForeName>Maureen</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Donovan</LastName><ForeName>Ramona</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Roggeman</LastName><ForeName>Nicole</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Saini</LastName><ForeName>Arun</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>West</LastName><ForeName>Nico</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ryder</LastName><ForeName>Alex</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharron</LastName><ForeName>Matt</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Colvin</LastName><ForeName>Camilla</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bysani</LastName><ForeName>Kris</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Monjure</LastName><ForeName>Tracey</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Resch</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Tiberghien</LastName><ForeName>Pierre</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Van Den Berghe</LastName><ForeName>Williams</ForeName><Initials>W</Initials></Investigator><Investigator ValidYN="Y"><LastName>Frade-Proud&#x2019;Hon-Clerc</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dedurwaerder-Tollot</LastName><ForeName>Sarah</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Baudelet</LastName><ForeName>Jean-Beno&#xee;t</ForeName><Initials>JB</Initials></Investigator><Investigator ValidYN="Y"><LastName>Leteurtre</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sadik</LastName><ForeName>Ahmed</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Resch</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dauger</LastName><ForeName>St&#xe9;phane</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Le Bourgeois</LastName><ForeName>Fleur</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Smaine</LastName><ForeName>Djamel</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orliaguet</LastName><ForeName>Gilles</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albinni</LastName><ForeName>Souha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Joram</LastName><ForeName>Nicolas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Boureille</LastName><ForeName>G&#xe9;raldine</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Gaillot</LastName><ForeName>Th&#xe9;ophile</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Herv&#xe9;</LastName><ForeName>Fran&#xe7;oise</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brissaud</LastName><ForeName>Olivier</ForeName><Initials>O</Initials></Investigator><Investigator ValidYN="Y"><LastName>Beguet</LastName><ForeName>Mathilde</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Dupic</LastName><ForeName>Laurent</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Albinni</LastName><ForeName>Souha</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>L&#xe9;ger</LastName><ForeName>Pierre-Louis</ForeName><Initials>PL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mallet</LastName><ForeName>Agn&#xe8;s</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chiusolo</LastName><ForeName>Fabrizio</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cillis</LastName><ForeName>Annagrazia</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Montanari</LastName><ForeName>Mauro</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Picardo</LastName><ForeName>Sergio</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bianchi</LastName><ForeName>Roberto</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Giugni</LastName><ForeName>Cristina</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cecchi</LastName><ForeName>Costanza</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Allegro</LastName><ForeName>Elisa</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bambi</LastName><ForeName>Franco</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Nellis</LastName><ForeName>Marianne</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Levy</LastName><ForeName>Tselia</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Paret</LastName><ForeName>Gideon</ForeName><Initials>G</Initials></Investigator><Investigator ValidYN="Y"><LastName>Vardi</LastName><ForeName>Amir</ForeName><Initials>A</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>12</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2019</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>6</Month><Day>10</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31821429</ArticleId><ArticleId IdType="pmc">PMC7081749</ArticleId><ArticleId IdType="doi">10.1001/jama.2019.17478</ArticleId><ArticleId IdType="pii">2757226</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Demaret P, Tucci M, Ducruet T, Trottier H, Lacroix J. Red blood cell transfusion in critically ill children (CME). Transfusion. 2014;54(2):365-375.</Citation><ArticleIdList><ArticleId IdType="pubmed">24517132</ArticleId></ArticleIdList></Reference><Reference><Citation>Rajasekaran S, Kort E, Hackbarth R, et al. . Red cell transfusions as an independent risk for mortality in critically ill children. J Intensive Care. 2016;4:2. doi:10.1186/s40560-015-0122-3</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s40560-015-0122-3</ArticleId><ArticleId IdType="pmc">PMC4704419</ArticleId><ArticleId IdType="pubmed">26744626</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Doctor A. Role of transfused red blood cells for shock and coagulopathy within remote damage control resuscitation. Shock. 2014;41(suppl 1):30-34. doi:10.1097/SHK.0000000000000089</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000089</ArticleId><ArticleId IdType="pubmed">24296434</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Carroll CL, Staff I, et al. . Duration of red blood cell storage is associated with increased incidence of deep vein thrombosis and in hospital mortality in patients with traumatic injuries. Crit Care. 2009;13(5):R151. doi:10.1186/cc8050</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8050</ArticleId><ArticleId IdType="pmc">PMC2784373</ArticleId><ArticleId IdType="pubmed">19772604</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones AR, Patel RP, Marques MB, et al. ; PROPPR Study Group . Older blood is associated with increased mortality and adverse events in massively transfused trauma patients: secondary analysis of the PROPPR Trial. Ann Emerg Med. 2019;73(6):650-661. doi:10.1016/j.annemergmed.2018.09.033</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.annemergmed.2018.09.033</ArticleId><ArticleId IdType="pmc">PMC6517091</ArticleId><ArticleId IdType="pubmed">30447946</ArticleId></ArticleIdList></Reference><Reference><Citation>Mack J, Kahn SR, Tinmouth A, Fergusson D, Hebert P, Lacroix J Dose-dependent effect of stored red blood: results of a sub-group analysis of the Age of Blood Evaluation (ABLE) Trial. Presented at: The 58th Annual American Society of Hematology Annual Meeting and Exposition; December 3-6, 2016; San Diego, CA.</Citation></Reference><Reference><Citation>Weinberg JA, McGwin G Jr, Vandromme MJ, et al. . Duration of red cell storage influences mortality after trauma. J Trauma. 2010;69(6):1427-1431. doi:10.1097/TA.0b013e3181fa0019</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181fa0019</ArticleId><ArticleId IdType="pmc">PMC3136808</ArticleId><ArticleId IdType="pubmed">21150522</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson DA, H&#xe9;bert P, Hogan DL, et al. . Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308(14):1443-1451. doi:10.1001/2012.jama.11953</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/2012.jama.11953</ArticleId><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Dhabangi A, Ainomugisha B, Cserti-Gazdewich C, et al. . Effect of transfusion of red blood cells with longer vs shorter storage duration on elevated blood lactate levels in children with severe anemia: the TOTAL randomized clinical trial. JAMA. 2015;314(23):2514-2523. doi:10.1001/jama.2015.13977</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2015.13977</ArticleId><ArticleId IdType="pubmed">26637812</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert PC, Fergusson DA, et al. ; ABLE Investigators; Canadian Critical Care Trials Group . Age of transfused blood in critically ill adults. N Engl J Med. 2015;372(15):1410-1418. doi:10.1056/NEJMoa1500704</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1500704</ArticleId><ArticleId IdType="pubmed">25853745</ArticleId></ArticleIdList></Reference><Reference><Citation>Heddle NM, Cook RJ, Arnold DM, et al. . Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016;375(20):1937-1945. doi:10.1056/NEJMoa1609014</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1609014</ArticleId><ArticleId IdType="pubmed">27775503</ArticleId></ArticleIdList></Reference><Reference><Citation>Cooper DJ, McQuilten ZK, Nichol A, et al. ; TRANSFUSE Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group . Age of red cells for transfusion and outcomes in critically ill adults. N Engl J Med. 2017;377(19):1858-1867. doi:10.1056/NEJMoa1707572</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1707572</ArticleId><ArticleId IdType="pubmed">28952891</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner ME, Ness PM, Assmann SF, et al. . Effects of red-cell storage duration on patients undergoing cardiac surgery. N Engl J Med. 2015;372(15):1419-1429. doi:10.1056/NEJMoa1414219</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="pubmed">25853746</ArticleId></ArticleIdList></Reference><Reference><Citation>Spinella PC, Dressler A, Tucci M, et al. ; Pediatric Acute Lung Injury and Sepsis Investigators Network . Survey of transfusion policies at US and Canadian children&#x2019;s hospitals in 2008 and 2009. Transfusion. 2010;50(11):2328-2335. doi:10.1111/j.1537-2995.2010.02708.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02708.x</ArticleId><ArticleId IdType="pubmed">20529008</ArticleId></ArticleIdList></Reference><Reference><Citation>Tucci M, Lacroix J, Fergusson D, et al. ; Canadian Critical Care Trials Group; Pediatric Critical Care Blood Research Network (BloodNet); Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network . The age of blood in pediatric intensive care units (ABC PICU): study protocol for a randomized controlled trial. Trials. 2018;19(1):404. doi:10.1186/s13063-018-2809-y</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13063-018-2809-y</ArticleId><ArticleId IdType="pmc">PMC6064163</ArticleId><ArticleId IdType="pubmed">30055634</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, Lacroix J, Gauthier M. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109(4):1033-1037. doi:10.1378/chest.109.4.1033</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.109.4.1033</ArticleId><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison AL, Gillis J, O&#x2019;Connell AJ, Schell DN, Dossetor DR, Mellis C. Quality of life of survivors of pediatric intensive care. Pediatr Crit Care Med. 2002;3(1):1-5. doi:10.1097/00130478-200201000-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00130478-200201000-00001</ArticleId><ArticleId IdType="pubmed">12793913</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Duhamel A, Salleron J, Grandbastien B, Lacroix J, Leclerc F; Groupe Francophone de R&#xe9;animation et d&#x2019;Urgences P&#xe9;diatriques (GFRUP) . PELOD-2: an update of the PEdiatric logistic organ dysfunction score. Crit Care Med. 2013;41(7):1761-1773. doi:10.1097/CCM.0b013e31828a2bbd</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e31828a2bbd</ArticleId><ArticleId IdType="pubmed">23685639</ArticleId></ArticleIdList></Reference><Reference><Citation>Karam O, Tucci M, Bateman ST, et al. . Association between length of storage of red blood cell units and outcome of critically ill children: a prospective observational study. Crit Care. 2010;14(2):R57. doi:10.1186/cc8953</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8953</ArticleId><ArticleId IdType="pmc">PMC2887178</ArticleId><ArticleId IdType="pubmed">20377853</ArticleId></ArticleIdList></Reference><Reference><Citation>Gauvin F, Spinella PC, Lacroix J, et al. ; Canadian Critical Care Trials Group and the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI) Network . Association between length of storage of transfused red blood cells and multiple organ dysfunction syndrome in pediatric intensive care patients. Transfusion. 2010;50(9):1902-1913. doi:10.1111/j.1537-2995.2010.02661.x</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1537-2995.2010.02661.x</ArticleId><ArticleId IdType="pubmed">20456697</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert PC, Hutchison JS, et al. ; TRIPICU Investigators; Canadian Critical Care Trials Group; Pediatric Acute Lung Injury and Sepsis Investigators Network . Transfusion strategies for patients in pediatric intensive care units. N Engl J Med. 2007;356(16):1609-1619. doi:10.1056/NEJMoa066240</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa066240</ArticleId><ArticleId IdType="pubmed">17442904</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttimann UE. PRISM III: an updated pediatric risk of mortality score. Crit Care Med. 1996;24(5):743-752. doi:10.1097/00003246-199605000-00004</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199605000-00004</ArticleId><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein B, Giroir B, Randolph A; International Consensus Conference on Pediatric Sepsis . International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8. doi:10.1097/01.PCC.0000149131.72248.E6</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.PCC.0000149131.72248.E6</ArticleId><ArticleId IdType="pubmed">15636651</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR, Artigas A, Brigham KL, et al. . The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med. 1994;149(3 Pt 1):818-824. doi:10.1164/ajrccm.149.3.7509706</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm.149.3.7509706</ArticleId><ArticleId IdType="pubmed">7509706</ArticleId></ArticleIdList></Reference><Reference><Citation>Thomas NJ, Shaffer ML, Willson DF, Shih MC, Curley MA. Defining acute lung disease in children with the oxygenation saturation index. Pediatr Crit Care Med. 2010;11(1):12-17. doi:10.1097/PCC.0b013e3181b0653d</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/PCC.0b013e3181b0653d</ArticleId><ArticleId IdType="pmc">PMC2936504</ArticleId><ArticleId IdType="pubmed">19561556</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, Gauvin F, Skippen P, Cox P, Langley JM, Matlow A. Nosocomial infections in the PICU: Epidemiology and control In: Fuhrman BP, Zimmerman JJ, eds. Pediatric Critical Care. 2nd ed St Louis, MO: Mosby Year Book; 2006:1394-1421. doi:10.1016/B978-032301808-1.50093-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/B978-032301808-1.50093-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Center for Disease Control CDC definitions for nosocomial infections, 1988. Am Rev Respir Dis. 1989;139(4):1058-1059. doi:10.1164/ajrccm/139.4.1058</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/ajrccm/139.4.1058</ArticleId><ArticleId IdType="pubmed">2539031</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandra T, Cohen J; International Sepsis Forum Definition of Infection in the ICU Consensus Conference . The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33(7):1538-1548. doi:10.1097/01.CCM.0000168253.91200.83</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000168253.91200.83</ArticleId><ArticleId IdType="pubmed">16003060</ArticleId></ArticleIdList></Reference><Reference><Citation>Zubair AC. Clinical impact of blood storage lesions. Am J Hematol. 2010;85(2):117-122.</Citation><ArticleIdList><ArticleId IdType="pubmed">20052749</ArticleId></ArticleIdList></Reference><Reference><Citation>Bakkour S, Acker JP, Chafets DM, et al. . Manufacturing method affects mitochondrial DNA release and extracellular vesicle composition in stored red blood cells. Vox Sang. 2016;111(1):22-32. doi:10.1111/vox.12390</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12390</ArticleId><ArticleId IdType="pubmed">26918437</ArticleId></ArticleIdList></Reference><Reference><Citation>Chai-Adisaksopha C, Alexander PE, Guyatt G, et al. . Mortality outcomes in patients transfused with fresher versus older red blood cells: a meta-analysis. Vox Sang. 2017;112(3):268-278. doi:10.1111/vox.12495</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/vox.12495</ArticleId><ArticleId IdType="pubmed">28220494</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Alessandro A, Zimring JC, Busch M. Chronological storage age and metabolic age of stored red blood cells: are they the same? Transfusion. 2019;59(5):1620-1623. doi:10.1111/trf.15248</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/trf.15248</ArticleId><ArticleId IdType="pubmed">30865302</ArticleId></ArticleIdList></Reference><Reference><Citation>McQuilten ZK, French CJ, Nichol A, Higgins A, Cooper DJ. Effect of age of red cells for transfusion on patient outcomes: a systematic review and meta-analysis. Transfus Med Rev. 2018;32(2):77-88. doi:10.1016/j.tmrv.2018.02.002</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tmrv.2018.02.002</ArticleId><ArticleId IdType="pubmed">29526337</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28719602</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>17</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">1549-1676</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>7</Issue><PubDate><Year>2017</Year><Month>Jul</Month></PubDate></JournalIssue><Title>PLoS medicine</Title><ISOAbbreviation>PLoS Med</ISOAbbreviation></Journal><ArticleTitle>Prehospital immune responses and development of multiple organ dysfunction syndrome following traumatic injury: A prospective cohort study.</ArticleTitle><Pagination><StartPage>e1002338</StartPage><MedlinePgn>e1002338</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e1002338</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1371/journal.pmed.1002338</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Almost all studies that have investigated the immune response to trauma have analysed blood samples acquired post-hospital admission. Thus, we know little of the immune status of patients in the immediate postinjury phase and how this might influence patient outcomes. The objective of this study was therefore to comprehensively assess the ultra-early, within 1-hour, immune response to trauma and perform an exploratory analysis of its relationship with the development of multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS AND FINDINGS" NlmCategory="RESULTS">The immune and inflammatory response to trauma was analysed in 89 adult trauma patients (mean age 41 years, range 18-90 years, 75 males) with a mean injury severity score (ISS) of 24 (range 9-66), from whom blood samples were acquired within 1 hour of injury (mean time to sample 42 minutes, range 17-60 minutes). Within minutes of trauma, a comprehensive leukocytosis, elevated serum pro- and anti-inflammatory cytokines, and evidence of innate cell activation that included neutrophil extracellular trap generation and elevated surface expression of toll-like receptor 2 and CD11b on monocytes and neutrophils, respectively, were observed. Features consistent with immune compromise were also detected, notably elevated numbers of immune suppressive CD16BRIGHT CD62LDIM neutrophils (82.07 x 106/l &#xb1; 18.94 control versus 1,092 x 106/l &#xb1; 165 trauma, p &lt; 0.0005) and CD14+HLA-DRlow/- monocytes (34.96 x 106/l &#xb1; 4.48 control versus 95.72 x 106/l &#xb1; 8.0 trauma, p &lt; 0.05) and reduced leukocyte cytokine secretion in response to lipopolysaccharide stimulation. Exploratory analysis via binary logistic regression found a potential association between absolute natural killer T (NKT) cell numbers and the subsequent development of MODS. Study limitations include the relatively small sample size and the absence of data relating to adaptive immune cell function.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our study highlighted the dynamic and complex nature of the immune response to trauma, with immune alterations consistent with both activation and suppression evident within 1 hour of injury. The relationship of these changes, especially in NKT cell numbers, to patient outcomes such as MODS warrants further investigation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hazeldine</LastName><ForeName>Jon</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4280-4889</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Naumann</LastName><ForeName>David N</ForeName><Initials>DN</Initials><Identifier Source="ORCID">0000-0003-2243-2325</Identifier><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toman</LastName><ForeName>Emma</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Davies</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bishop</LastName><ForeName>Jonathan R B</ForeName><Initials>JRB</Initials><Identifier Source="ORCID">0000-0003-1789-5886</Identifier><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Su</LastName><ForeName>Zhangjie</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hampson</LastName><ForeName>Peter</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dinsdale</LastName><ForeName>Robert J</ForeName><Initials>RJ</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crombie</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Midlands Air Ambulance, Unit 16 Enterprise Trading Estate, Brierley Hill, West Midlands, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Duggal</LastName><ForeName>Niharika Arora</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Harrison</LastName><ForeName>Paul</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-4610-8909</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Scar Free Foundation, Birmingham Centre for Burns Research, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belli</LastName><ForeName>Antonio</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-3211-9933</Identifier><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lord</LastName><ForeName>Janet M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdom.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2017</Year><Month>07</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>PLoS Med</MedlineTA><NlmUniqueID>101231360</NlmUniqueID><ISSNLinking>1549-1277</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D056704" MajorTopicYN="Y">Adaptive Immunity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004739" MajorTopicYN="N">England</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007964" MajorTopicYN="N">Leukocytosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors have declared that no competing interests exist.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2017</Year><Month>5</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2017</Year><Month>7</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>7</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28719602</ArticleId><ArticleId IdType="pmc">PMC5515405</ArticleId><ArticleId IdType="doi">10.1371/journal.pmed.1002338</ArticleId><ArticleId IdType="pii">PMEDICINE-D-17-00334</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Giannoudis PV. Current concepts of the inflammatory response after major trauma: an update. Injury. 2003; 34:397&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pubmed">12767787</ArticleId></ArticleIdList></Reference><Reference><Citation>Hazeldine J, Hampson P, Lord JM. The diagnostic and prognostic value of systems biology research in major traumatic and thermal injury: a review. Burns and Trauma. 2016. 
doi: 10.1186/s41038-016-0059-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s41038-016-0059-3</ArticleId><ArticleId IdType="pmc">PMC5030723</ArticleId><ArticleId IdType="pubmed">27672669</ArticleId></ArticleIdList></Reference><Reference><Citation>Hampson P, Dinsdale RJ, Wearn CM, Bamford AL, Bishop JR, Hazeldine J, et al.
Neutrophil Dysfunction, Immature Granulocytes, and Cell-free DNA are Early Biomarkers of Sepsis in Burn-injured Patients: A Prospective Observational Cohort Study. Ann.Surg. 2016. 
doi: 10.1097/SLA.0000000000001807
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001807</ArticleId><ArticleId IdType="pubmed">27232244</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. PLoS ONE. 2013. 
8: e68963
doi: 10.1371/journal.pone.0068963
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0068963</ArticleId><ArticleId IdType="pmc">PMC3722225</ArticleId><ArticleId IdType="pubmed">23894384</ArticleId></ArticleIdList></Reference><Reference><Citation>Li H, Itagaki K, Sandler N, Gallo D, Galenkamp A, Kaczmarek E, et al.
Mitochondrial damage-associated molecular patterns from fractures suppress pulmonary immune responses via formyl peptide receptors 1 and 2. J.Trauma Acute.Care Surg. 2015;78: 272&#x2013;279. doi: 10.1097/TA.0000000000000509
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000509</ArticleId><ArticleId IdType="pmc">PMC4357317</ArticleId><ArticleId IdType="pubmed">25757111</ArticleId></ArticleIdList></Reference><Reference><Citation>Marks W, Dropiewska G, Bryl E, Dudek R, Wieruszewski J, Stasiak M, et al. Immunomonitoring in patients with early moderate and severe head trauma. Cent. Eur. J. Public Health. 2013;38: 494&#x2013;499.</Citation></Reference><Reference><Citation>Perez-Barcena J, Regueiro V, Crespi C, Pierola J, Oliver A, Llompart-Pou JA, et al.
Expression of toll-like receptors 2 and 4 is upregulated during hospital admission in traumatic patients: lack of correlation with blunted innate immune responses. Ann.Surg. 2010;251: 521&#x2013;527. doi: 10.1097/SLA.0b013e3181cc8f84
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e3181cc8f84</ArticleId><ArticleId IdType="pubmed">20134316</ArticleId></ArticleIdList></Reference><Reference><Citation>Laudanski K, Miller-Graziano C, Xiao W, Mindrinos MN, Richards DR, De A, et al.
Cell-specific expression and pathway analyses reveal alterations in trauma-related human T cell and monocyte pathways. Proc.Natl.Acad.Sci.U.S.A
2006;103: 15564&#x2013;15569. doi: 10.1073/pnas.0607028103
</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0607028103</ArticleId><ArticleId IdType="pmc">PMC1592643</ArticleId><ArticleId IdType="pubmed">17032758</ArticleId></ArticleIdList></Reference><Reference><Citation>Manson J, Cole E, De'Ath HD, Vulliamy P, Meier U, Pennington D, et al.
Early changes within the lymphocyte population are associated with the development of multiple organ dysfunction syndrome in trauma patients. Crit Care
2016;20: 176
doi: 10.1186/s13054-016-1341-2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-016-1341-2</ArticleId><ArticleId IdType="pmc">PMC4895987</ArticleId><ArticleId IdType="pubmed">27268230</ArticleId></ArticleIdList></Reference><Reference><Citation>Timmermans K, Kox M, Vaneker M, van den Berg M, John A, van LA, et al.
Plasma levels of danger-associated molecular patterns are associated with immune suppression in trauma patients. Intensive Care Med. 2016;42: 551&#x2013;561. doi: 10.1007/s00134-015-4205-3
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-015-4205-3</ArticleId><ArticleId IdType="pmc">PMC5413532</ArticleId><ArticleId IdType="pubmed">26912315</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch.Surg. 2000;135: 291&#x2013;295.</Citation><ArticleIdList><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Arand M, Melzner H, Kinzl L, Bruckner UB, Gebhard F. Early inflammatory mediator response following isolated traumatic brain injury and other major trauma in humans. Langenbecks Arch.Surg. 2001;386: 241&#x2013;248.</Citation><ArticleIdList><ArticleId IdType="pubmed">11466564</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F, Koenderman L, Althuizen M, Pillay J, Kamp V, Leenen LP. Kinetics of the innate immune response after trauma: implications for the development of late onset sepsis. Shock
2013;40: 21&#x2013;27. doi: 10.1097/SHK.0b013e318295a40a
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e318295a40a</ArticleId><ArticleId IdType="pubmed">23603769</ArticleId></ArticleIdList></Reference><Reference><Citation>Visser T, Hietbrink F, Groeneveld KM, Koenderman L, Leenen LP. Isolated blunt chest injury leads to transient activation of circulating neutrophils. Eur.J.Trauma Emerg.Surg. 2011;37: 177&#x2013;184. doi: 10.1007/s00068-010-0041-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-010-0041-x</ArticleId><ArticleId IdType="pmc">PMC3150797</ArticleId><ArticleId IdType="pubmed">21837259</ArticleId></ArticleIdList></Reference><Reference><Citation>West SD, Goldberg D, Ziegler A, Krencicki M, Du Clos TW, Mold C. Transforming growth factor-beta, macrophage colony-stimulating factor and C-reactive protein levels correlate with CD14(high)CD16+ monocyte induction and activation in trauma patients. PLoS ONE. 2012;7: e52406
doi: 10.1371/journal.pone.0052406
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0052406</ArticleId><ArticleId IdType="pmc">PMC3532215</ArticleId><ArticleId IdType="pubmed">23285029</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolach B, Sazbon L, Gavrieli R, Broda A, Schlesinger M. Early immunological defects in comatose patients after acute brain injury. J.Neurosurg. 2001;94: 706&#x2013;711. doi: 10.3171/jns.2001.94.5.0706
</Citation><ArticleIdList><ArticleId IdType="doi">10.3171/jns.2001.94.5.0706</ArticleId><ArticleId IdType="pubmed">11354400</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasten KR, Goetzman HS, Reid MR, Rasper AM, Adediran SG, Robinson CT, et al.
Divergent adaptive and innate immunological responses are observed in humans following blunt trauma. BMC.Immunol. 2010;11: 4
doi: 10.1186/1471-2172-11-4
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2172-11-4</ArticleId><ArticleId IdType="pmc">PMC2823662</ArticleId><ArticleId IdType="pubmed">20100328</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao W, Mindrinos MN, Seok J, Cuschieri J, Cuenca AG, Gao H, et al.
A genomic storm in critically injured humans. J.Exp.Med. 2011;208: 2581&#x2013;2590. doi: 10.1084/jem.20111354
</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20111354</ArticleId><ArticleId IdType="pmc">PMC3244029</ArticleId><ArticleId IdType="pubmed">22110166</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanzant EL, Hilton RE, Lopez CM, Zhang J, Ungaro RF, Gentile LF, et al.
Advanced age is associated with worsened outcomes and a unique genomic response in severely injured patients with hemorrhagic shock. Crit Care
2015. 
19: 77
doi: 10.1186/s13054-015-0788-x
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0788-x</ArticleId><ArticleId IdType="pmc">PMC4404112</ArticleId><ArticleId IdType="pubmed">25880307</ArticleId></ArticleIdList></Reference><Reference><Citation>Orr SK, Butler KL, Hayden D, Tompkins RG, Serhan CN, Irimia D. Gene Expression of Proresolving Lipid Mediator Pathways Is Associated With Clinical Outcomes in Trauma Patients. Crit Care Med. 2015;43: 2642&#x2013;2650. doi: 10.1097/CCM.0000000000001312
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0000000000001312</ArticleId><ArticleId IdType="pmc">PMC4651815</ArticleId><ArticleId IdType="pubmed">26488221</ArticleId></ArticleIdList></Reference><Reference><Citation>Namas RA, Vodovotz Y, Almahmoud K, Abdul-Malak O, Zaaqoq A, Namas R, et al.
Temporal Patterns of Circulating Inflammation Biomarker Networks Differentiate Susceptibility to Nosocomial Infection Following Blunt Trauma in Humans. Ann.Surg. 2016; 263: 191&#x2013;198. doi: 10.1097/SLA.0000000000001001
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000001001</ArticleId><ArticleId IdType="pmc">PMC5136774</ArticleId><ArticleId IdType="pubmed">25371118</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeschke MG, Gauglitz GG, Finnerty CC, Kraft R, Mlcak RP, Herndon DN. Survivors versus nonsurvivors postburn: differences in inflammatory and hypermetabolic trajectories. Ann.Surg. 2014;259: 814&#x2013;823. doi: 10.1097/SLA.0b013e31828dfbf1
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0b013e31828dfbf1</ArticleId><ArticleId IdType="pmc">PMC3732513</ArticleId><ArticleId IdType="pubmed">23579577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kraft R, Herndon DN, Finnerty CC, Cox RA, Song J, Jeschke MG. Predictive Value of IL-8 for Sepsis and Severe Infections After Burn Injury: A Clinical Study. Shock
2015;43: 222&#x2013;227. doi: 10.1097/SHK.0000000000000294
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000294</ArticleId><ArticleId IdType="pmc">PMC4425645</ArticleId><ArticleId IdType="pubmed">25514427</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuschieri J, Bulger E, Schaeffer V, Sakr S, Nathens AB, Hennessy L, et al.
Early elevation in random plasma IL-6 after severe injury is associated with development of organ failure. Shock
2010;34: 346&#x2013;351. doi: 10.1097/SHK.0b013e3181d8e687
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e3181d8e687</ArticleId><ArticleId IdType="pmc">PMC3122160</ArticleId><ArticleId IdType="pubmed">20844410</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferreira LC, Regner A, Miotto KD, Moura S, Ikuta N, Vargas AE, et al.
Increased levels of interleukin-6, -8 and -10 are associated with fatal outcome following severe traumatic brain injury. Brain Inj. 2014;28: 1311&#x2013;1316. doi: 10.3109/02699052.2014.916818
</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/02699052.2014.916818</ArticleId><ArticleId IdType="pubmed">24830571</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, et al. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock 2007;28: 668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Muszynski JA, Nofziger R, Greathouse K, Nateri J, Hanson-Huber L, Steele L, et al.
Innate immune function predicts the development of nosocomial infection in critically injured children. Shock
2014;42: 313&#x2013;321. doi: 10.1097/SHK.0000000000000217
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000217</ArticleId><ArticleId IdType="pmc">PMC4167175</ArticleId><ArticleId IdType="pubmed">24978895</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouel-Cheron A, Allaouchiche B, Guignant C, Davin F, Floccard B, Monneret G. Early interleukin-6 and slope of monocyte human leukocyte antigen-DR: a powerful association to predict the development of sepsis after major trauma. PLoS ONE
2012;7: e33095
doi: 10.1371/journal.pone.0033095
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0033095</ArticleId><ArticleId IdType="pmc">PMC3303782</ArticleId><ArticleId IdType="pubmed">22431998</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C, et al.
Lack of recovery in monocyte human leukocyte antigen-DR expression is independently associated with the development of sepsis after major trauma. Crit Care
2010;14: R208
doi: 10.1186/cc9331
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc9331</ArticleId><ArticleId IdType="pmc">PMC3220028</ArticleId><ArticleId IdType="pubmed">21092108</ArticleId></ArticleIdList></Reference><Reference><Citation>Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society Series B (Methodological) 1995. 57: 289&#x2013;300.</Citation></Reference><Reference><Citation>Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, et al.
Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology
2010;21: 128&#x2013;138. doi: 10.1097/EDE.0b013e3181c30fb2
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/EDE.0b013e3181c30fb2</ArticleId><ArticleId IdType="pmc">PMC3575184</ArticleId><ArticleId IdType="pubmed">20010215</ArticleId></ArticleIdList></Reference><Reference><Citation>Steyerberg EW, Harrell FE Jr, Borsboom GJ, Eijkemans MJ, Vergouwe Y, Habbema JD. Internal validation of predictive models: efficiency of some procedures for logistic regression analysis. J.Clin.Epidemiol. 2001;54: 774&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pubmed">11470385</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu CL, Tangsombatvisit S, Rosenberg JM, Mandelbaum G, Gillespie EC, Gozani OP, et al.
Specific post-translational histone modifications of neutrophil extracellular traps as immunogens and potential targets of lupus autoantibodies. Arthritis Res.Ther. 2012;14: R25
doi: 10.1186/ar3707
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/ar3707</ArticleId><ArticleId IdType="pmc">PMC3392818</ArticleId><ArticleId IdType="pubmed">22300536</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Kamp VM, van HE, Visser T, Tak T, Lammers JW, et al.
A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. J.Clin.Invest
2012; 122: 327&#x2013;336. doi: 10.1172/JCI57990
</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI57990</ArticleId><ArticleId IdType="pmc">PMC3248287</ArticleId><ArticleId IdType="pubmed">22156198</ArticleId></ArticleIdList></Reference><Reference><Citation>Laborde RR, Lin Y, Gustafson MP, Bulur PA, Dietz AB. Cancer Vaccines in the World of Immune Suppressive Monocytes (CD14(+)HLA-DR(lo/neg) Cells): The Gateway to Improved Responses. Front Immunol. 2014;5: 147
doi: 10.3389/fimmu.2014.00147
</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00147</ArticleId><ArticleId IdType="pmc">PMC3983500</ArticleId><ArticleId IdType="pubmed">24772111</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhoff C, Biberthaler P, Mutschler WE, Faist E, Jochum M, Zedler S. Early down-regulation of the pro-inflammatory potential of monocytes is correlated to organ dysfunction in patients after severe multiple injury: a cohort study. Crit Care
2009; 13: R88
doi: 10.1186/cc7914
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc7914</ArticleId><ArticleId IdType="pmc">PMC2717459</ArticleId><ArticleId IdType="pubmed">19519886</ArticleId></ArticleIdList></Reference><Reference><Citation>Rainer TH, Ng MH, Lam NY, Chan TY, Cocks RA. Role of monocyte L-selectin in the development of post-traumatic organ failure. Resuscitation 2001;51: 139&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pubmed">11718969</ArticleId></ArticleIdList></Reference><Reference><Citation>Gentile LF, Cuenca AG, Efron PA, Ang D, Bihorac A, McKinley BA, et al.
Persistent inflammation and immunosuppression: a common syndrome and new horizon for surgical intensive care. J.Trauma Acute.Care Surg. 2012;72: 1491&#x2013;1501. doi: 10.1097/TA.0b013e318256e000
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318256e000</ArticleId><ArticleId IdType="pmc">PMC3705923</ArticleId><ArticleId IdType="pubmed">22695412</ArticleId></ArticleIdList></Reference><Reference><Citation>Nakagawa M, Terashima T, D'yachkova Y, Bondy GP, Hogg JC, van Eeden SF. Glucocorticoid-induced granulocytosis: contribution of marrow release and demargination of intravascular granulocytes. Circulation 1998;98: 2307&#x2013;2313.</Citation><ArticleIdList><ArticleId IdType="pubmed">9826319</ArticleId></ArticleIdList></Reference><Reference><Citation>Drifte G, Dunn-Siegrist I, Tissieres P, Pugin J. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. Crit Care Med. 2013;41: 820&#x2013;832. doi: 10.1097/CCM.0b013e318274647d
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e318274647d</ArticleId><ArticleId IdType="pubmed">23348516</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Ramakers BP, Kamp VM, Loi AL, Lam SW, Hietbrink F, et al.
Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. J.Leukoc.Biol. 2010;88: 211&#x2013;220. doi: 10.1189/jlb.1209793
</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.1209793</ArticleId><ArticleId IdType="pubmed">20400675</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauce D, Dong Y, Campillo-Gimenez L, Casulli S, Bayard C, Autran B, et al.
Reduced Oxidative Burst by Primed Neutrophils in the Elderly Individuals Is Associated With Increased Levels of the CD16bright/CD62Ldim Immunosuppressive Subset. J.Gerontol.A Biol.Sci.Med.Sci. 2017;72: 163&#x2013;172. doi: 10.1093/gerona/glw062
</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/gerona/glw062</ArticleId><ArticleId IdType="pubmed">27069096</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin Y, Gustafson MP, Bulur PA, Gastineau DA, Witzig TE, Dietz AB. Immunosuppressive CD14+HLA-DR(low)/- monocytes in B-cell non-Hodgkin lymphoma. Blood
2011;117: 872&#x2013;881. doi: 10.1182/blood-2010-05-283820
</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-05-283820</ArticleId><ArticleId IdType="pmc">PMC3035079</ArticleId><ArticleId IdType="pubmed">21063024</ArticleId></ArticleIdList></Reference><Reference><Citation>Vuk-Pavlovic S, Bulur PA, Lin Y, Qin R, Szumlanski CL, Zhao X, et al.
Immunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer. Prostate
2010;70: 443&#x2013;455. doi: 10.1002/pros.21078
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/pros.21078</ArticleId><ArticleId IdType="pmc">PMC2935631</ArticleId><ArticleId IdType="pubmed">19902470</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP, et al.
A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells. Gastroenterology
2008;135: 234&#x2013;243. doi: 10.1053/j.gastro.2008.03.020
</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2008.03.020</ArticleId><ArticleId IdType="pubmed">18485901</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoechst B, Voigtlaender T, Ormandy L, Gamrekelashvili J, Zhao F, Wedemeyer H, et al.
Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor. Hepatology
2009;50: 799&#x2013;807. doi: 10.1002/hep.23054
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.23054</ArticleId><ArticleId IdType="pmc">PMC6357774</ArticleId><ArticleId IdType="pubmed">19551844</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiu B, Lin Y, Grote DM, Ziesmer SC, Gustafson MP, Maas ML, et al.
IL-10 induces the development of immunosuppressive CD14(+)HLA-DR(low/-) monocytes in B-cell non-Hodgkin lymphoma. Blood Cancer J. 2015; 5: e328
doi: 10.1038/bcj.2015.56
</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/bcj.2015.56</ArticleId><ArticleId IdType="pmc">PMC4526782</ArticleId><ArticleId IdType="pubmed">26230952</ArticleId></ArticleIdList></Reference><Reference><Citation>Aneja R, Odoms K, Dunsmore K, Shanley TP, Wong HR. Extracellular heat shock protein-70 induces endotoxin tolerance in THP-1 cells. J.Immunol. 2006;177: 7184&#x2013;7192.</Citation><ArticleIdList><ArticleId IdType="pubmed">17082636</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenthal J, Thurman GW, Cusack N, Peterson VM, Malech HL, Ambruso DR. Neutrophils from patients after burn injury express a deficiency of the oxidase components p47-phox and p67-phox. Blood 1996;88: 4321&#x2013;4329.</Citation><ArticleIdList><ArticleId IdType="pubmed">8943869</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG, Rhind SG, Rizoli SB, Cuschieri J, Baker AJ, Shek PN, et al.
Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury. Shock
2013;40: 366&#x2013;374. doi: 10.1097/SHK.0000000000000038
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000000038</ArticleId><ArticleId IdType="pmc">PMC3913169</ArticleId><ArticleId IdType="pubmed">24088993</ArticleId></ArticleIdList></Reference><Reference><Citation>Benna JE, Dang PM, Gaudry M, Fay M, Morel F, Hakim J, et al. Phosphorylation of the respiratory burst oxidase subunit p67(phox) during human neutrophil activation. Regulation by protein kinase C-dependent and independent pathways. J.Biol.Chem. 1997; 272: 17204&#x2013;17208.</Citation><ArticleIdList><ArticleId IdType="pubmed">9202043</ArticleId></ArticleIdList></Reference><Reference><Citation>Nauseef WM, Volpp BD, McCormick S, Leidal KG, Clark RA. Assembly of the neutrophil respiratory burst oxidase. Protein kinase C promotes cytoskeletal and membrane association of cytosolic oxidase components. J.Biol.Chem. 1991;266: 5911&#x2013;5917.</Citation><ArticleIdList><ArticleId IdType="pubmed">1848559</ArticleId></ArticleIdList></Reference><Reference><Citation>Raad H, Paclet MH, Boussetta T, Kroviarski Y, Morel F, Quinn MT, et al.
Regulation of the phagocyte NADPH oxidase activity: phosphorylation of gp91phox/NOX2 by protein kinase C enhances its diaphorase activity and binding to Rac2, p67phox, and p47phox. FASEB J. 2009;23: 1011&#x2013;1022. doi: 10.1096/fj.08-114553
</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.08-114553</ArticleId><ArticleId IdType="pmc">PMC2660639</ArticleId><ArticleId IdType="pubmed">19028840</ArticleId></ArticleIdList></Reference><Reference><Citation>Tarlowe MH, Kannan KB, Itagaki K, Adams JM, Livingston DH, Hauser CJ. Inflammatory chemoreceptor cross-talk suppresses leukotriene B4 receptor 1-mediated neutrophil calcium mobilization and chemotaxis after trauma. J.Immunol. 2003;171: 2066&#x2013;2073.</Citation><ArticleIdList><ArticleId IdType="pubmed">12902512</ArticleId></ArticleIdList></Reference><Reference><Citation>Hirose T, Hamaguchi S, Matsumoto N, Irisawa T, Seki M, Tasaki O, et al.
Presence of neutrophil extracellular traps and citrullinated histone H3 in the bloodstream of critically ill patients. PLoS ONE. 2014;9: e111755
doi: 10.1371/journal.pone.0111755
</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0111755</ArticleId><ArticleId IdType="pmc">PMC4230949</ArticleId><ArticleId IdType="pubmed">25392950</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang H, Tohme S, Al-Khafaji AB, Tai S, Loughran P, Chen L, et al.
Damage-associated molecular pattern-activated neutrophil extracellular trap exacerbates sterile inflammatory liver injury. Hepatology
2015;62: 600&#x2013;614. doi: 10.1002/hep.27841
</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/hep.27841</ArticleId><ArticleId IdType="pmc">PMC4515210</ArticleId><ArticleId IdType="pubmed">25855125</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen MJ, Brohi K, Calfee CS, Rahn P, Chesebro BB, Christiaans SC, et al.
Early release of high mobility group box nuclear protein 1 after severe trauma in humans: role of injury severity and tissue hypoperfusion. Crit Care
2009;13: R174
doi: 10.1186/cc8152
</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc8152</ArticleId><ArticleId IdType="pmc">PMC2811903</ArticleId><ArticleId IdType="pubmed">19887013</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance HD, Vivian ME, Brohi K, Prowle JR, Pearse RM, Owen HC, et al.
Changes in gene expression following trauma are related to the age of transfused packed red blood cells. J.Trauma Acute.Care Surg. 2015;78: 535&#x2013;542. doi: 10.1097/TA.0000000000000534
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000000534</ArticleId><ArticleId IdType="pubmed">25710424</ArticleId></ArticleIdList></Reference><Reference><Citation>Torrance HD, Brohi K, Pearse RM, Mein CA, Wozniak E, Prowle JR, et al.
Association between gene expression biomarkers of immunosuppression and blood transfusion in severely injured polytrauma patients. Ann.Surg. 2015; 261: 751&#x2013;759. doi: 10.1097/SLA.0000000000000653
</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SLA.0000000000000653</ArticleId><ArticleId IdType="pubmed">24670848</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">32758298</PMID><DateCompleted><Year>2020</Year><Month>08</Month><Day>18</Day></DateCompleted><DateRevised><Year>2024</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>21</Volume><Issue>1</Issue><PubDate><Year>2020</Year><Month>Aug</Month><Day>05</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>A phase II, single-center, double-blind, randomized placebo-controlled trial to explore the efficacy and safety of intravenous melatonin in patients with COVID-19 admitted to the intensive care unit (MelCOVID study): a structured summary of a study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>699</StartPage><MedlinePgn>699</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">699</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13063-020-04632-4</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">&#x2022; Primary objective: to evaluate the effect of intravenous melatonin (IVM) on mortality in adult patients admitted to the intensive care unit (ICU) with COVID-19. &#x2022; Secondary objectives: &#x25e6; To evaluate the effect of IVM on ICU length of stay. &#x25e6; To evaluate the effect of IVM on the length of mechanical ventilation (MV). &#x25e6; To evaluate if the use of IVM is associated with an increase in the number of ventilator-free days. &#x25e6; To evaluate if the use of IVM is associated with a reduced number of failing organs as determined by the sequential organ failure assessment (SOFA) scale. &#x25e6; To evaluate if the use of IVM is associated with a reduction of the frequency and severity of COVID-19-associated thromboembolic phenomena. &#x25e6; To evaluate if the use of IVM is associated with a decreased systemic inflammatory response assessed by plasma levels of ferritin, D-dimer, C-reactive protein, procalcitonin and interleukin-6. &#x25e6; To evaluate if the use of IVM is associated with an improvement in hematologic parameters. &#x25e6; To evaluate if the use of IVM is associated with an improvement in biochemical parameters. &#x25e6; To evaluate if the use of IVM is associated with an improvement in blood gas analysis parameters. &#x25e6; To evaluate adverse events during the 28 day study period.</AbstractText><AbstractText Label="TRIAL DESIGN" NlmCategory="METHODS">Phase II, single center, double-blind, placebo-controlled randomized trial with a two-arm parallel group design and 2:1 allocation ratio.</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">Only critically ill adult patients that fulfill all of the inclusion criteria and none of the exclusion criteria will be included. The study will be conducted in a mixed ICU of a publicly funded tertiary referral center in Madrid, Spain with a 30-bed capacity and 1100 admissions per year. &#x2022; Inclusion criteria: &#x25e6; Patient, family member or legal guardian has provided written Informed Consent. &#x25e6; Age &#x3b5; 18 years. &#x25e6; Confirmed SARS-CoV-2 infection with compatible symptoms AND a positive RT-PCR. &#x25e6; Admission to the ICU with acute hypoxemic respiratory failure attributed to SARS-CoV-2 infection. &#x25e6; ICU length of stay of less than 7 days prior to randomization with or without MV and without signs of improvement in respiratory failure (MURRAY score at randomization greater or equal to the MURRAY score at ICU admission). &#x2022; Exclusion criteria: &#x25e6; Participant in a different COVID-19 study in which the study drug is under clinical development and hasn't been previously authorized for commercialization. &#x25e6; Liver enzymes &gt; 5 times the upper normal range. &#x25e6; Chronic kidney disease with GFR &lt; 30 mL/min/1.73 m<sup>2</sup> (stage 4 or greater) or need for hemodialysis. &#x25e6; Pregnancy. A pregnancy test will be performed on every woman younger than 55 years of age prior to inclusion. &#x25e6; Terminal surgical or medical illness. &#x25e6; Autoimmune disease. &#x25e6; Any patient condition that can prevent the study procedures to be carried out at the treating physician's judgement.</AbstractText><AbstractText Label="INTERVENTION AND COMPARATOR" NlmCategory="UNASSIGNED">All patients will receive standard-of-care treatment according to the current institutional protocols. In addition, patients will be randomized in a 2:1 ratio to receive: &#x2022; Experimental group (12 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous melatonin every 6 hours. Maximum daily dose 500 mg per day. &#x2022; Control group (6 patients): 7 days of 5 mg per Kg of actual body weight per day of intravenous identically-looking placebo every 6 hours. After 3 days of treatment, 3 intensive care physicians will evaluate the participant and decide whether or not to complete the treatment based on their clinical assessment: &#x2022; If objective or subjective signs of improvement or no worsening of the general clinical condition, respiratory failure, inflammatory state or multi-organ failure are observed, the participant will continue the treatment until completion. &#x2022; If an adverse effect or clinical impairment is observed that is objectively or subjectively attributable to the study drug the treatment will be stopped.</AbstractText><AbstractText Label="MAIN OUTCOME" NlmCategory="RESULTS">Mortality in each study group represented in frequency and time-to-event at day 28 after randomization RANDOMIZATION: The randomization sequence was created using SAS version 9.4 statistical software (programmed and validated macros) with a 2:1 allocation. No randomization seed was pre-specified. The randomization seed was generated using the time on the computer where the program was executed.</AbstractText><AbstractText Label="BLINDING (MASKING)" NlmCategory="UNASSIGNED">Participants, caregivers and study groups will be blinded to arm allocation.</AbstractText><AbstractText Label="NUMBERS TO BE RANDOMIZED (SAMPLE SIZE)" NlmCategory="UNASSIGNED">A total of 18 patients will be randomized in this trial: 12 to the experimental arm and 6 to the control arm.</AbstractText><AbstractText Label="TRIAL STATUS" NlmCategory="METHODS">Protocol version 2.0, June 5<sup>th</sup> 2020. Trial status: recruitment not started. The first patient is expected to be recruited in October 2020. The last patient is anticipated to be recruited in August 2021.</AbstractText><AbstractText Label="TRIAL REGISTRATION" NlmCategory="BACKGROUND">EU Clinical Trials Register. Date of trial registration: 10 July 2020. URL: https://www.clinicaltrialsregister.eu/ctr-search/trial/2020-001808-42/ES FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest of expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rodr&#xed;guez-Rubio</LastName><ForeName>Miguel</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Figueira</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Intensive Care Medicine Department, Hospital Universitario La Paz, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Acu&#xf1;a-Castroviejo</LastName><ForeName>Dar&#xed;o</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERfes, Ibs Granada, Granada, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Laboratories, San Cecilio University Hospital, Granada, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Borobia</LastName><ForeName>Alberto M</ForeName><Initials>AM</Initials><AffiliationInfo><Affiliation>Clinical Pharmacology Department, Clinical Trial Unit, Hospital Universitario La Paz - IdiPAZ, Madrid, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Escames</LastName><ForeName>Germaine</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Physiology, Faculty of Medicine, Biomedical Research Center, Health Science Technology Park, University of Granada, Granada, Spain. gescames@ugr.es.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CIBERfes, Ibs Granada, Granada, Spain. gescames@ugr.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de la Oliva</LastName><ForeName>Pedro</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0003-2444-0556</Identifier><AffiliationInfo><Affiliation>Pediatric Intensive Care Department, Hospital Universitario La Paz, Madrid, Spain. pedro.oliva@salud.madrid.org.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pediatrics, School of Medicine, Universidad Aut&#xf3;noma de Madrid, Madrid, Spain. pedro.oliva@salud.madrid.org.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D000078325">Clinical Trial Protocol</PublicationType><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>JL5DK93RCL</RegistryNumber><NameOfSubstance UI="D008550">Melatonin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008550" MajorTopicYN="Y">Melatonin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016032" MajorTopicYN="N">Randomized Controlled Trials as Topic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000093485" MajorTopicYN="Y">COVID-19 Drug Treatment</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017322" MajorTopicYN="N">Clinical Trials, Phase II as Topic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ARDS</Keyword><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Randomized Controlled Trial</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">intensive care</Keyword><Keyword MajorTopicYN="N">melatonin</Keyword><Keyword MajorTopicYN="N">protocol</Keyword><Keyword MajorTopicYN="N">treatment</Keyword></KeywordList><CoiStatement>GE and DA-C are Scientific Advisors of Pharmamel LTD, the Sponsor of the clinical trial.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>7</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>7</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>8</Month><Day>19</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2020</Year><Month>8</Month><Day>5</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32758298</ArticleId><ArticleId IdType="pmc">PMC7403786</ArticleId><ArticleId IdType="doi">10.1186/s13063-020-04632-4</ArticleId><ArticleId IdType="pii">10.1186/s13063-020-04632-4</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20118780</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>29</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1528-1140</ISSN><JournalIssue CitedMedium="Internet"><Volume>251</Volume><Issue>3</Issue><PubDate><Year>2010</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Annals of surgery</Title><ISOAbbreviation>Ann Surg</ISOAbbreviation></Journal><ArticleTitle>Red blood cell transfusion threshold in postsurgical pediatric intensive care patients: a randomized clinical trial.</ArticleTitle><Pagination><StartPage>421</StartPage><EndPage>427</EndPage><MedlinePgn>421-7</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/SLA.0b013e3181c5dc2e</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The optimal transfusion threshold after surgery in children is unknown. We analyzed the general surgery subgroup of the TRIPICU (Transfusion Requirements in Pediatric Intensive Care Units) study to determine the impact of a restrictive versus a liberal transfusion strategy on new or progressive multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The TRIPICU study, a prospective randomized controlled trial conducted in 17 centers, enrolled a total of 648 critically ill children with a hemoglobin equal to or below 9.5 g/dL within 7 days of pediatric intensive care unit (PICU) admission to receive prestorage leukocyte-reduced red-cell transfusion if their hemoglobin dropped below either 7.0 g/dL (restrictive) or 9.5 g/dL (liberal). A subgroup of 124 postoperative patients (60 randomized to restrictive and 64 to the liberal group) were analyzed. This study was registered at http://www.controlled-trials.com and carries the following ID ISRCTN37246456.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Participants in the restrictive and liberal groups were similar at randomization in age (restrictive vs. liberal: 53.5 +/- 51.8 vs. 73.7 +/- 61.8 months), severity of illness (pediatric risk of mortality [PRISM] score: 3.5 +/- 4.0 vs. 4.4 +/- 4.0), MODS (35% vs. 29%), need for mechanical ventilation (77% vs. 74%), and hemoglobin level (7.7 +/- 1.1 vs. 7.9 +/- 1.0 g/dL). The mean hemoglobin level remained 2.3 g/dL lower in the restrictive group after randomization. No significant differences were found for new or progressive MODS (8% vs. 9%; P = 0.83) or for 28-day mortality (2% vs. 2%; P = 0.96) in the restrictive versus liberal group. However, there was a statistically significant difference between groups for PICU length of stay (7.7 +/- 6.6 days for the restrictive group vs. 11.6 +/- 10.2 days for the liberal group; P = 0.03).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In this subgroup analysis of pediatric general surgery patients, we found no conclusive evidence that a restrictive red-cell transfusion strategy, as compared with a liberal one, increased the rate of new or progressive MODS or mortality.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Rouette</LastName><ForeName>Justine</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Pediatric Critical Care Unit, Sainte-Justine Hospital, Universit&#xe9; de Montr&#xe9;al, Montreal, QC.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trottier</LastName><ForeName>Helen</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Ducruet</LastName><ForeName>Thierry</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Beaunoyer</LastName><ForeName>Mona</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Lacroix</LastName><ForeName>Jacques</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Tucci</LastName><ForeName>Marisa</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><CollectiveName>Canadian Critical Care Trials Group</CollectiveName></Author><Author ValidYN="Y"><CollectiveName>PALISI Network</CollectiveName></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ISRCTN</DataBankName><AccessionNumberList><AccessionNumber>ISRCTN37246456</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>130770</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant><Grant><GrantID>84300</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Surg</MedlineTA><NlmUniqueID>0372354</NlmUniqueID><ISSNLinking>0003-4932</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015278" MajorTopicYN="N">Intensive Care Units, Pediatric</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName><QualifierName UI="Q000592" MajorTopicYN="Y">standards</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>2</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20118780</ArticleId><ArticleId IdType="doi">10.1097/SLA.0b013e3181c5dc2e</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">28007459</PMID><DateCompleted><Year>2017</Year><Month>08</Month><Day>09</Day></DateCompleted><DateRevised><Year>2017</Year><Month>11</Month><Day>16</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1424-3911</ISSN><JournalIssue CitedMedium="Internet"><Volume>17</Volume><Issue>1</Issue><PubDate><Year>2017</Year><Season>Jan-Feb</Season></PubDate></JournalIssue><Title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</Title><ISOAbbreviation>Pancreatology</ISOAbbreviation></Journal><ArticleTitle>Endothelial markers are associated with pancreatic necrosis and overall prognosis in acute pancreatitis: A preliminary cohort study.</ArticleTitle><Pagination><StartPage>45</StartPage><EndPage>50</EndPage><MedlinePgn>45-50</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.pan.2016.12.005</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1424-3903(16)31252-2</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Endothelial injury is believed to play an important role in the evolution of pancreatic microcirculatory dysfunction and pancreatic necrosis (PN) in patients with acute pancreatitis (AP). The aim of this study was to investigate the role of three endothelial markers (von Willebrand factor, vWF; E-selectin; endothelial protein C receptor, EPCR) in the early phase of AP, especially the relationship between endothelial markers and PN.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">From March 2015 to March 2016, 57 AP patients admitted within 72&#xa0;h of symptom onset in our hospital were included for this study. Blood samples were taken on admission and the clinical characteristics and outcomes of these patients were recorded. The levels of vWF, E-selectin and EPCR were measured using ELISA for analysis and compared with other severity markers of AP.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">All the three markers were significantly different in healthy control, mild, moderate and severe AP patients. Moreover, the endothelial markers, especially vWF, also showed significant difference in patients with different extent of PN, as well as those with or without MODS. Additionally, the levels of endothelial markers correlated well with other commonly used markers of AP severity.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Elevated endothelium-related mediators (vWF, E-selectin and EPCR) appear to participate in the development of PN and may be a potential indicator of overall prognosis. Our results may help clinicians better understand the pathophysiological process of the development of PN.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 IAP and EPC. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Yizhe</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ke</LastName><ForeName>Lu</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China. Electronic address: kkb9832@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meng</LastName><ForeName>Lei</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Qi</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tong</LastName><ForeName>Zhihui</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Yiyuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Weiqin</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Surgical Intensive Care Unit (SICU), Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China. Electronic address: njzy_pancrea@163.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Jieshou</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Jinling Hospital, Medical School of Nanjing University, No.305 Zhongshan East Road, Nanjing, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>12</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pancreatology</MedlineTA><NlmUniqueID>100966936</NlmUniqueID><ISSNLinking>1424-3903</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015703">Antigens, CD</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019040">E-Selectin</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000074283">Endothelial Protein C Receptor</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C478370">PROCR protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011956">Receptors, Cell Surface</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C546936">SELE protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014841">von Willebrand Factor</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000208" MajorTopicYN="N">Acute Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015703" MajorTopicYN="N">Antigens, CD</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019040" MajorTopicYN="N">E-Selectin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000074283" MajorTopicYN="N">Endothelial Protein C Receptor</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019283" MajorTopicYN="N">Pancreatitis, Acute Necrotizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011956" MajorTopicYN="N">Receptors, Cell Surface</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014841" MajorTopicYN="N">von Willebrand Factor</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute pancreatitis</Keyword><Keyword MajorTopicYN="N">E-selectin</Keyword><Keyword MajorTopicYN="N">Endothelial protein C receptor</Keyword><Keyword MajorTopicYN="N">Pancreatic necrosis</Keyword><Keyword MajorTopicYN="N">von Willebrand factor</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>12</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>12</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>8</Month><Day>10</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>12</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">28007459</ArticleId><ArticleId IdType="doi">10.1016/j.pan.2016.12.005</ArticleId><ArticleId IdType="pii">S1424-3903(16)31252-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">33933851</PMID><DateCompleted><Year>2021</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2022</Year><Month>12</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1878-1705</ISSN><JournalIssue CitedMedium="Internet"><Volume>97</Volume><PubDate><Year>2021</Year><Month>Aug</Month></PubDate></JournalIssue><Title>International immunopharmacology</Title><ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation></Journal><ArticleTitle>The role of IL-6/lymphocyte ratio in the peripheral blood of severe patients with COVID-19.</ArticleTitle><Pagination><StartPage>107569</StartPage><MedlinePgn>107569</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2021.107569</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1567-5769(21)00205-8</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">To investigate the prognostic value of a novel immune-inflammatory index, the interleukin-6-to-lymphocyte ratio (IL-6/LY), with the clinical outcomes of severe coronavirus disease 2019 (COVID-19) cases.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A cohort study of COVID-19 patients in Tongji Hospital, from January 2020 to February 2020, was evaluated. Kaplan-Meier method and the log-rank test was performed to analyze survival data. Univariate and multivariate analyses were performed with COX proportional hazard regression model. The primary and secondary outcomes were in-hospital mortality and multiple organ dysfunction syndrome (MODS), respectively.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Total 320 adult patients were enrolled in our analyses. Patients were divided into low IL-6/LY group and high IL-6/LY group based on the cutoff value with 2.50. The Kaplan-Meier survival curves showed that high-value group (IL-6/LY&#xa0;&#x2265;&#xa0;2.50) had a greater risk of poor prognosis (P&#xa0;&lt;&#xa0;0.001, respectively). Multivariate analysis indicated that IL-6/LY was the independent risk predictor for in-hospital mortality (hazard ratio [HR],&#xa0;3.404; 95% confidence interval [CI],&#xa0;1.090-10.633, P&#xa0;=&#xa0;0.035) and MODS development (HR, 4.143; 95%CI, 1.321-12.986, P&#xa0;=&#xa0;0.015). Meanwhile, IL-6/LY was positively correlated with the MuLBSTA score (r&#xa0;=&#xa0;0.137, P&#xa0;=&#xa0;0.031), suggesting that IL-6/LY was associated with long-term mortality (90-day). Furthermore, kinetic analysis revealed that the dynamic changes of inflammatory immune indexes were related to the severity of the disease.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The elevated IL-6/LY was related with the increased risk of poor prognosis. Not only that, IL-6/LY could be used for risk stratification and early clinical identification of high-risk patients.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Authors. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yang</LastName><ForeName>Boyi</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chang</LastName><ForeName>Xiaoyan</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Department of Nephrology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Jiabao</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of General Practice, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, Guangdong, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Wen</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Si</LastName><ForeName>Zhilong</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Gastrointestinal Surgery, The Forth Hospital of Wuhan Affiliated with Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Cuntai</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Geriatrics, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China. Electronic address: lihongniuniu2014@163.com.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Int Immunopharmacol</MedlineTA><NlmUniqueID>100965259</NlmUniqueID><ISSNLinking>1567-5769</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017052" MajorTopicYN="N">Hospital Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053208" MajorTopicYN="N">Kaplan-Meier Estimate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008214" MajorTopicYN="N">Lymphocytes</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015999" MajorTopicYN="N">Multivariate Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Coronavirus disease 2019</Keyword><Keyword MajorTopicYN="N">Immune-inflammatory index</Keyword><Keyword MajorTopicYN="N">Interleukin-6</Keyword><Keyword MajorTopicYN="N">Lymphocyte</Keyword><Keyword MajorTopicYN="N">Prognosis</Keyword></KeywordList><CoiStatement>The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>6</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>2</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>3</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>5</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>8</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>5</Month><Day>2</Day><Hour>20</Hour><Minute>51</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>3</Month><Day>12</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33933851</ArticleId><ArticleId IdType="pmc">PMC7953449</ArticleId><ArticleId IdType="doi">10.1016/j.intimp.2021.107569</ArticleId><ArticleId IdType="pii">S1567-5769(21)00205-8</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Huang C., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497&#x2013;506.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarzi-Puttini P., et al. COVID-19, cytokines and immunosuppression: what can we learn from severe acute respiratory syndrome? Clin. Exp. Rheumatol. 2020;38(2):337&#x2013;342.</Citation><ArticleIdList><ArticleId IdType="pubmed">32202240</ArticleId></ArticleIdList></Reference><Reference><Citation>O. World Health, Coronavirus disease (COVID-19): Situation Report128. 2019:2020.</Citation></Reference><Reference><Citation>Yin Y., Wunderink R.G. MERS, SARS and other coronaviruses as causes of pneumonia. Respirology. 2018;23(2):130&#x2013;137.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7169239</ArticleId><ArticleId IdType="pubmed">29052924</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu R., et al. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet. 2020;395(10224):565&#x2013;574.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159086</ArticleId><ArticleId IdType="pubmed">32007145</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan J.F.-W., et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020;395(10223):514&#x2013;523.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7159286</ArticleId><ArticleId IdType="pubmed">31986261</ArticleId></ArticleIdList></Reference><Reference><Citation>Oh M.D., et al. Viral load kinetics of MERS coronavirus infection. N. Engl. J. Med. 2016;375(13):1303&#x2013;1305.</Citation><ArticleIdList><ArticleId IdType="pubmed">27682053</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen N., et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet (London, England) 2020;395(10223):507&#x2013;513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135076</ArticleId><ArticleId IdType="pubmed">32007143</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta P., et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270045</ArticleId><ArticleId IdType="pubmed">32192578</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., et al. Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin. Infect. Dis. 2020:ciaa248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X., et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin. Infect. Dis. 2020:ciaa449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184354</ArticleId><ArticleId IdType="pubmed">32301997</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiappelli F., et al. COVID-19 Immunopathology and Immunotherapy. Bioinformation. 2020;16(3):219&#x2013;222.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7147500</ArticleId><ArticleId IdType="pubmed">32308263</ArticleId></ArticleIdList></Reference><Reference><Citation>O. World Health . World Health Organization; Geneva: 2020. Clinical Management of Severe Acute Respiratory Infection (SARI) When COVID-19 Disease is Suspected: Interim Guidance.</Citation></Reference><Reference><Citation>Ramirez M. Multiple organ dysfunction syndrome. Curr. Probl. Pediatr. Adolesc. Health Care. 2013;43(10):273&#x2013;277.</Citation><ArticleIdList><ArticleId IdType="pubmed">24295608</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamilloux Y., et al. Should we stimulate or suppress immune responses in COVID-19? Cytokine and anti-cytokine interventions. Autoimmun Rev. 2020:102567.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7196557</ArticleId><ArticleId IdType="pubmed">32376392</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang W., et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): The Perspectives of clinical immunologists from China. Clin. Immunol. 2020;214:108393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102614</ArticleId><ArticleId IdType="pubmed">32222466</ArticleId></ArticleIdList></Reference><Reference><Citation>Channappanavar R., Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin. Immunopathol. 2017;39(5):529&#x2013;539.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7079893</ArticleId><ArticleId IdType="pubmed">28466096</ArticleId></ArticleIdList></Reference><Reference><Citation>Chousterman B.G., et al. Cytokine storm and sepsis disease pathogenesis. Semin. Immunopathol. 2017;39(5):517&#x2013;528.</Citation><ArticleIdList><ArticleId IdType="pubmed">28555385</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054&#x2013;1062.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu C., et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern. Med. 2020:e200994.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7070509</ArticleId><ArticleId IdType="pubmed">32167524</ArticleId></ArticleIdList></Reference><Reference><Citation>Cifaldi L., et al. Inhibition of natural killer cell cytotoxicity by interleukin-6: implications for the pathogenesis of macrophage activation syndrome. Arthritis Rheumatol. 2015;67(11):3037&#x2013;3046.</Citation><ArticleIdList><ArticleId IdType="pubmed">26251193</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang F., et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia. J. Infect. Dis. 2020;221(11):1762&#x2013;1769.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7184346</ArticleId><ArticleId IdType="pubmed">32227123</ArticleId></ArticleIdList></Reference><Reference><Citation>S. Wan, et al., Characteristics of lymphocyte subsets and cytokines in peripheral blood of 123 hospitalized patients with 2019 novel coronavirus pneumonia (NCP), medRxiv (2020) 2020.02.10.20021832.</Citation></Reference><Reference><Citation>Xu Z., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8(4):420&#x2013;422.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Li T., et al. Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome. J. Infect. Dis. 2004;189(4):648&#x2013;651.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7109946</ArticleId><ArticleId IdType="pubmed">14767818</ArticleId></ArticleIdList></Reference><Reference><Citation>Cecere T.E., et al. Regulatory T cells in arterivirus and coronavirus infections: do they protect against disease or enhance it? Viruses. 2012;4(5):833&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3386620</ArticleId><ArticleId IdType="pubmed">22754651</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Y.-H., et al. Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J. Infect. 2020;80(4):394&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7102535</ArticleId><ArticleId IdType="pubmed">32109443</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J.J., et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020</Citation><ArticleIdList><ArticleId IdType="pubmed">32077115</ArticleId></ArticleIdList></Reference><Reference><Citation>Tufan A., et al. COVID-19, immune system response, hyperinflammation and repurposing antirheumatic drugs. Turk. J. Med. Sci. 2020;50(SI-1):620&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7195984</ArticleId><ArticleId IdType="pubmed">32299202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yonggang Z., et al. Pathogenic T cells and inflammatory monocytes incite inflammatory storm in severe COVID-19 patients. Natl. Sci. Rev. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7108005</ArticleId><ArticleId IdType="pubmed">34676125</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu B., et al. Why tocilizumab could be an effective treatment for severe COVID-19? J. Transl. Med. 2020;18(1):164.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7154566</ArticleId><ArticleId IdType="pubmed">32290839</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382(18):1708&#x2013;1720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine. 2020;55:102763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7165294</ArticleId><ArticleId IdType="pubmed">32361250</ArticleId></ArticleIdList></Reference><Reference><Citation>Busetto L., et al. Obesity and COVID-19: an Italian snapshot. Obesity (Silver Spring, Md.) 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7283686</ArticleId><ArticleId IdType="pubmed">32463545</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo W., et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020:e3319.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7228407</ArticleId><ArticleId IdType="pubmed">32233013</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang D., et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. Jama. 2020;323(11):1061&#x2013;1069.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7042881</ArticleId><ArticleId IdType="pubmed">32031570</ArticleId></ArticleIdList></Reference><Reference><Citation>Bikdeli B., et al. COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J. Am. Coll. Cardiol. 2020;S0735-1097(20):35008&#x2013;35017.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7164881</ArticleId><ArticleId IdType="pubmed">32311448</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang L., et al. Coronavirus disease 2019: coronaviruses and blood safety. Transfus. Med. Rev. 2020</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7135848</ArticleId><ArticleId IdType="pubmed">32107119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., et al. Coagulopathy and antiphospholipid antibodies in patients with Covid-19. N. Engl. J. Med. 2020;382(17):e38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7161262</ArticleId><ArticleId IdType="pubmed">32268022</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., et al. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J. Thromb. Haemost. 2020;18(5):1094&#x2013;1099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9906401</ArticleId><ArticleId IdType="pubmed">32220112</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao L., et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir. Res. 2020;21(1):83.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7156898</ArticleId><ArticleId IdType="pubmed">32293449</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">26998845</PMID><DateCompleted><Year>2017</Year><Month>07</Month><Day>03</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0852</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><PubDate><Year>2016</Year><Month>May</Month></PubDate></JournalIssue><Title>European journal of cancer (Oxford, England : 1990)</Title><ISOAbbreviation>Eur J Cancer</ISOAbbreviation></Journal><ArticleTitle>Phase III randomised clinical trial comparing primary surgery versus neoadjuvant chemotherapy in advanced epithelial ovarian cancer with high tumour load (SCORPION trial): Final analysis of peri-operative outcome.</ArticleTitle><Pagination><StartPage>22</StartPage><EndPage>33</EndPage><MedlinePgn>22-33</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejca.2016.01.017</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0959-8049(16)00072-1</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To establishing whether neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) is superior primary debulking surgery (PDS) in terms of clinical outcome as well as peri-operative morbidity in advanced epithelial ovarian cancer (AEOC) endowed with high tumour load (HTL).</AbstractText><AbstractText Label="MATERIAL AND METHODS">This is a single-Institution, superiority, randomised phase III trial enrolling supposed AEOC women. Patients considered pre-operatively eligible were triaged to staging laparoscopy to assess the predictive index (PI) of tumour load. All AEOC women with PI&#x2265;8 or&#x2264;12 (considered as HTL) were included. They were randomly assigned (1:1 ratio) to undergo either PDS followed by systemic adjuvant chemotherapy (arm A, standard), or NACT followed by IDS (NACT/IDS) (arm B, experimental). Co-primary outcome measures were postoperative complications (graded according to the Memorial Sloan Kettering Cancer Center&#xa0;surgical secondary events grading system) and progression free survival (PFS); secondary outcomes were overall survival, and quality of life (QoL). QoL was assessed using the EORTC QoL questionnaires. A sample size of 110 patients was required for the analysis of the first co-primary end-point (major peri-operative morbidity) whereas recruitment is still on-going to achieve the statistical power on PFS.</AbstractText><AbstractText Label="RESULTS">Between October 2011 and November 2014, we registered 280 AEOC. Of the 110 eligible women, 55 were assigned to arm A and 55 to arm B. Despite different extension of surgery, rates of complete residual disease (residual tumour=0&#xa0;cm) were superimposable between the groups (45.5% versus 57.7%; p=0.206). Twenty-nine patients (52.7%) in arm A experienced early grade III-IV complications versus three patients (5.7%) in IDS (p=0.0001). The most common complication was grade III and consisted of symptomatic pleural effusion requiring thoracic drainage (17/55 women (30.9%) in arm A versus 1/52 (1.9%) in arm B, p=0.0001). Three grade IV (5.4%) (i.e., two re-operations for postoperative haemorrhage and one septic multi-organ failure), and two grade V (3.6%) (two deaths for acute cardiopulmonary failure) early complications were observed in arm A only. Mean QoL scores of several scales/items were shown to ameliorate over time in both arms. Emotional functioning, cognitive functioning, nausea/vomiting, dyspnoea, insomnia and hair loss were statistically and clinically better in NACT/IDS compared to PDS arm.</AbstractText><AbstractText Label="CONCLUSIONS">Perioperative moderate/severe morbidity as well as QoL scores were shown to be more favourable in NACT/IDS arm than PDS in AEOC patients with very HTL. Completion of patient enrolment and analysis of survival data will clarify whether PDS with such a high rate of severe complications is an acceptable treatment in AEOC women with HTL.</AbstractText><CopyrightInformation>Copyright &#xa9; 2016 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Fagotti</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Minimally Invasive Gynecological Surgery, St. Maria Hospital, University of Perugia, Terni, Italy. Electronic address: anna.fagotti@rm.unicatt.it.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferrandina</LastName><ForeName>Gabriella</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vizzielli</LastName><ForeName>Giuseppe</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fanfani</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Department of Medicine and Aging Sciences, University "G. d'Annunzio" of Chieti-Pescara, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gallotta</LastName><ForeName>Valerio</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chiantera</LastName><ForeName>Vito</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Foundation for Research and Care "Giovanni Paolo II", Catholic University of the Sacred Heart and University of Molise, Campobasso, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Costantini</LastName><ForeName>Barbara</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margariti</LastName><ForeName>Pasquale Alessandro</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gueli Alletti</LastName><ForeName>Salvatore</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cosentino</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tortorella</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Scambia</LastName><ForeName>Giovanni</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Division of Gynecologic Oncology, Catholic University of the Sacred Heart, Rome, Italy.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Eur J Cancer</MedlineTA><NlmUniqueID>9005373</NlmUniqueID><ISSNLinking>0959-8049</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>BG3F62OND5</RegistryNumber><NameOfSubstance UI="D016190">Carboplatin</NameOfSubstance></Chemical><Chemical><RegistryNumber>P88XT4IS4D</RegistryNumber><NameOfSubstance UI="D017239">Paclitaxel</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001828" MajorTopicYN="N">Body Image</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016190" MajorTopicYN="N">Carboplatin</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000077216" MajorTopicYN="N">Carcinoma, Ovarian Epithelial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017024" MajorTopicYN="N">Chemotherapy, Adjuvant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D065426" MajorTopicYN="N">Cytoreduction Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009375" MajorTopicYN="N">Neoplasms, Glandular and Epithelial</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061646" MajorTopicYN="N">Operative Time</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010051" MajorTopicYN="N">Ovarian Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017239" MajorTopicYN="N">Paclitaxel</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Advanced ovarian cancer</Keyword><Keyword MajorTopicYN="N">Cytoreduction</Keyword><Keyword MajorTopicYN="N">Laparoscopy</Keyword><Keyword MajorTopicYN="N">Peri-operative complications</Keyword><Keyword MajorTopicYN="N">Quality of life</Keyword><Keyword MajorTopicYN="N">Randomised clinical trial</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>10</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2016</Year><Month>1</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>7</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26998845</ArticleId><ArticleId IdType="doi">10.1016/j.ejca.2016.01.017</ArticleId><ArticleId IdType="pii">S0959-8049(16)00072-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">25853746</PMID><DateCompleted><Year>2015</Year><Month>04</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1533-4406</ISSN><JournalIssue CitedMedium="Internet"><Volume>372</Volume><Issue>15</Issue><PubDate><Year>2015</Year><Month>Apr</Month><Day>09</Day></PubDate></JournalIssue><Title>The New England journal of medicine</Title><ISOAbbreviation>N Engl J Med</ISOAbbreviation></Journal><ArticleTitle>Effects of red-cell storage duration on patients undergoing cardiac surgery.</ArticleTitle><Pagination><StartPage>1419</StartPage><EndPage>1429</EndPage><MedlinePgn>1419-29</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1056/NEJMoa1414219</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Some observational studies have reported that transfusion of red-cell units that have been stored for more than 2 to 3 weeks is associated with serious, even fatal, adverse events. Patients undergoing cardiac surgery may be especially vulnerable to the adverse effects of transfusion.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We conducted a randomized trial at multiple sites from 2010 to 2014. Participants 12 years of age or older who were undergoing complex cardiac surgery and were likely to undergo transfusion of red cells were randomly assigned to receive leukocyte-reduced red cells stored for 10 days or less (shorter-term storage group) or for 21 days or more (longer-term storage group) for all intraoperative and postoperative transfusions. The primary outcome was the change in Multiple Organ Dysfunction Score (MODS; range, 0 to 24, with higher scores indicating more severe organ dysfunction) from the preoperative score to the highest composite score through day 7 or the time of death or discharge.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The median storage time of red-cell units provided to the 1098 participants who received red-cell transfusion was 7 days in the shorter-term storage group and 28 days in the longer-term storage group. The mean change in MODS was an increase of 8.5 and 8.7 points, respectively (95% confidence interval for the difference, -0.6 to 0.3; P=0.44). The 7-day mortality was 2.8% in the shorter-term storage group and 2.0% in the longer-term storage group (P=0.43); 28-day mortality was 4.4% and 5.3%, respectively (P=0.57). Adverse events did not differ significantly between groups except that hyperbilirubinemia was more common in the longer-term storage group.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The duration of red-cell storage was not associated with significant differences in the change in MODS. We did not find that the transfusion of red cells stored for 10 days or less was superior to the transfusion of red cells stored for 21 days or more among patients 12 years of age or older who were undergoing complex cardiac surgery. (Funded by the National Heart, Lung, and Blood Institute; RECESS ClinicalTrials.gov number, NCT00991341.).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>Marie E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>From Fairview-University Medical Center, Minneapolis (M.E.S., S.P., J.M.), and Mayo Clinic, Rochester (G.A.N.) - both in Minnesota; Johns Hopkins University (P.M.N., G.W.) and University of Maryland (R.C.) - both in Baltimore; New England Research Institutes, Data Coordinating Center, Watertown (S.F.A., S.G.), Boston Children's Hospital (S.R.S.), Massachusetts General Hospital (L.B., C.P.S.), Brigham and Women's Hospital (R.M.K.), Tufts University (R.E.), St. Elizabeth's Medical Center (R.H.), and Beth Israel Deaconess Medical Center (L.U.), Boston, and Baystate Medical Center, Springfield (R.E.) - all in Massachusetts; University of Pittsburgh and University of Pittsburgh-Mercy Hospital, Pittsburgh (D.J.T., P.D.); Puget Sound Blood Center and University of Washington (M.D.) and Swedish Medical Center (S.Y.) - all in Seattle; Duke University, Durham (E.B.-G., J.H.L., T.L.O.), and University of North Carolina, Chapel Hill (Y.P.) - both in North Carolina; McMaster University, Hamilton, ON, Canada (M.A.B.); Indiana-Ohio Heart and St. Joseph Hospital (V.S.) - both in Fort Wayne, IN; Rutgers Robert Wood Johnson Medical School, New Brunswick (J.L.C.), and Newark Beth Israel Medical Center, Newark (R.K.) - both in New Jersey; University of Iowa, Iowa City (T.R.); Aurora St. Luke's Medical Center (K.E.P.) and Froedert Memorial Lutheran Hospital (J.G.M.), Milwaukee, and Aspirus Heart and Vascular Institute, Wausau (R.M.) - all in Wisconsin; Vanderbilt University, Nashville (P.P.Y.); University of Texas Southwestern Medical Center, Dallas (P.E.G.); Children's Healthcare of Atlanta, Emory University, and Emory University Hospital, Atlanta (C.D.J.); St. Luke's-Texas Heart Institute, Houston (A.B.); Weill Cornell Medical College (M.M.C.) and Columbia University Medical Center (E.A.H.) - both in New York; University of Florida, Gainesville (C.T.K.); University of Oklahoma, Oklahoma City (P.R.R.); and University of North Dakota School of Medicine and Health Sciences, Fargo (C.D.).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ness</LastName><ForeName>Paul M</ForeName><Initials>PM</Initials></Author><Author ValidYN="Y"><LastName>Assmann</LastName><ForeName>Susan F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Triulzi</LastName><ForeName>Darrell J</ForeName><Initials>DJ</Initials></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>Steven R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Delaney</LastName><ForeName>Meghan</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Granger</LastName><ForeName>Suzanne</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Bennett-Guerrero</LastName><ForeName>Elliott</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Blajchman</LastName><ForeName>Morris A</ForeName><Initials>MA</Initials></Author><Author ValidYN="Y"><LastName>Scavo</LastName><ForeName>Vincent</ForeName><Initials>V</Initials></Author><Author ValidYN="Y"><LastName>Carson</LastName><ForeName>Jeffrey L</ForeName><Initials>JL</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>Jerrold H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Whitman</LastName><ForeName>Glenn</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>D'Andrea</LastName><ForeName>Pamela</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Pulkrabek</LastName><ForeName>Shelley</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ortel</LastName><ForeName>Thomas L</ForeName><Initials>TL</Initials></Author><Author ValidYN="Y"><LastName>Bornikova</LastName><ForeName>Larissa</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Raife</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Puca</LastName><ForeName>Kathleen E</ForeName><Initials>KE</Initials></Author><Author ValidYN="Y"><LastName>Kaufman</LastName><ForeName>Richard M</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Nuttall</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials></Author><Author ValidYN="Y"><LastName>Young</LastName><ForeName>Pampee P</ForeName><Initials>PP</Initials></Author><Author ValidYN="Y"><LastName>Youssef</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Engelman</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Greilich</LastName><ForeName>Philip E</ForeName><Initials>PE</Initials></Author><Author ValidYN="Y"><LastName>Miles</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Josephson</LastName><ForeName>Cassandra D</ForeName><Initials>CD</Initials></Author><Author ValidYN="Y"><LastName>Bracey</LastName><ForeName>Arthur</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Cooke</LastName><ForeName>Rhonda</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>McCullough</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Hunsaker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Uhl</LastName><ForeName>Lynne</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>McFarland</LastName><ForeName>Janice G</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Park</LastName><ForeName>Yara</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Cushing</LastName><ForeName>Melissa M</ForeName><Initials>MM</Initials></Author><Author ValidYN="Y"><LastName>Klodell</LastName><ForeName>Charles T</ForeName><Initials>CT</Initials></Author><Author ValidYN="Y"><LastName>Karanam</LastName><ForeName>Ravindra</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Pamela R</ForeName><Initials>PR</Initials></Author><Author ValidYN="Y"><LastName>Dyke</LastName><ForeName>Cornelius</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hod</LastName><ForeName>Eldad A</ForeName><Initials>EA</Initials></Author><Author ValidYN="Y"><LastName>Stowell</LastName><ForeName>Christopher P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00991341</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>R01 HL101382</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072331</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>UL1 RR025758</GrantID><Acronym>RR</Acronym><Agency>NCRR NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>N Engl J Med</MedlineTA><NlmUniqueID>0255562</NlmUniqueID><ISSNLinking>0028-4793</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):283-4. doi: 10.1056/NEJMc1505699.</RefSource><PMID Version="1">26176390</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>N Engl J Med. 2015 Jul 16;373(3):283. doi: 10.1056/NEJMc1505699.</RefSource><PMID Version="1">26176391</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001788" MajorTopicYN="N">Blood Grouping and Crossmatching</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="Y">Blood Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="Y">Cardiac Surgical Procedures</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057194" MajorTopicYN="N">Intention to Treat Analysis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009026" MajorTopicYN="N">Mortality</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000145" MajorTopicYN="N">classification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016016" MajorTopicYN="N">Proportional Hazards Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>4</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>4</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2017</Year><Month>5</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25853746</ArticleId><ArticleId IdType="mid">NIHMS696944</ArticleId><ArticleId IdType="pmc">PMC5442442</ArticleId><ArticleId IdType="doi">10.1056/NEJMoa1414219</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hess JR. An update on solutions for red cell storage. Vox Sang. 2006;91:13&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16756596</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess JR. Red cell changes during storage. Transfus Apher Sci. 2010;43:51&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">20558107</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Veldman TH, Doctor A, et al. Evolution of adverse changes in stored RBCs. Proc Natl Acad Sci U S A. 2007;104:17063&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2040393</ArticleId><ArticleId IdType="pubmed">17940021</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani A, Steiner ME, Hebbel RP. The dynamic regulation of microcirculatory conduit function: features relevant to transfusion medicine. Transfus Apher Sci. 2010;43:61&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2920132</ArticleId><ArticleId IdType="pubmed">20580315</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. oxygen delivery in transfusion with &#x201c;fresh&#x201d; and &#x201c;old&#x201d; red blood cells: the experimental evidence. Transfus Apher Sci. 2010;43:69&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918661</ArticleId><ArticleId IdType="pubmed">20646963</ArticleId></ArticleIdList></Reference><Reference><Citation>Triulzi DJ, Yazer MH. Clinical studies of the effect of blood storage on patient outcomes. Transfus Apher Sci. 2010;43:95&#x2013;106.</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zimrin AB, Hess JR. Current issues relating to the transfusion of stored red blood cells. Vox Sang. 2009;96:93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">19152602</ArticleId></ArticleIdList></Reference><Reference><Citation>Lelubre C, Piagnerelli M, Vincent JL. Association between duration of storage of transfused red blood cells and morbidity and mortality in adult patients: myth or reality? Transfusion. 2009;49:1384&#x2013;94.</Citation><ArticleIdList><ArticleId IdType="pubmed">19453985</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of &#x201c;old&#x201d; (versus &#x201c;fresh&#x201d;) red blood cells: are we at equipoise? Transfusion. 2010;50:600&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Watering L. Red cell storage and prognosis. Vox Sang. 2011;100:36&#x2013;45.</Citation><ArticleIdList><ArticleId IdType="pubmed">21175654</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Chin-Yee I, Fergusson D, et al. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg. 2005;100:1433&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Stafford-Smith M, Waweru PM, et al. A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion. 2009;49:1375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson DA, H&#xe9;bert P, Hogan DL, et al. Effect of fresh red blood cell transfusions on clinical outcomes in premature, very low-birth-weight infants: the ARIPI randomized trial. JAMA. 2012;308:1443&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">23045213</ArticleId></ArticleIdList></Reference><Reference><Citation>Elahi MM, Yii M, Matata BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. J Cardiothorac Vasc Anesth. 2008;22:455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503942</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch CGH, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. N Engl J Med. 2008;358:1229&#x2013;39.</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A. Effects of storage time of red cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46:1712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CH, Lau L, Krishnaswamy M, Gaskell M, Yii M. Age of transfused red cells and early outcomes after cardiac surgery. Ann Thorac Surg. 2008;86:554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640333</ArticleId></ArticleIdList></Reference><Reference><Citation>Edgren G, Kamper-J&#xf8;rgensen M, Eloranta S, et al. Duration of red blood cell storage and survival of transfused patients. Transfusion. 2010;50:1185&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3201703</ArticleId><ArticleId IdType="pubmed">20158690</ArticleId></ArticleIdList></Reference><Reference><Citation>Steiner ME, Assmann SF, Levy JH, et al. Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7) Transfus Apher Sci. 2010;43:107&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918709</ArticleId><ArticleId IdType="pubmed">20655807</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46:1120&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">16836558</ArticleId></ArticleIdList></Reference><Reference><Citation>Roback JD, Grossman BJ, Harris T, Hillyer CD, editors. Technical manual. 17th. Bethesda, MD: AABB Press; 2011. p. 192.</Citation></Reference><Reference><Citation>Zelen M. The randomization and stratification of patients to clinical trials. J Chronic Dis. 1974;27:365&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">4612056</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Hod EA, Brittenham GM, Billote GB, et al. Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. Blood. 2011;118:6675&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3242722</ArticleId><ArticleId IdType="pubmed">22021369</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitaker BI, Hinkins S.  The 2011 National blood collection and utilization survey report. Washington, DC: Department of Health and Human Services; 2013.   http://www.aabb.org/research/hemovigilance/bloodsurvey/Documents/11-nbcus-report.pdf.</Citation></Reference><Reference><Citation>Koch CG, Li L, Duncan AI, et al. Morbidity and mortality risk associated with red blood cell and blood-component transfusion in isolated coronary artery bypass grafting. Crit Care Med. 2006;34:1608&#x2013;16.</Citation><ArticleIdList><ArticleId IdType="pubmed">16607235</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert P, Fergusson D, et al. The Age of Blood Evaluation (ABLE) randomized controlled trial: study design. Transfus Med Rev. 2011;25:197&#x2013;205.</Citation><ArticleIdList><ArticleId IdType="pubmed">21550205</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15142885</PMID><DateCompleted><Year>2004</Year><Month>06</Month><Day>10</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1756-1833</ISSN><JournalIssue CitedMedium="Internet"><Volume>328</Volume><Issue>7451</Issue><PubDate><Year>2004</Year><Month>May</Month><Day>29</Day></PubDate></JournalIssue><Title>BMJ (Clinical research ed.)</Title><ISOAbbreviation>BMJ</ISOAbbreviation></Journal><ArticleTitle>Effects of transfusion with red cells filtered to remove leucocytes: randomised controlled trial in patients undergoing major surgery.</ArticleTitle><Pagination><StartPage>1281</StartPage><MedlinePgn>1281</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare postoperative complications in patients undergoing major surgery who received non-filtered or filtered red blood cell transfusions.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective, randomised, double blinded trial.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">19 hospitals throughout the Netherlands (three university; 10 clinical; six general).</AbstractText><AbstractText Label="PARTICIPANTS" NlmCategory="METHODS">1051 evaluable patients: 79 patients with ruptured aneurysm, 412 patients undergoing elective surgery for aneurysm, and 560 undergoing gastrointestinal surgery.</AbstractText><AbstractText Label="INTERVENTIONS" NlmCategory="METHODS">The non-filtered products had the buffy coat removed and were plasma reduced. The filtered products had the buffy coat removed, were plasma reduced, and filtered before storage to remove leucocytes.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Mortality and duration of stay in intensive care. Secondary end points were occurrence of multi-organ failure, infections, and length of hospital stay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">No significant differences were found in mortality (odds ratio for filtered v non-filtered 0.80, 95% confidence interval 0.53 to 1.21) and in mean stay in intensive care (- 0.4 day, - 1.6 to 0.6 day). In the filtered group the mean length of hospital stay was 2.4 days shorter (- 4.8 to 0.0 day; P = 0.050) and the incidence of multi-organ failure was 30% lower (odds ratio 0.70, 0.49 to 1.00; P = 0.050). There were no differences in rates of infection (0.98, 0.73 to 1.32).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">The use of filtered transfusions in some types of major surgery may reduce the length of hospital stay and the incidence of postoperative multi-organ failure.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>van Hilten</LastName><ForeName>Joost A</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Department of Immunohaematology and Blood Transfusion, Leiden University Medical Center and Sanquin Blood Supply, PO Box 9600, 2300 RC Leiden, Netherlands. J.A.van_Hilten@lumc.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van de Watering</LastName><ForeName>Leo M G</ForeName><Initials>LM</Initials></Author><Author ValidYN="Y"><LastName>van Bockel</LastName><ForeName>J Hajo</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>van de Velde</LastName><ForeName>Cornelis J H</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Kievit</LastName><ForeName>Job</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Ronald</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>van den Hout</LastName><ForeName>Wilbert B</ForeName><Initials>WB</Initials></Author><Author ValidYN="Y"><LastName>Geelkerken</LastName><ForeName>Robert H</ForeName><Initials>RH</Initials></Author><Author ValidYN="Y"><LastName>Roumen</LastName><ForeName>Rudi M H</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Wesselink</LastName><ForeName>Ronald M J</ForeName><Initials>RM</Initials></Author><Author ValidYN="Y"><LastName>Koopman-van Gemert</LastName><ForeName>Ankie W M M</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Koning</LastName><ForeName>Jan</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Brand</LastName><ForeName>Anneke</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016430">Clinical Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2004</Year><Month>05</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>BMJ</MedlineTA><NlmUniqueID>8900488</NlmUniqueID><ISSNLinking>0959-8138</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001014" MajorTopicYN="N">Aortic Aneurysm</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001019" MajorTopicYN="N">Aortic Rupture</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="N">Erythrocyte Transfusion</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005767" MajorTopicYN="N">Gastrointestinal Diseases</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007937" MajorTopicYN="N">Leukapheresis</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2004</Year><Month>6</Month><Day>21</Day><Hour>10</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2004</Year><Month>5</Month><Day>15</Day><Hour>5</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2004</Year><Month>5</Month><Day>29</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15142885</ArticleId><ArticleId IdType="pmc">PMC420164</ArticleId><ArticleId IdType="doi">10.1136/bmj.38103.735266.55</ArticleId><ArticleId IdType="pii">bmj.38103.735266.55</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wobbes T, Bemelmans BL, Kuypers JH, Beerthuizen GI, Theeuwes Ag. Risk of postoperative septic complications after abdominal surgical treatment in relation to perioperative blood transfusion. Surg Gynecol Obstet 1990;171: 59-62.</Citation><ArticleIdList><ArticleId IdType="pubmed">2360151</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinto V, Baldonedo R, Nicolas C, BPreez A, Aza J. Relationship of transfusion and infectious complications after gastric carcinoma operation. Transfusion 1991;31: 114-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">1996479</ArticleId></ArticleIdList></Reference><Reference><Citation>Spark JI, Chetter IC, Kester RC, Scott DJ. Allogeneic versus autologous blood during abdominal aortic aneurysm surgery. Eur J Vasc Endovasc Surg 1997;14: 482-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9467524</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, Blajchman MA, Wells G, Marshall J, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med 2001;29: 227-33.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Duffy G, Neal KR. Differences in postoperative infection rates between patients receiving autologous and allogeneic blood transfusion: a meta-analysis of published randomised and nonrandomised studies. Transfusion Med 1996;6: 325-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">8981727</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC, Blajchman MA. Deleterious clinical effects of transfusion-associated immunomodulation: fact or fiction? Blood 2000;97:5: 1180-95.</Citation><ArticleIdList><ArticleId IdType="pubmed">11222359</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharma AD, Sreeram G, Erb T, Grocott HP, Slaughter TF. Leukocyte-reduced blood transfusions: Perioperative indications, adverse effects and cost analysis. Anesth Analg 2000;90: 1315-23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10825313</ArticleId></ArticleIdList></Reference><Reference><Citation>Groeneveld AB, Raijmakers PG, Rauwerda JA, Hack CE. The inflammatory response to vascular surgery-associated ischaemia and reperfusion in man: effect on postoperative pulmonary function. Eur J Vasc Endovasc Surg 1997;14: 351-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">9413375</ArticleId></ArticleIdList></Reference><Reference><Citation>Rapaport FT, Dausset J. The possible role of leukocyte components in the production of the beneficial effects of blood transfusion in human transplantation. Transplant Proc 1983;15: 952-5.</Citation></Reference><Reference><Citation>Collier AC, Kalish LA, Busch MP, Gernsheimer T, Assmann T, Lane TA. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection. The viral activation transfusion study: a randomised controlled trial. JAMA 2001;285: 1592-601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268267</ArticleId></ArticleIdList></Reference><Reference><Citation>Houbiers JG, Brand A, van de Watering LM, Hermans J, Verwey PJ, Bijnen AB, et al. Randomised controlled trial comparing transfusion of leukocyte-depleted or buffy-coat-depleted blood in surgery for colorectal cancer. Lancet 1994;344: 573-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">7914960</ArticleId></ArticleIdList></Reference><Reference><Citation>Titlestad IL, Ebbesen LS, Ainsworth AP, Lillevang ST, Qvist N, Georgsen J. Leukocyte-depletion of blood components does not significantly reduce the risk of infectious complications. Results of a double-blinded, randomised study. Int J Colorectal Dis 2001;16: 147-53.</Citation><ArticleIdList><ArticleId IdType="pubmed">11459288</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LS, Anderson AJ, Christiansen PM, Hokland P, Juhl CO, Madsen G, et al. Postoperative infection and natural killer cell function following blood transfusion in patients undergoing elective colorectal surgery. Br J Surg 1992;79: 513-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">1611441</ArticleId></ArticleIdList></Reference><Reference><Citation>Tartter PI, Mohandas K, Azar P. Randomised trial comparing packed red blood cell transfusion with and without leukocyte depletion in gastrointestinal surgery. Am J Surg 1998;176: 462-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">9874434</ArticleId></ArticleIdList></Reference><Reference><Citation>Jensen LS, Kissmeyer-Nielsen P, Wolff B. Randomised comparison of leukocyte-depleted versus buffy-coat-poor blood transfusion and complications after colorectal surgery. Lancet 1996;348: 841-5.</Citation><ArticleIdList><ArticleId IdType="pubmed">8826808</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Multicentre randomised controlled trials in transfusion medicine. Transfusion Med Rev 2000;14: 137-50.</Citation><ArticleIdList><ArticleId IdType="pubmed">10782498</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Watering LM, Hermans J, Houbiers JG, van den Broek PJ, Bouter H, Boer F, et al. A beneficial effect of leukocyte depletion of transfused blood on postoperative mortality in patients undergoing cardiac surgery: a randomised clinical trial. Circulation 1998;97: 562-8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9494026</ArticleId></ArticleIdList></Reference><Reference><Citation>Goris RJ, te Boekhorst TP, Nuytinck JKS, Gimbrere JS. Multiple-organ failure. Generalized autodestructive inflammation? Arch Surg 1985;120: 1109.</Citation><ArticleIdList><ArticleId IdType="pubmed">4038052</ArticleId></ArticleIdList></Reference><Reference><Citation>Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342: 1334-49.</Citation><ArticleIdList><ArticleId IdType="pubmed">10793167</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathens AB, Marshall JC. Sepsis, SIRS and MODS: what's in a name? World J Surg 1996;20: 386-91.</Citation><ArticleIdList><ArticleId IdType="pubmed">8662129</ArticleId></ArticleIdList></Reference><Reference><Citation>Asimakopoulos G. Mechanisms of the systemic inflammatory response. Perfusion 1999;14: 269-77.</Citation><ArticleIdList><ArticleId IdType="pubmed">10456781</ArticleId></ArticleIdList></Reference><Reference><Citation>Moher D, Schulz KF, Altman DG. The CONSORT statement: revised recommendations for improving the quality of report of parallel-group randomised trials. Lancet 2001;357: 1191-4.</Citation><ArticleIdList><ArticleId IdType="pubmed">11323066</ArticleId></ArticleIdList></Reference><Reference><Citation>Assmann SF, Pocock SJ, Enos LE, Kasten LE. Subgroup analysis and other (mis)uses of baseline data in clinical trial. Lancet 2000;255: 1064-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">10744093</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. Prognosis in acute organ system failure. Ann Surg 1985;202: 685.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1250999</ArticleId><ArticleId IdType="pubmed">4073980</ArticleId></ArticleIdList></Reference><Reference><Citation>Garner JS, Jarvis WR, Emori TG, Horan TC, Hughes JM. CDC definitions for nosocomial infections. Am J Infect Control 1985;16: 128-40.</Citation><ArticleIdList><ArticleId IdType="pubmed">2841893</ArticleId></ArticleIdList></Reference><Reference><Citation>Desgagne A, Castilloux AM, Angers JF, LeLorier J. The use of the bootstrap statistical method for the pharmacoeconomic cost analysis of skewed data. Pharmacoeconomics 1998;13: 487-97.</Citation><ArticleIdList><ArticleId IdType="pubmed">10180748</ArticleId></ArticleIdList></Reference><Reference><Citation>Blumberg N, Heal JM, Cowles JW, Hicks GL Jr, Risher WH, Samuel PK, et al. Leukocyte-reduced transfusions in cardiac surgery. Results of an implementation trial. Am J Clin Pathol 2002;118: 376-81.</Citation><ArticleIdList><ArticleId IdType="pubmed">12219779</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgin YM, van de Watering LMG, Lorinser JE, Versteegh MIM, Eijsman L, van Oers MHJ, et al. The effect of prestorage-leukocyte-depletion of erythrocyte concentrates in cardiac surgery: a double-blind randomised clinical trial. Blood 2001;98(suppl): 828-9a.</Citation></Reference><Reference><Citation>Hebert PC, Fergusson D, Blajchman MA, Wells GA, Kmetic A, Coyle D, et al. Clinical outcomes following institutions of the Canadian universal leukoreduction program for red blood cell transfusions. JAMA 2003;289: 1941-9.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697796</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D, Hebert PC, Lee SK, Walker CR, Barrington KJ, Joseph L, et al. Clinical outcomes following institution of universal leukocyte depletion of blood transfusions for premature infants. JAMA 2003;289: 1950-6.</Citation><ArticleIdList><ArticleId IdType="pubmed">12697797</ArticleId></ArticleIdList></Reference><Reference><Citation>Dzik WH, Anderson JK, O'Neill EM, Assmann SF, Kalish LA, Stowell CP. A prospective, randomized clinical trial of universal WBC reduction. Transfusion 2002;42: 1114-22.</Citation><ArticleIdList><ArticleId IdType="pubmed">12430666</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36357273</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1008-1275</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>2</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Chinese journal of traumatology = Zhonghua chuang shang za zhi</Title><ISOAbbreviation>Chin J Traumatol</ISOAbbreviation></Journal><ArticleTitle>Evaluating the effect of montelukast tablets on respiratory complications in patients following blunt chest wall trauma: A double-blind, randomized clinical trial.</ArticleTitle><Pagination><StartPage>116</StartPage><EndPage>120</EndPage><MedlinePgn>116-120</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.cjtee.2022.10.002</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1008-1275(22)00106-7</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">Patients with multiple traumas are at high risk of developing respiratory complications, including pneumonia and acute respiratory distress syndrome. Many pulmonary complications are associated with systemic inflammation and pulmonary neutrophilic infiltration. Leukotriene-receptor antagonists are anti-inflammatory and anti-oxidant drugs subsiding airway inflammation. The present study investigates the effectiveness of montelukast in reducing pulmonary complications among trauma patients.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This randomized, double-blind, placebo-control trial was conducted in patients with multiple blunt traumas and evidence of lung contusion detected via CT scan. We excluded patients if they met at least one of the following conditions: &lt; 16 years old, history of cardiopulmonary diseases or positive history of montelukast-induced hypersensitivity reactions. Patients were allocated to the treatment (10&#xa0;mg of montelukast) or placebo group using permuted block randomization method. The primary measured outcome was the volume of pulmonary contusion at the end of the trial. The secondary outcomes were intensive care unit and hospital length of stay, ventilation days, multi-organ failure, and the in-hospital mortality rate.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In total, 65 eligible patients (treatment&#xa0;=&#xa0;31, placebo&#xa0;=&#xa0;34) were included for the final analysis. The treatment group had more pulmonary contusion volume (mean (SD), mm<sup>3</sup>) at the right (68726.97 (93656.54) vs. 59730.27 (76551.74)) and the left side (67501.71 (91514.04) vs. 46502.21 (80604.21)), higher initial C-reactive peptide level (12.16 (10.58) vs. 10.85 (17.87)) compared to the placebo group, but the differences were not statistically significant (p&#xa0;&gt;&#xa0;0.05). At the end of the study, the mean (SD) of pulmonary contusion volume (mm<sup>3</sup>) (right side&#xa0;=&#xa0;116748.74 (361705.12), left side&#xa0;=&#xa0;64522.03 (117266.17)) of the treatment group were comparable to that of the placebo group (right side&#xa0;=&#xa0;40051.26 (64081.56), left side&#xa0;=&#xa0;25929.12 (47417.13), p&#xa0;=&#xa0;0.228 and 0.082, respectively). Moreover, both groups have statistically similar hospital (mean (SD), days) (10.87 (9.83) vs. 13.05 (10.12)) and intensive care unit length of stays (mean (SD), days) (7.16 (8.15) vs. 7.82 (7.48)). Of note, the frequency of the in-hospital complications (treatment vs. control group) including acute respiratory distress syndrome (12.9% vs. 8.8%, p&#xa0;=&#xa0;0.71), pneumonia (19.4% vs. 17.6%, p&#xa0;=&#xa0;0.85), multi-organ failure (12.9% vs. 17.6%, p&#xa0;=&#xa0;0.58) and the mortality rate (22.6% vs. 14.7%, p&#xa0;=&#xa0;0.41) were comparable between the groups.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Administrating montelukast has no preventive or therapeutic effects on lung contusion or its complications.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022. Production and hosting by Elsevier B.V.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heydari</LastName><ForeName>Soleyman</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Baqiyatallah University of Medical Sciences, Tehran, Iran; Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Khoshmohabat</LastName><ForeName>Hadi</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Akerdi</LastName><ForeName>Ali Taheri</ForeName><Initials>AT</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran. Electronic address: ata.110.iran@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ahmadpour</LastName><ForeName>Fathollah</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paydar</LastName><ForeName>Shahram</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Trauma Research Center, Shahid Rajaee (Emtiaz) Trauma Hospital, Shiraz University of Medical Sciences, Shiraz, Iran.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>10</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin J Traumatol</MedlineTA><NlmUniqueID>100886162</NlmUniqueID><ISSNLinking>1008-1275</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>MHM278SD3E</RegistryNumber><NameOfSubstance UI="C093875">montelukast</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D013607">Tablets</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D035441" MajorTopicYN="Y">Thoracic Wall</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011014" MajorTopicYN="Y">Pneumonia</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="Y">Wounds, Nonpenetrating</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013898" MajorTopicYN="Y">Thoracic Injuries</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055370" MajorTopicYN="Y">Lung Injury</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003288" MajorTopicYN="Y">Contusions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="Y">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013607" MajorTopicYN="N">Tablets</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Acute respiratory distress syndrome</Keyword><Keyword MajorTopicYN="N">Contusions</Keyword><Keyword MajorTopicYN="N">Injuries</Keyword><Keyword MajorTopicYN="N">Leukotrienes</Keyword><Keyword MajorTopicYN="N">Montelukast</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>9</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>10</Day><Hour>22</Hour><Minute>5</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>10</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36357273</ArticleId><ArticleId IdType="pmc">PMC9558713</ArticleId><ArticleId IdType="doi">10.1016/j.cjtee.2022.10.002</ArticleId><ArticleId IdType="pii">S1008-1275(22)00106-7</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Leonard J.M., Zhang C.X., Lu L., et al. Extrathoracic multiple trauma dysregulates neutrophil function and exacerbates pneumonia-induced lung injury. J&#xa0;Trauma Acute Care Surg. 2021;90:924&#x2013;934. doi: 10.1097/TA.0000000000003147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003147</ArticleId><ArticleId IdType="pmc">PMC8932930</ArticleId><ArticleId IdType="pubmed">34016916</ArticleId></ArticleIdList></Reference><Reference><Citation>Janicova A., Relja B. Neutrophil phenotypes and functions in trauma and trauma-related sepsis. Shock. 2021;56:16&#x2013;29. doi: 10.1097/SHK.0000000000001695.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001695</ArticleId><ArticleId IdType="pubmed">33201022</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;rmann P., Auner B., Schimunek L., et al. Leukotriene B4 indicates lung injury and on-going inflammatory changes after severe trauma in a porcine long-term model. Prostaglandins Leukot Essent Fatty Acids. 2017;127:25&#x2013;31. doi: 10.1016/j.plefa.2017.09.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.plefa.2017.09.014</ArticleId><ArticleId IdType="pubmed">29156155</ArticleId></ArticleIdList></Reference><Reference><Citation>Auner B., Geiger E.V., Henrich D., et al. Circulating leukotriene B4 identifies respiratory complications after trauma. Mediat Inflamm. 2012;2012 doi: 10.1155/2012/536156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/536156</ArticleId><ArticleId IdType="pmc">PMC3317019</ArticleId><ArticleId IdType="pubmed">22529525</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou Y.Y., Sun B.W. Recent advances in neutrophil chemotaxis abnormalities during sepsis. Chin J Traumatol. 2022;S1008&#x2013;1275(22) doi: 10.1016/j.cjtee.2022.06.002. 00062-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjtee.2022.06.002</ArticleId><ArticleId IdType="pmc">PMC9751578</ArticleId><ArticleId IdType="pubmed">35786510</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan H., Gupta A., Singh T.G., et al. Mechanistic insight on the role of leukotriene receptors in ischemic&#x2013;reperfusion injury. Pharmacol Rep. 2021;73:1240&#x2013;1254. doi: 10.1007/s43440-021-00258-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s43440-021-00258-8</ArticleId><ArticleId IdType="pubmed">33818747</ArticleId></ArticleIdList></Reference><Reference><Citation>David B.A., Kubes P. Exploring the complex role of chemokines and chemoattractants in&#xa0;vivo on leukocyte dynamics. Immunol Rev. 2019;289:9&#x2013;30. doi: 10.1111/imr.12757.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12757</ArticleId><ArticleId IdType="pubmed">30977202</ArticleId></ArticleIdList></Reference><Reference><Citation>St&#xf6;rmann P., Wagner N., K&#xf6;hler K., et al. Monotrauma is associated with enhanced remote inflammatory response and organ damage, while polytrauma intensifies both in porcine trauma model. Eur J Trauma Emerg Surg. 2020;46:31&#x2013;42. doi: 10.1007/s00068-019-01098-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00068-019-01098-1</ArticleId><ArticleId IdType="pubmed">30864051</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H.I., Park J., Konecna B., et al. Plasma and wound fluids from trauma patients suppress neutrophil extracellular respiratory burst. J&#xa0;Trauma Acute Care Surg. 2022;92:330&#x2013;338. doi: 10.1097/TA.0000000000003461.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0000000000003461</ArticleId><ArticleId IdType="pmc">PMC8792304</ArticleId><ArticleId IdType="pubmed">34789698</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi A., Pergola C., Cuzzocrea S., et al. The role of 5-lipoxygenase and leukotrienes in shock and ischemia-reperfusion injury. Sci World J. 2007;7:56&#x2013;74. doi: 10.1100/tsw.2007.34.</Citation><ArticleIdList><ArticleId IdType="doi">10.1100/tsw.2007.34</ArticleId><ArticleId IdType="pmc">PMC5901353</ArticleId><ArticleId IdType="pubmed">17334599</ArticleId></ArticleIdList></Reference><Reference><Citation>Aggarwal A., Baker C., Evans T., et al. G-CSF and IL-8 but not GM-CSF correlate with severity of pulmonary neutrophilia in acute respiratory distress syndrome. Eur Respir J. 2000;15:895&#x2013;901.</Citation><ArticleIdList><ArticleId IdType="pubmed">10853855</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J.B., Eggler J.F. In: Inflammatory Cells and Mediators in Bronchial Asthma. Agrawal D.K., Townley R.G., editors. CRC Press, LLC; Boca Raton, FL: 1991. Leukotriene receptors in the airways; pp. 147&#x2013;169.</Citation></Reference><Reference><Citation>Al-Amran F.G., Hadi N.R., Hashim A.M. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats. Eur J Cardio Thorac Surg. 2013;43:421&#x2013;427. doi: 10.1093/ejcts/ezs312.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ejcts/ezs312</ArticleId><ArticleId IdType="pubmed">22851661</ArticleId></ArticleIdList></Reference><Reference><Citation>El-Benna J., Hurtado-Nedelec M., Marzaioli V., et al. Priming of the neutrophil respiratory burst: role in host defense and inflammation. Immunol Rev. 2016;273:180&#x2013;193. doi: 10.1111/imr.12447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12447</ArticleId><ArticleId IdType="pubmed">27558335</ArticleId></ArticleIdList></Reference><Reference><Citation>Allayee H., Hartiala J., Lee W., et al. The effect of montelukast and low-dose theophylline on cardiovascular disease risk factors in asthmatics. Chest. 2007;132:868&#x2013;874. doi: 10.1378/chest.07-0831.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.07-0831</ArticleId><ArticleId IdType="pubmed">17646220</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai M.J., Chang W.A., Tsai P.H., et al. Montelukast induces apoptosis-inducing factor-mediated cell death of lung cancer cells. Int J Mol Sci. 2017;18:1353. doi: 10.3390/ijms18071353.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms18071353</ArticleId><ArticleId IdType="pmc">PMC5535846</ArticleId><ArticleId IdType="pubmed">28672809</ArticleId></ArticleIdList></Reference><Reference><Citation>Dutton R.P., Stansbury L.G., Leone S., et al. Trauma mortality in mature trauma systems: are we doing better? An analysis of trauma mortality patterns, 1997&#x2013;2008. J&#xa0;Trauma. 2010;69:620&#x2013;626. doi: 10.1097/TA.0b013e3181bbfe2a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181bbfe2a</ArticleId><ArticleId IdType="pubmed">20093983</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorreh F., Esmaeili M.H., Yousefichaijan P., et al. Efficacy of montelukast for prevention of upper respiratory tract infection in children: a randomized, placebo-controlled trial. Pharmaceut Sci. 2020;26:193&#x2013;197. doi: 10.34172/PS.2020.7.</Citation><ArticleIdList><ArticleId IdType="doi">10.34172/PS.2020.7</ArticleId></ArticleIdList></Reference><Reference><Citation>Rupprecht T., Rupprecht C., Harms D., et al. Leukotriene receptor blockade as a life-saving treatment in severe bronchopulmonary dysplasia. Respiration. 2014;88:285&#x2013;290. doi: 10.1159/000365488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000365488</ArticleId><ArticleId IdType="pubmed">25195568</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">16878192</PMID><DateCompleted><Year>2007</Year><Month>04</Month><Day>12</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>22</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1516-3180</ISSN><JournalIssue CitedMedium="Print"><Volume>124</Volume><Issue>2</Issue><PubDate><Year>2006</Year><Month>Mar</Month><Day>02</Day></PubDate></JournalIssue><Title>Sao Paulo medical journal = Revista paulista de medicina</Title><ISOAbbreviation>Sao Paulo Med J</ISOAbbreviation></Journal><ArticleTitle>Effects of single dose of dexamethasone on patients with systemic inflammatory response.</ArticleTitle><Pagination><StartPage>90</StartPage><EndPage>95</EndPage><MedlinePgn>90-5</MedlinePgn></Pagination><Abstract><AbstractText Label="CONTEXT AND OBJECTIVE" NlmCategory="OBJECTIVE">Systemic inflammatory response syndrome (SIRS) is a very common condition among critically ill patients. SIRS, sepsis, septic shock and multiple organ dysfunction syndrome (MODS) can lead to death. Our aim was to investigate the efficacy of a single dose of dexamethasone for blocking the progression of systemic inflammatory response syndrome.</AbstractText><AbstractText Label="DESIGN AND SETTING" NlmCategory="METHODS">Prospective, randomized, double-blind, single-center study in a postoperative intensive care unit (Surgical Support Unit) at Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study involved 29 patients with SIRS. All eligible patients were prospectively randomized to receive either a single dose of 0.2 mg/kg of dexamethasone or placebo, after SIRS was diagnosed. The patients were monitored over a seven-day period using Sequential Organ Failure Assessment score (SOFA).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The respiratory system showed an improvement on the first day after dexamethasone was administered, demonstrated by the improved PaO2/FiO2 ratio (p &lt; 0.05). The cardiovascular system of patients requiring vasopressor therapy also improved over the first two days, with a better evolution in the dexamethasone group (p &lt; 0.05). Non-surviving patients presented higher lactate assays than did survivors (p &lt; 0.05) during this period.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Dexamethasone enhanced the effects of vasopressor drugs and evaluation of the respiratory system showed improvements (better PaO2/FiO2 ratio), one day after its administration. Despite these improvements, the single dose of dexamethasone did not block the evolution of SIRS.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cicarelli</LastName><ForeName>Domingos Dias</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Surgical Support Unit, Anesthesia Division, Department of Surgery, Hospital das Cl&#xed;nicas, Faculdade de Medicina, Universidade de S&#xe3;o Paulo, S&#xe3;o Paulo, Brazil. dcicarelli@uol.com.br</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bense&#xf1;or</LastName><ForeName>F&#xe1;bio Ely Martins</ForeName><Initials>FE</Initials></Author><Author ValidYN="Y"><LastName>Vieira</LastName><ForeName>Joaquim Edson</ForeName><Initials>JE</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Sao Paulo Med J</MedlineTA><NlmUniqueID>100897261</NlmUniqueID><ISSNLinking>1516-3180</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000893">Anti-Inflammatory Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014662">Vasoconstrictor Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>7S5I7G3JQL</RegistryNumber><NameOfSubstance UI="D003907">Dexamethasone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000893" MajorTopicYN="N">Anti-Inflammatory Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003907" MajorTopicYN="N">Dexamethasone</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014662" MajorTopicYN="N">Vasoconstrictor Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration &amp; dosage</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="CONTEXTO E OBJETIVO:">A s&#xed;ndrome da resposta inflamat&#xf3;ria sist&#xea;mica (SRIS) acomete muitos pacientes internados em unidades de terapia intensiva. A evolu&#xe7;&#xe3;o destes pacientes com SRIS para sepse, choque s&#xe9;ptico e s&#xed;ndrome da disfun&#xe7;&#xe3;o de m&#xfa;ltiplos &#xf3;rg&#xe3;os (SDMO) pode conduzi-los rapidamente para o &#xf3;bito. A proposta do trabalho &#xe9; avaliar a efic&#xe1;cia da dexametasona em dose &#xfa;nica como tratamento da SRIS.</AbstractText><AbstractText Label="TIPO DE ESTUDO E LOCAL:">Estudo prospectivo, aleat&#xf3;rio, duplamente encoberto, realizado na Unidade de Terapia Intensiva p&#xf3;s-operat&#xf3;ria (Unidade de Apoio Cir&#xfa;rgico) do Hospital das Cl&#xed;nicas da Faculdade de Medicina da Universidade de S&#xe3;o Paulo.</AbstractText><AbstractText Label="M&#xc9;TODOS:">Foram estudados 29 pacientes com diagn&#xf3;stico de SRIS. Os participantes foram aleatoriamente divididos em dois grupos que receberam dexametasona (0,2 mg/kg em dose &#xfa;nica) ou placebo ap&#xf3;s o diagn&#xf3;stico de SRIS. Os pacientes foram acompanhados durante sete dias de interna&#xe7;&#xe3;o na UTI atrav&#xe9;s do escore SOFA <i>(Sequential Organ Failure Assessment)</i>.</AbstractText><AbstractText Label="RESULTADOS:">Os pacientes que receberam dexametasona apresentaram melhora do sistema respirat&#xf3;rio no primeiro dia, com aumento da rela&#xe7;&#xe3;o PaO<sub>2</sub>/FiO<sub>2</sub> (p &lt; 0,05). Entre os pacientes que faziam uso de vasopressores, os que receberam dexametasona tiveram diminui&#xe7;&#xe3;o da necessidade destas medica&#xe7;&#xf5;es nos primeiros dois dias ap&#xf3;s a dose de dexametasona (p &lt; 0,05).</AbstractText><AbstractText Label="CONCLUS&#xc3;O:">A dexametasona diminuiu a necessidade de medica&#xe7;&#xf5;es vasopressoras e causou aumento da rela&#xe7;&#xe3;o PaO<sub>2</sub>/FiO<sub>2</sub> no primeiro dia ap&#xf3;s sua administra&#xe7;&#xe3;o. Apesar destes efeitos, a dexametasona em dose &#xfa;nica n&#xe3;o bloqueou a evolu&#xe7;&#xe3;o dos pacientes com SRIS.</AbstractText></OtherAbstract><CoiStatement><b>Conflicts of interest:</b> Not declared.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2005</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2006</Year><Month>2</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>4</Month><Day>14</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2006</Year><Month>8</Month><Day>1</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2006</Year><Month>3</Month><Day>2</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">16878192</ArticleId><ArticleId IdType="pmc">PMC11060357</ArticleId><ArticleId IdType="doi">10.1590/s1516-31802006000200008</ArticleId><ArticleId IdType="pii">S1516-31802006000200008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644&#x2013;1655.</Citation><ArticleIdList><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Sepsis, sepsis syndrome, and systemic inflammatory response syndrome (SIRS). Gulliver in Laputa. JAMA. 1995;273(2):155&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799497</ArticleId></ArticleIdList></Reference><Reference><Citation>Rangel-Frausto MS, Pittet D, Costigan M, Hwang T, Davis CS, Wenzel RP. The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. JAMA. 1995;273(2):117&#x2013;123.</Citation><ArticleIdList><ArticleId IdType="pubmed">7799491</ArticleId></ArticleIdList></Reference><Reference><Citation>Christman JW, Lancaster LH, Blackwell TS. Nuclear factor kappa B: a pivotal role in the systemic inflammatory response syndrome and new target for therapy. Intensive Care Med. 1998;24(11):1131&#x2013;1138.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7094907</ArticleId><ArticleId IdType="pubmed">9876974</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen-Heininger YM, Poynter ME, Baeuerle PA. Recent advances towards understanding redox mechanisms in the activation of nuclear factor kappa B. Free Radic Biol Med. 2000;28(9):1317&#x2013;1327.</Citation><ArticleIdList><ArticleId IdType="pubmed">10924851</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheinman RI, Cogswell PC, Lofquist AK, Baldwin AS., Jr Role of transcriptional activation of I kappa B alpha in mediation of immunosuppression by glucocorticoids. Science. 1995;270(5234):283&#x2013;286.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569975</ArticleId></ArticleIdList></Reference><Reference><Citation>Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NF-kappa B activity through induction of I kappa B synthesis. Science. 1995;270(5234):286&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">7569976</ArticleId></ArticleIdList></Reference><Reference><Citation>Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med. 1996;24(1):163&#x2013;172.</Citation><ArticleIdList><ArticleId IdType="pubmed">8565523</ArticleId></ArticleIdList></Reference><Reference><Citation>Bihari DJ, Tinker J. Steroids in intensive care. Br J Hosp Med. 1982;28(4):323&#x2013;324. 328-30.</Citation><ArticleIdList><ArticleId IdType="pubmed">6753992</ArticleId></ArticleIdList></Reference><Reference><Citation>Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med. 1998;26(4):645&#x2013;650.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559600</ArticleId></ArticleIdList></Reference><Reference><Citation>Schumer W. Controversy in shock research. Pro: The role of steroids in septic shock. Circ Shock. 1981;8(6):667&#x2013;671.</Citation><ArticleIdList><ArticleId IdType="pubmed">7337944</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin L, Cook DJ, Carlet J, et al. Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. Crit Care Med. 1995;23(8):1430&#x2013;1439.</Citation><ArticleIdList><ArticleId IdType="pubmed">7634816</ArticleId></ArticleIdList></Reference><Reference><Citation>Demling RH, Smith M, Gunther R, Wandzilak T. Endotoxin-induced lung injury in unanesthetized sheep: effect of methylprednisolone. Circ Shock. 1981;8(3):351&#x2013;360.</Citation><ArticleIdList><ArticleId IdType="pubmed">7249263</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes GS., Jr. Naloxone and methylprednisolone sodium succinate enhance sympathomedullary discharge in patients with septic shock. Life Sci. 1984;35(23):2319&#x2013;2326.</Citation><ArticleIdList><ArticleId IdType="pubmed">6390057</ArticleId></ArticleIdList></Reference><Reference><Citation>Kass EH. High-dose corticosteroids for septic shock. N Engl J Med. 1984;311(18):1178&#x2013;1179.</Citation><ArticleIdList><ArticleId IdType="pubmed">6482936</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheagren JN. Septic shock and corticosteroids. N Engl J Med. 1981;305(8):456&#x2013;458.</Citation><ArticleIdList><ArticleId IdType="pubmed">7254284</ArticleId></ArticleIdList></Reference><Reference><Citation>Lederer V. Betamethasone sodium phosphate injection: highdose regimen in septic shock. Clin Ther. 1984;6(5):719&#x2013;726.</Citation><ArticleIdList><ArticleId IdType="pubmed">6383616</ArticleId></ArticleIdList></Reference><Reference><Citation>Lefering R, Neugebauer E. Steroid controversy in sepsis and septic shock: a meta-analysis. Crit Care Med. 1995;23(7):1294&#x2013;1303.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600840</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicholson DP. Corticosteroids in the treatment of septic shock and the adult respiratory distress syndrome. Med Clin North Am. 1983;67(3):717&#x2013;724.</Citation><ArticleIdList><ArticleId IdType="pubmed">6341730</ArticleId></ArticleIdList></Reference><Reference><Citation>Ottosson J, Brandberg A, Erikson B, Hedman L, Dawidson I, S&#xf6;derberg R. Experimental septic shock - effects of corticosteroids. Circ Shock. 1982;9(6):571&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">6758979</ArticleId></ArticleIdList></Reference><Reference><Citation>Saito T, Takanashi M, Gallagher E, et al. Corticosteroid effect on early beta-adrenergic down-regulation during circulatory shock: hemodynamic study and beta-adrenergic receptor assay. Intensive Care Med. 1995;21(3):204&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790605</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Kellermann W, Forst H, et al. Low-dose hydrocortisone infusion attenuates the systemic inflammatory response syndrome. The Phospholipase A2 Study Group. Clin Investig. 1994;72(10):782&#x2013;787.</Citation><ArticleIdList><ArticleId IdType="pubmed">7865982</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. JAMA. 2002;288(7):862&#x2013;871.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186604</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J. From mega to more reasonable doses of corticosteroids: a decade to recreate hope. Crit Care Med. 1999;27(4):672&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321643</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E, Evans T. Corticosteroids and septic shock. JAMA. 2002;288(7):886&#x2013;887.</Citation><ArticleIdList><ArticleId IdType="pubmed">12186608</ArticleId></ArticleIdList></Reference><Reference><Citation>Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. Crit Care Med. 1999;27(4):723&#x2013;732.</Citation><ArticleIdList><ArticleId IdType="pubmed">10321661</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998;280(2):159&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">9669790</ArticleId></ArticleIdList></Reference><Reference><Citation>Reade MC, Young JD. Consent for observational studies in critical care: time to open Pandora's Box. Anaesthesia. 2003;58(1):1&#x2013;3.</Citation><ArticleIdList><ArticleId IdType="pubmed">12492660</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbald WJ, Doig G, Inman KJ. Sepsis, SIRS and infection. Intensive Care Med. 1995;21(4):299&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pubmed">7650251</ArticleId></ArticleIdList></Reference><Reference><Citation>Schimmer BP, Parker KL. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Gilman AG, Limbird LE, editors. Goodman &amp; Gilman's The Pharmacological Basis of Therapeutics. 9th ed. St Louis: McGraw-Hill; 1996. pp. 1459&#x2013;1485.</Citation></Reference><Reference><Citation>Cook R, Cook D, Tilley J, Lee K, Marshall J, Canadian Critical Care Trials Group Multiple organ dysfunction: baseline and serial component scores. Crit Care Med. 2001;29(11):2046&#x2013;2050.</Citation><ArticleIdList><ArticleId IdType="pubmed">11700393</ArticleId></ArticleIdList></Reference><Reference><Citation>Muckart DJ, Bhagwanjee S. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference definitions of the systemic inflammatory response syndrome and allied disorders in relation to critically injured patients. Crit Care Med. 1997;25(11):1789&#x2013;1795.</Citation><ArticleIdList><ArticleId IdType="pubmed">9366759</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, Moreno R, Takala J, et al. The SOFA (Sepsis-related Organ Failure Assessment) score to describe organ dysfunction/failure. On behalf of the Working Group on Sepsis-Related Problems of the European Society of Intensive Care Medicine. Intensive Care Med. 1996;22(7):707&#x2013;710.</Citation><ArticleIdList><ArticleId IdType="pubmed">8844239</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendon&#xe7;a A, Cantraine F, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society on Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernard GR. Quantification of organ dysfunction: seeking standardization. Crit Care Med. 1998;26(11):1767&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pubmed">9824054</ArticleId></ArticleIdList></Reference><Reference><Citation>Timsit JF, Fosse JP, Troch&#xe9; G, et al. Calibration and discrimination by daily Logistic Organ Dysfunction scoring comparatively with daily Sequential Organ Failure Assessment scoring for predicting hospital mortality in critically ill patients. Crit Care Med. 2002;30(9):2003&#x2013;2013.</Citation><ArticleIdList><ArticleId IdType="pubmed">12352033</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettila V, Pettila M, Sarna S, Voutilainen P, Takkunen O. Comparison of multiple organ dysfunction scores in the prediction of hospital mortality in the critically ill. Crit Care Med. 2002;30(8):1705&#x2013;1711.</Citation><ArticleIdList><ArticleId IdType="pubmed">12163780</ArticleId></ArticleIdList></Reference><Reference><Citation>P&#xf3;voa P, Almeida E, Moreira P, et al. C-reactive protein as an indicator of sepsis. Intensive Care Med. 1998;24(10):1052&#x2013;1056.</Citation><ArticleIdList><ArticleId IdType="pubmed">9840239</ArticleId></ArticleIdList></Reference><Reference><Citation>Levy MM, Fink MP, Marshall JC, et al. 2001 SCCM/ESICM/ ACCP/ATS/SIS International Sepsis Definitions Conference. Intensive Care Med. 2003;29(4):530&#x2013;538.</Citation><ArticleIdList><ArticleId IdType="pubmed">12664219</ArticleId></ArticleIdList></Reference><Reference><Citation>MacLaren R, Jung R. Stress-dose corticosteroid therapy for sepsis and acute lung injury or acute respiratory distress syndrome in critically ill adults. Pharmacotherapy. 2002;22(9):1140&#x2013;1156.</Citation><ArticleIdList><ArticleId IdType="pubmed">12222550</ArticleId></ArticleIdList></Reference><Reference><Citation>Manglik S, Flores E, Lubarsky L, Fernandez F, Chhibber VL, Tayek JA. Glucocorticoid insufficiency in patients who present to the hospital with severe sepsis: a prospective clinical trial. Crit Care Med. 2003;31(6):1668&#x2013;1675.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794402</ArticleId></ArticleIdList></Reference><Reference><Citation>Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348(2):138&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">12519925</ArticleId></ArticleIdList></Reference><Reference><Citation>Matot I, Sprung CL. Corticosteroids in septic shock: resurrection of the last rites? Crit Care Med. 1998;26(4):627&#x2013;630.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559592</ArticleId></ArticleIdList></Reference><Reference><Citation>Carlet J, International Sepsis Forum Immunological therapy in sepsis: currently available. Intensive Care Med. 2001;27(Suppl 1):S93&#x2013;103.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307373</ArticleId></ArticleIdList></Reference><Reference><Citation>Meduri GU, Kanangat S. Glucocorticoid treatment of sepsis and acute respiratory distress syndrome: time for a critical reappraisal. Crit Care Med. 1998;26(4):630&#x2013;633.</Citation><ArticleIdList><ArticleId IdType="pubmed">9559593</ArticleId></ArticleIdList></Reference><Reference><Citation>Thompson BT. Glucocorticoids and acute lung injury. Crit Care Med. 2003;31(4 Suppl):S253&#x2013;S257.</Citation><ArticleIdList><ArticleId IdType="pubmed">12682449</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin GS, Bernard GR, International Sepsis Forum Airway and lung in sepsis. Intensive Care Med. 2001;27(Suppl 1):S63&#x2013;S79.</Citation><ArticleIdList><ArticleId IdType="pubmed">11307371</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobayashi S, Gando S, Morimoto Y, Nanzaki S, Kemmotsu O. Serial measurement of arterial lactate concentrations as a prognostic indicator in relation to the incidence of disseminated intravascular coagulation in patients with systemic inflammatory response syndrome. Surg Today. 2001;31(10):853&#x2013;859.</Citation><ArticleIdList><ArticleId IdType="pubmed">11759877</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinarello CA. The Acute-Phase response. In: Bennett JC, Plum F, editors. Cecil Textbook of Medicine. 20th ed. Philadelphia: Saunders; 1996. pp. 1567&#x2013;1569.</Citation></Reference><Reference><Citation>Reny JL, Vuagnat A, Ract C, Benoit MO, Safar M, Fagon JY. Diagnosis and follow-up of infections in intensive care patients: value of C-reactive protein compared with other clinical and biological variables. Crit Care Med. 2002;30(3):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pubmed">11990910</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschaikowsky K, Hedwig-Geissing M, Schiele A, Bremer F, Schywalsky M, Sch&#xfc;ttler J. Coincidence of pro- and anti-inflammatory responses in the early phase of severe sepsis: Longitudinal study of mononuclear histocompatibility leukocyte antigen-DR expression, procalcitonin, C-reactive protein, and changes in T-cell subsets in septic and postoperative patients. Crit Care Med. 2002;30(5):1015&#x2013;1023.</Citation><ArticleIdList><ArticleId IdType="pubmed">12006796</ArticleId></ArticleIdList></Reference><Reference><Citation>Soares AJ, David CMN. A avalia&#xe7;&#xe3;o do comportamento da prote&#xed;na C-reativa em pacientes com sepse na UTI. Rev Bras Ter Intensiva. 2002;14(4):156&#x2013;165.</Citation></Reference><Reference><Citation>Luzzani A, Polati E, Dorizzi R, Rungatscher A, Pavan R, Merlini A. Comparison of procalcitonin and C-reactive protein as markers of sepsis. Crit Care Med. 2003;31(6):1737&#x2013;1741.</Citation><ArticleIdList><ArticleId IdType="pubmed">12794413</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38318959</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>24</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2753-670X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>02</Day></PubDate></JournalIssue><Title>Interdisciplinary cardiovascular and thoracic surgery</Title><ISOAbbreviation>Interdiscip Cardiovasc Thorac Surg</ISOAbbreviation></Journal><ArticleTitle>Postoperative intra-abdominal hypertension predicts worse hospital outcomes in children after cardiac surgery: a pilot study&#x2020;.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ivae019</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/icvts/ivae019</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Our goal was to determine the incidence and characteristics of postoperative intra-abdominal hypertension (IAH) in paediatric patients undergoing open-heart surgery.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This single-centre study included consecutive children (aged &lt;16&#x2009;years) who underwent open-heart surgery between July 2020 and February 2021. Patients who entered the study were followed until in-hospital death or hospital discharge. The study consisted of 2 parts. Part I was a prospective observational cohort study that was designed to discover the association between exposures and IAH. Postoperative intra-abdominal pressure was measured immediately after admission to the intensive care unit and every 6&#x2009;h thereafter. Part II was a cross-sectional study to compare the hospital-related adverse outcomes between the IAH and the no-IAH cohorts.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Postoperatively, 24.7% (38/154) of the patients exhibited IAH, whereas 3.9% (6/154) developed abdominal compartment syndrome. The majority (29/38, 76.3%) of IAH cases occurred within the first 24&#x2009;h in the intensive care unit. Multivariable analysis showed that the Society of Thoracic Surgeons-European Association for Cardio-Thoracic Surgery score [odds ratio (OR)&#x2009;=&#x2009;1.86, 95% confidence interval (CI) 1.23-2.83, P&#x2009;=&#x2009;0.004], right-sided heart lesion (OR&#x2009;=&#x2009;5.60, 95% CI 2.34-13.43, P&#x2009;&lt;&#x2009;0.001), redo sternotomy (OR&#x2009;=&#x2009;4.35, 95% CI 1.64-11.57, P&#x2009;=&#x2009;0.003), high baseline intra-abdominal pressure (OR&#x2009;=&#x2009;1.43, 95% CI 1.11-1.83, P&#x2009;=&#x2009;0.005), prolonged cardiopulmonary bypass duration (OR&#x2009;=&#x2009;1.01, 95% CI 1.00-1.01, P&#x2009;=&#x2009;0.005) and deep hypothermic circulatory arrest (OR&#x2009;=&#x2009;5.14, 95% CI 1.15-22.98, P&#x2009;=&#x2009;0.032) were independent predictors of IAH occurrence. IAH was associated with greater inotropic support (P&#x2009;&lt;&#x2009;0.001), more gastrointestinal complications (P&#x2009;=&#x2009;0.001), sepsis (P&#x2009;=&#x2009;0.003), multiple organ dysfunction syndrome (P&#x2009;&lt;&#x2009;0.001) and prolonged intensive care unit stay (z = -4.916, P&#x2009;&lt;&#x2009;0.001) and hospitalization (z = -4.710, P&#x2009;&lt;&#x2009;0.001). The occurrence of a composite outcome (P&#x2009;=&#x2009;0.009) was significantly increased in patients with IAH.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">IAH is common in children undergoing cardiac surgery and is associated with worse hospital outcomes. Several factors may be associated with the development of IAH, including basic cardiac physiology and perioperative factors.</AbstractText><AbstractText Label="TRIAL INFORMATION" NlmCategory="UNASSIGNED">This study was registered in the Chinese Clinical Trial Registry (Trial number: ChiCTR2000034322)URL site: https://www.chictr.org.cn/hvshowproject.html?id=41363&amp;v=1.4.</AbstractText><CopyrightInformation>&#xa9; The Author(s) 2024. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Yunyi</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Luo</LastName><ForeName>Shuhua</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0003-0191-4747</Identifier><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xie</LastName><ForeName>Yuxuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Anesthesiology, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Yue</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fang</LastName><ForeName>Yibing</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Surgery, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Shouping</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deng</LastName><ForeName>Lijing</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Intensive Care Medicine, West China Hospital of Sichuan University, Chengdu, 610041, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Interdiscip Cardiovasc Thorac Surg</MedlineTA><NlmUniqueID>9918540787006676</NlmUniqueID><ISSNLinking>2753-670X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Abdominal compartment syndrome</Keyword><Keyword MajorTopicYN="N">Cardiac surgery</Keyword><Keyword MajorTopicYN="N">Gastrointestinal complication</Keyword><Keyword MajorTopicYN="N">Intra-abdominal hypertension</Keyword><Keyword MajorTopicYN="N">Paediatrics</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>8</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>2</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>13</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>6</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38318959</ArticleId><ArticleId IdType="pmc">PMC10882438</ArticleId><ArticleId IdType="doi">10.1093/icvts/ivae019</ArticleId><ArticleId IdType="pii">7601456</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dabrowski W, Rzecki Z.. Intra-abdominal and abdominal perfusion pressure in patients undergoing coronary artery bypass graft surgery. Acta Clin Belg 2009;64:216&#x2013;24.</Citation><ArticleIdList><ArticleId IdType="pubmed">19670561</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#x131;l&#x131;&#xe7; B, Yap&#x131;c&#x131; N, Yap&#x131;c&#x131; F, Kavakl&#x131; AS, Kudsio&#x11f;lu T, K&#x131;l&#x131;&#xe7; A. et al. Factors associated with increased intra-abdominal pressure in patients undergoing cardiac surgery. Turk Gogus Kalp Damar Cerrahisi Derg 2020;28:134&#x2013;42.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7067007</ArticleId><ArticleId IdType="pubmed">32175154</ArticleId></ArticleIdList></Reference><Reference><Citation>Smit M, Werner MJM, Lansink-Hartgring AO, Dieperink W, Zijlstra JG, van Meurs M.. How central obesity influences intra-abdominal pressure: a prospective, observational study in cardiothoracic surgical patients. Ann Intensive Care 20166:99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5056912</ArticleId><ArticleId IdType="pubmed">27726116</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzeffi MA, Stafford P, Wallace K, Bernstein W, Deshpande S, Odonkor P. et al. Intra-abdominal Hypertension and Postoperative Kidney Dysfunction in Cardiac Surgery Patients. J Cardiothorac Vasc Anesth 2016;30:1571&#x2013;7</Citation><ArticleIdList><ArticleId IdType="pubmed">27590464</ArticleId></ArticleIdList></Reference><Reference><Citation>Nazer R, Albarrati A, Ullah A, Alamro S, Kashour T.. Intra-abdominal hypertension in obese patients undergoing coronary surgery: a prospective observational study. Surgery 2019;166:1128&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">31353080</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyson N, Efthymiou C.. Predictive risk factors for intra-abdominal hypertension after cardiac surgery. Interact CardioVasc Thorac Surg 2021. 10;32:719&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691507</ArticleId><ArticleId IdType="pubmed">33471093</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirkpatrick AW, Roberts DJ, De Waele J, Jaeschke R, Malbrain ML, De Keulenaer B, Pediatric Guidelines Sub-Committee for the World Society of the Abdominal Compartment Syndrome et al.Intra-abdominal hypertension and the abdominal compartment syndrome: updated consensus definitions and clinical practice guidelines from the World Society of the Abdominal Compartment Syndrome. Intensive Care Med 2013;39:1190&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3680657</ArticleId><ArticleId IdType="pubmed">23673399</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Bougmiza IM, Chehab MS, Bafaqih HA, AlMohaimeed SA, Malbrain ML.. Incidence, Risk Factors, and Prognosis of Intra-Abdominal Hypertension in Critically Ill Children: a Prospective Epidemiological Study. J Intensive Care Med 2016;31:403&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">25922384</ArticleId></ArticleIdList></Reference><Reference><Citation>Thabet FC, Ejike JC.. Intra-abdominal hypertension and abdominal compartment syndrome in pediatrics. A review. J Crit Care 2017;41:275&#x2013;82.</Citation><ArticleIdList><ArticleId IdType="pubmed">28614762</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanayem NS, Dearani JA, Welke KF, B&#xe9;land MJ, Shen I, Ebels T.. Gastrointestinal complications associated with the treatment of patients with congenital cardiac disease: consensus definitions from the Multi-Societal Database Committee for Pediatric and Congenital Heart Disease. Cardiol Young 2008;18 Suppl 2:240&#x2013;4.</Citation><ArticleIdList><ArticleId IdType="pubmed">19063798</ArticleId></ArticleIdList></Reference><Reference><Citation>Butts RJ, Scheurer MA, Zyblewski SC, Wahlquist AE, Nietert PJ, Bradley SM. et al. A composite outcome for neonatal cardiac surgery research. J Thorac Cardiovasc Surg 2014;147:428&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4004075</ArticleId><ArticleId IdType="pubmed">23587468</ArticleId></ArticleIdList></Reference><Reference><Citation>Moga MA, Manlhiot C, Marwali EM, McCrindle BW, Van Arsdell GS, Schwartz SM.. Hyperglycemia after pediatric cardiac surgery: impact of age and residual lesions. Crit Care Med 2011;39:266&#x2013;72.</Citation><ArticleIdList><ArticleId IdType="pubmed">21057314</ArticleId></ArticleIdList></Reference><Reference><Citation>Koponen T, Karttunen J, Musialowicz T, Pietil&#xe4;inen L, Uusaro A, Lahtinen P.. Vasoactive-inotropic score and the prediction of morbidity and mortality after cardiac surgery. Br J Anaesth 2019;122:428&#x2013;36.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6435836</ArticleId><ArticleId IdType="pubmed">30857599</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalfino L, Sicolo A, Paparella D, Mongelli M, Rubino G, Brienza N.. Intra-abdominal hypertension in cardiac surgery. Interact CardioVasc Thorac Surg 2013;17:644&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3781798</ArticleId><ArticleId IdType="pubmed">23820668</ArticleId></ArticleIdList></Reference><Reference><Citation>Blaser AR, Bj&#xf6;rck M, De Keulenaer B, Regli A.. Abdominal compliance: a bench-to-bedside review. J Trauma Acute Care Surg 2015;78:1044&#x2013;53.</Citation><ArticleIdList><ArticleId IdType="pubmed">25909429</ArticleId></ArticleIdList></Reference><Reference><Citation>Iyer D, D'Amours S, Aneman A.. Intra-abdominal hypertension in postoperative cardiac surgery patients. Crit Care Resusc 2014;16:214&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">25161025</ArticleId></ArticleIdList></Reference><Reference><Citation>Holmes JH 4th, Connolly NC, Paull DL, Hill ME, Guyton SW, Ziegler SF. et al. Magnitude of the inflammatory response to cardiopulmonary bypass and its relation to adverse clinical outcomes. Inflamm Res 2002;51:579&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pubmed">12558191</ArticleId></ArticleIdList></Reference><Reference><Citation>Tofukuji M, Stahl GL, Metais C, Tomita M, Agah A, Bianchi C. et al. Mesenteric dysfunction after cardiopulmonary bypass: role of complement C5a. Ann Thorac Surg 2000;69:799&#x2013;807.</Citation><ArticleIdList><ArticleId IdType="pubmed">10750764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramser M, Glauser PM, Glass TR, Weixler B, Grapow MTR, Hoffmann H. et al. Abdominal Decompression after Cardiac Surgery: outcome of 42 Patients with Abdominal Compartment Syndrome. World J Surg 2021;45:1242&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pubmed">33481080</ArticleId></ArticleIdList></Reference><Reference><Citation>Ferguson LP, Gandiya T, Kaselas C, Sheth J, Hasan A, Gabra HO.. Gastrointestinal complications associated with the surgical treatment of heart disease in children. J Pediatr Surg 2017;52:414&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">27916446</ArticleId></ArticleIdList></Reference><Reference><Citation>Deindl P, Wagner J, Herden U, Schulz-J&#xfc;rgensen S, Schild R, Vettorazzi E. et al. Monitoring intra-abdominal pressure after liver transplantation in children. Pediatr Transplant 2019;23:e13565.</Citation><ArticleIdList><ArticleId IdType="pubmed">31471942</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheatham ML, Malbrain ML.. Cardiovascular implications of abdominal compartment syndrome. Acta Clin Belg 2007;62 Suppl 1:98&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469707</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">31008819</PMID><DateCompleted><Year>2020</Year><Month>06</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>06</Month><Day>01</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1531-2291</ISSN><JournalIssue CitedMedium="Internet"><Volume>33</Volume><Issue>5</Issue><PubDate><Year>2019</Year><Month>May</Month></PubDate></JournalIssue><Title>Journal of orthopaedic trauma</Title><ISOAbbreviation>J Orthop Trauma</ISOAbbreviation></Journal><ArticleTitle>Early Immunologic Response in Multiply Injured Patients With Orthopaedic Injuries Is Associated With Organ Dysfunction.</ArticleTitle><Pagination><StartPage>220</StartPage><EndPage>228</EndPage><MedlinePgn>220-228</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/BOT.0000000000001437</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">To quantify the acute immunologic biomarker response in multiply injured patients with axial and lower extremity fractures and to explore associations with adverse short-term outcomes including organ dysfunction and nosocomial infection (NI).</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">Prospective cohort study.</AbstractText><AbstractText Label="SETTING" NlmCategory="METHODS">Level 1 academic trauma center.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">Consecutive multiply injured patients, 18-55 years of age, with major pelvic and lower extremity orthopaedic injuries (all pelvic/acetabular fractures, operative femur and tibia fractures) that presented as a trauma activation and admitted to the intensive care unit from April 2015 through October 2016. Sixty-one patients met inclusion criteria.</AbstractText><AbstractText Label="INTERVENTION" NlmCategory="METHODS">Blood was collected upon presentation to the hospital and at the following time points: 8, 24, 48 hours, and daily during intensive care unit admission. Blood was processed by centrifugation, separation into 1.0-mL plasma aliquots, and cryopreserved within 2 hours of collection.</AbstractText><AbstractText Label="MAIN OUTCOME MEASUREMENTS" NlmCategory="METHODS">Plasma analyses of protein levels of cytokines/chemokines were performed using a Luminex panel Bioassay of 20 immunologic mediators. Organ dysfunction was measured by the Marshall Multiple Organ Dysfunction score (MODScore) and nosocomial infection (NI) was recorded. Patients were stratified into low (MODS &#x2264; 4; n = 34) and high (MODS &gt; 4; n = 27) organ dysfunction groups.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The MODS &gt;4 group had higher circulating levels of interleukin (IL)-6, IL-8, IL-10, monocyte chemoattractant protein-1 (MCP-1), IL-1 receptor antagonist (IL-1RA), and monokine induced by interferon gamma (MIG) compared with the MODS &#x2264;4 group at nearly all time points. MODS &gt;4 exhibited lower levels of IL-21 and IL-22 compared with MODS &#x2264;4. Patients who developed NI (n = 24) had higher circulating concentrations of IL-10, MIG, and high mobility group box 1 (HMGB1) compared with patients who did not develop NI (n = 37).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Temporal quantification of immune mediators identified 8 biomarkers associated with greater levels of organ dysfunction in polytrauma patients with major orthopaedic injuries.</AbstractText><AbstractText Label="LEVEL OF EVIDENCE" NlmCategory="METHODS">Prognostic Level II. See Instructions for Authors for a complete description of levels of evidence.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gaski</LastName><ForeName>Greg E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Metzger</LastName><ForeName>Cameron</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McCarroll</LastName><ForeName>Tyler</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wessel</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Adler</LastName><ForeName>Jeremy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cutshall</LastName><ForeName>Andrew</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brown</LastName><ForeName>Krista</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vodovotz</LastName><ForeName>Yoram</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Billiar</LastName><ForeName>Timothy R</ForeName><Initials>TR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Inflammation and Regenerative Modeling, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McKinley</LastName><ForeName>Todd O</ForeName><Initials>TO</Initials><AffiliationInfo><Affiliation>Indiana University Health Methodist Hospital, Indianapolis, IN.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Orthopaedic Surgery, Indiana University School of Medicine, Indianapolis, IN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Orthop Trauma</MedlineTA><NlmUniqueID>8807705</NlmUniqueID><ISSNLinking>0890-5339</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>4</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>6</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31008819</ArticleId><ArticleId IdType="doi">10.1097/BOT.0000000000001437</ArticleId><ArticleId IdType="pii">00005131-201905000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17215732</PMID><DateCompleted><Year>2007</Year><Month>02</Month><Day>08</Day></DateCompleted><DateRevised><Year>2019</Year><Month>12</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0022-5282</ISSN><JournalIssue CitedMedium="Print"><Volume>62</Volume><Issue>1</Issue><PubDate><Year>2007</Year><Month>Jan</Month></PubDate></JournalIssue><Title>The Journal of trauma</Title><ISOAbbreviation>J Trauma</ISOAbbreviation></Journal><ArticleTitle>Tissue oxygen saturation predicts the development of organ dysfunction during traumatic shock resuscitation.</ArticleTitle><Pagination><StartPage>44</StartPage><EndPage>55</EndPage><MedlinePgn>44-54; discussion 54-5</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Near-infrared spectroscopy (NIRS) can continuously and noninvasively monitor tissue oxygen saturation (StO2) in muscle and may be an indicator of shock severity. Our purpose was to evaluate how well StO2 predicted outcome in high-risk torso trauma patients presenting in shock.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The primary outcome in this prospective study was multiple organ dysfunction syndrome (MODS). StO2 data were obtained upon hospital arrival and for 24 hours along with other known predictors of hypoperfusion and clinical outcomes. Clinicians were blinded to StO2 measurements.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven Level I trauma centers enrolled 383 patients, 50 of whom developed MODS. Minimum StO2 performed similarly to maximum base deficit (BD) in discrimination of MODS patients. The sensitivity for both measures (StO2 cutoff = 75%; BD cutoff = 6 mEq/L) was 78%, the specificity was 34% to 39%, the positive predictive value was 18% to 20% and the negative predictive value was 88% to 91%. StO2 and BD were also comparable in predicting death.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">NIRS-derived muscle StO2 measurements perform similarly to BD in identifying poor perfusion and predicting the development of MODS or death after severe torso trauma, yet have the additional advantages of being continuous and noninvasive.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cohn</LastName><ForeName>Stephen M</ForeName><Initials>SM</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Texas Health Science Center, San Antonio, Texas 78229, USA. cohn@uthscsa.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nathens</LastName><ForeName>Avery B</ForeName><Initials>AB</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Frederick A</ForeName><Initials>FA</Initials></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Puyana</LastName><ForeName>Juan Carlos</ForeName><Initials>JC</Initials></Author><Author ValidYN="Y"><LastName>Moore</LastName><ForeName>Ernest E</ForeName><Initials>EE</Initials></Author><Author ValidYN="Y"><LastName>Beilman</LastName><ForeName>Gregory J</ForeName><Initials>GJ</Initials></Author><Author ValidYN="Y"><CollectiveName>StO2 in Trauma Patients Trial Investigators</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D023362">Evaluation Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Trauma</MedlineTA><NlmUniqueID>0376373</NlmUniqueID><ISSNLinking>0022-5282</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008991" MajorTopicYN="N">Monitoring, Physiologic</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018482" MajorTopicYN="N">Muscle, Skeletal</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="N">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012680" MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012774" MajorTopicYN="N">Shock, Traumatic</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019265" MajorTopicYN="N">Spectroscopy, Near-Infrared</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2007</Year><Month>2</Month><Day>9</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>1</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17215732</ArticleId><ArticleId IdType="doi">10.1097/TA.0b013e31802eb817</ArticleId><ArticleId IdType="pii">00005373-200701000-00005</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">38470396</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>27</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2501-062X</ISSN><JournalIssue CitedMedium="Internet"><Volume>62</Volume><Issue>3</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>01</Day></PubDate></JournalIssue><Title>Romanian journal of internal medicine = Revue roumaine de medecine interne</Title><ISOAbbreviation>Rom J Intern Med</ISOAbbreviation></Journal><ArticleTitle>A tagging polymorphism in fat mass and obesity-associated (<i>FTO</i>) gene is associated with sepsis status in children.</ArticleTitle><Pagination><StartPage>279</StartPage><EndPage>285</EndPage><MedlinePgn>279-285</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.2478/rjim-2024-0008</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Sepsis is one of the most common causes of death in patients admitted to intensive care units (ICUs). The development of sepsis is significantly influenced by genetic predisposition. In this study, we highlight a potential association between a variant of the fat mass and obesity-associated (<i>FTO</i>) gene and risk of sepsis in children and adolescents.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We investigated a first-intron tagging <i>FTO</i> polymorphism (rs17817449) by comparing a severe condition (SC) group, comprising 598 paediatric patients (ages 0-19 years) admitted to an ICU with fever, systemic inflammatory response syndrome (SIRS), sepsis, severe sepsis, septic shock, or multiple organ dysfunction syndrome (MODS), with a control group consisting of 616 healthy young adults.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">We observed a lower prevalence (<i>p</i> &lt; 0.01; OR = 0.59, 95% CI = 0.39-0.87) of the <i>FTO</i> TT genotype in febrile and SIRS patients compared to patients with severe illness. There was a borderline trend towards a lower prevalence of the <i>FTO</i> TT genotype in the control group compared to the SC group (<i>p</i> &lt; 0.09, OR = 0.81, 95% CI = 0.62-1.06).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings suggest that rs17817449, a common <i>FTO</i> polymorphism, may be a predictor of sepsis in paediatric patients, and that higher body weight is protective against this clinical complication.</AbstractText><CopyrightInformation>&#xa9; 2024 Petr Jabandziev et al., published by Sciendo.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Jabandziev</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Central European Institute of Technology, &#x17d;erot&#xed;novo n&#xe1;m. 617/9, 601 77, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hubacek</LastName><ForeName>Jaroslav Alois</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>4Experimental Medicine Centre, Institute for Clinical and Experimental Medicine, V&#xed;de&#x148;sk&#xe1; 1958/9, 140 21, Prague, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>5Third Department of Internal Medicine, First Faculty of Medicine, Charles University, U Nemocnice 1, 121 08, Prague, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalek</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>6Department of Quantitative Methods, University of Defence, Kounicova 156/65, 662 10, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jouza</LastName><ForeName>Martin</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Papez</LastName><ForeName>Jan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pecl</LastName><ForeName>Jakub</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaba</LastName><ForeName>Katerina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>1Department of Pediatrics, University Hospital Brno, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Slaby</LastName><ForeName>Ondrej</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>3Central European Institute of Technology, &#x17d;erot&#xed;novo n&#xe1;m. 617/9, 601 77, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Urik</LastName><ForeName>Milan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aulicka</LastName><ForeName>Stefania</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kunovsky</LastName><ForeName>Lumir</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>7Department of Gastroenterology and Internal Medicine, University Hospital Brno, Jihlavsk&#xe1; 340, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>8Department of Surgery, University Hospital Brno, Jihlavsk&#xe1; 340, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michalek</LastName><ForeName>Jaroslav</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>9Cellthera Ltd., V&#xed;de&#x148;sk&#xe1; 119, 619 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dominik</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kratochvil</LastName><ForeName>Milan</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Klucka</LastName><ForeName>Jozef</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Stourac</LastName><ForeName>Petr</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>2Faculty of Medicine, Masaryk University, &#x10c;ernopoln&#xed; 212/9, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>10Department of Pediatric Anesthesiology and Intensive Care Medicine, University Hospital Brno, Kamenice 5, 625 00, Brno, Czech Republic.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Rom J Intern Med</MedlineTA><NlmUniqueID>9304507</NlmUniqueID><ISSNLinking>1220-4749</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="D000071516">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.14.11.33</RegistryNumber><NameOfSubstance UI="C526492">FTO protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071516" MajorTopicYN="Y">Alpha-Ketoglutarate-Dependent Dioxygenase FTO</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="Y">Sepsis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002675" MajorTopicYN="N">Child, Preschool</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007223" MajorTopicYN="N">Infant</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007231" MajorTopicYN="N">Infant, Newborn</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="N">Polymorphism, Genetic</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">child</Keyword><Keyword MajorTopicYN="N">genetic predisposition to the disease</Keyword><Keyword MajorTopicYN="N">genotype</Keyword><Keyword MajorTopicYN="N">obesity</Keyword><Keyword MajorTopicYN="N">sepsis</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>10</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>28</Day><Hour>2</Hour><Minute>29</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>12</Hour><Minute>46</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>3</Month><Day>12</Day><Hour>11</Hour><Minute>4</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38470396</ArticleId><ArticleId IdType="doi">10.2478/rjim-2024-0008</ArticleId><ArticleId IdType="pii">rjim-2024-0008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>BONE R.C., BALK R.A., CERRA F.B., DELLINGER R.P., FEIN A.M., KNAUS W.A., et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992; 101 :1644-55.</Citation></Reference><Reference><Citation>RELLO J., VALENZUELA-S&#xc1;NCHEZ F., RUIZ-RODRIGUEZ M., MOYANO S. Sepsis: A review of advances in management. Adv Ther. 2017; 34 :2393-411.</Citation></Reference><Reference><Citation>KAWASAKI T. Update on pediatric sepsis: a review. J Intensive Care. 2017; 5 :47.</Citation></Reference><Reference><Citation>SINGER M., DEUTSCHMAN C.S., SEYMOUR C.W., SHANKAR-HARI M., ANNANE D., BAUER M., et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315 :801-10.</Citation></Reference><Reference><Citation>MENON K., SCHLAPBACH L.J., AKECH S., ARGENT A., BIBAN P., CARROL E.D., et al. Pediatric Sepsis Definition Taskforce of the Society of Critical Care Medicine. Criteria for pediatric sepsis-a systematic review and meta-analysis by the pediatric sepsis definition taskforce . Crit Care Med. 2022; 50 :21-36.</Citation></Reference><Reference><Citation>CARDOSO T., TEIXEIRA-PINTO A., RODRIGUES P.P., ARAG&#xc3;O I., COSTA-PEREIRA A., SARMENTO A.E. Predisposition, insult/infection, response and organ dysfunction (PIRO): a pilot clinical staging system for hospital mortality in patients with infection. PLoS One. 2013; 8 :e70806.</Citation></Reference><Reference><Citation>FONT M.D., THYAGARAJAN B., KHANNA A.K. Sepsis and Septic Shock - Basics of diagnosis, pathophysiology and clinical decision making. Med Clin North Am. 2020; 104 :573-585.</Citation></Reference><Reference><Citation>LU H., WEN D., WANG X., GAN L., DU J., SUN J., et al. Host genetic variants in sepsis risk: a field synopsis and meta-analysis . Crit Care 2019; 23 :26.</Citation></Reference><Reference><Citation>JABANDZIEV P., SMEREK M., MICHALEK J., FEDORA M., KOSINOVA L., HUBACEK J.A., et al. Multiple gene-to-gene interactions in children with sepsis: a combination of five gene variants predicts outcome of life-threatening sepsis. Crit Care 2014; 18 :R1.</Citation></Reference><Reference><Citation>RAUTANEN A., MILLS T.C., GORDON A.C., HUTTON P., STEFFENS M., NUAMAH R., et al. Genome-wide association study of survival from sepsis due to pneumonia: an observational cohort study. Lancet Respir Med. 2015; 3 :53-60.</Citation></Reference><Reference><Citation>SCHERAG A., SCH&#xd6;NEWECK F., KESSELMEIER M., TAUDIEN S., PLATZER M., FELDER M., et al. Genetic factors of the disease course after sepsis: A genome-wide study for 28day mortality . EBioMedicine. 2016; 12 :239-46.</Citation></Reference><Reference><Citation>KUPERMAN E.F., SHOWALTER J.W., LEHMAN E.B., LEIB A.E., KRASCHNEWSKI J.L. The impact of obesity on sepsis mortality: a retrospective review . BMC Infect Dis 2013; 13 :377.</Citation></Reference><Reference><Citation>TRIVEDI V., BAVISHI C., JEAN R. Impact of obesity on sepsis mortality: A systematic review. J Crit Care 2015; 30 :518-24.</Citation></Reference><Reference><Citation>DINA C., MEYRE D., GALLINA S., DURAND E., K&#xd6;RNER A., JACOBSON P., et al. Variation in FTO contributes to childhood obesity and severe adult obesity. Nature Genet. 2007; 39 :724-6.</Citation></Reference><Reference><Citation>DAY F.R., LOOS R.J. Developments in obesity genetics in the era of genome-wide association studies . J Nutrigenet Nutrigenomics. 2011; 4 :222-38.</Citation></Reference><Reference><Citation>GERKEN T., GIRARD C.A., TUNG Y.C., WEBBY C.J., SAUDEK V., HEWITSON K.S., et al. The obesity-associated FTO gene encodes a 2-oxoglutarate-dependent nucleic acid demethylase . Science. 2017; 318 :1469-72.</Citation></Reference><Reference><Citation>MICHALEK J., SVETLIKOVA P., FEDORA M., KLIMOVIC M., KLAPACOVA L., BARTOSOVA D., et al. Bactericidal permeability increasing protein gene variants in children with sepsis. Intensive Care Med. 2007; 33 :2158-64.</Citation></Reference><Reference><Citation>MICHALEK J, SVETLIKOVA P, FEDORA M, KLIMOVIC M, KLAPACOVA L, BARTOSOVA D, et al. Interleukin-6 gene variants and the risk of sepsis development in children . Hum Immunol. 2007;68:756-60.</Citation></Reference><Reference><Citation>LEVY M.M., FINK M.P., MARSHALL J.C., ABRAHAM E., ANGUS D., COOK D., et al. 2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference . Crit Care Med. 2003; 31 :1250-6.</Citation></Reference><Reference><Citation>HUBACEK J.A., STANEK V., GEBAUEROV&#xc1; M., PILIPCINCOV&#xc1; A., DLOUH&#xc1; D., POLEDNE R., et al. A FTO variant and risk of acute coronary syndrome. Clin Chim Acta. 2010; 411 :1069-72.</Citation></Reference><Reference><Citation>C&#xcd;FKOV&#xc1; R., SKODOV&#xc1; Z., BRUTHANS J., AD&#xc1;MKOV&#xc1; V., JOZ&#xcd;FOV&#xc1; M., GALOVCOV&#xc1; M., et al. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis. 2010; 211 :676-81.</Citation></Reference><Reference><Citation>KOBZOV&#xc1; J., VIGNEROV&#xc1; J., BL&#xc1;HA P., KREJCOVSK&#xdd; L., RIEDLOV&#xc1; J. The 6th nationwide anthropological survey of children and adolescents in the Czech Republic in 2001. Centr Eur J Public Health. 2004; 12 :126-130.</Citation></Reference><Reference><Citation>AGRESTI A. Categorical Data Analysis. 3rd ed. Hoboken, 2013; NJ: Wiley. ISBN: 978-0-470-46363-5.</Citation></Reference><Reference><Citation>S&#xd8;RENSEN T.I., NIELSEN G.G., ANDERSEN P.K., TEASDALE T.W. Genetic and environmental influences on premature death in adult adoptees . N Engl J Med. 1988; 318 :727-32.</Citation></Reference><Reference><Citation>DAVID V.L., ERCISLI M.F., ROGOBETE A.F., BOIA E.S., HORHAT R., NITU R., et al. Early prediction of sepsis incidence in critically ill patients using specific genetic polymorphisms . Biochem Genet. 2017; 55 :193-203.</Citation></Reference><Reference><Citation>SRINIVASAN L., PAGE G., KIRPALANI H., MURRAY J.C., DAS A., HIGGINS R.D., et al. Genome-wide association study of sepsis in extremely premature infants . Arch Dis Child Fetal Neonatal Ed. 2017; 102 :F439-45.</Citation></Reference><Reference><Citation>FENG Y., WANG F., PAN H., QIU S., L&#xdc; J., WU L., et al. Obesity-associated gene FTO rs9939609 polymorphism in relation to the risk of tuberculosis . BMC Infect Dis. 2014; 14 :592.</Citation></Reference><Reference><Citation>CRONIN R.M., FIELD J.R., BRADFORD Y., SHAFFER C.M., CARROLL R.J., MOSLEY J.D., et al. Phenome-wide association studies demonstrating pleiotropy of genetic variants within FTO with and without adjustment for body mass index . Front Genet 2014; 5 :250.</Citation></Reference><Reference><Citation>LUO J., WANG F., SUN F., YUE T., ZHOU Q., YANG C., et al. Targeted inhibition of FTO demethylase protects mice against LPS-induced septic shock by suppressing NLRP3 inflammasome . Front Immunol. 2021; 12 :663295.</Citation></Reference><Reference><Citation>WANG H., WANG Q., CHEN J., CHEN C. Association among the gut microbiome, the serum metabolomic profile and RNA m6A methylation in sepsis-associated encephalopathy. Front Genet. 2022; 13 :859727.</Citation></Reference><Reference><Citation>DUBEY P.K., PATIL M., SINGH S., DUBEY S., AHUJA P., VERMA S.K., et al. Increased m6A-RNA methylation and FTO suppression is associated with myocardial inflammation and dysfunction during endotoxemia in mice. Mol Cell Biochem. 2022; 477 :129-41.</Citation></Reference><Reference><Citation>WANG W., ZHANG T.N., YANG N., WEN R., WANG Y.J., ZHANG B.L., et al. Transcriptome-wide identification of altered RNA m6A profiles in cardiac tissue of rats with LPS-induced myocardial injury. Front Immunol. 2023; 14 :1122317.</Citation></Reference><Reference><Citation>TUERDIMAIMAITI D., ABUDUAINI B., KANG S., JIAO J., LI M., MADENIYATI W., TUERDI B., et al. Genome-wide identification and functional analysis of dysregulated alternative splicing profiles in sepsis. J Inflamm (Lond). 2023; 20 :31.</Citation></Reference><Reference><Citation>ZHANG Q, BAO X, CUI M, WANG C, JI J, JING J, et al. Identification and validation of key biomarkers based on RNA methylation genes in sepsis. Front Immunol. 2023; 14 :1231898.</Citation></Reference><Reference><Citation>CROSS D., DRURY R., HIL J., POLLARD A.J. Epigenetics in sepsis: Understanding its role in endothelial dysfunction, immunosuppression, and potential therapeutics. Front Immunol. 2019; 10 :1363.</Citation></Reference><Reference><Citation>HERTEL J.K., JOHANSSON S., SONESTEDT E., JONSSON A., LIE R.T., PLATOU C.G., et al. FTO, type 2 diabetes, and weight gain throughout adult life: a meta-analysis of 41,504 subjects from the Scandinavian HUNT, MDC, and MPP studies. Diabetes. 2011; 60 :1637-44.</Citation></Reference><Reference><Citation>HUBACEK J.A., DLOUHA D., KLEMENTOVA M., LANSKA V., NESKUDLA T., PELIKANOVA T. The FTO variant is associated with chronic complications of diabetes mellitus in Czech population . Gene. 2018; 642 :220-4.</Citation></Reference><Reference><Citation>HUANG X., ZHAO J., YANG M., LI M., ZHENG J. Association between FTO gene polymorphism (rs9939609 T/A) and cancer risk: a meta-analysis. Eur J Cancer Care. 2017; 26(5).</Citation></Reference><Reference><Citation>HUBACEK J.A., VIKLICKY O., DLOUHA D., BLOUDICKOVA S., KUBINOVA R., PEASEY A., et al. The FTO gene polymorphism is associated with end-stage renal disease: two large independent case-control studies in a general population. Nephrol Dial Transplant. 2012; 27 :1030-5.</Citation></Reference><Reference><Citation>ZIMMERMANN E., KRING S.I., BERENTZEN T.L., HOLST C., PERS T.H., HANSEN T., et al. Fatness-associated FTO gene variant increases mortality independent of fatness - in cohorts of Danish men. PLoS One. 2009; 4 :e4428.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18468416</PMID><DateCompleted><Year>2008</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>10</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0038-2361</ISSN><JournalIssue CitedMedium="Print"><Volume>46</Volume><Issue>1</Issue><PubDate><Year>2008</Year><Month>Feb</Month></PubDate></JournalIssue><Title>South African journal of surgery. Suid-Afrikaanse tydskrif vir chirurgie</Title><ISOAbbreviation>S Afr J Surg</ISOAbbreviation></Journal><ArticleTitle>Gastric trauma: a straightforward injury, but no room for complacency.</ArticleTitle><Pagination><StartPage>10</StartPage><EndPage>13</EndPage><MedlinePgn>10-3</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Injuries to the stomach are common following abdominal trauma, and there are few management controversies. This study was undertaken to document experience with the management of gastric injuries in a single surgical ward in a tertiary institution.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">This prospective study was of a cohort of all patients found at laparotomy to have gastric injuries, over a 7-year period (1998-2004). Demographic data, clinical presentation, findings at laparotomy, and outcomes were documented. Prophylactic antibiotics were given at induction of anaesthesia. All patients found to have gastric injuries were given antifungal therapy.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Of the 488 patients undergoing laparotomy for abdominal trauma over this period, 99 (20%) were found to have gastric injuries, of whom 6 were female (M:F ratio 14:1). The mean age (+/- standard deviation (SD)) was 28.9 +/- 11.1 years. Mean delay before surgery was 7.6 +/- 5.2 hours. Seventeen patients presented in shock. Injury mechanisms were firearms (52), stabbing (43) and blunt trauma (4). The mean injury severity score (ISS) was 13.6 +/- 7.4. Forty-two patients required management in the intensive care unit (ICU), with a mean ICU stay of 4.7 +/- 4.6 hours. Twenty-nine patients developed complications, and 14 died. There was only 1 gastric injury-related complication. Causes of death were multiple organ dysfunction syndrome (MODS) (8) and hypovolaemic shock (4), septic shock (1) and renal failure (1). Patients presenting in shock had a significantly higher mortality than those without shock (p&lt;0.0001). Delay before laparotomy did not influence outcome. There were 20 patients with isolated gastric injuries, none of whom died. Mean hospital stay was 8.8 +/- 7.7 days.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">We reaffirm that stomach injuries are common following abdominal trauma. Isolated gastric injuries are uncommon. Complications specific to gastric injuries are uncommon but devastating. Mortality is related to associated injuries.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Madiba</LastName><ForeName>T E</ForeName><Initials>TE</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of KwaZulu-Natal and King Edward VIII Hospital, Durban.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hlophe</LastName><ForeName>M</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>South Africa</Country><MedlineTA>S Afr J Surg</MedlineTA><NlmUniqueID>2984854R</NlmUniqueID><ISSNLinking>0038-2361</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000007" MajorTopicYN="N">Abdominal Injuries</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019072" MajorTopicYN="N">Antibiotic Prophylaxis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007813" MajorTopicYN="N">Laparotomy</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013270" MajorTopicYN="N">Stomach</DescriptorName><QualifierName UI="Q000293" MajorTopicYN="Y">injuries</QualifierName><QualifierName UI="Q000601" MajorTopicYN="Y">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>13</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18468416</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">18503956</PMID><DateCompleted><Year>2008</Year><Month>07</Month><Day>22</Day></DateCompleted><DateRevised><Year>2022</Year><Month>03</Month><Day>16</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1557-3117</ISSN><JournalIssue CitedMedium="Internet"><Volume>27</Volume><Issue>6</Issue><PubDate><Year>2008</Year><Month>Jun</Month></PubDate></JournalIssue><Title>The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation</Title><ISOAbbreviation>J Heart Lung Transplant</ISOAbbreviation></Journal><ArticleTitle>Plasma biomarkers of myocardial fibrosis and remodeling in terminal heart failure patients supported by mechanical circulatory support devices.</ArticleTitle><Pagination><StartPage>589</StartPage><EndPage>596</EndPage><MedlinePgn>589-96</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.healun.2008.02.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">In this study we analyzed putative biomarkers for myocardial remodeling in plasma from 55 endstage heart failure patients with the need for mechanical circulatory support (MCS). We compared our data to 40 healthy controls and examined if MCS by either ventricular assist devices or total artificial hearts has an impact on plasma concentrations of remodeling biomarkers.</AbstractText><AbstractText Label="METHODS &amp; RESULTS" NlmCategory="RESULTS">Plasma biomarkers were analysed pre and 30 days post implantation of a MCS device using commercially available enzyme linked immunosorbent assays (ELISA). We observed that the plasma concentrations of remodeling biomarkers: tissue inhibitor of metalloproteinase 1 (TIMP1), tenascin C (TNC), galectin 3 (LGALS3), osteopontin (OPN) and of neurohumoral biomarker brain natriuretic peptide (BNP), are significantly elevated in patients with terminal heart failure compared to healthy controls. We did not find elevated plasma concentrations for matrix metalloproteinase 2 (MMP2) and procollagen I C-terminal peptide (PCIP). However, only BNP plasma levels were reduced by MCS, whereas the concentrations of remodeling biomarkers remained elevated or even increased further 30 days after MCS. LGALS3 plasma concentrations at device implantation were significantly higher in patients who did not survive MCS due to multi organ failure (MOF).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings indicate that mechanical unloading in endstage heart failure is not reflected by a rapid reduction of remodeling plasma biomarkers.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Milting</LastName><ForeName>Hendrik</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Herz- und Diabeteszentrum NRW, Erich und Hanna Klessmann Institut f&#xfc;r Kardiovaskul&#xe4;re Forschung und Entwicklung, Bad Oeynhausen, Germany. hmilting@hdz-nrw.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ellinghaus</LastName><ForeName>Peter</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Seewald</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Cakar</LastName><ForeName>Hamdin</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Bohms</LastName><ForeName>Birte</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Kassner</LastName><ForeName>Astrid</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>K&#xf6;rfer</LastName><ForeName>Reiner</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Klein</LastName><ForeName>Martina</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Krahn</LastName><ForeName>Thomas</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Kruska</LastName><ForeName>Lothar</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>El Banayosy</LastName><ForeName>Aly</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Kramer</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Heart Lung Transplant</MedlineTA><NlmUniqueID>9102703</NlmUniqueID><ISSNLinking>1053-2498</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D037502">Galectin 3</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019063">Tenascin</NameOfSubstance></Chemical><Chemical><RegistryNumber>106441-73-0</RegistryNumber><NameOfSubstance UI="D053495">Osteopontin</NameOfSubstance></Chemical><Chemical><RegistryNumber>114471-18-0</RegistryNumber><NameOfSubstance UI="D020097">Natriuretic Peptide, Brain</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.24</RegistryNumber><NameOfSubstance UI="D020778">Matrix Metalloproteinase 2</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.4.24.7</RegistryNumber><NameOfSubstance UI="D020781">Matrix Metalloproteinase 1</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004719" MajorTopicYN="N">Endomyocardial Fibrosis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D037502" MajorTopicYN="N">Galectin 3</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006333" MajorTopicYN="N">Heart Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006353" MajorTopicYN="Y">Heart-Assist Devices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020781" MajorTopicYN="N">Matrix Metalloproteinase 1</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020778" MajorTopicYN="N">Matrix Metalloproteinase 2</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020097" MajorTopicYN="N">Natriuretic Peptide, Brain</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053495" MajorTopicYN="N">Osteopontin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019063" MajorTopicYN="N">Tenascin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020257" MajorTopicYN="Y">Ventricular Remodeling</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2007</Year><Month>10</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>2</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>2</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>7</Month><Day>23</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>5</Month><Day>28</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18503956</ArticleId><ArticleId IdType="doi">10.1016/j.healun.2008.02.018</ArticleId><ArticleId IdType="pii">S1053-2498(08)00187-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">25945439</PMID><DateCompleted><Year>2017</Year><Month>04</Month><Day>07</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1972-6007</ISSN><JournalIssue CitedMedium="Internet"><Volume>166</Volume><Issue>2</Issue><PubDate><Year>2015</Year></PubDate></JournalIssue><Title>La Clinica terapeutica</Title><ISOAbbreviation>Clin Ter</ISOAbbreviation></Journal><ArticleTitle>White gauze test: a novel technique in preventing post-hepatectomy bile leak.</ArticleTitle><Pagination><StartPage>e102</StartPage><EndPage>e104</EndPage><MedlinePgn>e102-4</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.7417/CT.2015.1828</ELocationID><Abstract><AbstractText Label="BACKGROUND">Post-hepatectomy bile leak may lead to undesired morbidity. Multiple methods have been employed to identify this leak but can be inconclusive and taxing. This novel white gauze test is a simple and reliable method.</AbstractText><AbstractText Label="MATERIALS AND METHODS">This is a prospective study performed from January 2010 until March 2011. All open hepatic resection were included. Dry white gauze is compressed onto the transected surface and observed for bile staining. The leaking duct is repaired immediately upon detection. The process is repeated until negative. Drain was removed on postoperative day-5. Post-operative bile leak is defined as: 1. Bilirubin concentration of the drain fluid is 3 times or higher than serum; 2. Presence of intra-abdominal bile collection on imaging and upon drainage; 3. Bile leak demonstrated on postoperative cholangiography.</AbstractText><AbstractText Label="RESULTS">42 patients were recruited. Seven (16.7%) patients were cirrhotic with Child-Pugh A. White gauze test were positive for intra-operative bile leaks in 29 patients (70%), which were primarily repaired. As a result, there was no postoperative bile leak in this series. One mortality was detected in this series due to postoperative pancreatic fistula and multi organ failure.</AbstractText><AbstractText Label="CONCLUSIONS">The White Gauze Test is a useful method for the prevention of bile leakage after hepatic resection. It is safe, quick and cheap.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Yugasaravanan</LastName><ForeName>K</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, 56000, Kuala Lumpur.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Affirul</LastName><ForeName>C A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Medical Faculty, Universiti Sains Islam Malaysia, Jalan Pandan Utama, 55100, Kuala Lumpur, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zamri</LastName><ForeName>Z</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, 56000, Kuala Lumpur.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Azlanudin</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, 56000, Kuala Lumpur.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bong</LastName><ForeName>J J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, Universiti Kebangsaan Malaysia Medical Centre, 56000, Kuala Lumpur.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Ter</MedlineTA><NlmUniqueID>0372604</NlmUniqueID><ISSNLinking>0009-9074</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001646" MajorTopicYN="Y">Bile</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006498" MajorTopicYN="Y">Hepatectomy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007432" MajorTopicYN="N">Intraoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015503" MajorTopicYN="Y">Surgical Sponges</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Bile leak</Keyword><Keyword MajorTopicYN="N">Complications</Keyword><Keyword MajorTopicYN="N">Hepatectomy</Keyword><Keyword MajorTopicYN="N">Liver resection</Keyword><Keyword MajorTopicYN="N">Post-operative</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">25945439</ArticleId><ArticleId IdType="doi">10.7417/CT.2015.1828</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19054512</PMID><DateCompleted><Year>2010</Year><Month>03</Month><Day>11</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>09</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>40</Volume><Issue>5</Issue><PubDate><Year>2009</Year><Month>May</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Elevated systemic IL-18 and neopterin levels are associated with posttraumatic complications among patients with multiple injuries: a prospective cohort study.</ArticleTitle><Pagination><StartPage>528</StartPage><EndPage>534</EndPage><MedlinePgn>528-34</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2008.08.007</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Posttraumatic systemic inflammatory response syndrome (SIRS), sepsis and their subsequent complication, the multiple-organ dysfunction syndrome (MODS), remain major complications following polytrauma. This prospective clinical study aimed at evaluating the association between these and plasma interleukin-18 (IL-18) and neopterin levels.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Inclusion in the series required an Injury Severity Score (ISS) &gt;16, age 16-65 years, admission within 6 h of the accident and survival &gt;48 h; 55 patients were enrolled. Over 14 days, plasma neopterin and IL-18 levels and the clinical course regarding MODS, SIRS and sepsis were recorded daily using the Marshall Score for MODS and the ACCP/SCCM criteria for SIRS and sepsis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Neopterin and IL-18 plasma levels were increased in +MODS cases as compared with -MODS cases over almost the entire observation period. IL-18 concentrations over days 3-6 were significantly increased among participants with sepsis. These increases were all apparent 2-3 days before the clinical diagnosis of sepsis or MODS was made. In contrast, no significant differences in neopterin and IL-18 plasma levels were observed between participants with and without SIRS.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Determinations of neopterin and IL-18 concentrations might represent early markers for posttraumatic complications such as MODS and sepsis. They might help to differentiate between SIRS and sepsis and thereby guide the timing of the surgery for polytrauma. Neopterin and IL-18 levels should be used together with the clinical status and other inflammatory markers (IL-6, IL-8, etc.) for prediction of posttraumatic complications.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Mommsen</LastName><ForeName>P</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Trauma Department, Hanover Medical School, Carl-Neuberg-Strasse 1, 30625 Hanover, Germany. mommsen.philipp@mh-hannover.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frink</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Pape</LastName><ForeName>H C</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Probst</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Gaulke</LastName><ForeName>R</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Krettek</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>F</ForeName><Initials>F</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2008</Year><Month>12</Month><Day>02</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020382">Interleukin-18</NameOfSubstance></Chemical><Chemical><RegistryNumber>670-65-5</RegistryNumber><NameOfSubstance UI="D019798">Neopterin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003937" MajorTopicYN="N">Diagnosis, Differential</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004797" MajorTopicYN="N">Enzyme-Linked Immunosorbent Assay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015601" MajorTopicYN="N">Injury Severity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020382" MajorTopicYN="N">Interleukin-18</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019798" MajorTopicYN="N">Neopterin</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011237" MajorTopicYN="N">Predictive Value of Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2008</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2008</Year><Month>7</Month><Day>18</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2008</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>12</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19054512</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2008.08.007</ArticleId><ArticleId IdType="pii">S0020-1383(08)00386-0</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20819508</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>31</Day></DateCompleted><DateRevised><Year>2022</Year><Month>04</Month><Day>08</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2542-5641</ISSN><JournalIssue CitedMedium="Internet"><Volume>123</Volume><Issue>12</Issue><PubDate><Year>2010</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Chinese medical journal</Title><ISOAbbreviation>Chin Med J (Engl)</ISOAbbreviation></Journal><ArticleTitle>Effects of traditional Chinese medicine on intestinal mucosal permeability in early phase of severe acute pancreatitis.</ArticleTitle><Pagination><StartPage>1537</StartPage><EndPage>1542</EndPage><MedlinePgn>1537-42</MedlinePgn></Pagination><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Traditional Chinese medicine has been used widely for many years in China to treat acute pancreatitis. We have investigated the effects of Dachengqi decoction on intestinal mucosal permeability and outcome in patients with severe acute pancreatitis (SAP).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty patients with sustained SAP that required admission to the surgical intensive care unit were enrolled prospectively in the study. All of these patients were divided randomly into the Dachengqi decoction group (n = 20) and control group (n = 20) on admission. Intestinal permeability was assessed by measuring absorption of two metabolically inert markers, lactulose (L) and mannitol (M), which were administered orally. Serum concentrations of endotoxin (lipopolysaccharide, LPS) and the ratio of lactulose to mannitol in urine (L/M) were detected in all patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Compared with those in the control group, urinary L/M ratio decreased significantly in the Dachengqi decoction group on the 7th day after admission (P = 0.001). Also, serum concentrations of LPS were reduced on the 5th and 7th day after admission (P = 0.006, P = 0.008, respectively). Incidence of multiple organ dysfunction syndrome (MODS) and pancreatic infection was significantly lower in the Dachengqi decoction group compared with those in the control group (P = 0.038,P = 0.025, respectively).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Dachengqi decoction may promote the recovery of intestinal mucosal permeability and decrease the incidence of MODS and pancreatic infection in patients with SAP.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Xuan Wu Hospital of Capital Medical University, Beijing 100053, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Fei</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jia</LastName><ForeName>Jian-guo</ForeName><Initials>JG</Initials></Author><Author ValidYN="Y"><LastName>Diao</LastName><ForeName>Yong-peng</ForeName><Initials>YP</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Zong-xin</ForeName><Initials>ZX</Initials></Author><Author ValidYN="Y"><LastName>Sun</LastName><ForeName>Jia-bang</ForeName><Initials>JB</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>China</Country><MedlineTA>Chin Med J (Engl)</MedlineTA><NlmUniqueID>7513795</NlmUniqueID><ISSNLinking>0366-6999</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004365">Drugs, Chinese Herbal</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004365" MajorTopicYN="N">Drugs, Chinese Herbal</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007413" MajorTopicYN="N">Intestinal Mucosa</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008516" MajorTopicYN="N">Medicine, Chinese Traditional</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010195" MajorTopicYN="N">Pancreatitis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20819508</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21988742</PMID><DateCompleted><Year>2012</Year><Month>02</Month><Day>02</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1745-6215</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><PubDate><Year>2011</Year><Month>Oct</Month><Day>11</Day></PubDate></JournalIssue><Title>Trials</Title><ISOAbbreviation>Trials</ISOAbbreviation></Journal><ArticleTitle>The effect of C1-esterase inhibitor on systemic inflammation in trauma patients with a femur fracture - The CAESAR study: study protocol for a randomized controlled trial.</ArticleTitle><Pagination><StartPage>223</StartPage><MedlinePgn>223</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/1745-6215-12-223</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Systemic inflammation in response to a femur fracture and the additional fixation is associated with inflammatory complications, such as acute respiratory distress syndrome and multiple organ dysfunction syndrome. The injury itself, but also the additional procedure of femoral fixation induces a release of pro-inflammatory cytokines such as interleukin-6. This results in an aggravation of the initial systemic inflammatory response, and can cause an increased risk for the development of inflammatory complications. Recent studies have shown that administration of the serum protein C1-esterase inhibitor can significantly reduce the release of circulating pro-inflammatory cytokines in response to acute systemic inflammation.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">Attenuation of the surgery-induced additional systemic inflammatory response by perioperative treatment with C1-esterase inhibitor of trauma patients with a femur fracture.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The study is designed as a double-blind randomized placebo-controlled trial. Trauma patients with a femur fracture, Injury Severity Score &#x2265; 18 and age 18-80 years are included after obtaining informed consent. They are randomized for administration of 200 U/kg C1-esterase inhibitor intravenously or placebo (saline 0.9%) just before the start of the procedure of femoral fixation. The primary endpoint of the study is &#x394; interleukin-6, measured at t = 0, just before start of the femur fixation surgery and administration of C1-esterase inhibitor, and t = 6, 6 hours after administration of C1-esterase inhibitor and the femur fixation.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study intents to identify C1-esterase inhibitor as a safe and potent anti-inflammatory agent, that is capable of suppressing systemic inflammation in trauma patients. This might facilitate early total care procedures by lowering the risk of inflammation in response to the surgical intervention. This could result in increased functional outcomes and reduced health care related costs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Heeres</LastName><ForeName>Marjolein</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, University Medical Centre Utrecht, Heidelberglaan 100, 3508 GA, Utrecht, The Netherlands. M.Heeres-2@umcutrecht.nl</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Visser</LastName><ForeName>Tjaakje</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>van Wessem</LastName><ForeName>Karlijn J P</ForeName><Initials>KJ</Initials></Author><Author ValidYN="Y"><LastName>Koenderman</LastName><ForeName>Anky H L</ForeName><Initials>AH</Initials></Author><Author ValidYN="Y"><LastName>Strengers</LastName><ForeName>Paul F W</ForeName><Initials>PF</Initials></Author><Author ValidYN="Y"><LastName>Koenderman</LastName><ForeName>Leo</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Leenen</LastName><ForeName>Luke P H</ForeName><Initials>LP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT01275976</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>10</Month><Day>11</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Trials</MedlineTA><NlmUniqueID>101263253</NlmUniqueID><ISSNLinking>1745-6215</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050718">Complement C1 Inhibitor Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002985" MajorTopicYN="Y">Clinical Protocols</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050718" MajorTopicYN="N">Complement C1 Inhibitor Protein</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005264" MajorTopicYN="N">Femoral Fractures</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2011</Year><Month>7</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>10</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>10</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2012</Year><Month>2</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>10</Month><Day>11</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21988742</ArticleId><ArticleId IdType="pmc">PMC3198691</ArticleId><ArticleId IdType="doi">10.1186/1745-6215-12-223</ArticleId><ArticleId IdType="pii">1745-6215-12-223</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Hietbrink F, Koenderman L, Rijkers G, Leenen L. Trauma: the role of the innate immune system. World J Emerg Surg. 2006;1:15. doi: 10.1186/1749-7922-1-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1749-7922-1-15</ArticleId><ArticleId IdType="pmc">PMC1481567</ArticleId><ArticleId IdType="pubmed">16759367</ArticleId></ArticleIdList></Reference><Reference><Citation>Hietbrink F, Oudijk EJ, Braams R, Koenderman L, Leenen L. Aberrant regulation of polymorphonuclear phagocyte responsiveness in multitrauma patients. Shock. 2006;26(6):558&#x2013;564. doi: 10.1097/01.shk.0000233196.40989.78.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000233196.40989.78</ArticleId><ArticleId IdType="pubmed">17117129</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillay J, Hietbrink F, Koenderman L, Leenen LP. The systemic inflammatory response induced by trauma is reflected by multiple phenotypes of blood neutrophils. Injury. 2007;38(12):1365&#x2013;1372. doi: 10.1016/j.injury.2007.09.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.016</ArticleId><ArticleId IdType="pubmed">18061190</ArticleId></ArticleIdList></Reference><Reference><Citation>Ulvik A, Kvale R, Wentzel-Larsen T, Flaatten H. Multiple organ failure after trauma affects even long-term survival and functional status. Crit Care. 2007;11(5):R95..</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2556737</ArticleId><ArticleId IdType="pubmed">17784940</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38(12):1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruickshank AM, Fraser WD, Burns HJ, Van Damme J, Shenkin A. Response of serum interleukin-6 in patients undergoing elective surgery of varying severity. Clin Sci (Lond) 1990;79(2):161&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">2167805</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Smith RM, Bellamy MC, Morrison JF, Dickson RA, Guillou PJ. Stimulation of the inflammatory system by reamed and unreamed nailing of femoral fractures. An analysis of the second hit. J Bone Joint Surg Br. 1999;81(2):356&#x2013;361. doi: 10.1302/0301-620X.81B2.8988.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.81B2.8988</ArticleId><ArticleId IdType="pubmed">10204951</ArticleId></ArticleIdList></Reference><Reference><Citation>Gebhard F, Pfetsch H, Steinbach G, Strecker W, Kinzl L, Bruckner UB. Is interleukin 6 an early marker of injury severity following major trauma in humans? Arch Surg. 2000;135(3):291&#x2013;295. doi: 10.1001/archsurg.135.3.291.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archsurg.135.3.291</ArticleId><ArticleId IdType="pubmed">10722030</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, Harwood PJ, Loughenbury P, Van Griensven M, Krettek C, Pape HC. Correlation between IL-6 levels and the systemic inflammatory response score: can an IL-6 cutoff predict a SIRS state? J Trauma. 2008;65(3):646&#x2013;652. doi: 10.1097/TA.0b013e3181820d48.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e3181820d48</ArticleId><ArticleId IdType="pubmed">18784579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kobbe P, Vodovotz Y, Kaczorowski DJ, Mollen KP, Billiar TR, Pape HC. Patterns of cytokine release and evolution of remote organ dysfunction after bilateral femur fracture. Shock. 2008;30(1):43&#x2013;47. doi: 10.1097/SHK.0b013e31815d190b.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0b013e31815d190b</ArticleId><ArticleId IdType="pubmed">18562923</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Griensven MV, Hildebrand FF, Tzioupis CT, Sommer KL, Krettek CC, Giannoudis PV. Systemic inflammatory response after extremity or truncal fracture operations. J Trauma. 2008;65(6):1379&#x2013;1384. doi: 10.1097/TA.0b013e31818c8e8c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31818c8e8c</ArticleId><ArticleId IdType="pubmed">19077630</ArticleId></ArticleIdList></Reference><Reference><Citation>Morley JR, Smith RM, Pape HC, MacDonald DA, Trejdosiewitz LK, Giannoudis PV. Stimulation of the local femoral inflammatory response to fracture and intramedullary reaming: a preliminary study of the source of the second hit phenomenon. J Bone Joint Surg Br. 2008;90(3):393&#x2013;399. doi: 10.1302/0301-620X.90B3.19688.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.90B3.19688</ArticleId><ArticleId IdType="pubmed">18310768</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Van Griensven M, Rice J, Gansslen A, Hildebrand F, Zech S, Winny M, Lichtinghagen R, Krettek C. Major secondary surgery in blunt trauma patients and perioperative cytokine liberation: determination of the clinical relevance of biochemical markers. J Trauma. 2001;50(6):989&#x2013;1000. doi: 10.1097/00005373-200106000-00004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200106000-00004</ArticleId><ArticleId IdType="pubmed">11426112</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschoeke SK, Hellmuth M, Hostmann A, Ertel W, Oberholzer A. The early second hit in trauma management augments the proinflammatory immune response to multiple injuries. J Trauma. 2007;62(6):1396&#x2013;1403. doi: 10.1097/TA.0b013e318047b7f0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e318047b7f0</ArticleId><ArticleId IdType="pubmed">17563655</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Giannoudis P, Krettek C. The timing of fracture treatment in polytrauma patients: relevance of damage control orthopedic surgery. Am J Surg. 2002;183(6):622&#x2013;629. doi: 10.1016/S0002-9610(02)00865-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9610(02)00865-6</ArticleId><ArticleId IdType="pubmed">12095590</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC. Effects of changing strategies of fracture fixation on immunologic changes and systemic complications after multiple trauma: damage control orthopedic surgery. J Orthop Res. 2008;26(11):1478&#x2013;1484. doi: 10.1002/jor.20697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jor.20697</ArticleId><ArticleId IdType="pubmed">18524013</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Grimme K, Van Griensven M, Sott AH, Giannoudis P, Morley J, Roise O, Ellingsen E, Hildebrand F, Wiebe B, Krettek C. Impact of intramedullary instrumentation versus damage control for femoral fractures on immunoinflammatory parameters: prospective randomized analysis by the EPOFF Study Group. J Trauma. 2003;55(1):7&#x2013;13. doi: 10.1097/01.TA.0000075787.69695.4E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.TA.0000075787.69695.4E</ArticleId><ArticleId IdType="pubmed">12855874</ArticleId></ArticleIdList></Reference><Reference><Citation>Morshed S, Miclau T III, Bembom O, Cohen M, Knudson MM, Colford JM Jr. Delayed internal fixation of femoral shaft fracture reduces mortality among patients with multisystem trauma. J Bone Joint Surg Am. 2009;91(1):3&#x2013;13. doi: 10.2106/JBJS.H.00338.</Citation><ArticleIdList><ArticleId IdType="doi">10.2106/JBJS.H.00338</ArticleId><ArticleId IdType="pmc">PMC2663326</ArticleId><ArticleId IdType="pubmed">19122073</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Hildebrand F, Pertschy S, Zelle B, Garapati R, Grimme K, Krettek C, Reed RL. Changes in the management of femoral shaft fractures in polytrauma patients: from early total care to damage control orthopedic surgery. J Trauma. 2002;53(3):452&#x2013;461. doi: 10.1097/00005373-200209000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-200209000-00010</ArticleId><ArticleId IdType="pubmed">12352480</ArticleId></ArticleIdList></Reference><Reference><Citation>Pape HC, Tsukamoto T, Kobbe P, Tarkin I, Katsoulis S, Peitzman A. Assessment of the clinical course with inflammatory parameters. Injury. 2007;38(12):1358&#x2013;1364. doi: 10.1016/j.injury.2007.09.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.09.026</ArticleId><ArticleId IdType="pubmed">18048038</ArticleId></ArticleIdList></Reference><Reference><Citation>Dorresteijn MJ, Visser T, Cox LA, Bouw MP, Pillay J, Koenderman AH, Strengers PF, Leenen LP, van der Hoeven JG, Koenderman L, Pickkers P. C1-esterase inhibitor attenuates the inflammatory response during human endotoxemia. Crit Care Med. 2010;38(11):2139&#x2013;2145. doi: 10.1097/CCM.0b013e3181f17be4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/CCM.0b013e3181f17be4</ArticleId><ArticleId IdType="pubmed">20693886</ArticleId></ArticleIdList></Reference><Reference><Citation>Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev. 2000;52(1):91&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pubmed">10699156</ArticleId></ArticleIdList></Reference><Reference><Citation>Zeerleder S, Caliezi C, van Mierlo G, Eerenberg-Belmer A, Sulzer I, Hack CE, Wuillemin WA. Administration of C1 inhibitor reduces neutrophil activation in patients with sepsis. Clin Diagn Lab Immunol. 2003;10(4):529&#x2013;535.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC164269</ArticleId><ArticleId IdType="pubmed">12853381</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu D, Lu F, Qin G, Fernandes SM, Li J, Davis AE III. C1 inhibitor-mediated protection from sepsis. J Immunol. 2007;179(6):3966&#x2013;3972.</Citation><ArticleIdList><ArticleId IdType="pubmed">17785834</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahador M, Cross AS. From therapy to experimental model: a hundred years of endotoxin administration to human subjects. J Endotoxin Res. 2007;13(5):251&#x2013;279. doi: 10.1177/0968051907085986.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0968051907085986</ArticleId><ArticleId IdType="pubmed">17986486</ArticleId></ArticleIdList></Reference><Reference><Citation>The Declaration of Helsinki.  (September 20th 2011) [ http://www.wma.net/en/30publications/10policies/b3/]</Citation></Reference><Reference><Citation>The Good Clinical Practice Guidelines.  (September 20th 2011) [ http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002874.pdf]</Citation></Reference><Reference><Citation>Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101(6):1644&#x2013;1655. doi: 10.1378/chest.101.6.1644.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.101.6.1644</ArticleId><ArticleId IdType="pubmed">1303622</ArticleId></ArticleIdList></Reference><Reference><Citation>Vincent JL, de Mendonca A, Cantraine F, Moreno R, Takala J, Suter PM, Sprung CL, Colardyn F, Blecher S. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Crit Care Med. 1998;26(11):1793&#x2013;1800. doi: 10.1097/00003246-199811000-00016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199811000-00016</ArticleId><ArticleId IdType="pubmed">9824069</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28(6):668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>Stensballe J, Christiansen M, Tonnesen E, Espersen K, Lippert FK, Rasmussen LS. The early IL-6 and IL-10 response in trauma is correlated with injury severity and mortality. Acta Anaesthesiol Scand. 2009;53(4):515&#x2013;521. doi: 10.1111/j.1399-6576.2008.01801.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-6576.2008.01801.x</ArticleId><ArticleId IdType="pubmed">19317866</ArticleId></ArticleIdList></Reference><Reference><Citation>Bull K, Spiegelhalter DJ. Survival analysis in observational studies. Stat Med. 1997;16(9):1041&#x2013;1074. doi: 10.1002/(SICI)1097-0258(19970515)16:9&lt;1041::AID-SIM506&gt;3.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-0258(19970515)16:9&lt;1041::AID-SIM506&gt;3.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">9160498</ArticleId></ArticleIdList></Reference><Reference><Citation>O'Brien PC, Fleming TR. A multiple testing procedure for clinical trials. Biometrics. 1979;35(3):549&#x2013;556. doi: 10.2307/2530245.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2530245</ArticleId><ArticleId IdType="pubmed">497341</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol. 1999;36(4-5):225&#x2013;232. doi: 10.1016/S0161-5890(99)00048-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0161-5890(99)00048-6</ArticleId><ArticleId IdType="pubmed">10403475</ArticleId></ArticleIdList></Reference><Reference><Citation>Wouters D, Wagenaar-Bos I, van Ham M, Zeerleder S. C1 inhibitor: just a serine protease inhibitor? New and old considerations on therapeutic applications of C1 inhibitor. Expert Opin Biol Ther. 2008;8(8):1225&#x2013;1240. doi: 10.1517/14712598.8.8.1225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14712598.8.8.1225</ArticleId><ArticleId IdType="pubmed">18613773</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirschfink M, Mollnes TE. C1-inhibitor: an anti-inflammatory reagent with therapeutic potential. Expert Opin Pharmacother. 2001;2(7):1073&#x2013;1083. doi: 10.1517/14656566.2.7.1073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1517/14656566.2.7.1073</ArticleId><ArticleId IdType="pubmed">11583058</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-Bersma RJ, Abbink JJ, Thijs LG, Hack CE. Proteolytic inactivation of plasma C1- inhibitor in sepsis. J Clin Invest. 1989;84(2):443&#x2013;450. doi: 10.1172/JCI114185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI114185</ArticleId><ArticleId IdType="pmc">PMC548902</ArticleId><ArticleId IdType="pubmed">2668333</ArticleId></ArticleIdList></Reference><Reference><Citation>de Zwaan C, Kleine AH, Diris JH, Glatz JF, Wellens HJ, Strengers PF, Tissing M, Hack CE, van Dieijen-Visser MP, Hermens WT. Continuous 48-h C1-inhibitor treatment, following reperfusion therapy, in patients with acute myocardial infarction. Eur Heart J. 2002;23(21):1670&#x2013;1677.</Citation><ArticleIdList><ArticleId IdType="pubmed">12398824</ArticleId></ArticleIdList></Reference><Reference><Citation>Struber M, Hagl C, Hirt SW, Cremer J, Harringer W, Haverich A. C1-esterase inhibitor in graft failure after lung transplantation. Intensive Care Med. 1999;25(11):1315&#x2013;1318. doi: 10.1007/s001340051065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s001340051065</ArticleId><ArticleId IdType="pubmed">10654221</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20219387</PMID><DateCompleted><Year>2011</Year><Month>03</Month><Day>22</Day></DateCompleted><DateRevised><Year>2011</Year><Month>06</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Jul</Month></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Prediction of mortality in intensive care unit cardiac surgical patients.</ArticleTitle><Pagination><StartPage>104</StartPage><EndPage>109</EndPage><MedlinePgn>104-9</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejcts.2010.01.053</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">The purpose of this study was to develop a specific postoperative score in intensive care unit (ICU) cardiac surgical patients for the assessment of organ dysfunction and survival. To prove the reliability of the new scoring system, we compared its performance to existing ICU scores.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This prospective study consisted of all consecutive adult patients admitted after cardiac surgery to our ICU over a period of 5.5 years. Variables were evaluated using the patients of the first year who stayed in ICU for at least 24h. The reproducibility was then tested in two validation sets using all patients. Performance was assessed with the Hosmer-Lemeshow (HL) goodness-of-fit test and receiver operating characteristic (ROC) curves and compared with the Acute Physiology and Chronic Health Evaluation (APACHE II) and Multiple Organ Dysfunction Score (MODS). The outcome measure was defined as 30-day mortality.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 6007 patients were admitted to the ICU after cardiac surgery. Mean HL values for the new score were 5.8 (APACHE II, 11.3; MODS, 9.7) for the construction set, 7.2 (APACHE II, 8.0; MODS, 4.5) for the validation set I and 4.9 for the validation set II. The mean area under the ROC curve was 0.91 (APACHE II, 0.86; MODS, 0.84) for the new score in the construction set, 0.88 (APACHE II, 0.84; MODS, 0.84) in the validation set I and 0.92 in the validation set II.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most of general ICU scoring systems use extensive data collection and focus on the first day of ICU stay. Despite this fact, general scores do not perform well in the prediction of outcome in cardiac surgical patients. Our new 10-variable risk index performs very well, with calibration and discrimination very high, better than general severity systems, and it is an appropriate tool for daily risk stratification in ICU cardiac surgery patients. Thus, it may serve as an expert system for diagnosing organ failure and predicting mortality in ICU cardiac surgical patients.</AbstractText><CopyrightInformation>Copyright 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hekmat</LastName><ForeName>Khosro</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Cardiothoracic Surgery, Friedrich-Schiller-University, Jena, Germany. hekmat@med.uni-jena.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Doerr</LastName><ForeName>Fabian</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Kroener</LastName><ForeName>Axel</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Heldwein</LastName><ForeName>Matthias</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Bossert</LastName><ForeName>Torsten</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Badreldin</LastName><ForeName>Akmal M A</ForeName><Initials>AM</Initials></Author><Author ValidYN="Y"><LastName>Lichtenberg</LastName><ForeName>Artur</ForeName><Initials>A</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>03</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Eur J Cardiothorac Surg. 2011 May;39(5):797; author reply 797-8. doi: 10.1016/j.ejcts.2010.09.004.</RefSource><PMID Version="1">20940100</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="Y">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004812" MajorTopicYN="N">Epidemiologic Methods</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005858" MajorTopicYN="N" Type="Geographic">Germany</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="Y">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011182" MajorTopicYN="N">Postoperative Care</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011184" MajorTopicYN="N">Postoperative Period</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>1</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2010</Year><Month>1</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>3</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20219387</ArticleId><ArticleId IdType="doi">10.1016/j.ejcts.2010.01.053</ArticleId><ArticleId IdType="pii">S1010-7940(10)00117-X</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19932032</PMID><DateCompleted><Year>2011</Year><Month>01</Month><Day>20</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-734X</ISSN><JournalIssue CitedMedium="Internet"><Volume>37</Volume><Issue>4</Issue><PubDate><Year>2010</Year><Month>Apr</Month></PubDate></JournalIssue><Title>European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery</Title><ISOAbbreviation>Eur J Cardiothorac Surg</ISOAbbreviation></Journal><ArticleTitle>Regulated upon activation, normal T-cell expressed and secreted chemokine and interleukin-6 in rheumatic pulmonary hypertension, targets for therapeutic decisions.</ArticleTitle><Pagination><StartPage>853</StartPage><EndPage>858</EndPage><MedlinePgn>853-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ejcts.2009.10.010</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Recent studies have highlighted the possible influence of chemokines and cytokines on several types of pulmonary arterial hypertension (PAH). Increasing interest has also been focussed on their role as a cause of post-cardiopulmonary bypass (CPB) organ dysfunction.</AbstractText><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Chemokines and cytokines are involved in the pathobiology of rheumatic PAH.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Serum levels of the chemokine, regulated upon activation, normal T-cell expressed and secreted (RANTES) and the cytokine interleukin-6 (IL-6) were measured by enzyme-linked immunosorbent assay (ELISA) in 35 patients with rheumatic mitral valve disease and 10 matched healthy subjects (control group). Eleven patients (31.4%) had severe pulmonary hypertension. Subsequently, 23 patients underwent mitral valve replacement. The relation of RANTES and IL-6 circulating level with postoperative organ dysfunction was analysed through multiple organ dysfunction score (MODS).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with severe PAH have a significantly higher mean serum level of RANTES compared with other patients (6138.6+/-3543.8 pg/ml vs 1818.2+/-475.2 pg/ml, p=0.0003). The serum level of IL-6 in the patients was statistically different from that of the control (378+/-50.8 pg/ml vs 262+/-90.5 pg/ml, respectively, p=0.002). Patients who required postoperative inotropes had higher preoperative and post-CPB levels of both RANTES and IL-6. While patients with postoperative lung dysfunction had higher levels of IL-6 preoperatively and post-CPB and lower levels of RANTES post-CPB.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">RANTES and IL-6 should be investigated as potential therapeutic targets in the control of rheumatic PAH. Improved understanding of the contribution of RANTES and IL-6 to adverse postoperative complications can lead to improved patient outcome.</AbstractText><CopyrightInformation>Copyright (c) 2009 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Serag</LastName><ForeName>Amany R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Cardiology, Menoufyia University, Shebin El-Kom, Egypt.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hazaa</LastName><ForeName>Sahar M</ForeName><Initials>SM</Initials></Author><Author ValidYN="Y"><LastName>Afifi</LastName><ForeName>Ibtesam K</ForeName><Initials>IK</Initials></Author><Author ValidYN="Y"><LastName>Ghoname</LastName><ForeName>Naglaa F</ForeName><Initials>NF</Initials></Author><Author ValidYN="Y"><LastName>Serag</LastName><ForeName>Amro R</ForeName><Initials>AR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Eur J Cardiothorac Surg</MedlineTA><NlmUniqueID>8804069</NlmUniqueID><ISSNLinking>1010-7940</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C483024">CCL5 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018946">Chemokine CCL5</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018946" MajorTopicYN="N">Chemokine CCL5</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019918" MajorTopicYN="N">Heart Valve Prosthesis Implantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006976" MajorTopicYN="N">Hypertension, Pulmonary</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008944" MajorTopicYN="N">Mitral Valve Insufficiency</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008946" MajorTopicYN="N">Mitral Valve Stenosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012214" MajorTopicYN="N">Rheumatic Heart Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>4</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>9</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>10</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>1</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19932032</ArticleId><ArticleId IdType="doi">10.1016/j.ejcts.2009.10.010</ArticleId><ArticleId IdType="pii">S1010-7940(09)00987-7</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19939284</PMID><DateCompleted><Year>2010</Year><Month>04</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>11</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>6</Issue><PubDate><Year>2009</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Clinical relevance of the interleukin 10 promoter polymorphisms in Chinese Han patients with major trauma: genetic association studies.</ArticleTitle><Pagination><StartPage>R188</StartPage><MedlinePgn>R188</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc8182</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">An excessive inflammatory response is thought to account for the pathogenesis of sepsis and multiple organ dysfunction syndrome (MODS) after severe trauma. The interleukin-10 (IL-10) is a potent anti-inflammatory cytokine. The objectives of this prospective study were to investigate the distribution of IL-10 promoter polymorphisms in a cohort of 308 Chinese Han patients with major trauma, and to identify associations of IL-10 promoter polymorphisms with IL-10 production and incidence of sepsis and MODS.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A total of 308 patients with major trauma were included in this study. The genotypes of polymorphisms -1082, -819 and -592 were determined by polymerase chain reaction-restriction fragment length polymorphism. The IL-10 levels in the supernatants were determined with enzyme-linked immunoabsorbent assay.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The -1082A and -592A alleles were significantly associated with lower lipopolysaccharide-induced IL-10 production in an allele-dose dependent fashion. There was no significant difference for the -819 polymorphism. Except for the -1082 polymorphism, the -819 and -592 polymorphisms were not significantly associated with sepsis morbidity rate and MOD scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our results further confirm the functionality of the IL-10 promoter single nucleotide polymorphisms in relation to IL-10 production. They also suggest that individual difference in IL-10 production in trauma patients might be at least in part related to genetic variations in the IL-10 promoter region.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zeng</LastName><ForeName>Ling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>State Key Laboratory of Trauma, Burns and Combined Injury, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Yuzhong District, Chongqing, 400042, PR China. zengling_1025@126.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gu</LastName><ForeName>Wei</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Kehong</ForeName><Initials>K</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Dongpo</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Lianyang</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Du</LastName><ForeName>Dingyuan</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Hu</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qing</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>Huang</LastName><ForeName>Suna</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Jianxin</ForeName><Initials>J</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2009</Year><Month>11</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Crit Care. 2010;14(1):119. doi: 10.1186/cc8839.</RefSource><PMID Version="1">20236506</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D044466" MajorTopicYN="N">Asian People</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002681" MajorTopicYN="N" Type="Geographic">China</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005787" MajorTopicYN="N">Gene Frequency</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056726" MajorTopicYN="Y">Genetic Association Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014644" MajorTopicYN="N">Genetic Variation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011110" MajorTopicYN="Y">Polymorphism, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011401" MajorTopicYN="Y">Promoter Regions, Genetic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>10</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>11</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>11</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>1</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2009</Year><Month>11</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19939284</ArticleId><ArticleId IdType="pmc">PMC2811917</ArticleId><ArticleId IdType="doi">10.1186/cc8182</ArticleId><ArticleId IdType="pii">cc8182</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Wang ZG, Jiang JX. An overview of research advances in road traffic trauma in China. Traffic Injury Prevention. 2003;4:9&#x2013;16. doi: 10.1080/15389580309860.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15389580309860</ArticleId><ArticleId IdType="pubmed">14522656</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang JX. Posttraumatic stress and immune dissonance. Chin J Traumatol. 2008;11:203&#x2013;208. doi: 10.1016/S1008-1275(08)60044-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1008-1275(08)60044-9</ArticleId><ArticleId IdType="pubmed">18667117</ArticleId></ArticleIdList></Reference><Reference><Citation>Lausevic Z, Ausevic ML, Trbojevic-Stankovic J, Krstic S, Stojimirovic B. Predicting multiple organ failure in patients with severe trauma. Can J Surg. 2008;51:97&#x2013;102.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2386337</ArticleId><ArticleId IdType="pubmed">18377749</ArticleId></ArticleIdList></Reference><Reference><Citation>Lenz A, Franklin GA, Cheadle WG. Systemic inflammation after trauma. Injury. 2007;38:1336&#x2013;1345. doi: 10.1016/j.injury.2007.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.injury.2007.10.003</ArticleId><ArticleId IdType="pubmed">18048040</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang JX. Genomic polymorphisms and sepsis. Chin J Traumatol. 2005;21:45&#x2013;49.</Citation></Reference><Reference><Citation>Gu W, Du DY, Huang J, Zhang LY, Liu Q, Zhu PF, Wang ZG, Jiang JX. Functional significance of gene polymorphisms in the promoter of myeloid differentiation-2. Ann Surg. 2007;246:151&#x2013;158. doi: 10.1097/01.sla.0000262788.67171.3f.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.sla.0000262788.67171.3f</ArticleId><ArticleId IdType="pmc">PMC1899213</ArticleId><ArticleId IdType="pubmed">17592304</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosmann TR. Properties and functions of interleukin-10. Adv Immunol. 1994;56:1&#x2013;26. full_text.</Citation><ArticleIdList><ArticleId IdType="pubmed">8073945</ArticleId></ArticleIdList></Reference><Reference><Citation>Mosser DM, Zhang X. Interleukin-10: new perspectives on an old cytokine. Immunol Rev. 2008;226:205&#x2013;218. doi: 10.1111/j.1600-065X.2008.00706.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-065X.2008.00706.x</ArticleId><ArticleId IdType="pmc">PMC2724982</ArticleId><ArticleId IdType="pubmed">19161426</ArticleId></ArticleIdList></Reference><Reference><Citation>Welborn Mr, Moldawer LL, Seeger JM, Minter RM, Huber TS. Role of endogenous interleukin-10 in local and distant organ injury after visceral ischemia-reperfusion. Shock. 2003;20:35&#x2013;40. doi: 10.1097/01.SHK.0000071062.67193.b6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.SHK.0000071062.67193.b6</ArticleId><ArticleId IdType="pubmed">12813366</ArticleId></ArticleIdList></Reference><Reference><Citation>Neidhardt R, Keel M, Steckholzer U, Safret A, Ungethuem U, Trentz O, Ertel W. Relationship of interleukin-10 plasma levels to severity of injury and clinical outcome in injured patients. J Trauma. 1997;42:863&#x2013;871. doi: 10.1097/00005373-199705000-00017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-199705000-00017</ArticleId><ArticleId IdType="pubmed">9191668</ArticleId></ArticleIdList></Reference><Reference><Citation>Maier B, Lefering R, Lehnert M, Laurer HL, Steudel WI, Neugebauer EA, Marzi I. Early versus late onset of multiple organ failure is associated with differing patterns of plasma cytokine biomarker expression and outcome after severe trauma. Shock. 2007;28:668&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pubmed">18092384</ArticleId></ArticleIdList></Reference><Reference><Citation>McDaniel DO, Hamilton J, Brock M, May W, Calcote L, Tee LY, Vick L, Newman DB, Vick K, Harrison S, Timberlake G, Toevs C. Molecular analysis of inflammatory markers in trauma patients at risk of postinjury complications. J Trauma. 2007;63:147&#x2013;157. doi: 10.1097/TA.0b013e31806bf0ab.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TA.0b013e31806bf0ab</ArticleId><ArticleId IdType="pubmed">17622883</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendorp RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence on cytokine production and fatal meningococcal disease. Lancet. 1997;349:170&#x2013;173. doi: 10.1016/S0140-6736(96)06413-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)06413-6</ArticleId><ArticleId IdType="pubmed">9111542</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart D, Fulton WB, Wilson C, Monitto CL, Paidas CN, Reeves RH, De Maio A. Genetic contribution to the septic response in a mouse model. Shock. 2002;18:342&#x2013;347. doi: 10.1097/00024382-200210000-00009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200210000-00009</ArticleId><ArticleId IdType="pubmed">12392278</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner DM, Williams DM, Sankaran D, Lazarus M, Sinnott PJ, Hutchinson IV. An investigation of polymorphism in the interleukin-10 gene promoter. Eur J Immunogenet. 1997;24:1&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">9043871</ArticleId></ArticleIdList></Reference><Reference><Citation>Fowler EV, Eri R, Hume G, Johnstone S, Pandeya N, Lincoln D, Templeton D, Radford-Smith GL. TNF alpha and IL10 SNPs act together to predict disease behavior in Crohn's disease. J Med Genet. 2005;42:523&#x2013;528. doi: 10.1136/jmg.2004.027425.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2004.027425</ArticleId><ArticleId IdType="pmc">PMC1736076</ArticleId><ArticleId IdType="pubmed">15937090</ArticleId></ArticleIdList></Reference><Reference><Citation>He G, Zhang J, Li XW, Chen WY, Pan YX, Yang FP, Gu NF, Feng GY, Yang SL, He JY, Liu BX, Peng YW, Liu J, He L. Interleukin-10-1082 promoter polymorphism is associated with schizophrenia in a Han Chinese sib-pair study. Neurosci Lett. 2006;394:1&#x2013;4. doi: 10.1016/j.neulet.2005.06.054.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2005.06.054</ArticleId><ArticleId IdType="pubmed">16378687</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang J, Ni H, Chen L, Song WQ. Interleukin-10 promoter polymorphism in patients with hepatitis B virus infection or hepatocellular carcinomain Chinese Han ethnic population. Hepatobiliary Pancreat Dis Int. 2005;5:60&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481285</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Hei P, Deng L, Lin J. Interleukin-10 gene promoter polymorphisms and their protein production in peritoneal fluid in patients with endometriosis. Mol Hum Reprod. 2007;13:135&#x2013;140. doi: 10.1093/molehr/gal106.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/molehr/gal106</ArticleId><ArticleId IdType="pubmed">17178764</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma SL, Tang NL, Lam LC, Chiu HF. The association between promoter polymorphism of the interleukin-10 gene and Alzheimer's disease. Neurobiol Aging. 2005;26:1005&#x2013;1010. doi: 10.1016/j.neurobiolaging.2004.08.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.08.010</ArticleId><ArticleId IdType="pubmed">15748779</ArticleId></ArticleIdList></Reference><Reference><Citation>Gong MN, Thompson BT, Williams PL, Zhou W, Wang MZ, Pothier L, Christiani DC. Interleukin-10 polymorphism in position - 1082 and acute respiratory distress syndrome. Eur Respir J. 2006;27:674&#x2013;681. doi: 10.1183/09031936.06.00046405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/09031936.06.00046405</ArticleId><ArticleId IdType="pmc">PMC3090261</ArticleId><ArticleId IdType="pubmed">16585075</ArticleId></ArticleIdList></Reference><Reference><Citation>Stanilova SA, Miteva LD, Karakolev ZT, Stefanov CS. Interleukin-10-1082 promoter polymorphism in association with cytokine production and sepsis susceptibility. Intensive Care Med. 2006;32:260&#x2013;266. doi: 10.1007/s00134-005-0022-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00134-005-0022-4</ArticleId><ArticleId IdType="pubmed">16435103</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder O, Laun RA, Held B, Ekkernkamp A, Schulte KM. Association of interleukin-10 promoter polymorphism with the incidence of multiple organ dysfunction following major trauma: results of a prospective pilot study. Shock. 2004;21:306&#x2013;310. doi: 10.1097/00024382-200404000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200404000-00003</ArticleId><ArticleId IdType="pubmed">15179129</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero JM, Lopez PS, Cozar JM, Carretero R, Canton J, Vazquez F, Concha A, Tallada M, Garrido F, Ruiz-Cabello F. A polymorphism in the interleukin-10 promoter affects the course of disease in patients with clear-cell renal carcinoma. Hum Immunol. 2009;70:60&#x2013;64. doi: 10.1016/j.humimm.2008.10.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2008.10.020</ArticleId><ArticleId IdType="pubmed">19027043</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F, Qu YB, Tang YX, Cao DZ, Sun P, Xia ZL. Lack of association between cytokine gene polymorphisms and silicosis and pulmonary tuberculosis in Chinese iron miners. J Occup Health. 2008;50:445&#x2013;454. doi: 10.1539/joh.L8006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1539/joh.L8006</ArticleId><ArticleId IdType="pubmed">18931463</ArticleId></ArticleIdList></Reference><Reference><Citation>Schroeder O, Schulte KM, Schroeder J, Ekkernkamp A, Laun RA. The -1082 interleukin-10 polymorphism is associated with acute respiratory failure after major trauma: a prospective cohort study. Surgery. 2008;143:233&#x2013;242. doi: 10.1016/j.surg.2007.07.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.surg.2007.07.040</ArticleId><ArticleId IdType="pubmed">18242340</ArticleId></ArticleIdList></Reference><Reference><Citation>The Abbreviated Injury Scale. Barrington. Illinois: Association for the Advancement of Automotive Medicine. 2005.</Citation></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple organ dysfunction score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Power and Sample Size Program. http://biostat.mc.vanderbilt.edu/twiki/bin/view/Main/PowerSampleSize</Citation></Reference><Reference><Citation>Chung BS, Lee JK, Choi MH, Park MH, Choi D, Hong ST. Single nucleotide polymorphisms of cytokine genes are associated with fibrosis of the intrahepatic bile duct wall in human clonorchiasis. Korean J Parasitol. 2009;47:145&#x2013;151. doi: 10.3347/kjp.2009.47.2.145.</Citation><ArticleIdList><ArticleId IdType="doi">10.3347/kjp.2009.47.2.145</ArticleId><ArticleId IdType="pmc">PMC2688796</ArticleId><ArticleId IdType="pubmed">19488421</ArticleId></ArticleIdList></Reference><Reference><Citation>Tseng LH, Storer B, Petersdorf E, Lin MT, Chien JW, Grogan BM, Malkki M, Chen PJ, Zhao LP, Martin PJ, Hansen JA. IL10 and IL10 receptor gene variation and outcomes after unrelated and related hematopoietic cell transplantation. Transplantation. 2009;87:704&#x2013;710. doi: 10.1097/TP.0b013e318195c474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0b013e318195c474</ArticleId><ArticleId IdType="pmc">PMC3019105</ArticleId><ArticleId IdType="pubmed">19295315</ArticleId></ArticleIdList></Reference><Reference><Citation>Pachkoria K, Lucena MI, Crespo E, Ruiz-Cabello F, Lopez-Ortega S, Fernandez M, Romero-Gomez M, Madrazo A, Duran JA, De Dios AM, Borraz Y, Navarro JM, Andrade RJ. Analysis of IL-10, IL-4 and TNF-a polymorphisms in drug-induced liver injury (DILI) and its outcome. J Hepatol. 2008;49:107&#x2013;114. doi: 10.1016/j.jhep.2008.03.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jhep.2008.03.017</ArticleId><ArticleId IdType="pubmed">18485518</ArticleId></ArticleIdList></Reference><Reference><Citation>Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic associations with complex outcomes. Lancet. 2003;361:865&#x2013;872. doi: 10.1016/S0140-6736(03)12715-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(03)12715-8</ArticleId><ArticleId IdType="pubmed">12642066</ArticleId></ArticleIdList></Reference><Reference><Citation>Westendrop RG, Langermans JA, Huizinga TW, Elouali AH, Verweij CL, Boomsma DI, Vandenbroucke JP. Genetic influence of cytokine production and fatal meningococcal disease. Lancet. 1997;349:170&#x2013;173. doi: 10.1016/S0140-6736(96)06413-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(96)06413-6</ArticleId><ArticleId IdType="pubmed">9111542</ArticleId></ArticleIdList></Reference><Reference><Citation>MOTIF Search. http://motif.genome.jp</Citation></Reference><Reference><Citation>Keijsers V, Verweij CL, Westendorp RGJ, Breedveld FC, Huizinga TWJ. IL10 polymorphisms in relation to production and rheumatoid arthritis. Arthritis Rheum. 1997;40:179&#x2013;185. doi: 10.1002/art.1780400123.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400123</ArticleId><ArticleId IdType="pubmed">9008614</ArticleId></ArticleIdList></Reference><Reference><Citation>Rad R, Dossumbekova A, Neu B, Lang R, Bauer S, Saur D, Gerhard M, Prinz C. Cytokine gene polymorphism influence mucosal cytokine expression, gastric inflammation and host specific colonization during Helicobacter pylori infection. Gut. 2004;53:1082&#x2013;1089. doi: 10.1136/gut.2003.029736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gut.2003.029736</ArticleId><ArticleId IdType="pmc">PMC1774164</ArticleId><ArticleId IdType="pubmed">15247172</ArticleId></ArticleIdList></Reference><Reference><Citation>Reid CL, Perrey C, Pravica V, Hutchinson IV, Campbell IT. Genetic variation in proinflammatory and anti-inflammatory cytokine production in multiple organ dysfunction syndrome. Crit Care Med. 2003;30:2216&#x2013;2221. doi: 10.1097/00003246-200210000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200210000-00007</ArticleId><ArticleId IdType="pubmed">12394947</ArticleId></ArticleIdList></Reference><Reference><Citation>Giannoudis PV, van Griensven M, Tsiridis E, Pape HC. The genetic predisposition to adverse outcome after trauma. J Bone Joint Surg Br. 2007;89:1273&#x2013;1279. doi: 10.1302/0301-620X.89B10.19022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1302/0301-620X.89B10.19022</ArticleId><ArticleId IdType="pubmed">17957062</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen AQ, Wang J, Feng K, Zhu PF, Wang ZG, Jiang JX. Effects of haplotypes in the interleukin 1 beta promoter on lipopolysacchride-induced interleukin 1 beta expression. Shock. 2006;26:25&#x2013;30. doi: 10.1097/01.shk.0000223125.56888.c7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000223125.56888.c7</ArticleId><ArticleId IdType="pubmed">16783194</ArticleId></ArticleIdList></Reference><Reference><Citation>Hildebrand F, Pape HC, van Griensven M, Meier S, Hasenkamp S, Krettek C, Stuhrmann M. Genentic predisposition for a compromised immune system after multiple trauma. Shock. 2005;24:518&#x2013;522. doi: 10.1097/01.shk.0000184212.97488.4e.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000184212.97488.4e</ArticleId><ArticleId IdType="pubmed">16317381</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19595327</PMID><DateCompleted><Year>2010</Year><Month>10</Month><Day>15</Day></DateCompleted><DateRevised><Year>2016</Year><Month>11</Month><Day>25</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1879-0267</ISSN><JournalIssue CitedMedium="Internet"><Volume>41</Volume><Issue>5</Issue><PubDate><Year>2010</Year><Month>May</Month></PubDate></JournalIssue><Title>Injury</Title><ISOAbbreviation>Injury</ISOAbbreviation></Journal><ArticleTitle>Is dopexamine superior to dopamine in the treatment of multiple trauma patients--a prospective, double-blind, randomised study.</ArticleTitle><Pagination><StartPage>499</StartPage><EndPage>505</EndPage><MedlinePgn>499-505</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.injury.2009.06.018</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The goal of this prospective, randomised, double-blind clinical trial study was to assess the effects of dopexamine hydrochloride on organ failure, inflammatory mediators and splanchnic oxygenation in blunt multiple trauma patients at high risk of multiple organ dysfunction syndrome (MODS).</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">We performed a prospective randomised controlled trial on 30 consecutive blunt multiple trauma patients with ISS&gt;or=16, age 18-60 years and initial blood pressure &gt;or=120 mmHg initially admitted to our level I trauma centre. Patients were randomised to treatment with dopamine (n=15) or dopexamine (n=15) for 48 h after admission. Outcome in terms of mortality, MODS, splanchnic perfusion, complications, duration of stay was statistically analysed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Dopexamine treatment was associated with impaired organ function and an increased duration of ventilation and ICU stay compared with patients who received dopamine treatment. The acute inflammatory response was increased in the Dopexamine group while a decreased pHi and MEGX formation and increased serum lactate levels were measured.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">The indication to use dopexamine hydrochloride appears questionable. In the absence of an antiinflammatory effect, dopexamine demonstrated a disadvantageous ICU course in regards to the organ function and the duration of treatment. In addition, a decreased pHi and MEGX formation suggested a deterioration of splanchnic oxygenation.</AbstractText><CopyrightInformation>(c) 2009 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Probst</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Trauma Surgery, Hannover Medical School, 30623 Hannover, Germany. probst.christian@mh-hannover.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hildebrand</LastName><ForeName>Frank</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>van Griensven</LastName><ForeName>Martijn</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Baur</LastName><ForeName>Hellmut</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Mahlke</LastName><ForeName>Lutz</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Krettek</LastName><ForeName>Christian</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Pape</LastName><ForeName>Hans-Christoph</ForeName><Initials>HC</Initials></Author><Author ValidYN="Y"><LastName>Grotz</LastName><ForeName>Martin Rolf Wolfgang</ForeName><Initials>MR</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Injury</MedlineTA><NlmUniqueID>0226040</NlmUniqueID><ISSNLinking>0020-1383</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014665">Vasodilator Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>398E7Z7JB5</RegistryNumber><NameOfSubstance UI="C046318">dopexamine</NameOfSubstance></Chemical><Chemical><RegistryNumber>98PI200987</RegistryNumber><NameOfSubstance UI="D008012">Lidocaine</NameOfSubstance></Chemical><Chemical><RegistryNumber>D8Q99HC770</RegistryNumber><NameOfSubstance UI="C001173">monoethylglycinexylidide</NameOfSubstance></Chemical><Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber><NameOfSubstance UI="D004298">Dopamine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001794" MajorTopicYN="N">Blood Pressure</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003422" MajorTopicYN="N">Critical Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="Y">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005753" MajorTopicYN="N">Gastric Mucosa</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007902" MajorTopicYN="N">Length of Stay</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008012" MajorTopicYN="N">Lidocaine</DescriptorName><QualifierName UI="Q000031" MajorTopicYN="N">analogs &amp; derivatives</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010101" MajorTopicYN="N">Oxygen Consumption</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013152" MajorTopicYN="N">Splanchnic Circulation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014665" MajorTopicYN="N">Vasodilator Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014781" MajorTopicYN="N">Viscera</DescriptorName><QualifierName UI="Q000098" MajorTopicYN="Y">blood supply</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014949" MajorTopicYN="N">Wounds, Nonpenetrating</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2009</Year><Month>3</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2009</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2009</Year><Month>6</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>7</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19595327</ArticleId><ArticleId IdType="doi">10.1016/j.injury.2009.06.018</ArticleId><ArticleId IdType="pii">S0020-1383(09)00310-6</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">26068807</PMID><DateCompleted><Year>2016</Year><Month>05</Month><Day>05</Day></DateCompleted><DateRevised><Year>2018</Year><Month>12</Month><Day>02</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1877-0568</ISSN><JournalIssue CitedMedium="Internet"><Volume>101</Volume><Issue>5</Issue><PubDate><Year>2015</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Orthopaedics &amp; traumatology, surgery &amp; research : OTSR</Title><ISOAbbreviation>Orthop Traumatol Surg Res</ISOAbbreviation></Journal><ArticleTitle>Early inflammatory response in polytraumatized patients: Cytokines and heat shock proteins. A pilot study.</ArticleTitle><Pagination><StartPage>607</StartPage><EndPage>611</EndPage><MedlinePgn>607-11</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.otsr.2015.03.014</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1877-0568(15)00107-3</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">In the initial phases after polytrauma there is an hyperinflammatory state that sometimes leads to multiple organ dysfunction syndrome (MODS) and death, and that appears to be responsible for posttraumatic immunosuppression; among the trigger endogenous stimuli, heat shock proteins (HSPs) have been proposed. The objectives of this study were to analyze if some inflammatory mediators can be considered prognostic biomarkers of outcome, and the possible role of HSPA1A in posttraumatic immunosuppression.</AbstractText><AbstractText Label="HYPOTHESIS" NlmCategory="OBJECTIVE">Cytokines and HSPs could be early prognostic biomarkers of inflammatory and immune response in polytrauma patients.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">A prospective observational descriptive pilot study was carried out, evaluating the early inflammatory and stress response of 18 polytraumatized patients (ISS&gt;16) on hospital admission, at 12hours, 24hours, and 48hours posttrauma. Variable means were compared using non-parametric tests; qualitative and quantitative variables were analyzed using a Spearman's correlation test.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Seven patients met criteria for MODS. Statistically significant changes were recorded in leukocyte count, C-reactive-protein (CRP), IL-6, TNF-&#x3b1;, and IL-1&#xdf; concentrations. HSPA1A levels were significantly higher immediately after the accident followed by gradual lowering. Anti-Hsp70 antibodies showed a significant reduction in all the studied time-points. MODS did not influence either plasma levels of leukocytes, fibrinogen, RCP or anti-Hsp70, but patients with MODS had higher plasma levels of IL-6 and TNF-&#x3b1; and a slower decrease of HSPA1A concentrations.</AbstractText><AbstractText Label="DISCUSSION" NlmCategory="CONCLUSIONS">The higher serum concentrations of TNF-&#x3b1; and IL-6 found in patients with MODS, suggests a possible role as potential early predictive markers for systemic inflammatory response and clinical complications. The higher levels of HSPA1A in patients with MODS, allows proposing HSPA1A as a useful prognostic trauma biomarker early after severe injury and to consider a "damage control surgery". The significant reduction in the levels of anti-Hsp70 antibodies could reflect a part of posttraumatic immunosuppression and hydrocortisone treatment might be suggested.</AbstractText><AbstractText Label="LEVEL III" NlmCategory="METHODS">case-control study.</AbstractText><CopyrightInformation>Copyright &#xa9; 2015 Elsevier Masson SAS. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Guisasola</LastName><ForeName>M C</ForeName><Initials>MC</Initials><AffiliationInfo><Affiliation>Medicina y Cirug&#xed;a Experimental, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Dr. Esquerdo 46, 28007 Madrid, Spain; Facultad de Medicina, UCM, Madrid, Spain. Electronic address: mguisasola@mce.hggm.es.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ortiz</LastName><ForeName>A</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chana</LastName><ForeName>F</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain; Facultad de Medicina, UCM, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Alonso</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vaquero</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Cirug&#xed;a Ortop&#xe9;dica y Traumatolog&#xed;a, Hospital General Universitario "Gregorio Mara&#xf1;&#xf3;n", Madrid, Spain; Facultad de Medicina, UCM, Madrid, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2015</Year><Month>06</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Orthop Traumatol Surg Res</MedlineTA><NlmUniqueID>101494830</NlmUniqueID><ISSNLinking>1877-0568</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018840">HSP70 Heat-Shock Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C490786">HSPA1A protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>9007-41-4</RegistryNumber><NameOfSubstance UI="D002097">C-Reactive Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002097" MajorTopicYN="N">C-Reactive Protein</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D042241" MajorTopicYN="N">Early Diagnosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018840" MajorTopicYN="N">HSP70 Heat-Shock Proteins</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007958" MajorTopicYN="N">Leukocyte Count</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009104" MajorTopicYN="N">Multiple Trauma</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018746" MajorTopicYN="N">Systemic Inflammatory Response Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="Y">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Cytokines</Keyword><Keyword MajorTopicYN="N">Heat shock proteins</Keyword><Keyword MajorTopicYN="N">Inflammatory response</Keyword><Keyword MajorTopicYN="N">Polytrauma</Keyword><Keyword MajorTopicYN="N">Posttraumatic immunosuppresion</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>8</Month><Day>5</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2014</Year><Month>11</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>3</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2015</Year><Month>6</Month><Day>13</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2016</Year><Month>5</Month><Day>6</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26068807</ArticleId><ArticleId IdType="doi">10.1016/j.otsr.2015.03.014</ArticleId><ArticleId IdType="pii">S1877-0568(15)00107-3</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">22777113</PMID><DateCompleted><Year>2013</Year><Month>02</Month><Day>14</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>21</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1540-0514</ISSN><JournalIssue CitedMedium="Internet"><Volume>38</Volume><Issue>4</Issue><PubDate><Year>2012</Year><Month>Oct</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Resuscitation of traumatic hemorrhagic shock patients with hypertonic saline-without dextran-inhibits neutrophil and endothelial cell activation.</ArticleTitle><Pagination><StartPage>341</StartPage><EndPage>350</EndPage><MedlinePgn>341-50</MedlinePgn></Pagination><Abstract><AbstractText>Posttraumatic inflammation and excessive neutrophil activation cause multiple organ dysfunction syndrome (MODS), a major cause of death among hemorrhagic shock patients. Traditional resuscitation strategies may exacerbate inflammation; thus, novel fluid treatments are needed to reduce such posttraumatic complications. Hypertonic resuscitation fluids inhibit inflammation and reduce MODS in animal models. Here we studied the anti-inflammatory efficacy of hypertonic fluids in a controlled clinical trial. Trauma patients in hypovolemic shock were resuscitated in a prehospital setting with 250 mL of either 7.5% hypertonic saline (HS; n = 9), 7.5% hypertonic saline + 6% dextran 70 (HSD; n = 8), or 0.9% normal saline (NS; n = 17). Blood samples were collected on hospital admission and 12 and 24 h after resuscitation. Multicolor flow cytometry was used to quantify neutrophil expression of cell-surface activation/adhesion (CD11b, CD62L, CD64) and degranulation (CD63, CD66b, CD35) markers as well as oxidative burst activity. Circulating concentrations of soluble intercellular adhesion molecule-1 (sICAM-1), vascular cell adhesion molecule-1 (sVACM-1), P- and E-selectins, myeloperoxidase (MPO), and matrix metalloproteinase 9 (MMP-9) were assessed by immunoassay. Multiple organ dysfunction syndrome, leukocytosis, and mortality were lower in the HS and HSD groups than in the NS group. However, these differences were not statistically significant. Hypertonic saline prevented priming and activation and neutrophil oxidative burst and CD11b and CD66b expression. Hypertonic saline also reduced circulating markers of neutrophil degranulation (MPO and MMP-9) and endothelial cell activation (sICAM-1, sVCAM-1, soluble E-selectin, and soluble P-selectin). Hypertonic saline + 6% dextran 70 was less capable than HS of suppressing the upregulation of most of these activation markers. This study demonstrates that initial resuscitation with HS, but neither NS nor HSD, can attenuate posttraumatic neutrophil and endothelial cell activation in hemorrhagic shock patients. These data suggest that hypertonic resuscitation without dextran may inhibit posttraumatic inflammation. However, despite this effect, neither HS nor HSD reduced MODS in trauma patients with hemorrhagic shock.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Junger</LastName><ForeName>Wolfgang G</ForeName><Initials>WG</Initials><AffiliationInfo><Affiliation>Department of Surgery, Beth Israel Deaconess Medical Center, Harvard Medical School and Ludwig Boltzmann Institute for Experimental and Clinical Traumatology, Vienna, Austria. wjunger@bidmc.harvard.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhind</LastName><ForeName>Shawn G</ForeName><Initials>SG</Initials></Author><Author ValidYN="Y"><LastName>Rizoli</LastName><ForeName>Sandro B</ForeName><Initials>SB</Initials></Author><Author ValidYN="Y"><LastName>Cuschieri</LastName><ForeName>Joseph</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Shiu</LastName><ForeName>Maria Y</ForeName><Initials>MY</Initials></Author><Author ValidYN="Y"><LastName>Baker</LastName><ForeName>Andrew J</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Linglin</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Shek</LastName><ForeName>Pang N</ForeName><Initials>PN</Initials></Author><Author ValidYN="Y"><LastName>Hoyt</LastName><ForeName>David B</ForeName><Initials>DB</Initials></Author><Author ValidYN="Y"><LastName>Bulger</LastName><ForeName>Eileen M</ForeName><Initials>EM</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL077866</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>PR043034</GrantID><Acronym>PR</Acronym><Agency>OCPHP CDC HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM060475</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077867</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM076101</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 HL073233</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 GM051477</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R29 GM051477</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI-080582</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI072287</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077873</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077871</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077881</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077908</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077887</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077885</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>CAPMC</Acronym><Agency> CIHR</Agency><Country>Canada</Country></Grant><Grant><GrantID>U01 HL077865</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077863</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077908</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077872</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>5U01HL077863</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077873</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM-51477</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077866</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077887</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>GM-60475</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>AI-072287</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077881</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 AI080582</GrantID><Acronym>AI</Acronym><Agency>NIAID NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077867</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077885</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>HL077865</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL077872</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012462">Saline Solution, Hypertonic</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D042783" MajorTopicYN="N">Endothelial Cells</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020896" MajorTopicYN="N">Hypovolemia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018375" MajorTopicYN="N">Neutrophil Activation</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012151" MajorTopicYN="Y">Resuscitation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012462" MajorTopicYN="N">Saline Solution, Hypertonic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012771" MajorTopicYN="N">Shock, Hemorrhagic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2012</Year><Month>7</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>2</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2013</Year><Month>10</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">22777113</ArticleId><ArticleId IdType="mid">NIHMS392121</ArticleId><ArticleId IdType="pmc">PMC3455119</ArticleId><ArticleId IdType="doi">10.1097/SHK.0b013e3182635aca</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Duchesne JC, Barbeau JM, Islam TM, Wahl G, Greiffenstein P, et al. Damage control resuscitation: from emergency department to the operating room. Am Surg. 2011;77:201&#x2013;206.</Citation><ArticleIdList><ArticleId IdType="pubmed">21337881</ArticleId></ArticleIdList></Reference><Reference><Citation>Davidson GH, Hamlat CA, Rivara FP, Koepsell TD, Jurkovich GJ, et al. Long-term survival of adult trauma patients. JAMA. 2011;305:1001&#x2013;1007.</Citation><ArticleIdList><ArticleId IdType="pubmed">21386078</ArticleId></ArticleIdList></Reference><Reference><Citation>Angele MK, Schneider CP, Chaudry IH. Bench-to-bedside review: latest results in hemorrhagic shock. Crit Care. 2008;12:218.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2575549</ArticleId><ArticleId IdType="pubmed">18638356</ArticleId></ArticleIdList></Reference><Reference><Citation>Brattstrom O, Granath F, Rossi P, Oldner A. Early predictors of morbidity and mortality in trauma patients treated in the intensive care unit. Acta Anaesthesiol Scand. 2010;54:1007&#x2013;1017.</Citation><ArticleIdList><ArticleId IdType="pubmed">20626360</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsukamoto T, Chanthaphavong RS, Pape HC. Current theories on the pathophysiology of multiple organ failure after trauma. Injury. 2010;41:21&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pubmed">19729158</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishima S, Aikawa N. Neutrophil-mediated tissue injury and its modulation. Intensive Care Med. 1995;3:277&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">7790621</ArticleId></ArticleIdList></Reference><Reference><Citation>Angle N, Cabello-Passini R, Hoyt DB, Loomis WH, Shreve A, et al. Hypertonic saline infusion: can it regulate human neutrophil function? Shock. 2000;14:503&#x2013;508.</Citation><ArticleIdList><ArticleId IdType="pubmed">11092681</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG, Hoyt DB, Davis RE, Herdon-Remelius C, Namiki S, et al. Hypertonicity regulates the function of human neutrophils by modulating chemoattractant receptor signaling and activating mitogen-activated protein kinase p38. J Clin Invest. 1998;101:2768&#x2013;2779.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC508868</ArticleId><ArticleId IdType="pubmed">9637711</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Shukla A, Namiki S, Insel PA, Junger WG. A putative osmoreceptor system that controls neutrophil function through the release of ATP, its conversion to adenosine, and activation of A2 adenosine and P2 receptors. J Leukoc Biol. 2004;76:245&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pubmed">15107462</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpelini S, Rhind SG, Tien H, Spencer Netto AC, et al. Effects of hypertonic saline on the development of acute lung injury following traumatic shock. J Organ Dysfunction. 2008;4:99&#x2013;105.</Citation></Reference><Reference><Citation>Angle N, Hoyt DB, Cabello-Passini R, Herdon-Remelius C, Loomis W, et al. Hypertonic saline resuscitation reduces neutrophil margination by suppressing neutrophil L selectin expression. J Trauma. 1998;45:7&#x2013;12.</Citation><ArticleIdList><ArticleId IdType="pubmed">9680004</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizoli SB, Kapus A, Fan J, Li YH, Marshall JC, et al. Immunomodulatory effects of hypertonic resuscitation on the development of lung inflammation following hemorrhagic shock. J Immunol. 1998;161:6288&#x2013;6296.</Citation><ArticleIdList><ArticleId IdType="pubmed">9834118</ArticleId></ArticleIdList></Reference><Reference><Citation>Rotstein OD. Novel strategies for immunomodulation after trauma: revisiting hypertonic saline as a resuscitation strategy for hemorrhagic shock. J Trauma. 2000;49:580&#x2013;583.</Citation><ArticleIdList><ArticleId IdType="pubmed">11038073</ArticleId></ArticleIdList></Reference><Reference><Citation>Shukla A, Hashiguchi N, Chen Y, Coimbra R, Hoyt DB, Junger WG. Osmotic regulation of cell function and possible clinical applications. Shock. 2004;21:391&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">15087814</ArticleId></ArticleIdList></Reference><Reference><Citation>Rizoli SB, Rhind SG, Shek PN, Inaba K, Filips D, et al. The immunomodulatory effects of hypertonic saline resuscitation in patients sustaining traumatic hemorrhagic shock: a randomized, controlled, double-blinded trial. Ann Surg. 2006;243:47&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1449974</ArticleId><ArticleId IdType="pubmed">16371736</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, Cuschieri J, Warner K, Maier RV. Hypertonic resuscitation modulates the inflammatory response in patients with traumatic hemorrhagic shock. Ann Surg. 2007;245:635&#x2013;641.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877049</ArticleId><ArticleId IdType="pubmed">17414614</ArticleId></ArticleIdList></Reference><Reference><Citation>Tyagi R, Donaldson K, Loftus CM, Jallo J. Hypertonic saline: a clinical review. Neurosurg Rev. 2007;30:277&#x2013;289.</Citation><ArticleIdList><ArticleId IdType="pubmed">17574484</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y, Hashiguchi N, Yip L, Junger WG. Hypertonic saline enhances neutrophil elastase release through activation of P2 and A3 receptors. Am J Physiol Cell Physiol. 2006;290:C1051&#x2013;C1059.</Citation><ArticleIdList><ArticleId IdType="pubmed">16282197</ArticleId></ArticleIdList></Reference><Reference><Citation>Murao Y, Hoyt DB, Loomis W, Namiki S, Patel N, et al. Does the timing of hypertonic saline resuscitation affect its potential to prevent lung damage? Shock. 2000;14:18&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">10909888</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushchin V, Alam HB, Rhee P, Kirkpatrick JR, Koustova E. cDNA profiling in leukocytes exposed to hypertonic resuscitation fluids. J Am Coll Surg. 2003;197:426&#x2013;432.</Citation><ArticleIdList><ArticleId IdType="pubmed">12946798</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, May S, Kerby JD, Emerson S, Stiell IG, et al. Out-of-hospital hypertonic resuscitation after traumatic hypovolemic shock: a randomized, placebo controlled trial. Ann Surg. 2011;253:431&#x2013;441.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3232054</ArticleId><ArticleId IdType="pubmed">21178763</ArticleId></ArticleIdList></Reference><Reference><Citation>Hager M, Cowland JB, Borregaard N. Neutrophil granules in health and disease. J Intern Med. 2010;268:25&#x2013;34.</Citation><ArticleIdList><ArticleId IdType="pubmed">20497300</ArticleId></ArticleIdList></Reference><Reference><Citation>Livaditi O, Kotanidou A, Psarra A, Dimopoulou I, Sotiropoulou C, et al. Neutrophil CD64 expression and serum IL-8: sensitive early markers of severity and outcome in sepsis. Cytokine. 2007;36:283&#x2013;290.</Citation><ArticleIdList><ArticleId IdType="pubmed">17368039</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin TC, Li CY, Tsai CS, Ku CH, Wu CT, et al. Neutrophil-mediated secretion and activation of matrix metalloproteinase-9 during cardiac surgery with cardiopulmonary bypass. Anesth Analg. 2005;100:1554&#x2013;1560.</Citation><ArticleIdList><ArticleId IdType="pubmed">15920174</ArticleId></ArticleIdList></Reference><Reference><Citation>Boldt J, Muller M, Kuhn D, Linke LC, Hempelmann G. Circulating adhesion molecules in the critically ill: a comparison between trauma and sepsis patients. Intensive Care Med. 1996;22:122&#x2013;128.</Citation><ArticleIdList><ArticleId IdType="pubmed">8857119</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM. 7.5% saline and 7.5% saline/6% dextran for hypovolemic shock. J Trauma. 2011;70 (5 Suppl):S27&#x2013;S29.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3111047</ArticleId><ArticleId IdType="pubmed">21666775</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Chen Y, Pauzenberger R, Hirsh MI, Junger WG. Hypertonic saline up-regulates A3 adenosine receptor expression of activated neutrophils and increases acute lung injury after sepsis. Crit Care Med. 2008;36:2569&#x2013;2575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2643471</ArticleId><ArticleId IdType="pubmed">18679117</ArticleId></ArticleIdList></Reference><Reference><Citation>Dubick MA, Bruttig SP, Wade CE. Issues of concern regarding the use of hypertonic/hyperoncotic fluid resuscitation of hemorrhagic hypotension. Shock. 2006;25:321&#x2013;328.</Citation><ArticleIdList><ArticleId IdType="pubmed">16670632</ArticleId></ArticleIdList></Reference><Reference><Citation>Rhee P, Wang D, Ruff P, Austin B, DeBraux S, et al. Human neutrophil activation and increased adhesion by various resuscitation fluids. Crit Care Med. 2000;28:74&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pubmed">10667502</ArticleId></ArticleIdList></Reference><Reference><Citation>Ljungstr&#xf6;m KG. Safety of dextran in relation to other colloids - Ten years experience with hapten inhibition. Infusionsther Transfusionsmed. 1993;20:206&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pubmed">7508309</ArticleId></ArticleIdList></Reference><Reference><Citation>Loomis WH, Namiki S, Ostrom RS, Insel PA, Junger WG. Hypertonic stress increases T cell interleukin-2 expression through a mechanism that involves ATP release, P2 receptor, and p38 MAPK activation. J Biol Chem. 2003;278:4590&#x2013;4596.</Citation><ArticleIdList><ArticleId IdType="pubmed">12464620</ArticleId></ArticleIdList></Reference><Reference><Citation>Yip L, Cheung CW, Corriden R, Chen Y, Insel PA, et al. Hypertonic stress regulates T-cell function by the opposing actions of extracellular adenosine triphosphate and adenosine. Shock. 2007;27:242&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">17304104</ArticleId></ArticleIdList></Reference><Reference><Citation>Woehrle T, Yip L, Manohar M, Sumi Y, Yao Y, et al. Hypertonic stress regulates T cell function via pannexin-1 hemichannels and P2X receptors. J Leukoc Biol. 2010;88:1181&#x2013;1189.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2996895</ArticleId><ArticleId IdType="pubmed">20884646</ArticleId></ArticleIdList></Reference><Reference><Citation>Junger WG. Immune cell regulation by autocrine purinergic signalling. Nat Rev Immunol. 2011;11:201&#x2013;212.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4209705</ArticleId><ArticleId IdType="pubmed">21331080</ArticleId></ArticleIdList></Reference><Reference><Citation>Bulger EM, Tower CM, Warner KJ, Garland T, Cuschieri J, et al. Increased neutrophil adenosine a3 receptor expression is associated with hemorrhagic shock and injury severity in trauma patients. Shock. 2011;36:435&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3204900</ArticleId><ArticleId IdType="pubmed">21841534</ArticleId></ArticleIdList></Reference><Reference><Citation>Inoue Y, Tanaka H, Sumi Y, Woehrle T, Chen Y, et al. A3 adenosine receptor inhibition improves the efficacy of hypertonic saline resuscitation. Shock. 2011;35:178&#x2013;183.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3038630</ArticleId><ArticleId IdType="pubmed">20661181</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">20655807</PMID><DateCompleted><Year>2010</Year><Month>12</Month><Day>10</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">1473-0502</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>1</Issue><PubDate><Year>2010</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis</Title><ISOAbbreviation>Transfus Apher Sci</ISOAbbreviation></Journal><ArticleTitle>Addressing the question of the effect of RBC storage on clinical outcomes: the Red Cell Storage Duration Study (RECESS) (Section 7).</ArticleTitle><Pagination><StartPage>107</StartPage><EndPage>116</EndPage><MedlinePgn>107-16</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.transci.2010.05.014</ELocationID><Abstract><AbstractText>The question of whether storage of red blood cells (RBCs) alters their capacity to deliver oxygen and affects patient outcomes remains in a state of clinical equipoise. Studies of the changes which occur while RBCs are stored have led to several physiologically plausible hypotheses that these changes impair RBC function when the units are transfused. Although there is some evidence of this effect in vivo from animal model experiments, the results of several largely retrospective patient studies have not been consistent. Some studies have shown an association between worse clinical outcomes and transfusion of RBC which have been stored for longer periods of time, while others have found no effect. Three multicenter, randomized, controlled trials have been developed to address this important, but currently unanswered, question. Two clinical trials, one in low birth weight neonates and the other in intensive care unit patients, are enrolling subjects in Canada (the Age of Red Blood Cells in Premature Infants; the Age of Blood Study). The third trial, which is being developed in the United States, is the Red Cell Storage Duration Study (RECESS). This is a multicenter, randomized, controlled trial in which patients undergoing complex cardiac surgical procedures who are likely to require RBC transfusion will be randomized to receive RBC units stored for either 10 or fewer days or 21 or more days. Randomization will only occur if the blood bank has enough units of RBC of both storage times to meet the crossmatch request; hence, subjects randomized to the 21 day arm will receive RBC of the same storage time as they would have following standard inventory practice of "oldest units out first". The primary outcome is the change in the Multiple Organ Dysfunction Score (MODS), a composite measure of multiorgan dysfunction, by day 7. Secondary outcomes include the change in the MODS by day 28, all-cause mortality, and several composite and single measures of specific organ system function. The estimated total sample size required will be 1434 evaluable subjects (717 per arm).</AbstractText><CopyrightInformation>(c) 2010. Published by Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Steiner</LastName><ForeName>M E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Pediatric Hematology/Oncology, University of Minnesota, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Assmann</LastName><ForeName>S F</ForeName><Initials>SF</Initials></Author><Author ValidYN="Y"><LastName>Levy</LastName><ForeName>J H</ForeName><Initials>JH</Initials></Author><Author ValidYN="Y"><LastName>Marshall</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Pulkrabek</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Sloan</LastName><ForeName>S R</ForeName><Initials>SR</Initials></Author><Author ValidYN="Y"><LastName>Triulzi</LastName><ForeName>D</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Stowell</LastName><ForeName>C P</ForeName><Initials>CP</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00991341</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>U01 HL072346</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072289</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072291</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072290</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072274</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072331</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072359</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072248</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072191</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072033</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072196</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072268</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072305</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072028</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072283</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072299</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072355</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U01 HL072072</GrantID><Acronym>HL</Acronym><Agency>NHLBI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2010</Year><Month>07</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Transfus Apher Sci</MedlineTA><NlmUniqueID>101095653</NlmUniqueID><ISSNLinking>1473-0502</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S88TT14065</RegistryNumber><NameOfSubstance UI="D010100">Oxygen</NameOfSubstance></Chemical></ChemicalList><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001793" MajorTopicYN="N">Blood Preservation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006348" MajorTopicYN="N">Cardiac Surgical Procedures</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017707" MajorTopicYN="Y">Erythrocyte Transfusion</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004912" MajorTopicYN="N">Erythrocytes</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>7</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>12</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>8</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20655807</ArticleId><ArticleId IdType="mid">NIHMS208949</ArticleId><ArticleId IdType="pmc">PMC2918709</ArticleId><ArticleId IdType="doi">10.1016/j.transci.2010.05.014</ArticleId><ArticleId IdType="pii">S1473-0502(10)00097-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Steiner M, Stowell C. Does red blood cell storage affect clinical outcome? When in doubt, do the experiment. Transfusion. 2009;49:1286&#x2013;90.</Citation><ArticleIdList><ArticleId IdType="pubmed">19602209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hess J. Red cell changes during storage. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pubmed">20558107</ArticleId></ArticleIdList></Reference><Reference><Citation>Somani A, Hebbell R. The microcirculation and RBC transfusion. Transfus Aph Sci. 2010;43</Citation></Reference><Reference><Citation>Tsai AG, Hofmann A, Cabrales P, Intaglietta M. Perfusion vs. oxygen delivery as targets for blood transfusion: the experimental evidence. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2918661</ArticleId><ArticleId IdType="pubmed">20646963</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakr Y. Techniques to assess tissue oxygenation in the clinical setting. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pubmed">20692624</ArticleId></ArticleIdList></Reference><Reference><Citation>Triulzi D, Yazer M. Clinical Studies of the effect of blood storage on patient outcomes. Transfus Aph Sci. 2010;43</Citation><ArticleIdList><ArticleId IdType="pubmed">20656558</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Chin-Yee I, Fergusson D, et al. A pilot trial evaluating the clinical effects of prolonged storage of red cells. Anesth Analg. 2005;100:1433&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">15845701</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett-Guerrero E, Stafford-Smith M, Waweru PM, Bredehoeft SJ, Campbell ML, Haley NR, Phillips-Bute B, Newman MF, Bandarenko N. A prospective, double-blind, randomized clinical feasibility trial of controlling the storage age of red blood cells for transfusion in cardiac surgical patients. Transfusion. 2009;49:1375&#x2013;83.</Citation><ArticleIdList><ArticleId IdType="pubmed">19389021</ArticleId></ArticleIdList></Reference><Reference><Citation>Vamvakas EC. Meta-analysis of clinical studies of the purported deleterious effects of &#x201c;old&#x201d; (versus &#x201c;fresh&#x201d;) red blood cells: are we at equipoise? Transfusion. 2010;50:600&#x2013;10.</Citation><ArticleIdList><ArticleId IdType="pubmed">20042031</ArticleId></ArticleIdList></Reference><Reference><Citation>Fergusson D, Hutton B, Hogan DL, et al. The age of red blood cells in premature infants (ARIPI) randomized, controlled trial: study design. Transfus Med Rev. 2009;23:55&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pubmed">19056034</ArticleId></ArticleIdList></Reference><Reference><Citation>The Age of Blood (ABLE) Study.  [2/2/10].   http://www.controlled-trials.com/ISRCTN44878718/</Citation></Reference><Reference><Citation>Transfusion Medicine and Hemostasis Clinical Trials Network (TMHCTN)  [2/2/10].   http://www.tmhnetwork.org/</Citation></Reference><Reference><Citation>New England Research Institutes.  [2/2/10].   http://neriscience.com/</Citation></Reference><Reference><Citation>Elahi MM, Yii M, Matata BM. Significance of oxidants and inflammatory mediators in blood of patients undergoing cardiac surgery. Journal of Cardiothoracic and Vascular Anesthesia. 2008;22:455&#x2013;67.</Citation><ArticleIdList><ArticleId IdType="pubmed">18503942</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson RG, Thurer RL, Kruskall MS, et al. Comparison of two transfusion strategies after elective operations for myocardial revascularization. J Thorac Cardiovasc Surg. 1992;104:307&#x2013;14.</Citation><ArticleIdList><ArticleId IdType="pubmed">1495291</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Cristou NV, et al. Multiple Organ Dysfunction Score: A reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652.</Citation><ArticleIdList><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Koch CG, Li L, Sessler DI, et al. Duration of red-cell storage and complications after cardiac surgery. NEJM. 2008;358:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">18354101</ArticleId></ArticleIdList></Reference><Reference><Citation>Van de Watering L, Lorinser J, Versteegh M, Westendord R, Brand A. Effects of storage time of red blood cell transfusions on the prognosis of coronary artery bypass graft patients. Transfusion. 2006;46:1712&#x2013;8.</Citation><ArticleIdList><ArticleId IdType="pubmed">17002627</ArticleId></ArticleIdList></Reference><Reference><Citation>Yap CH, Lau L, Krishnaswamy M, Gaskell M, Yii M. Age of transfused red cells and early outcomes after cardiac surgery. Ann Thoracic Surg. 2008;86:554&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">18640333</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng CK, Trethewey D, Sadek I. Comprehensive survey of red blood cell unit life cycle at a large teaching institution in eastern Canada. Transfusion. 2010;50:160&#x2013;165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19761550</ArticleId></ArticleIdList></Reference><Reference><Citation>Carson JL, Duff A, Poses RM, et al. Effect of anaemia and cardiovascular disease on surgical mortality and morbidity. Lancet. 1996;348:1055&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8874456</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Yetisir E, Martin C, et al. Is a low transfusion threshold safe in critically ill patients with cardiovascular diseases? Crit Care Med. 2001;29:227&#x2013;234.</Citation><ArticleIdList><ArticleId IdType="pubmed">11246298</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu O, Bayoumi N, Vickers MA, Clark P. ABO(H) blood groups and vascular disease: a systematic review and meta-analysis. J Thromb Haemost. 2008;6:62&#x2013;9.</Citation><ArticleIdList><ArticleId IdType="pubmed">17973651</ArticleId></ArticleIdList></Reference><Reference><Citation>Alghamdi AA, Davis A, Brister S, Corey P, Logan A. Development and validation of Transfusion Risk Understanding Scoring Tool (TRUST) to stratify cardiac surgery patients according to their blood transfusion needs. Transfusion. 2006;46:1120&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">16836558</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelen M. The randomization and stratification of patients to clinical trials. J Chron Dis. 1974;27:365&#x2013;75.</Citation><ArticleIdList><ArticleId IdType="pubmed">4612056</ArticleId></ArticleIdList></Reference><Reference><Citation>H&#xe9;bert PC, Wells G, Blachman MJ, Marshall J, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. New Engl J Med. 1999;340:409&#x2013;417.</Citation><ArticleIdList><ArticleId IdType="pubmed">9971864</ArticleId></ArticleIdList></Reference><Reference><Citation>Knaus WA, Wagner DP. Multiple system organ failure: epidemiology and prognosis. Crit Care Med. 1989;5:221&#x2013;232.</Citation><ArticleIdList><ArticleId IdType="pubmed">2650815</ArticleId></ArticleIdList></Reference><Reference><Citation>Ceriani R, Mazzoni M, Bortone F, Gandini S, et al. Application of the sequential organ failure assessment score to cardiac surgical patients. Chest. 2003;123:1229&#x2013;1239.</Citation><ArticleIdList><ArticleId IdType="pubmed">12684316</ArticleId></ArticleIdList></Reference><Reference><Citation>Hekmat K, Kroener A, Stuetzer H, Schwinger RH, et al. Daily assessment of organ dysfunction and survival in intensive care unit cardiac surgical patients. Annals Thorac Surg. 2005;79:1555&#x2013;1562.</Citation><ArticleIdList><ArticleId IdType="pubmed">15854933</ArticleId></ArticleIdList></Reference><Reference><Citation>Bilgin YM, van de Watering L, Eijsman L, Versteegh MIM, et al. Double-blind randomized controlled trial on the effect of leukocyte-depleted erythrocyte transfusions in cardiac valve surgery. Circulation. 2004;109:2755&#x2013;2760.</Citation><ArticleIdList><ArticleId IdType="pubmed">15148271</ArticleId></ArticleIdList></Reference><Reference><Citation>Patila T, Kukkonen S, Vento A, et al. Relation of the sequential organ failue assessment score to morbidity and mortality after cardiac surgery. Ann Thorac Surg. 2006;82:2072&#x2013;2079.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126112</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzoni M, De Maria M, Bortone F, et al. Long term outcome of survivors of prolonged intensive care treatment after cardiac surgery. Ann Thorac Surg. 2006;82:2080&#x2013;2088.</Citation><ArticleIdList><ArticleId IdType="pubmed">17126114</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilkinson JD, Pollack MM, Ruttimann UE, et al. Outcome of pediatric patients with multiple organ system failure. Crit Care Med. 1986;14:271&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">3956214</ArticleId></ArticleIdList></Reference><Reference><Citation>Proulx F, Fayon M, Farrell CA, et al. Epidemiology of sepsis and multiple organ dysfunction syndrome in children. Chest. 1996;109:1033&#x2013;1037.</Citation><ArticleIdList><ArticleId IdType="pubmed">8635327</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollack MM, Patel KM, Ruttiman UE. PRISM III: an updated Pediatric Risk of Mortality Score. Crit Care Med. 1996;24:743&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">8706448</ArticleId></ArticleIdList></Reference><Reference><Citation>Graciano AL, Balko JA, Rahn DS, Ahmad N, Giroir BP. The Pediatric Multiple Organ Dysfunction Score (P-MODS): development and validation of an objective scale to measure the severity of multiple organ dysfunction in critically ill children. Crit Care Med. 2005;33:1484&#x2013;1491.</Citation><ArticleIdList><ArticleId IdType="pubmed">16003052</ArticleId></ArticleIdList></Reference><Reference><Citation>Leteurtre S, Martinot A, Duhamel A, Proulx F, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational multicentre study. Lancet. 2003;362:192&#x2013;197.38.</Citation><ArticleIdList><ArticleId IdType="pubmed">12885479</ArticleId></ArticleIdList></Reference><Reference><Citation>Lacroix J, H&#xe9;bert PC, Hutchison JS, Hume HA, et al. Transfusion strategies for patients in pediatric intensive care units. New Engl J Med. 2007;356:1609&#x2013;1619.</Citation><ArticleIdList><ArticleId IdType="pubmed">17442904</ArticleId></ArticleIdList></Reference><Reference><Citation>Shime N, Kageyama K, Ashida H, Tanaka Y. Application of modified sequential organ failure assessment score in children after cardiac surgery. J Cardiothorac Vasc Anesthesia. 2001;15:463&#x2013;468.</Citation><ArticleIdList><ArticleId IdType="pubmed">11505351</ArticleId></ArticleIdList></Reference><Reference><Citation>Slichter SJ, Kaufman RM, Assmann SF, McCullough J, et al. Dose of prophylactic platelet pransfusions and prevention of hemorrhage. New Eng J Med. 2010;362:600&#x2013;613.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2951321</ArticleId><ArticleId IdType="pubmed">20164484</ArticleId></ArticleIdList></Reference><Reference><Citation>Collier AC, Kalish LA, Busch MP, Gernsheimer T, et al. Leukocyte-reduced red blood cell transfusions in patients with anemia and human immunodeficiency virus infection: The Viral Activation Transfusion Study: a randomized controlled trial. J Amer Med Assoc. 2001;285:1592&#x2013;1601.</Citation><ArticleIdList><ArticleId IdType="pubmed">11268267</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee MT, Piomelli S, Granger S, Miller ST, et al. Stroke Prevention Trial in Sickle Cell Anemia (STOP): Extended follow-up and final results. Blood. 2006;108:847&#x2013;852.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1895848</ArticleId><ArticleId IdType="pubmed">16861341</ArticleId></ArticleIdList></Reference><Reference><Citation>Adams RJ, Brambilla D, Optimizing Primary Stroke Prevention in Sickle Cell Anemia (STOP 2) Trial Investigators Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. New Engl J Med. 2005;353:2769&#x2013;2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">16382063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">21232130</PMID><DateCompleted><Year>2011</Year><Month>12</Month><Day>07</Day></DateCompleted><DateRevised><Year>2021</Year><Month>10</Month><Day>20</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1466-609X</ISSN><JournalIssue CitedMedium="Internet"><Volume>15</Volume><Issue>1</Issue><PubDate><Year>2011</Year></PubDate></JournalIssue><Title>Critical care (London, England)</Title><ISOAbbreviation>Crit Care</ISOAbbreviation></Journal><ArticleTitle>Increased serum soluble Fas after major trauma is associated with delayed neutrophil apoptosis and development of sepsis.</ArticleTitle><Pagination><StartPage>R20</StartPage><MedlinePgn>R20</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1186/cc9965</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Deregulated apoptosis and overshooting neutrophil functions contribute to immune and organ dysfunction in sepsis and multiple organ failure (MOF). In the present study, we determined the role of soluble Fas (sFas) in the regulation of posttraumatic neutrophil extrinsic apoptosis and the development of sepsis.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Forty-seven major trauma patients, 18 with and 29 without sepsis development during the first 10 days after trauma, were enrolled in this prospective study. Seventeen healthy volunteers served as controls. Blood samples from severely injured patients were analyzed at day 1, day 5 and day 9 after major trauma. sFas levels, plasma levels of neutrophil elastase (PMNE) and levels of interleukin (IL)-6 were quantified by enzyme-linked immunosorbent assay and related to patients' Sequential Organ Failure Assessment (SOFA) score and Multiple Organ Dysfunction Score (MODS). Neutrophil apoptosis was determined by propidium iodide staining of fragmented DNA and flow cytometry. sFas-mediated effects on neutrophil apoptosis were investigated in cells cultured with agonistic anti-Fas antibodies in the presence of recombinant sFas, sFas-depleted serum or untreated serum from septic patients.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Serum levels of sFas in patients who later developed sepsis were significantly increased at day 5 (P &lt; 0.01) and day 9 (P &lt; 0.05) after trauma compared with patients with uneventful recovery. Apoptosis of patient neutrophils was significantly decreased during the observation period compared with control cells. Moreover, Fas-mediated apoptosis of control neutrophils was efficiently inhibited by recombinant sFas and serum from septic patients. Depletion of sFas from septic patient sera diminished the antiapoptotic effects. In septic patients, sFas levels were positively correlated with SOFA at day 1 (r = 0.7, P &lt; 0.001), day 5 (r = 0.62, P &lt; 0.01) and day 9 (r = 0.58, P &lt; 0.01) and with PMNE and leukocyte counts (r = 0.49, P &lt; 0.05 for both) as well as MODS at day 5 (r = 0.56, P &lt; 0.01) after trauma.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Increased sFas in patients with sepsis development impairs neutrophil extrinsic apoptosis and shows a positive correlation with the organ dysfunction scores and PMNE. Therefore, sFas might be a therapeutic target to prevent posttrauma hyperinflammation and sepsis.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Paunel-G&#xf6;rg&#xfc;l&#xfc;</LastName><ForeName>Adnana</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Trauma and Hand Surgery, University Hospital D&#xfc;sseldorf, Moorenstrasse 5, D-40225 D&#xfc;sseldorf, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Floh&#xe9;</LastName><ForeName>Sascha</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Scholz</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Windolf</LastName><ForeName>Joachim</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>L&#xf6;gters</LastName><ForeName>Tim</ForeName><Initials>T</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2011</Year><Month>01</Month><Day>13</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Crit Care</MedlineTA><NlmUniqueID>9801902</NlmUniqueID><ISSNLinking>1364-8535</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D053222">Fas Ligand Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053222" MajorTopicYN="N">Fas Ligand Protein</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009504" MajorTopicYN="N">Neutrophils</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015599" MajorTopicYN="N">Trauma Severity Indices</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2010</Year><Month>7</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2010</Year><Month>12</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2011</Year><Month>1</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2011</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2011</Year><Month>1</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2011</Year><Month>12</Month><Day>13</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2011</Year><Month>1</Month><Day>13</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">21232130</ArticleId><ArticleId IdType="pmc">PMC3222054</ArticleId><ArticleId IdType="doi">10.1186/cc9965</ArticleId><ArticleId IdType="pii">cc9965</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Savill JS, Wyllie AH, Henson JE, Walport MJ, Henson PM, Haslett C. Macrophage phagocytosis of aging neutrophils in inflammation: programmed cell death in the neutrophil leads to its recognition by macrophages. J Clin Invest. 1989;83:865&#x2013;875. doi: 10.1172/JCI113970.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI113970</ArticleId><ArticleId IdType="pmc">PMC303760</ArticleId><ArticleId IdType="pubmed">2921324</ArticleId></ArticleIdList></Reference><Reference><Citation>Nathan C. Points of control in inflammation. Nature. 2002;420:846&#x2013;852. doi: 10.1038/nature01320.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature01320</ArticleId><ArticleId IdType="pubmed">12490957</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham E. Neutrophils and acute lung injury. Crit Care Med. 2003;31:S195&#x2013;S199. doi: 10.1097/01.CCM.0000057843.47705.E8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000057843.47705.E8</ArticleId><ArticleId IdType="pubmed">12682440</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramaiah SK, Jaeschke H. Role of neutrophils in the pathogenesis of acute inflammatory liver injury. Toxicol Pathol. 2007;35:757&#x2013;766. doi: 10.1080/01926230701584163.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01926230701584163</ArticleId><ArticleId IdType="pubmed">17943649</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuligowski M, Kitching A, Hickey M. Leukocyte recruitment to the inflamed glomerulus: A critical role for platelet-derived P-selectin in the absence of rolling. J Immunol. 2006;176:6991&#x2013;6999.</Citation><ArticleIdList><ArticleId IdType="pubmed">16709860</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown KA, Brain SD, Pearson JD, Edgeworth JD, Lewis SM, Treacher DF. Neutrophils in development of multiple organ failure in sepsis. Lancet. 2006;368:157&#x2013;169. doi: 10.1016/S0140-6736(06)69005-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(06)69005-3</ArticleId><ArticleId IdType="pubmed">16829300</ArticleId></ArticleIdList></Reference><Reference><Citation>Donnelly SC, MacGregor I, Zamani A, Gordon MW, Robertson CE, Steedman DJ, Little K, Haslett C. Plasma elastase levels and the development of the adult respiratory distress syndrome. Am J Respir Crit Care Med. 1995;151:1428&#x2013;1433.</Citation><ArticleIdList><ArticleId IdType="pubmed">7735596</ArticleId></ArticleIdList></Reference><Reference><Citation>Bhatia R, Dent C, Topley N, Pallister I. Neutrophil priming for elastase release in adult blunt trauma patients. J Trauma. 2006;60:590&#x2013;596. doi: 10.1097/01.ta.0000205614.51885.ff.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ta.0000205614.51885.ff</ArticleId><ArticleId IdType="pubmed">16531859</ArticleId></ArticleIdList></Reference><Reference><Citation>Savill J. Apoptosis in resolution of inflammation. J Leukoc Biol. 1997;61:375&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">9103222</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol Today. 1995;16:569&#x2013;574. doi: 10.1016/0167-5699(95)80079-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-5699(95)80079-4</ArticleId><ArticleId IdType="pubmed">8579749</ArticleId></ArticleIdList></Reference><Reference><Citation>Siegel RM, Chan FK, Chun HJ, Lenardo MJ. The multifaceted role of Fas signaling in immune cell homeostasis and autoimmunity. Nat Immunol. 2000;1:469&#x2013;474. doi: 10.1038/82712.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/82712</ArticleId><ArticleId IdType="pubmed">11101867</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagata S. Fas ligand-induced apoptosis. Annu Rev Genet. 1999;33:29&#x2013;55. doi: 10.1146/annurev.genet.33.1.29.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.genet.33.1.29</ArticleId><ArticleId IdType="pubmed">10690403</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheng J, Zhou T, Liu C, Shapiro JP, Brauer MJ, Kiefer MC, Barr PJ, Mountz JD. Protection from Fas-mediated apoptosis by a soluble form of the Fas molecule. Science. 1994;263:1759&#x2013;1762. doi: 10.1126/science.7510905.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.7510905</ArticleId><ArticleId IdType="pubmed">7510905</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascino I, Fiucci G, Papoff G, Ruberti G. Three functional soluble forms of the human apoptosis-inducing Fas molecule are produced by alternative splicing. J Immunol. 1995;154:2706&#x2013;2713.</Citation><ArticleIdList><ArticleId IdType="pubmed">7533181</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777&#x2013;1783. doi: 10.1084/jem.182.6.1777.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.182.6.1777</ArticleId><ArticleId IdType="pmc">PMC2192231</ArticleId><ArticleId IdType="pubmed">7500022</ArticleId></ArticleIdList></Reference><Reference><Citation>Song E, Chen J, Ouyang N, Su F, Wang M, Heemann U. Soluble Fas ligand released by colon adenocarcinoma cells induces host lymphocyte apoptosis: an active mode of immune evasion in colon cancer. Br J Cancer. 2001;85:1047&#x2013;1054. doi: 10.1054/bjoc.2001.2042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1054/bjoc.2001.2042</ArticleId><ArticleId IdType="pmc">PMC2375090</ArticleId><ArticleId IdType="pubmed">11592778</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, Itoh N, Suda T, Nagata S. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806&#x2013;809. doi: 10.1038/364806a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/364806a0</ArticleId><ArticleId IdType="pubmed">7689176</ArticleId></ArticleIdList></Reference><Reference><Citation>Matute-Bello G, Liles WC, Steinberg KP, Kiener PA, Mongovin S, Chi EY, Jonas M, Martin TR. Soluble Fas ligand induces epithelial cell apoptosis in humans with acute lung injury (ARDS) J Immunol. 1999;163:2217&#x2013;2225.</Citation><ArticleIdList><ArticleId IdType="pubmed">10438964</ArticleId></ArticleIdList></Reference><Reference><Citation>Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996;184:429&#x2013;440. doi: 10.1084/jem.184.2.429.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.184.2.429</ArticleId><ArticleId IdType="pmc">PMC2192712</ArticleId><ArticleId IdType="pubmed">8760796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez MF, Watson RW, Parodo J, Evans D, Foster D, Steinberg M, Rotstein OD, Marshall JC. Dysregulated expression of neutrophil apoptosis in the systemic inflammatory response syndrome. Arch Surg. 1997;132:1263&#x2013;1270.</Citation><ArticleIdList><ArticleId IdType="pubmed">9403528</ArticleId></ArticleIdList></Reference><Reference><Citation>Chitnis D, Dickerson C, Munster AM, Winchurch RA. Inhibition of apoptosis in polymorphonuclear neutrophils from burn patients. J Leukoc Biol. 1996;59:835&#x2013;839.</Citation><ArticleIdList><ArticleId IdType="pubmed">8691068</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenspan L, McLellan BA, Greig H. Abbreviated Injury Scale and Injury Severity Score: a scoring chart. J Trauma. 1985;25:60&#x2013;64. doi: 10.1097/00005373-198501000-00010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00005373-198501000-00010</ArticleId><ArticleId IdType="pubmed">3965737</ArticleId></ArticleIdList></Reference><Reference><Citation>Calandra T, Cohen J. International Sepsis Forum Definition of Infection in the ICU Consensus Conference. The international sepsis forum consensus conference on definitions of infection in the intensive care unit. Crit Care Med. 2005;33:1538&#x2013;1548. doi: 10.1097/01.CCM.0000168253.91200.83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.CCM.0000168253.91200.83</ArticleId><ArticleId IdType="pubmed">16003060</ArticleId></ArticleIdList></Reference><Reference><Citation>Marshall JC, Cook DJ, Christou NV, Bernard GR, Sprung CL, Sibbald WJ. Multiple Organ Dysfunction Score: a reliable descriptor of a complex clinical outcome. Crit Care Med. 1995;23:1638&#x2013;1652. doi: 10.1097/00003246-199510000-00007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-199510000-00007</ArticleId><ArticleId IdType="pubmed">7587228</ArticleId></ArticleIdList></Reference><Reference><Citation>Maianski NA, Mul FP, van Buul JD, Roos D, Kuijpers TW. Granulocyte colony-stimulating factor inhibits the mitochondria-dependent activation of caspase-3 in neutrophils. Blood. 2002;99:672&#x2013;679. doi: 10.1182/blood.V99.2.672.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.2.672</ArticleId><ArticleId IdType="pubmed">11781253</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271&#x2013;279. doi: 10.1016/0022-1759(91)90198-O.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-1759(91)90198-O</ArticleId><ArticleId IdType="pubmed">1710634</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837&#x2013;845. doi: 10.2307/2531595.</Citation><ArticleIdList><ArticleId IdType="doi">10.2307/2531595</ArticleId><ArticleId IdType="pubmed">3203132</ArticleId></ArticleIdList></Reference><Reference><Citation>Paunel-G&#xf6;rg&#xfc;l&#xfc; A, Z&#xf6;rnig M, L&#xf6;gters T, Altrichter J, Rabenhorst U, Cinatl J, Windolf J, Scholz M. Mcl-1-mediated Impairment of the intrinsic apoptosis pathway in circulating neutrophils from critically ill patients can be overcome by Fas stimulation. J Immunol. 2009;183:6198&#x2013;6206.</Citation><ArticleIdList><ArticleId IdType="pubmed">19841168</ArticleId></ArticleIdList></Reference><Reference><Citation>Maianski NA, Maianski AN, Kujpers TW, Roos D. Apoptosis of neutrophils. Acta Haematol. 2004;111:56&#x2013;66. doi: 10.1159/000074486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000074486</ArticleId><ArticleId IdType="pubmed">14646345</ArticleId></ArticleIdList></Reference><Reference><Citation>Tilton B, Andjelkovic M, Didichenko SA, Hemmings BA, Thelen M. G-Protein-coupled receptors and Fc&#x3b3;-receptors mediate activation of Akt/protein kinase B in human phagocytes. J Biol Chem. 1997;272:28096&#x2013;28101. doi: 10.1074/jbc.272.44.28096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.44.28096</ArticleId><ArticleId IdType="pubmed">9346964</ArticleId></ArticleIdList></Reference><Reference><Citation>McLeish KR, Knall C, Ward RA, Gerwins P, Coxon PY, Klein JB, Johnson GL. Activation of mitogen-activated protein kinase cascades during priming of human neutrophils by TNF-&#x3b1; and GM-CSF. J Leukoc Biol. 1998;64:537&#x2013;545.</Citation><ArticleIdList><ArticleId IdType="pubmed">9766635</ArticleId></ArticleIdList></Reference><Reference><Citation>Derouet M, Thomas L, Cross A, Moots RJ, Edwards SW. Granulocyte macrophage colony-stimulating factor signaling and proteasome inhibition delay neutrophil apoptosis by increasing the stability of Mcl-1. J Biol Chem. 2004;279:26915&#x2013;26921. doi: 10.1074/jbc.M313875200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M313875200</ArticleId><ArticleId IdType="pubmed">15078892</ArticleId></ArticleIdList></Reference><Reference><Citation>Papathanassoglou ED, Moynihan JA, Vermillion DL, McDermott MP, Ackerman MH. Soluble fas levels correlate with multiple organ dysfunction severity, survival and nitrate levels, but not with cellular apoptotic markers in critically ill patients. Shock. 2000;14:107&#x2013;112. doi: 10.1097/00024382-200014020-00005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-200014020-00005</ArticleId><ArticleId IdType="pubmed">10947151</ArticleId></ArticleIdList></Reference><Reference><Citation>Marsik C, Halama T, Cardona F, Wlassits W, Mayr F, Pleiner J, Jilma B. Regulation of Fas (APO-1, CD95) and Fas ligand expression in leukocytes during systemic inflammation in humans. Shock. 2003;20:493&#x2013;496. doi: 10.1097/01.shk.0000097248.97298.ea.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000097248.97298.ea</ArticleId><ArticleId IdType="pubmed">14625471</ArticleId></ArticleIdList></Reference><Reference><Citation>Torre D, Tambini R, Manfredi M, Mangani V, Livi P, Maldifassi V, Campi P, Speranza F. Circulating levels of FAS/APO-1 in patients with the systemic inflammatory response syndrome. Diagn Microbiol Infect Dis. 2003;45:233&#x2013;236. doi: 10.1016/S0732-8893(02)00550-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0732-8893(02)00550-3</ArticleId><ArticleId IdType="pubmed">12729991</ArticleId></ArticleIdList></Reference><Reference><Citation>De Freitas I, Fernandez-Somoza M, Essenfeld-Sekler, Cardier JE. Serum levels of the apoptosis-associated molecules, tumor necrosis factor-&#x3b1;/tumor necrosis factor type-I receptor and Fas/FasL, in sepsis. Chest. 2004;125:2238&#x2013;2246. doi: 10.1378/chest.125.6.2238.</Citation><ArticleIdList><ArticleId IdType="doi">10.1378/chest.125.6.2238</ArticleId><ArticleId IdType="pubmed">15189947</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitani K, Nishioka Y, Yamabe K, Ogawa H, Miki T, Yanagawa H, Sone S. Soluble Fas in malignant pleural effusion and its expression in lung cancer cells. Cancer Sci. 2003;94:302&#x2013;307. doi: 10.1111/j.1349-7006.2003.tb01437.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1349-7006.2003.tb01437.x</ArticleId><ArticleId IdType="pmc">PMC11160079</ArticleId><ArticleId IdType="pubmed">12824926</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee KS, Choi YH, Kim YS, Baik SH, Oh YJ, Sheen SS, Park JH, Hwang SC, Park KJ. Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis. Respir Med. 2008;102:464&#x2013;469. doi: 10.1016/j.rmed.2007.10.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rmed.2007.10.001</ArticleId><ArticleId IdType="pubmed">17988850</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwase M, Kondo G, Watanabe H, Takaoka S, Uchida M, Ohashi M, Nagumo M. Regulation of Fas-mediated apoptosis in neutrophils after surgery-induced acute inflammation. J Surg Res. 2006;134:114&#x2013;123. doi: 10.1016/j.jss.2005.10.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jss.2005.10.013</ArticleId><ArticleId IdType="pubmed">16376940</ArticleId></ArticleIdList></Reference><Reference><Citation>Liacos C, Katsaragakis S, Konstadoulakis MM, Messaris EG, Papanicolaou M, Georgiadis GG, Menenakos E, Vasiliadi-Chioti A, Androulakis G. Apoptosis in cells of bronchoalveolar lavage: a cellular reaction in patients who die with sepsis and respiratory failure. Crit Care Med. 2001;29:2310&#x2013;2317. doi: 10.1097/00003246-200112000-00013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00003246-200112000-00013</ArticleId><ArticleId IdType="pubmed">11801832</ArticleId></ArticleIdList></Reference><Reference><Citation>Fialkow L, Fochesatto Filho L, Bozzetti MC, Milani AR, Rodrigues Filho EM, Ladniuk RM, Pierozan P, de Moura RM, Prolla JC, Vachon E, Downey GP. Neutrophil apoptosis: a marker of disease severity in sepsis and sepsis-induced acute respiratory distress syndrome. Crit Care. 2006;10:R155. doi: 10.1186/cc5090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/cc5090</ArticleId><ArticleId IdType="pmc">PMC1794458</ArticleId><ArticleId IdType="pubmed">17092345</ArticleId></ArticleIdList></Reference><Reference><Citation>Silvestris F, Grinello D, Tucci M, Cafforio P, Dammacco F. Enhancement of T cell apoptosis correlates with increased serum levels of soluble Fas (CD95/Apo-1) in active lupus. Lupus. 2003;12:8&#x2013;14. doi: 10.1191/0961203303lu250oa.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu250oa</ArticleId><ArticleId IdType="pubmed">12587820</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma Y, Ye F, Lv W, Cheng Q, Chen H, Xie X. Correlation between soluble Fas level and apoptosis of T cells in ovarian carcinoma. Eur J Obstet Gynaecol Reprod Biol. 2008;138:204&#x2013;211. doi: 10.1016/j.ejogrb.2007.06.025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejogrb.2007.06.025</ArticleId><ArticleId IdType="pubmed">17826886</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhry MA, Ahmad S, Thompson KD, Sayeed MM. T-lymphocyte Ca2+ signalling and proliferative responses during sepsis. Shock. 1994;1:466&#x2013;471. doi: 10.1097/00024382-199406000-00012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00024382-199406000-00012</ArticleId><ArticleId IdType="pubmed">7735977</ArticleId></ArticleIdList></Reference><Reference><Citation>Roth G, Moser B, Krenn C, Brunner M, Haisjackl M, Almer G, Gerlitz S, Wolner E, Boltz-Nitulescu G, Ankersmit HJ. Susceptibility to programmed cell death in T-lymphocytes from septic patients: a mechanism for lymphopenia and Th2 predominance. Biochem Biophys Res Commun. 2003;308:840&#x2013;846. doi: 10.1016/S0006-291X(03)01482-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-291X(03)01482-7</ArticleId><ArticleId IdType="pubmed">12927795</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudziak D, Nimmerjahn F, Bornkamm GW, Laux G. Alternative splicing generates putative soluble CD83 proteins that inhibit T cell proliferation. J Immunol. 2005;174:6672&#x2013;6676.</Citation><ArticleIdList><ArticleId IdType="pubmed">15905506</ArticleId></ArticleIdList></Reference><Reference><Citation>Munder M, Schneider H, Luckner C, Giese T, Langhans CD, Fuentes JM, Kropf P, Mueller I, Kolb A, Modolell M, Ho AD. Suppression of T-cell functions by human granulocyte arginase. Blood. 2006;108:1627&#x2013;1634. doi: 10.1182/blood-2006-11-010389.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-11-010389</ArticleId><ArticleId IdType="pubmed">16709924</ArticleId></ArticleIdList></Reference><Reference><Citation>Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, K&#xfc;bler H, Yancey D, Dahm P, Vieweg J. Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res. 2008;14:8270&#x2013;8278. doi: 10.1158/1078-0432.CCR-08-0165.</Citation><ArticleIdList><ArticleId IdType="doi">10.1158/1078-0432.CCR-08-0165</ArticleId><ArticleId IdType="pubmed">19088044</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">19408487</PMID><DateCompleted><Year>2009</Year><Month>05</Month><Day>19</Day></DateCompleted><DateRevised><Year>2009</Year><Month>05</Month><Day>04</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0001-5423</ISSN><JournalIssue CitedMedium="Print"><Volume>50</Volume><Issue>4</Issue><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Acta chirurgiae plasticae</Title><ISOAbbreviation>Acta Chir Plast</ISOAbbreviation></Journal><ArticleTitle>Hemocoagulation disorders in extensively burned patients: pilot study for scoring of the DIC.</ArticleTitle><Pagination><StartPage>115</StartPage><EndPage>118</EndPage><MedlinePgn>115-8</MedlinePgn></Pagination><Abstract><AbstractText Label="GOAL OF THE STUDY" NlmCategory="OBJECTIVE">To apply results of the hemocoagulation parameters to the DIC (disseminated intravascular coagulation) score system. Compare parameters of the DIC score in patients with extensive burn trauma (hospitalized at the Intensive Care Unit, ICU) and patients with lesser extent of burn injury (hospitalized at the standard unit). To use these data within the evidence based medicine for the prediction of organ damage and multi-organ failure.</AbstractText><AbstractText Label="TYPE OF STUDY" NlmCategory="METHODS">Prospective study.</AbstractText><AbstractText Label="MATERIAL AND METHODS" NlmCategory="METHODS">We have included total of 36 patients in the group within four months. Twelve patients were hospitalized at the ICU, 24 patients were hospitalized at the intermedial care and standard unit. Repeatedly, we have taken blood from patients to evaluate the hemocoagulation parameters. In patients hospitalized at the ICU, the blood was taken from the central vein (prior to the drawn, the access was flushed with 100 ml of F1/1, the blood was taken from different access than from the one administering heparin), in patients hospitalized at the standard unit the blood was taken from a peripheral vein. The results were then put into the tables established according to the ISTH (International Society on Thrombosis and Hemostasis). Next, the DIC score was calculated to predict severity of hemocoagulation balance disorders in burn trauma, or occurrence of complications during the treatment.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Part 1: We have evaluated 12 patients (4 females) hospitalized at the ICU. At the day of injury the overt DIC score reached 1.25 (0-3), fifth day after the injury the average value of overt DIC score was 1.83 (0-3), one day after the autotransplantation it was 2.08 (0-3) and at the day of discharge from the hospital 0. In the deceased patient the DIC score reached value of 2. Part 2: We evaluated 24 patients (10 females) hospitalized at the standard unit. The extent of their burn injury was 5.9% TBSA (0.5-12% TBSA), age 49.13 years (17-94 years). At the day of injury the overt DIC score reached 0.25 (0-2). Fifth day after the injury the average value of overt DIC score was 1.66 (0-2). Day after the autotransplantation it was 1.83 (0-3) and at the day of discharge 0.02 (0-2).</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">During the treatment of the patients with various extent of burn injury, none of the patients' scores reached values that would mean occurrence of obvious "overt" DIC.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lipov&#xfd;</LastName><ForeName>B</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Burns and Reconstructive Surgery, Medical Faculty, Masaryk University Brno, Czech Republic. B.Lipovy@seznam.cz</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kaloudov&#xe1;</LastName><ForeName>Y</ForeName><Initials>Y</Initials></Author><Author ValidYN="Y"><LastName>Mat&#xfd;skov&#xe1;</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Penka</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Rihov&#xe1;</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Brychta</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>Czech Republic</Country><MedlineTA>Acta Chir Plast</MedlineTA><NlmUniqueID>0370301</NlmUniqueID><ISSNLinking>0001-5423</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005338">Fibrin Fibrinogen Degradation Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C036309">fibrin fragment D</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015897" MajorTopicYN="N">Comorbidity</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004211" MajorTopicYN="N">Disseminated Intravascular Coagulation</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005338" MajorTopicYN="N">Fibrin Fibrinogen Degradation Products</DescriptorName><QualifierName UI="Q000032" MajorTopicYN="N">analysis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>5</Month><Day>5</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>1</Month><Day>1</Day><Hour>0</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>5</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">19408487</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">17644265</PMID><DateCompleted><Year>2008</Year><Month>08</Month><Day>19</Day></DateCompleted><DateRevised><Year>2008</Year><Month>02</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0305-4179</ISSN><JournalIssue CitedMedium="Print"><Volume>34</Volume><Issue>2</Issue><PubDate><Year>2008</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Burns : journal of the International Society for Burn Injuries</Title><ISOAbbreviation>Burns</ISOAbbreviation></Journal><ArticleTitle>Snapshot assessment of RNA-expression in severely burned patients using the PAXgene Blood RNA system: a pilot study.</ArticleTitle><Pagination><StartPage>197</StartPage><EndPage>204</EndPage><MedlinePgn>197-204</MedlinePgn></Pagination><Abstract><AbstractText>Severe burn induces destabilization of the immune system and the likelihood of multiple organ dysfunction syndrome. Current studies focus on RNA-expression analyses of immune system cells, however, the present methods of analysis are complex, potentially altered by artefacts and therefore not feasible for routine analyses. The new PAXgene Blood RNA System provides "snapshot" analysis of RNA by immediate cell lysis and prevention of RNA-degradation. Using this system the aim of this study was to analyse intracellular cytokine RNA-expression under clinical conditions. Whole blood samples (PAXgene tubes) of nine severely burned patients were drawn at admission and 6, 12, 24, 48 and 72h after trauma during routine treatment. Four healthy individuals served as control. Analysis of RNA-expression of TNF-alpha as pro-inflammatory and IL-10 as anti-inflammatory mediator was performed by RT-PCR. The RNA-expression of TNF-alpha was increased at 72h after burn. The increase occurred mainly in surviving patients. In contrast, RNA-expression of IL-10 was elevated already at 24h and the difference between surviving and deceased patients occurred earlier. We demonstrate for the first time a "snapshot" analysis of cytokine RNA-expression in severely burned patients under routine conditions. The results correspond well to current hypothesis of posttraumatic MODS development.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Landes</LastName><ForeName>J</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Traumatology and Orthopaedic Surgery, Ludwig-Maximilians-University of Munich, Nussbaumstrasse 20, D-80336 Munich, Germany. juergen.landes@med.uni-muechen.de</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langer</LastName><ForeName>S</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Kirchhoff</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Schuetz</LastName><ForeName>C</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Joneidi-Jafari</LastName><ForeName>H</ForeName><Initials>H</Initials></Author><Author ValidYN="Y"><LastName>Stegmaier</LastName><ForeName>J</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Mutschler</LastName><ForeName>W</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Biberthaler</LastName><ForeName>P</ForeName><Initials>P</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2007</Year><Month>07</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Burns</MedlineTA><NlmUniqueID>8913178</NlmUniqueID><ISSNLinking>0305-4179</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012333">RNA, Messenger</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>130068-27-8</RegistryNumber><NameOfSubstance UI="D016753">Interleukin-10</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001800" MajorTopicYN="N">Blood Specimen Collection</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002056" MajorTopicYN="N">Burns</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016753" MajorTopicYN="N">Interleukin-10</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D010865" MajorTopicYN="N">Pilot Projects</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012333" MajorTopicYN="N">RNA, Messenger</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2006</Year><Month>11</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2007</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2007</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2007</Year><Month>7</Month><Day>24</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">17644265</ArticleId><ArticleId IdType="doi">10.1016/j.burns.2007.02.008</ArticleId><ArticleId IdType="pii">S0305-4179(07)00062-9</ArticleId></ArticleIdList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">15718917</PMID><DateCompleted><Year>2005</Year><Month>07</Month><Day>11</Day></DateCompleted><DateRevised><Year>2020</Year><Month>12</Month><Day>09</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1073-2322</ISSN><JournalIssue CitedMedium="Print"><Volume>23</Volume><Issue>3</Issue><PubDate><Year>2005</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Shock (Augusta, Ga.)</Title><ISOAbbreviation>Shock</ISOAbbreviation></Journal><ArticleTitle>Enhanced enzymatic degradation of tryptophan by indoleamine 2,3-dioxygenase contributes to the tryptophan-deficient state seen after major trauma.</ArticleTitle><Pagination><StartPage>209</StartPage><EndPage>215</EndPage><MedlinePgn>209-15</MedlinePgn></Pagination><Abstract><AbstractText>Decreased lymphocyte proliferation, lymphopenia, immunodepression, and opportunistic infections are common after major trauma. Early alimentation in these patients corrects lymphopenia, enhances immunity, and reduces the incidence of infections, but the underlying mechanisms are poorly understood. Tryptophan is essential for the production and function of rapidly proliferating cells such as lymphocytes. Tryptophan is enzymatically degraded by indoleamine 2,3-dioxygenase (IDO), whose activity is solely dependent on expression of interferon-gamma (IFN-gamma). Because increased expression of IFN-gamma has been reported in trauma patients, we investigated whether enhanced IDO-mediated tryptophan degradation is associated with lymphopenia and poor outcomes after major trauma. The incidence of bacteremic sepsis (BS), adult respiratory distress syndrome (ARDS), multiple organ dysfunction/failure syndromes (MODS/MOF), and death was prospectively documented in 22 trauma patients with a mean ISS of 24.9 +/- 2.2. Sequential blood samples were obtained from admission through postinjury day 10. Five patients developed BS, three of whom developed ARDS; two of the three ARDS patients developed MOF and died on day 10. Trauma patients had significantly lower tryptophan levels (days 1-10), higher kynurenine:tryptophan ratios (days 1-2), and fewer lymphocytes (days 1-4) than healthy volunteers (P &lt; 0.05). Although patients with poor outcomes (i.e., BS, ARDS, MOF, and death) had significantly lower tryptophan levels and greater lymphopenia on several days after injury, the sample size was too small to draw any definitive conclusions. These data indicate that decreased plasma tryptophan levels and lymphopenia typically occur after major trauma. A concomitant increase in kynurenine suggests that the observed tryptophan deficiency is caused, in part, by IDO-mediated tryptophan degradation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Pellegrin</LastName><ForeName>Katharina</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Surgery, M. L. King, Jr./Drew Medical Center, Los Angeles, California, USA. kathpellegrin@aol.com</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Neurauter</LastName><ForeName>Gabriele</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Wirleitner</LastName><ForeName>Barbara</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fleming</LastName><ForeName>Arthur W</ForeName><Initials>AW</Initials></Author><Author ValidYN="Y"><LastName>Peterson</LastName><ForeName>Verlyn M</ForeName><Initials>VM</Initials></Author><Author ValidYN="Y"><LastName>Fuchs</LastName><ForeName>Dietmar</ForeName><Initials>D</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Shock</MedlineTA><NlmUniqueID>9421564</NlmUniqueID><ISSNLinking>1073-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D050503">Indoleamine-Pyrrole 2,3,-Dioxygenase</NameOfSubstance></Chemical><Chemical><RegistryNumber>343-65-7</RegistryNumber><NameOfSubstance UI="D007737">Kynurenine</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical><Chemical><RegistryNumber>8DUH1N11BX</RegistryNumber><NameOfSubstance UI="D014364">Tryptophan</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 1.13.11.11</RegistryNumber><NameOfSubstance UI="D014366">Tryptophan Oxygenase</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016470" MajorTopicYN="N">Bacteremia</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002648" MajorTopicYN="N">Child</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D050503" MajorTopicYN="N">Indoleamine-Pyrrole 2,3,-Dioxygenase</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007737" MajorTopicYN="N">Kynurenine</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008231" MajorTopicYN="N">Lymphopenia</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009102" MajorTopicYN="N">Multiple Organ Failure</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012128" MajorTopicYN="N">Respiratory Distress Syndrome</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018805" MajorTopicYN="N">Sepsis</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014364" MajorTopicYN="N">Tryptophan</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000172" MajorTopicYN="Y">deficiency</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014366" MajorTopicYN="N">Tryptophan Oxygenase</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014947" MajorTopicYN="N">Wounds and Injuries</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="Y">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2005</Year><Month>7</Month><Day>12</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2005</Year><Month>2</Month><Day>19</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">15718917</ArticleId><ArticleId IdType="pii">00024382-200503000-00003</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>